title|doi
Bidirectional relationship between olfaction and Parkinson’s disease|10.1038/s41531-024-00838-4
Slovak database of speech affected by neurodegenerative diseases|10.1038/s41597-024-04171-6
Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record|10.1002/mds.30075
Cortical complexity alterations in motor subtypes of Parkinson's disease: A surface‐based morphometry analysis of fractal dimension|10.1111/ejn.16612
Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer’s disease, dementia with Lewy bodies and vascular dementia|10.1007/s00401-024-02824-9
MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity|10.1038/s41531-024-00841-9
Seeding activity of skin misfolded tau as a biomarker for tauopathies|10.1186/s13024-024-00781-1
Enhancement and evaluation for deep learning-based classification of volumetric neuroimaging with 3D-to-2D knowledge distillation|10.1038/s41598-024-80938-6
Associations of motor and neuropsychiatric symptoms with comorbidities in prodromal Parkinson’s disease|10.3389/fnagi.2024.1452766
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons|10.1186/s13024-024-00779-9
A multi-region single nucleus transcriptomic atlas of Parkinson’s disease|10.1038/s41597-024-04117-y
Longitudinal decline in DAT binding in Parkinson’s disease: connections with sleep disturbances|10.1186/s12916-024-03766-5
High‐molecular‐weight oligomer tau (HMWoTau) species are dramatically increased in Braak‐stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005)|10.1096/fj.202401704r
Reduced striatal M4-cholinergic signaling following dopamine loss contributes to parkinsonian and l -DOPA–induced dyskinetic behaviors|10.1126/sciadv.adp6301
Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes|10.1038/s41467-024-54253-7
A worldwide study of subcortical shape as a marker for clinical staging in Parkinson’s disease|10.1038/s41531-024-00825-9
Circulating blood circular RNA in Parkinson’s Disease; from involvement in pathology to diagnostic tools in at-risk individuals|10.1038/s41531-024-00839-3
Relative sparing of dopaminergic terminals in the caudate nucleus is a feature of rest tremor in Parkinson’s disease|10.1038/s41531-024-00818-8
Peripheral immune cell abundance differences link blood mitochondrial DNA copy number and Parkinson’s disease|10.1038/s41531-024-00831-x
The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson’s disease|10.3389/fncir.2024.1463941
PathogenicLRRK2mutations cause loss of primary cilia and Neurturin in striatal parvalbumin interneurons|10.26508/lsa.202402922
Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome‐Wide Association Study|10.1002/mds.30054
Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits|10.1038/s41588-024-01973-7
Identification and In Vitro and In Vivo Characterization of KAC-50.1 as a Potential α-Synuclein PET Radioligand|10.1021/acschemneuro.4c00493
Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease|10.1038/s41588-024-01972-8
A framework for translational therapy development in deep brain stimulation|10.1038/s41531-024-00829-5
Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain|10.1038/s41531-024-00830-y
The p.Gly2019Ser is a common LRRK2 pathogenic variant among Egyptians with familial and sporadic Parkinson’s disease|10.1038/s41531-024-00826-8
Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human alpha synuclein|10.1038/s41531-024-00824-w
Dopaminergic Axon Tracts Within a Hyaluronic Acid Hydrogel Encasement to Restore the Nigrostriatal Pathway|10.1002/adhm.202402997
Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease|10.1111/cts.70066
Exploring the layers of fatigue in Parkinson’s Disease: A comprehensive analysis of its prevalence and contributing factors|10.1016/j.prdoa.2024.100288
α-synuclein overexpression and the microbiome shape the gut and brain metabolome in mice|10.1038/s41531-024-00816-w
Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles|10.7554/elife.92775.3
Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2|10.1038/s41531-024-00822-y
Randomized crossover trial on motor and non-motor outcome of directional deep brain stimulation in Parkinson’s disease|10.1038/s41531-024-00812-0
Are rare heterozygous SYNJ1 variants associated with Parkinson’s disease?|10.1038/s41531-024-00809-9
Autosomal recessive VWA1-related disorder: comprehensive analysis of phenotypic variability and genetic mutations|10.1093/braincomms/fcae377
Biomarker Assessment in Parkinson’s Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures|10.3233/adr-240110
Participant-reported personal utility of genetic testing for Parkinson’s disease and interest in clinical trial participation|10.1038/s41531-024-00805-z
Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson’s disease|10.1093/brain/awae303
Medication recommendation for Parkinson’s disease based on dynamics of symptom progression|10.1038/s41598-024-76941-6
Oral and gut microbiome profiles in people with early idiopathic Parkinson’s disease|10.1038/s43856-024-00630-8
Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2|10.1038/s41531-024-00819-7
The Black and African American Connections to Parkinson’s Disease (BLAAC PD) study protocol|10.1186/s12883-024-03914-7
Multiple sclerosis subgroups: Data-driven clusters based on patient-reported outcomes and a large clinical sample|10.1177/13524585241282763
PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner|10.1038/s41419-024-07124-4
Parkinson’s families project: a UK-wide study of early onset and familial Parkinson’s disease|10.1038/s41531-024-00778-z
Integrating brainstem and cortical functional architectures|10.1038/s41593-024-01787-0
Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related neurodegenerative deficits|10.1038/s41467-024-53168-7
Neuronal BAG3 attenuates tau hyperphosphorylation, synaptic dysfunction, and cognitive deficits induced by traumatic brain injury via the regulation of autophagy-lysosome pathway|10.1007/s00401-024-02810-1
High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson’s disease|10.1073/pnas.2406009121
Single-cell somatic copy number variants in brain using different amplification methods and reference genomes|10.1038/s42003-024-06940-w
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease|10.1186/s13024-024-00756-2
POLCAM: instant molecular orientation microscopy for the life sciences|10.1038/s41592-024-02382-8
Brain-first forms of Parkinson's disease are over-represented in patients with non-responsive resting tremor|10.1016/j.nbd.2024.106691
ScRNAbox: empowering single-cell RNA sequencing on high performance computing systems|10.1186/s12859-024-05935-y
SNPs in cytochromes P450 catalyzing cholesterol degradation in brain are associated with Parkinson’s disease|10.3389/fphar.2024.1477009
Surface‐Based Morphometry Analysis of the Cerebral Cortex in Patients With Probable Idiopathic Rapid Eye Movement Sleep Behavior Disorder|10.1002/brb3.70057
RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes|10.1038/s41467-024-52723-6
Graphene Microelectrode Arrays, 4D Structured Illumination Microscopy, and a Machine Learning Spike Sorting Algorithm Permit the Analysis of Ultrastructural Neuronal Changes During Neuronal Signaling in a Model of Niemann–Pick Disease Type C|10.1002/advs.202402967
APOE contributes to longitudinal impulse control disorders progression in Parkinson’s disease|10.1186/s12888-024-06084-5
Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy|10.1186/s12974-024-03221-5
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts|10.1038/s41531-024-00789-w
VPS13B is localized at the interface between Golgi cisternae and is a functional partner of FAM177A1|10.1083/jcb.202311189
Topography of Cholinergic Nerve Terminal Vulnerability and Balance Self-Efficacy in Parkinson's Disease|10.31083/j.jin2309178
CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET|10.1038/s41467-024-52298-2
Activation of parkin by a molecular glue|10.1038/s41467-024-51889-3
Advancing Parkinson’s Disease Research in Canada: The Canadian Open Parkinson Network (C-OPN) Cohort|10.3233/jpd-240213
An interpretable deep learning framework identifies proteomic drivers of Alzheimer’s disease|10.3389/fcell.2024.1379984
Head-up Tilt Sleeping to Treat Orthostatic Intolerance in a Patient with Advanced Parkinson’s Disease: A Case Report|10.1159/000541424
How storage post sampling influences the stability of sebum when used for mass spectrometry metabolomics analysis?|10.1038/s41598-024-71598-7
NeuroBooster Array: A Genome‐Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations|10.1002/mds.29902
A Novel MAG Variant Causes Hereditary Spastic Paraplegia in a Consanguineous Pakistani Family|10.3390/genes15091203
Structural and Functional Characterization of the Most Frequent Pathogenic PRKN Substitution p.R275W|10.3390/cells13181540
RTP801 interacts with the tRNA ligase complex and dysregulates its RNA ligase activity in Alzheimer’s disease|10.1093/nar/gkae776
Understanding what aspects of Parkinson’s disease matter most to patients and families|10.1038/s41598-024-71555-4
Spatial single-cell isotope tracing reveals heterogeneity of de novo fatty acid synthesis in cancer|10.1038/s42255-024-01118-4
SVA Regulation of Transposable Element Clustered Transcription within the Major Histocompatibility Complex Genomic Class II Region of the Parkinson’s Progression Markers Initiative|10.3390/genes15091185
A novel super-resolution microscopy platform for cutaneous alpha-synuclein detection in Parkinson’s disease|10.3389/fnmol.2024.1431549
Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials|10.3233/jpd-240035
Cohort-specific Boolean models highlight different regulatory modules during Parkinson’s disease progression|10.1016/j.isci.2024.110956
Selection of DNA aptamers that prevent the fibrillization of α-synuclein protein in cellular and mouse models|10.1016/j.omtn.2024.102251
SynBot is an open-source image analysis software for automated quantification of synapses|10.1016/j.crmeth.2024.100861
Validating New Symptom Emergence as a Patient-Centric Outcome Measure for PD Clinical Trials|10.1016/j.parkreldis.2024.107118
An Inducible Luminescent System to Explore Parkinson’s Disease-Associated Genes|10.3390/ijms25179493
Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer's disease and older controls in multi‐ethnic populations|10.1002/alz.14208
Inflammation and heterogeneity in synucleinopathies|10.3389/fimmu.2024.1432342
Shared and distinct cortical morphometric alterations in five neuropsychiatric symptoms of Parkinson’s disease|10.1038/s41398-024-03070-z
Medication improves velocity, reaction time, and movement time but not amplitude or error during memory‐guided reaching in Parkinson's disease|10.14814/phy2.16150
Sensorimotor functioning changes in response to global exercise versus handwriting upper limb exercise training in Parkinson’s disease, results from a phase II randomised controlled trial|10.1371/journal.pone.0309217
Single-Molecule Fingerprinting Reveals Different Growth Mechanisms in Seed Amplification Assays for Different Polymorphs of α-Synuclein Fibrils|10.1021/acschemneuro.4c00185
Synthesis at the Interface of Chemistry and Biology|10.1021/acs.accounts.4c00320
Diffusion tensor metrics, motor and non-motor symptoms in de novo Parkinson’s disease|10.1007/s00234-024-03452-6
Acceptability of digital health technologies in early Parkinson's disease: lessons from WATCH-PD|10.3389/fdgth.2024.1435693
Dynamic balance and gait impairments in Parkinson’s disease: novel cholinergic patterns|10.1093/braincomms/fcae286
Cell-specific expression of key mitochondrial enzymes limits OXPHOS in astrocytes of the adult human neocortex and hippocampal formation|10.1038/s42003-024-06751-z
Phosphoglycerate kinase is a central leverage point in Parkinson’s disease–driven neuronal metabolic deficits|10.1126/sciadv.adn6016
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies|10.1126/science.abm6131
Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early‐ to Mid‐Stage Parkinson's Disease Modification Trials|10.1002/mdc3.14191
IAPP - oligomerisation levels in plasma of people with type 2 diabetes|10.1038/s41598-024-70255-3
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers|10.1038/s41531-024-00763-6
MRI subtypes in Parkinson’s disease across diverse populations and clustering approaches|10.1038/s41531-024-00759-2
Sleep duration in middle-aged years of life predicts the age of diagnosis of Parkinson’s disease|10.1016/j.sleepx.2024.100123
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy|10.1186/s13024-024-00747-3
Loss-of-function variants in ITSN1 confer high risk of Parkinson’s disease|10.1038/s41531-024-00752-9
Exposure to household pesticides and Parkinson's disease in the Parkinson's Progression Markers Initiative cohort|10.3389/fneur.2024.1411468
A worldwide study of white matter microstructural alterations in people living with Parkinson’s disease|10.1038/s41531-024-00758-3
Acoustically targeted measurement of transgene expression in the brain|10.1126/sciadv.adj7686
LRRK2 kinase activity is necessary for development and regeneration in Nematostella vectensis|10.1186/s13064-024-00193-3
Multiple sclerosis in LRRK2 G2019S Parkinson’s disease and isolated nigral degeneration in a homozygous variant carrier|10.3389/fneur.2024.1450654
Naturally occurring hyperactive variants of human parkin|10.1038/s42003-024-06656-x
Contrastive machine learning reveals Parkinson’s disease specific features associated with disease severity and progression|10.1038/s42003-024-06648-x
Long-Term Dementia Risk in Parkinson Disease|10.1212/wnl.0000000000209699
Real‐world smartphone data can trace the behavioural impact of epilepsy: A case study|10.1111/ene.16433
The digital signature of emergent tremor in Parkinson’s disease|10.1038/s41531-024-00754-7
A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders|10.3233/jpd-230257
Contributions of network structure, chemoarchitecture and diagnostic categories to transitions between cognitive topographies|10.1038/s41551-024-01242-2
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis|10.1038/s41531-024-00744-9
Lysosomal TBK1 responds to amino acid availability to relieve Rab7-dependent mTORC1 inhibition|10.1038/s44318-024-00180-8
Transcriptomics and weighted protein network analyses of the LRRK2 protein interactome reveal distinct molecular signatures for sporadic and LRRK2 Parkinson’s Disease|10.1038/s41531-024-00761-8
ABCA7-dependent induction of neuropeptide Y is required for synaptic resilience in Alzheimer’s disease through BDNF/NGFR signaling|10.1016/j.xgen.2024.100642
Clinical genetic testing in Parkinson’s disease should become part of routine patient care|10.1093/brain/awae181
Dual-task gait has prognostic value for cognitive decline in Parkinson’s disease|10.1016/j.jocn.2024.06.006
Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson’s disease|10.1073/pnas.2402206121
A genetic and proteomic comparison of key AD biomarkers across tissues|10.1002/alz.14139
Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study|10.1093/brain/awae142
Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale|10.1002/mds.29925
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis|10.1038/s41467-024-50686-2
Comprehensive real time remote monitoring for Parkinson’s disease using Quantitative DigitoGraphy|10.1038/s41531-024-00751-w
Characterizing a complex CT-rich haplotype in intron 4 of SNCA using large-scale targeted amplicon long-read sequencing|10.1038/s41531-024-00749-4
Parkinson's Disease Gene Screening in Familial Cases from Central and South America|10.1002/mds.29931
Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials|10.3233/jpd-230446
Cognitive dysfunction in animal models of human lewy-body dementia|10.3389/fnagi.2024.1369733
The activities of daily living partially mediate the relationship between rapid eye movement sleep behavior disorder and depressive symptoms in Parkinson's disease|10.3389/fneur.2024.1357721
Unfolded protein response markers Grp78 and eIF2alpha are upregulated with increasing alpha‐synuclein levels in Lewy body disease|10.1111/nan.12999
Adult-onset deletion of ATP13A2 in mice induces progressive nigrostriatal pathway dopaminergic degeneration and lysosomal abnormalities|10.1038/s41531-024-00748-5
Targeted co-expression networks for the study of traits|10.1038/s41598-024-67329-7
[18F]Flotaza for Aβ Plaque Diagnostic Imaging: Evaluation in Postmortem Human Alzheimer’s Disease Brain Hippocampus and PET/CT Imaging in 5xFAD Transgenic Mice|10.3390/ijms25147890
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update|10.3233/jpd-240272
Machine learning for predicting cognitive decline within five years in Parkinson’s disease: Comparing cognitive assessment scales with DAT SPECT and clinical biomarkers|10.1371/journal.pone.0304355
Unveiling a novel memory center in human brain: neurochemical identification of the nucleus incertus, a key pontine locus implicated in stress and neuropathology|10.1186/s40659-024-00523-z
Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center|10.1038/s41597-024-03485-9
Digital biomarkers for non-motor symptoms in Parkinson’s disease: the state of the art|10.1038/s41746-024-01144-2
Detecting rhythmic spiking through the power spectra of point process model residuals|10.1088/1741-2552/ad6188
Immune responses to oligomeric α-synuclein in Parkinson’s disease peripheral blood mononuclear cells|10.1007/s00415-024-12554-3
Single cell transcriptomes and multiscale networks from persons with and without Alzheimer’s disease|10.1038/s41467-024-49790-0
Identification of Parkinson’s disease PACE subtypes and repurposing treatments through integrative analyses of multimodal data|10.1038/s41746-024-01175-9
Gba1 E326K renders motor and non-motor symptoms with pathologic α-syn, tau and glial activation|10.1093/brain/awae222
Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson's Disease: The FIRE-UP PD study|10.1016/j.cct.2024.107619
Sex differences in the association between Body Mass Index and cognitive function in Parkinson disease: a cross-sectional study|10.3389/fnut.2024.1420225
AI-based differential diagnosis of dementia etiologies on multimodal data|10.1038/s41591-024-03118-z
Florbetaben amyloid PET acquisition time: Influence on Centiloids and interpretation|10.1002/alz.13893
Regional Differences in Microbial Infiltration of Brain Tissue from Alzheimer’s Disease Patients and Control Individuals|10.3390/brainsci14070677
Cognitive Symptoms in Cross-Sectional Parkinson Disease Cohort Evaluated by Human-in-the-Loop Machine Learning and Natural Language Processing|10.1212/cpj.0000000000200334
A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2|10.1016/j.jbc.2024.107469
Concerns with the new biological research criteria for synucleinopathy – Authors' reply|10.1016/s1474-4422(24)00233-3
Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia|10.1016/j.ajhg.2024.05.017
Parkinson's disease: Still waiting for a cure|10.1111/cts.13898
Profiling people with Parkinson's disease at risk of cognitive decline: Insights from PPMI and ICICLE‐PD data|10.1002/dad2.12625
Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions|10.1016/j.neuron.2024.06.002
Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology|10.1016/j.neuro.2024.06.016
TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons|10.1016/j.cell.2024.05.030
Associations of cholinergic system integrity with cognitive decline in GBA1 and LRRK2 mutation carriers|10.1038/s41531-024-00743-w
Increased mean diffusivity of the caudal motor SNc identifies patients with REM sleep behaviour disorder and Parkinson’s disease|10.1038/s41531-024-00731-0
Changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer’s disease|10.1038/s41598-024-65010-7
Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease|10.1002/mds.29892
Revised criteria for the diagnosis and staging of Alzheimer’s disease|10.1038/s41591-024-02988-7
The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1|10.1126/sciadv.adk1296
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup|10.1002/alz.13859
Selective Activation of the Spinal Cord with Epidural Electrical Stimulation|10.3390/brainsci14070650
Assessment tools for cognitive performance in Parkinson’s disease and its genetic contributors|10.3389/fneur.2024.1413187
Divergent landscapes of A-to-I editing in postmortem and living human brain|10.1038/s41467-024-49268-z
Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD|10.1038/s41594-024-01338-y
Prediction of motor and non-motor Parkinson’s disease symptoms using serum lipidomics and machine learning: a 2-year study|10.1038/s41531-024-00741-y
Synchronous Measurements of Extracellular Action Potentials and Neurochemical Activity with Carbon Fiber Electrodes in Nonhuman Primates|10.1523/eneuro.0001-24.2024
The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson’s disease|10.1038/s41598-024-65640-x
An interpretable machine learning‐based cerebrospinal fluid proteomics clock for predicting age reveals novel insights into brain aging|10.1111/acel.14230
Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease|10.1002/mdc3.14145
Randomized controlled trial of intermittent hypoxia in Parkinson’s disease: study rationale and protocol|10.1186/s12883-024-03702-3
Open-source platform for kinematic analysis of mouse forelimb movement|10.1016/j.xpro.2024.103140
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial|10.1038/s41591-024-03101-8
Very low levels of ABCA7 in the cerebrum and Alzheimer’s disease onset between the ages of 60 and 80 independently of APOE|10.1093/jnen/nlae060
The hexosamine biosynthetic pathway rescues lysosomal dysfunction in Parkinson’s disease patient iPSC derived midbrain neurons|10.1038/s41467-024-49256-3
Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset|10.1038/s41467-024-48961-3
Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease|10.1038/s44220-024-00256-8
Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates|10.1038/s41531-024-00735-w
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology|10.1038/s41467-024-49402-x
Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer’s disease tauopathies|10.1038/s41467-024-49258-1
Advancing surgical instrument safety: A screen of oxidative and alkaline prion decontaminants using real-time quaking-induced conversion with prion-coated steel beads as surgical instrument mimetic|10.1371/journal.pone.0304603
An Ethnographic Study of Patient Life Experience in Early-Stage Parkinson’s Disease in the United States and Germany|10.1007/s40120-024-00632-7
Fox Insight at 5 years - a cohort of 54,000 participants contributing longitudinal patient-reported outcome, genetic, and microbiome data relating to Parkinson’s disease|10.1038/s41597-024-03407-9
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months|10.1038/s41531-024-00721-2
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease|10.1186/s40035-024-00421-0
Mitochondrial DNA Instability Supersedes Parkin Mutations in Driving Mitochondrial Proteomic Alterations and Functional Deficits in Polg Mutator Mice|10.3390/ijms25126441
Motor skill learning modulates striatal extracellular vesicles’ content in a mouse model of Huntington’s disease|10.1186/s12964-024-01693-9
Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation|10.1186/s13024-024-00738-4
Systematic rare variant analyses identify RAB32 as a susceptibility gene for familial Parkinson’s disease|10.1038/s41588-024-01787-7
Genome-wide determinants of mortality and motor progression in Parkinson’s disease|10.1038/s41531-024-00729-8
Mechanism of human PINK1 activation at the TOM complex in a reconstituted system|10.1126/sciadv.adn7191
Relationship between sex biases in gene expression and sex biases in autism and Alzheimer’s disease|10.1186/s13293-024-00622-2
A machine learning contest enhances automated freezing of gait detection and reveals time-of-day effects|10.1038/s41467-024-49027-0
Causal Forest Machine Learning Analysis of Parkinson’s Disease in Resting-State Functional Magnetic Resonance Imaging|10.3390/tomography10060068
Building national patient registries in Mexico: insights from the MexOMICS Consortium|10.3389/fdgth.2024.1344103
Late‐onset Krabbe disease presenting as spastic paraplegia – implications of GCase and CTSB/D|10.1002/acn3.52078
The immune system in Parkinson’s disease: what we know so far|10.1093/brain/awae177
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative|10.3233/jpd-230363
Motor dysfunction in Parkinson’s patients: depression differences in a latent growth model|10.3389/fnagi.2024.1393887
Neurocognitive health in LGBTQIA+ older adults: current state of research and recommendations|10.3389/fnhum.2024.1394374
Outcome Selection for Research Studies in Movement Disorders|10.1002/mdc3.14087
An interpretable deep learning Bayesian optimized random forest framework for the diagnosis of Parkinson's disease in structural magnetic resonance images|10.1002/ima.23106
ePresentations|10.1111/ene.16338
Occupational Pesticide Exposure in Parkinson’s Disease Related to GBA and LRRK2 Variants|10.3233/jpd-240015
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS|10.1038/s41591-024-02937-4
Alpha-synuclein aggregates are phosphatase resistant|10.1186/s40478-024-01785-0
Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein|10.1038/s41467-024-49016-3
Neuroprotective Strategies and Cell-Based Biomarkers for Manganese-Induced Toxicity in Human Neuroblastoma (SH-SY5Y) Cells|10.3390/biom14060647
Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome|10.1002/mdc3.14089
High-Yield α-Synuclein Purification and Ionic Strength Modification Pivotal to Seed Amplification Assay Performance and Reproducibility|10.3390/ijms25115988
Digital outcome measures from smartwatch data relate to non-motor features of Parkinson’s disease|10.1038/s41531-024-00719-w
Dysregulated Wnt and NFAT signaling in a Parkinson’s disease LRRK2 G2019S knock-in model|10.1038/s41598-024-63130-8
Genetic analysis and natural history of Parkinson’s disease due to the LRRK2 G2019S variant|10.1093/brain/awae073
Development and characterization of phospho-ubiquitin antibodies to monitor PINK1-PRKN signaling in cells and tissue|10.1080/15548627.2024.2356490
Exploring the role of underrepresented populations in polygenic risk scores for neurodegenerative disease risk prediction|10.3389/fnins.2024.1380860
A data-driven single-cell and spatial transcriptomic map of the human prefrontal cortex|10.1126/science.adh1938
Epistatic Features and Machine Learning Improve Alzheimer’s Disease Risk Prediction Over Polygenic Risk Scores|10.3233/jad-230236
Profiling complex repeat expansions in RFC1 in Parkinson’s disease|10.1038/s41531-024-00723-0
Association of body mass index with rapid eye movement sleep behavior disorder in Parkinson’s disease|10.3389/fneur.2024.1388131
Impulse control disorders and use of dopamine agonists in early onset Parkinson’s disease|10.3389/fneur.2024.1404904
KAT8 compound inhibition inhibits the initial steps of PINK1-dependant mitophagy|10.1038/s41598-024-60602-9
A cross‐sectional study of α‐synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function|10.1002/alz.13858
Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy|10.1038/s41531-024-00679-1
A person-centered approach to characterizing longitudinal ambulatory impairment in Parkinson's disease|10.1038/s41598-024-62179-9
Sleep disturbances, cognitive decline, and AD biomarkers alterations in early Parkinson's disease|10.1002/acn3.52089
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease|10.1038/s41531-024-00714-1
A neurocomputational view of the effects of Parkinson’s disease on speech production|10.3389/fnhum.2024.1383714
Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health‐related comorbidities in a community‐dwelling cohort|10.1002/alz.13835
iATPSnFR2: A high-dynamic-range fluorescent sensor for monitoring intracellular ATP|10.1073/pnas.2314604121
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances|10.1038/s41531-024-00716-z
The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson’s disease comorbidity|10.1186/s13073-024-01335-2
Deciphering the role of a SINE-VNTR-Alu retrotransposon polymorphism as a biomarker of Parkinson’s disease progression|10.1038/s41598-024-61753-5
Characterizing molecular and synaptic signatures in mouse models of late‐onset Alzheimer's disease independent of amyloid and tau pathology|10.1002/alz.13828
Automatic geometry-based estimation of the locus coeruleus region on T1-weighted magnetic resonance images|10.3389/fnins.2024.1375530
Synapsin E-domain is essential for α-synuclein function|10.7554/elife.89687.3
Hippocampal aggregation signatures of pathogenic UBQLN2 in amyotrophic lateral sclerosis and frontotemporal dementia|10.1093/brain/awae140
Detecting the symptoms of Parkinson’s disease with non-standard video|10.1186/s12984-024-01362-5
Exploring the Interactions between two Ligands, UCB-J and UCB-F, and Synaptic Vesicle Glycoprotein 2 Isoforms|10.1021/acschemneuro.4c00029
Structural underpinnings and long-term effects of resilience in Parkinson’s disease|10.1038/s41531-024-00699-x
The 2022 symposium on dementia and brain aging in low‐ and middle‐income countries: Highlights on research, diagnosis, care, and impact|10.1002/alz.13836
Associations of sleep disorders with serum neurofilament light chain levels in Parkinson’s disease|10.1186/s12883-024-03642-y
Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021|10.1016/s0140-6736(24)00685-8
If You Don’t Ask, You Won’t Know: Inclusive Recruitment Strategies for the Parkinson Progression Markers Initiative (PPMI)|10.1016/j.parkreldis.2024.106689
Mutation of the ALS/FTD-associated RNA-binding protein FUS affects axonal development|10.1523/jneurosci.2148-23.2024
Positron Emission Tomography with [18F]ROStrace Reveals Progressive Elevations in Oxidative Stress in a Mouse Model of Alpha-Synucleinopathy|10.3390/ijms25094943
In vivo validation of late‐onset Alzheimer's disease genetic risk factors|10.1002/alz.13840
Longitudinal study investigating the influence of COMT gene polymorphism on cortical thickness changes in Parkinson's disease over four years|10.1038/s41598-024-60828-7
Novel Variants Linked to the Prodromal Stage of Parkinson’s Disease (PD) Patients|10.3390/diagnostics14090929
Activation and Purification of ß‐Glucocerebrosidase by Exploiting its Transporter LIMP‐2 – Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease|10.1002/advs.202401641
Lysosomal genes contribute to Parkinson’s disease near agriculture with high intensity pesticide use|10.1038/s41531-024-00703-4
Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson’s Disease Diagnosis and Duration|10.3233/jpd-230390
Changes in Oxidised Phospholipids in Response to Oxidative Stress in Microtubule-Associated Protein Tau (MAPT) Mutant Dopamine Neurons|10.3390/antiox13050508
Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson’s Disease|10.3233/jpd-230402
Development and Implementation of an Innovative Framework for Automated Radiomics Analysis in Neuroimaging|10.3390/jimaging10040096
Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers|10.1038/s41531-024-00706-1
Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons|10.1073/pnas.2318943121
Predicting the occurrence of mild cognitive impairment in Parkinson’s disease using structural MRI data|10.3389/fnins.2024.1375395
Resequencing the complete SNCA locus in Indian patients with Parkinson’s disease|10.1038/s41531-024-00676-4
Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation|10.1038/s41531-024-00694-2
Self-supervised learning for human activity recognition using 700,000 person-days of wearable data|10.1038/s41746-024-01062-3
Technical challenges in REM sleep microstructure classification: A study of patients with REM sleep behaviour disorder|10.1111/jsr.14208
Predictors of stress resilience in Parkinson’s disease and associations with symptom progression|10.1038/s41531-024-00692-4
Mitochondrial import stress and PINK1-mediated mitophagy: the role of the PINK1-TOMM-TIMM23 supercomplex|10.1080/15548627.2024.2340399
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses|10.1016/s1474-4422(24)00121-2
Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in aDrosophilaknock-in tauopathy model|10.1101/gr.278576.123
Visualizing chaperone-mediated multistep assembly of the human 20S proteasome|10.1038/s41594-024-01268-9
Biological Staging of the Parkinson’s Progression Markers Initiative (PPMI) Cohort Using the Research Neuronal α-synuclein Disease Integrated Staging System (NSD-ISS) (P11-3.009)|10.1212/wnl.0000000000204771
RASP: Optimal Single Puncta Detection in Complex Cellular Backgrounds|10.1021/acs.jpcb.4c00174
Rational design of structure‐based vaccines targeting misfolded alpha‐synuclein conformers of Parkinson's disease and related disorders|10.1002/btm2.10665
[125I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [18F]Flotaza and [125I]IBETA in Postmortem Human Alzheimer’s Disease|10.3390/neurolint16020031
Factors Influencing Patient Disclosure of Parkinson's Disease Genetic Testing Results to Relatives|10.1002/mdc3.14043
A RAB7A phosphoswitch coordinates Rubicon Homology protein regulation of Parkin-dependent mitophagy|10.1083/jcb.202309015
An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys|10.1016/j.jneumeth.2024.110133
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders|10.1186/s13024-024-00723-x
Fusion of biomedical imaging studies for increased sample size and diversity: a case study of brain MRI|10.3389/fradi.2024.1283392
Transcriptomics of Human Brain Tissue in Parkinson’s Disease: a Comparison of Bulk and Single-cell RNA Sequencing|10.1007/s12035-024-04124-5
Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy|10.1038/s41419-024-06534-8
Orthogonal analysis of mitochondrial function in Parkinson’s disease patients|10.1038/s41419-024-06617-6
RedOx regulation of LRRK2 kinase activity by active site cysteines|10.1038/s41531-024-00683-5
Alterations in Blood Methylome as Potential Epigenetic Biomarker in Sporadic Parkinson's Disease|10.1002/ana.26923
An X Chromosome Transcriptome Wide Association Study Implicates ARMCX6 in Alzheimer’s Disease|10.3233/jad-231075
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease|10.1007/s11357-024-01116-0
Identification and structural characterization of small molecule inhibitors of PINK1|10.1038/s41598-024-58285-3
Real-World Experiences of Parkinson's Disease OFF Time and Role of Demographics|10.17294/2330-0698.2057
Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology|10.1002/dad2.12589
Experimental capture of miRNA targetomes: disease-specific 3′UTR library-based miRNA targetomics for Parkinson’s disease|10.1038/s12276-024-01202-5
Genetic and multi‐omic risk assessment of Alzheimer's disease implicates core associated biological domains|10.1002/trc2.12461
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease|10.1038/s41591-024-02886-y
RNA sequencing of olfactory bulb in Parkinson's disease reveals gene alterations associated with olfactory dysfunction|10.1016/j.nbd.2024.106514
The integrated stress response pathway and neuromodulator signaling in the brain: lessons learned from dystonia|10.1172/jci177833
Investigating the aspect of asymmetry in brain-first versus body-first Parkinson’s disease|10.1038/s41531-024-00685-3
Genotype–phenotype correlation in PRKN-associated Parkinson’s disease|10.1038/s41531-024-00677-3
Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue|10.1038/s41467-024-46832-5
Development and characterization of a non-human primate model of disseminated synucleinopathy|10.3389/fnana.2024.1355940
Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson's disease|10.1101/2024.03.22.586364
Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2|10.1101/2024.03.26.586828
Single-cell multiplex chromatin and RNA interactions in ageing human brain|10.1038/s41586-024-07239-w
Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders|10.1007/s11357-024-01120-4
TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models|10.1038/s41593-024-01610-w
Parkinson’s Disease is Predominantly a Genetic Disease|10.3233/jpd-230376
Spatial transcriptomics reveals molecular dysfunction associated with cortical Lewy pathology|10.1038/s41467-024-47027-8
The oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling, and therapeutic implications|10.1101/2024.03.21.24304693
[3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain|10.1007/s00221-024-06815-w
Biochemical Fractionation of Human α-Synuclein in a Drosophila Model of Synucleinopathies|10.3390/ijms25073643
Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson’s disease|10.3389/fimmu.2024.1349030
Reticulon 2 deficiency results in an autosomal recessive distal motor neuropathy with lower limb spasticity|10.1093/brain/awae091
Conquering Neurologic Diseases in Primary Care|10.1016/j.pop.2024.03.001
Interpretable discriminant analysis for functional data supported on random nonlinear domains with an application to Alzheimer’s disease|10.1093/jrsssb/qkae023
Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles|10.7554/elife.92775
BridGE: a pathway-based analysis tool for detecting genetic interactions from GWAS|10.1038/s41596-024-00954-8
Peripheral neuronal activation shapes the microbiome and alters gut physiology|10.1016/j.celrep.2024.113953
RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors|10.1083/jcb.202307092
Deep Learning–based Approach for Brainstem and Ventricular MR Planimetry: Application in Patients with Progressive Supranuclear Palsy|10.1148/ryai.230151
Profiling Protein–Protein Interactions in the Human Brain by Refined Cofractionation Mass Spectrometry|10.1021/acs.jproteome.3c00685
A topographical atlas of α-synuclein dosage and cell type-specific expression in adult mouse brain and peripheral organs|10.1038/s41531-024-00672-8
AccessPD as a next generation registry to accelerate Parkinson’s disease research|10.1038/s41531-024-00651-z
Differential Cognitive Effects of Unilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease|10.1002/ana.26903
In Silico Investigation of Parkin-Activating Mutations Using Simulations and Network Modeling|10.3390/biom14030365
Targeting short-chain fatty acids receptors signalling for neurological disorders treatment|10.37349/ent.2024.00073
Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder|10.1016/j.ebiom.2024.105065
Turning alterations detected by mobile health technology in idiopathic REM sleep behavior disorder|10.1038/s41531-024-00682-6
Characterizing enteric neurons in dopamine transporter (DAT)‐Cre reporter mice reveals dopaminergic subtypes with dual‐transmitter content|10.1111/ejn.16307
Improved measurement of disease progression in people living with early Parkinson’s disease using digital health technologies|10.1038/s43856-024-00481-3
Perspectives of People At-Risk on Parkinson’s Prevention Research|10.3233/jpd-230436
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial|10.1002/mds.29762
SRF transcriptionally regulates the oligodendrocyte cytoskeleton during CNS myelination|10.1073/pnas.2307250121
APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia|10.1038/s41586-024-07185-7
Biallelic NAA60 variants with impaired n-terminal acetylation capacity cause autosomal recessive primary familial brain calcifications|10.1038/s41467-024-46354-0
Disease progression strikingly differs in research and real-world Parkinson’s populations|10.1038/s41531-024-00667-5
Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease|10.1007/s00401-024-02706-0
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021|10.1016/s0140-6736(24)00476-8
PINK1 regulated mitophagy is evident in skeletal muscles|10.1080/27694127.2024.2326402
Correlation of Presynaptic and Postsynaptic Proteins with Pathology in Alzheimer’s Disease|10.3390/ijms25063130
The clinical and genetic spectrum of inherited glycosylphosphatidylinositol deficiency disorders|10.1093/brain/awae056
Alternative splicing expands the clinical spectrum of NDUFS6-related mitochondrial disorders|10.1016/j.gim.2024.101117
Soluble and insoluble lysates from the human A53T mutant α-synuclein transgenic mouse model induces α-synucleinopathy independent of injection site|10.21203/rs.3.rs-3982325/v1
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression|10.1186/s40035-024-00403-2
Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra|10.1002/acn3.52034
Seeding Activity of Skin Misfolded Tau as a Biomarker for Tauopathies|10.21203/rs.3.rs-3968879/v1
Assessing methylation detection for primary human tissue using Nanopore sequencing|10.1101/2024.02.29.581569
Combinatorial selective ER-phagy remodels the ER during neurogenesis|10.1038/s41556-024-01356-4
Determination of optimal vibration dose to treat Parkinson's disease gait symptoms: A clinical trial|10.1016/j.prdoa.2024.100248
Dopamine neuron activity encodes the length of upcoming contralateral movement sequences|10.1016/j.cub.2024.01.067
Federated learning for multi-omics: A performance evaluation in Parkinson’s disease|10.1016/j.patter.2024.100945
Lessons from inducible pluripotent stem cell models on neuronal senescence in aging and neurodegeneration|10.1038/s43587-024-00586-3
The Human Affectome|10.1016/j.neubiorev.2023.105450
Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes|10.1093/brain/awae069
Vaccination with structurally adapted fungal protein fibrils induces immunity to Parkinson’s disease|10.1093/brain/awae061
Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system|10.1101/2024.02.26.582098
Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes|10.1101/2024.02.26.582055
Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism|10.1101/2024.02.25.581985
Tom20 gates PINK1 activity and mediates its tethering of the TOM and TIM23 translocases upon mitochondrial stress|10.1073/pnas.2313540121
Identification of 27 allele-specific regulatory variants in Parkinson’s disease using a massively parallel reporter assay|10.1038/s41531-024-00659-5
Lifespan reference curves for harmonizing multi-site regional brain white matter metrics from diffusion MRI|10.1101/2024.02.22.581646
Exploiting macro- and micro-structural brain changes for improved Parkinson’s disease classification from MRI data|10.1038/s41531-024-00647-9
GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians|10.1002/mds.29753
Gait patterns during overground and virtual omnidirectional treadmill walking|10.1186/s12984-023-01286-6
Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage|10.1002/alz.13729
Single-cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, aging, and disease|10.1016/j.celrep.2024.113784
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes|10.1186/s40035-024-00401-4
Staging of progressive supranuclear palsy-Richardson syndrome using MRI brain charts for the human lifespan|10.1093/braincomms/fcae055
Common genetic risk for Parkinson's disease and dysfunction of the endo-lysosomal system|10.1098/rstb.2022.0517
Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants|10.1002/psp4.13112
Endo-lysosomal dysfunction in neurodegenerative diseases: opinion on current progress and future direction in the use of exosomes as biomarkers|10.1098/rstb.2022.0387
Retromer-dependent lysosomal stress in Parkinson's disease|10.1098/rstb.2022.0376
Role of the LRRK2 C-terminal tail in domain crosstalk|10.1042/bcj20230477
Common mitochondrial deletions in RNA-Seq: evaluation of bulk, single-cell, and spatial transcriptomic datasets|10.1038/s42003-024-05877-4
Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo|10.1002/ana.26884
Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases|10.3390/ijms25042364
Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s disease.|10.21203/rs.3.rs-3631708/v1
Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase|10.1038/s41467-024-45692-3
Deep learning‐based BMI inference from structural brain MRI reflects brain alterations following lifestyle intervention|10.1002/hbm.26595
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients|10.1038/s41531-024-00652-y
Fluorescence microscopy shadow imaging for neuroscience|10.3389/fncel.2024.1330100
Differences in brain aging between sexes in Parkinson’s disease|10.1038/s41531-024-00646-w
Perspective Strategies for Interventions in Parkinsonism: Remedying the Neglected Role of TPPP|10.3390/cells13040338
The Impact of 90 Parkinson’s Disease-Risk Single Nucleotide Polymorphisms on Urinary Bis(monoacylglycerol)phosphate Levels in the Prodromal and PD Cohorts|10.3390/ijms25042286
Multiscale Modeling of Magnetoelectric Nanoparticles for the Analysis of Spatially Selective Neural Stimulation|10.1002/adhm.202302871
O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology|10.1038/s41589-024-01551-2
The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer’s Disease Pathology|10.3390/cells13040331
Efficacy of biologically-directed daylight therapy on sleep and circadian rhythm in Parkinson's disease: a randomised, double-blind, parallel-group, active-controlled, phase 2 clinical trial|10.1016/j.eclinm.2024.102474
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease|10.1186/s40035-024-00400-5
Sequential CRISPR screening reveals partial NatB inhibition as a strategy to mitigate alpha-synuclein levels in human neurons|10.1126/sciadv.adj4767
Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutation|10.1038/s41531-024-00645-x
Associations between Sleep Disorders and Impulsive-Compulsive Behaviors in Parkinson's Disease: A Prospective Cohort Study|10.1159/000536555
CURTAIN—A unique web-based tool for exploration and sharing of MS-based proteomics data|10.1073/pnas.2312676121
Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay|10.1002/alz.13658
Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms|10.1073/pnas.2313465121
Pathways controlling neurotoxicity and proteostasis in mitochondrial complex I deficiency|10.1093/hmg/ddae018
Three-step docking by WIPI2, ATG16L1, and ATG3 delivers LC3 to the phagophore|10.1126/sciadv.adj8027
Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease|10.1002/mds.29725
A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease|10.3390/ijms25031827
An analysis of data leakage and generalizability in MRI based classification of Parkinson's Disease using explainable 2D Convolutional Neural Networks|10.1016/j.dsp.2024.104407
Evaluation of ATN PD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease|10.1212/wnl.0000000000208033
3D bioprinting of human neural tissues with functional connectivity|10.1016/j.stem.2023.12.009
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research|10.1016/s1474-4422(23)00405-2
A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis|10.1016/j.bbi.2024.02.007
Design and high-throughput implementation of MALDI-TOF/MS-based assays for Parkin E3 ligase activity|10.1016/j.crmeth.2024.100712
Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis|10.1016/j.parkreldis.2023.105954
SARS-CoV-2 infection causes dopaminergic neuron senescence|10.1016/j.stem.2023.12.012
The lipid flippase ATP10B enables cellular lipid uptake under stress conditions|10.1016/j.bbamcr.2023.119652
The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons|10.1016/j.stemcr.2024.01.001
GABAergic regulation of striatal spiny projection neurons depends upon their activity state|10.1371/journal.pbio.3002483
Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab‐Berbers|10.1002/mds.29735
Longitudinal brain structure changes in Parkinson’s disease: A replication study|10.1371/journal.pone.0295069
Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer’s disease, restores synapse integrity and memory in a disease mouse model|10.7554/elife.89453.3
Serotonin transporter density in isolated rapid eye movement sleep behavioral disorder|10.3389/frsle.2023.1298854
Longitudinal faster anxiety progression of GBA variant carriers in the early Parkinson’s disease cohort|10.3389/fnins.2024.1353759
Subspace corrected relevance learning with application in neuroimaging|10.1016/j.artmed.2024.102786
Discovering genetic mechanisms underlying the co-occurrence of Parkinson’s disease and non-motor traits|10.1038/s41531-024-00638-w
Small RNA Changes in Plasma Have Potential for Early Diagnosis of Alzheimer’s Disease before Symptom Onset|10.3390/cells13030207
PICALO: principal interaction component analysis for the identification of discrete technical, cell-type, and environmental factors that mediate eQTLs|10.1186/s13059-023-03151-0
The AfrAbia+plus Parkinson's Disease Genomic Consortium|10.1016/s1474-4422(23)00453-2
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease|10.1038/s41531-023-00627-5
Early-stage idiopathic Parkinson’s disease is associated with reduced circular RNA expression|10.1038/s41531-024-00636-y
Fast, multicolour optical sectioning overextended fields of view with patternedillumination and machine learning|10.1364/boe.510912
Interaction of PINK1 with nucleotides and kinetin|10.1126/sciadv.adj7408
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?|10.1002/mds.29707
Intracellular delivery of Parkin-RING0-based fragments corrects Parkin-induced mitochondrial dysfunction through interaction with SLP-2|10.1186/s12967-024-04850-3
Alpha-synuclein regulates nucleolar DNA double-strand break repair in melanoma|10.1101/2024.01.13.575526
Functional ataxia in a specialized ataxia center|10.1016/j.parkreldis.2024.106006
Novel loss-of-function variants expand ABCC9-related intellectual disability and myopathy syndrome|10.1093/brain/awae010
Immunological shifts during early-stage Parkinson’s disease identified with DNA methylation data on longitudinally collected blood samples|10.1038/s41531-023-00626-6
Systems-level analyses dissociate genetic regulators of reactive oxygen species and energy production|10.1073/pnas.2307904121
Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model|10.1038/s41467-024-44732-2
Neural heterogeneity controls computations in spiking neural networks|10.1073/pnas.2311885121
Smaller total and subregional cerebellar volumes in posttraumatic stress disorder: a mega-analysis by the ENIGMA-PGC PTSD workgroup|10.1038/s41380-023-02352-0
Toward the quantification of α-synuclein aggregates with digital seed amplification assays|10.1073/pnas.2312031121
A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells|10.1038/s41531-023-00624-8
Analysis of rare Parkinson’s disease variants in millions of people|10.1038/s41531-023-00608-8
Blood DNA methylation profiling identifies cathepsin Z dysregulation in pulmonary arterial hypertension|10.1038/s41467-023-44683-0
Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera|10.1073/pnas.2306682120
Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies|10.1038/s42003-023-05725-x
Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies|10.3389/fncel.2023.1328269
Radiomic tractometry reveals tract-specific imaging biomarkers in white matter|10.1038/s41467-023-44591-3
Proxy-analysis of the genetics of cognitive decline in Parkinson’s disease through polygenic scores|10.1038/s41531-023-00619-5
The Association of Antidepressant Use and Impulse Control Disorder in Parkinson's Disease|10.1016/j.jagp.2023.12.024
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease|10.1186/s13024-023-00687-4
Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson’s disease and dementia with Lewy bodies|10.1186/s40478-023-01711-w
Detection of mosaic and population-level structural variants with Sniffles2|10.1038/s41587-023-02024-y
Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson’s Disease and parkinsonism|10.1186/s12883-023-03506-x
A fluid-walled microfluidic platform for human neuron microcircuits and directed axotomy|10.1039/d4lc00107a
An Eye on the First Surgical Side: Appreciating the Potential Impacts of a Second DBS Lead on Ipsilateral Symptoms|10.5334/tohm.918
An individualized tractography pipeline for the nucleus basalis of Meynert lateral tract|10.1162/imag_a_00067
Association of Specific Leg Muscle Strength and Motor Features in Parkinson’s Disease|10.1155/2024/5580870
Brain structure ages—A new biomarker for multi‐disease classification|10.1002/hbm.26558
Clinical prediction of GBA carrier status in Parkinson’s disease|10.1016/j.prdoa.2024.100251
Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study|10.1111/cts.13720
Cortical and subcortical functional connectivity and cognitive impairment in Parkinson’s disease|10.1016/j.nicl.2024.103610
Deep Learning and fMRI-based Pipeline for Optimization of Deep Brain Stimulation During Parkinson’s Disease Treatment: Towards Rapid Semi-automated Stimulation Optimization|10.1109/jtehm.2024.3448392
Distinctive clinical and imaging trajectories in SWEDD and Parkinson’s disease patients|10.1016/j.nicl.2024.103592
Elevated Mood Induced by Subthalamic Nucleus Deep Brain Stimulation: A Video-Recorded Case Report|10.5334/tohm.900
Genome-wide meta-analysis of short-tandem repeats for Parkinson's disease risk using genotype imputation|10.1093/braincomms/fcae146
Harmonization of CSF and imaging biomarkers in Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification|10.1016/j.nbd.2023.106373
Identification of Parkinson's Disease Subtypes with Distinct Brain Atrophy Progression and its Association with Clinical Progression|10.1093/psyrad/kkae002
Improving Dysarthric Speech Segmentation With Emulated and Synthetic Augmentation|10.1109/jtehm.2024.3375323
Infrared nanoimaging of neuronal ultrastructure and nanoparticle interaction with cells|10.1039/d3nr04948e
Investigation of the genetic aetiology of Lewy body diseases with and without dementia|10.1093/braincomms/fcae190
Leveraging sex-genetic interactions to understand brain disorders: recent advances and current gaps|10.1093/braincomms/fcae192
Multi-head Graph Convolutional Network for Structural Connectome Classification|10.1007/978-3-031-55088-1_3
Parkinson’s disease psychosis associated with accelerated multidomain cognitive decline|10.1136/bmjment-2024-301062
Pathologic RFC1 repeat expansions do not contribute to the development of inflammatory neuropathies|10.1093/braincomms/fcae163
Patient Selection for Deep Brain Stimulation for Pantothenate Kinase-Associated Neurodegeneration|10.5334/tohm.929
Preventing Shift from Pneumocephalus During Deep Brain Stimulation Surgery: Don’t Give Up the ‘Fork in the Brain’|10.5334/tohm.873
Temporal evolution of microstructural integrity in cerebellar peduncles in Parkinson’s disease: Stage-specific patterns and dopaminergic correlates|10.1016/j.nicl.2024.103679
Thermodynamic characterization of amyloid polymorphism by microfluidic transient incomplete separation|10.1039/d3sc05371g
Valosin-containing-protein pathogenic variant p.R487H in Parkinson’s disease|10.1016/j.prdoa.2024.100236
Sleep disorders and mortality: A prospective study in the Canadian longitudinal study on aging|10.1016/j.sleep.2023.12.023
Comparative analysis of methods to reduce activation signature gene expression in PBMCs|10.1038/s41598-023-49611-2
MAPT Locus in Parkinson’s Disease Patients of Ashkenazi Origin: A Stratified Analysis|10.3390/genes15010046
Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease|10.1038/s41588-023-01584-8
Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer’s disease, restores synapse integrity and memory in a disease mouse model|10.7554/elife.89453
PyRates—A code-generation tool for modeling dynamical systems in biology and beyond|10.1371/journal.pcbi.1011761
Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2|10.3390/cells13010053
Biallelic NUDT2 variants defective in mRNA decapping cause a neurodevelopmental disease|10.1093/brain/awad434
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?|10.1002/mds.29688
Automated identification of uncertain cases in deep learning-based classification of dopamine transporter SPECT to improve clinical utility and acceptance|10.1007/s00259-023-06566-w
Different impulse control disorder evolution patterns and white matter microstructural damage in the progression of Parkinson’s disease|10.3389/fnagi.2023.1260630
Targeting Rab‐RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's disease|10.1002/psc.3563
Biallelic BORCS8 variants cause an infantile-onset neurodegenerative disorder with altered lysosome dynamics|10.1093/brain/awad427
Comparison of state-of-the-art deep learning architectures for detection of freezing of gait in Parkinson’s disease|10.3389/fneur.2023.1306129
Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2|10.1126/science.adi9926
Multiomics analysis identifies novel facilitators of human dopaminergic neuron differentiation|10.1038/s44319-023-00024-2
NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62|10.1038/s41467-023-44033-0
Association of cardiovascular disease management drugs with Lewy body dementia: a case–control study|10.1093/braincomms/fcad346
PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formation|10.3389/fnmol.2023.1269387
scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles|10.1186/s13059-023-03129-y
Prediction of dyskinesia in Parkinson’s disease patients using machine learning algorithms|10.1038/s41598-023-49617-w
Dynamic behaviour restructuring mediates dopamine-dependent credit assignment|10.1038/s41586-023-06941-5
Parkinson’s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B|10.1126/sciadv.adj1205
Cell type directed design of synthetic enhancers|10.1038/s41586-023-06936-2
GABAA Receptor Benzodiazepine Binding Sites and Motor Impairments in Parkinson’s Disease|10.3390/brainsci13121711
Molecular Mechanisms of Cationic Fusogenic Liposome Interactions with Bacterial Envelopes|10.1021/jacs.3c11463
Alpha-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinsons disease|10.1101/2023.12.11.571045
Evaluating the ability of a predictive vision-based machine learning model to measure changes in gait in response to medication and DBS within individuals with Parkinson’s disease|10.1186/s12938-023-01175-y
Microbial amyloids in neurodegenerative amyloid diseases|10.1111/febs.17023
Toward Omics-Scale Quantitative Mass Spectrometry Imaging of Lipids in Brain Tissue Using a Multiclass Internal Standard Mixture|10.1021/acs.analchem.3c02724
Co‐Existent Probable RBD and PD: Disease Progression, Medication Response, and Clinical Trial Implications|10.1002/mdc3.13890
Association of Family History and Polygenic Risk Score With Longitudinal Prognosis in Parkinson Disease|10.1212/nxg.0000000000200115
Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta‐Analysis|10.1002/mds.29682
Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson's disease and Dementia with Lewy bodies|10.1101/2023.12.07.570569
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases|10.1038/s41531-023-00604-y
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type alpha-synuclein pathology|10.1101/2023.12.05.569878
From policy to practice: Lessons learned from an open science funding initiative|10.1371/journal.pcbi.1011626
Gut mucosal cells transfer α-synuclein to the vagus nerve|10.1172/jci.insight.172192
Multimodal assessment of mitochondrial function in Parkinson's disease|10.1093/brain/awad364
Altered dynamic functional network connectivity in drug-naïve Parkinson’s disease patients with excessive daytime sleepiness|10.3389/fnagi.2023.1282962
Organ aging signatures in the plasma proteome track health and disease|10.1038/s41586-023-06802-1
Population fraction of Parkinson’s disease attributable to preventable risk factors|10.1038/s41531-023-00603-z
Basal activity of PINK1 and PRKN in cell models and rodent brain|10.1080/15548627.2023.2286414
A mitochondrial inside-out iron-calcium signal reveals drug targets for Parkinson’s disease|10.1016/j.celrep.2023.113544
Cell-free RNA signatures predict Alzheimer’s disease|10.1016/j.isci.2023.108534
Cerebrospinal fluid biomarkers profile in scans without evidence of dopaminergic deficits (SWEDD)|10.1016/j.ibneur.2023.10.001
Cytokine activity in Parkinson's disease|10.1042/ns20220063
In vitro modeling of the human dopaminergic system using spatially arranged ventral midbrain–striatum–cortex assembloids|10.1038/s41592-023-02080-x
Inhibition of Parkinson’s disease–related LRRK2 by type I and type II kinase inhibitors: Activity and structures|10.1126/sciadv.adk6191
Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson’s Disease|10.1007/s11481-023-10094-7
Predicting cognitive decline in a low‐dimensional representation of brain morphology|10.1002/alz.081611
Strategies for quantifying the enzymatic activities of glycoside hydrolases within cells and in vivo|10.1016/j.cbpa.2023.102403
The Michael J. Fox Foundation's quest for a cure for Parkinson's disease: an interview with Nicole Polinski|10.1242/dmm.050605
Challenges and innovations in brain PET analysis of neurodegenerative disorders: a mini-review on partial volume effects, small brain region studies, and reference region selection|10.3389/fnins.2023.1293847
Regulation of expression quantitative trait loci by SVA retrotransposons within the major histocompatibility complex|10.1177/15353702231209411
Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications|10.7554/elife.91645.2
Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation|10.1126/sciadv.adi8716
In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker|10.3390/ijms242216445
Association of liver fibrosis with cognitive decline in Parkinson’s disease|10.1016/j.jocn.2023.11.019
Impaired cholinergic integrity of the colon and pancreas in dementia with Lewy bodies|10.1093/brain/awad391
Hippocampal glial inflammatory markers are differentially altered in a novel mouse model of perimenopausal cerebral amyloid angiopathy|10.3389/fnagi.2023.1280218
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study|10.1002/mds.29611
Total-Body Irradiation Alters White Matter Volume and Microstructural Integrity in Rhesus Macaques|10.1016/j.ijrobp.2023.11.014
Evaluating the Utility of REVEL and CADD for Interpreting Variants in Amyotrophic Lateral Sclerosis Genes|10.1155/2023/8620557
Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model|10.1038/s41467-023-42876-1
A genetic and transcriptomic assessment of the KTN1 gene in Parkinson’s disease risk|10.1016/j.neurobiolaging.2023.11.001
Enduring questions in regenerative biology and the search for answers|10.1038/s42003-023-05505-7
Targeting sleep and the circadian system as a novel treatment strategy for Parkinson’s disease|10.1007/s00415-023-12073-7
Inhibition of striatal dopamine release by the L‐type calcium channel inhibitor isradipine co‐varies with risk factors for Parkinson's|10.1111/ejn.16180
Intensive whole-brain 7T MRI case study of volitional control of brain activity in deep absorptive meditation states|10.1093/cercor/bhad408
ZEBRA: a hierarchically integrated gene expression atlas of the murine and human brain at single-cell resolution|10.1093/nar/gkad990
Long‐Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease|10.1002/mds.29610
Corneal confocal microscopy demonstrates varying degrees of neurodegeneration in atypical parkinsonian disorders|10.1016/j.parkreldis.2023.105899
13C and 15N resonance assignments of alpha synuclein fibrils amplified from Lewy Body Dementia tissue|10.1007/s12104-023-10156-0
Frequency of Hereditary and GBA1‐Related Parkinsonism in Latin America: A Systematic Review and Meta‐Analysis|10.1002/mds.29614
Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging|10.1038/s41467-023-42822-1
Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants|10.1002/mds.29647
Cross species systems biology discovers glial DDR2, STOM, and KANK2 as therapeutic targets in progressive supranuclear palsy|10.1038/s41467-023-42626-3
1 Sex Differences in Associations Between APOE ε2 and Longitudinal Cognitive Decline|10.1017/s1355617723005398
6 Association Between American Football Play and Parkinson's Disease: Analysis of the Fox Insight Data Set|10.1017/s1355617723005507
A role for the subthalamic nucleus in aversive learning|10.1016/j.celrep.2023.113328
Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons|10.1016/j.nbd.2023.106328
hipFG: high-throughput harmonization and integration pipeline for functional genomics data|10.1093/bioinformatics/btad673
LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification|10.1126/sciadv.adh9543
RTP801 mediates transneuronal toxicity in culture via extracellular vesicles|10.1002/jev2.12378
Shifting the trajectory of therapeutic development for neurological and psychiatric disorders|10.1126/scitranslmed.adg4775
PFTK1 kinase regulates axogenesis during development via RhoA activation|10.1186/s12915-023-01732-w
Free water imaging unravels unique patterns of longitudinal structural brain changes in Parkinson’s disease subtypes|10.3389/fneur.2023.1278065
Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts|10.1007/s00415-023-12058-6
Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis|10.1073/pnas.2315171120
Saturation mutagenesis of α-synuclein reveals monomer fold that modulates aggregation|10.1126/sciadv.adh3457
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases|10.1038/s41467-023-42305-3
Bi-allelic truncating variants in CASP2 underlie a neurodevelopmental disorder with lissencephaly|10.1038/s41431-023-01461-2
Assessing impulse control behaviors in early Parkinson’s disease: a longitudinal study|10.3389/fneur.2023.1275170
In humans, striato-pallido-thalamic projections are largely segregated by their origin in either the striosome-like or matrix-like compartments|10.3389/fnins.2023.1178473
Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase|10.7554/elife.87098
Original research: initial development of a pragmatic tool to estimate cognitive decline risk focusing on potentially modifiable factors in Parkinson’s disease|10.3389/fnins.2023.1278817
Senescent Schwann cells induced by aging and chronic denervation impair axonal regeneration following peripheral nerve injury|10.15252/emmm.202317907
Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome|10.1002/alz.13506
Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients|10.1038/s41531-023-00586-x
Structure of LRRK1 and mechanisms of autoinhibition and activation|10.1038/s41594-023-01109-1
The elephant in the room: critical reflections on mortality rates among individuals with Parkinson’s disease|10.1038/s41531-023-00588-9
Challenges of Parkinson's disease GWASs in African people|10.1016/s1474-4422(23)00361-7
Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson’s disease|10.1038/s41598-023-45078-3
α-synuclein seed amplification in Parkinson's disease – Authors' reply|10.1016/s1474-4422(23)00371-x
MRI-based multivariate gray matter volumetric distance for predicting motor symptom progression in Parkinson's disease|10.1038/s41598-023-44322-0
Enablers and challenges of spatial omics, a melting pot of technologies|10.15252/msb.202110571
Identification of high-performing antibodies for Vacuolar protein sorting-associated protein 35 (hVPS35) for use in Western Blot, immunoprecipitation and immunofluorescence|10.12688/f1000research.133696.2
Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations|10.3389/fncel.2023.1229213
Membrane remodeling properties of the Parkinson’s disease protein LRRK2|10.1073/pnas.2309698120
Profiling migraine patients according to clinical and psychophysical characteristics: clinical validity of distinct migraine clusters|10.1007/s10072-023-07118-8
Cognitive Predictors of Responsiveness to Reactive Step Training in People with Parkinson’s Disease at Fall-Risk|10.1016/j.neulet.2023.137517
Evaluation of an Adapted Semi-Automated DNA Extraction for Human Salivary Shotgun Metagenomics|10.3390/biom13101505
Cerebral Gray and White Matter Monogalactosyl Diglyceride Levels Rise with the Progression of Alzheimer’s Disease|10.3233/jad-230543
Adaptor protein-3 produces synaptic vesicles that release phasic dopamine|10.1073/pnas.2309843120
Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders|10.1186/s40478-023-01653-3
Magnetic Resonance Imaging Biomarkers of Punding in Parkinson’s Disease|10.3390/brainsci13101423
Machine learning nominates the inositol pathway and novel genes in Parkinson’s disease|10.1093/brain/awad345
Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort|10.1002/alz.13482
Inflammatory Blood Biomarkers Are Associated with Long-Term Clinical Disease Severity in Parkinson’s Disease|10.3390/ijms241914915
Predicting cognitive decline in a low-dimensional representation of brain morphology|10.1038/s41598-023-43063-4
Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications|10.7554/elife.91645
Patients with progressive supranuclear palsy need to be seen sooner and more frequently|10.1016/j.parkreldis.2023.105883
Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson’s Disease Project|10.1371/journal.pone.0292180
Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease|10.1016/j.parkreldis.2023.105822
Development of a highly potent and selective degrader of LRRK2|10.1016/j.bmcl.2023.129449
Exploratory correlation of the human structural connectome with non‐MRI variables in Alzheimer's disease|10.1002/dad2.12511
Mental health disparities and the role of perceived discrimination among Latinx individuals living with Parkinson's disease|10.1016/j.parkreldis.2023.105867
Parallel neurodegenerative phenotypes in sporadic Parkinson’s disease fibroblasts and midbrain dopamine neurons|10.1016/j.pneurobio.2023.102501
Simulations predict differing phase responses to excitation vs. inhibition in theta-resonant pyramidal neurons|10.1152/jn.00160.2023
Targeting LRRK2 mRNA stability in Parkinson’s disease|10.1016/j.tins.2023.10.003
The importance of a healthy mouth in Parkinson's disease|10.1016/s0140-6736(23)01466-6
Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop|10.1007/s13311-023-01440-x
Understanding the potential causes of gastrointestinal dysfunctions in multiple system atrophy|10.1016/j.nbd.2023.106296
A genome-wide association study coupled with machine learning approaches to identify influential demographic and genomic factors underlying Parkinson’s disease|10.3389/fgene.2023.1230579
clrDV: a differential variability test for RNA-Seq data based on the skew-normal distribution|10.7717/peerj.16126
Wearables for Parkinson's: Fast‐Paced toward Novel Outcome Measures|10.1002/mds.29608
Artificial intelligence for neurodegenerative experimental models|10.1002/alz.13479
Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates|10.1093/brain/awad331
Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease|10.1002/adma.202304654
Clinical severity in Parkinson’s disease is determined by decline in cortical compensation|10.1093/brain/awad325
Proteome census upon nutrient stress reveals Golgiphagy membrane receptors|10.1038/s41586-023-06657-6
Validating virtual administration of neuropsychological testing in Parkinson disease: a pilot study|10.1038/s41598-023-42934-0
Journal Production Guidance for Software and Data Citations|10.1038/s41597-023-02491-7
Longitudinal dysregulation of long non-coding RNAs in Parkinson’s disease|10.1177/15353702231198078
Neurophysiological signatures of cortical micro-architecture|10.1038/s41467-023-41689-6
Patient-specific models link neurotransmitter receptor mechanisms with motor and visuospatial axes of Parkinson’s disease|10.1038/s41467-023-41677-w
Cholinergic innervation topography in GBA-associated de novo Parkinson’s disease patients|10.1093/brain/awad323
Integrating multimodal and multiscale connectivity blueprints of the human cerebral cortex in health and disease|10.1371/journal.pbio.3002314
FLED: a full-length eccDNA detector for long-reads sequencing data|10.1093/bib/bbad388
Identifying prodromal symptoms at high specificity for Parkinson’s disease|10.3389/fnagi.2023.1232387
Temporal landscape of mitochondrial proteostasis governed by the UPR mt|10.1126/sciadv.adh8228
Frontotemporal Dementia-Parkinsonism Due to <em>MAPT</em>&nbsp;Gene Variant Presenting with Rest and Action Tremor|10.5334/tohm.804
Analyzing alternative splicing in Alzheimer’s disease postmortem brain: a cell-level perspective|10.3389/fnmol.2023.1237874
Comparison of two protocols for the generation of iPSC-derived human astrocytes|10.1186/s12575-023-00218-x
Microglia-dependent neuroprotective effects of 4-octyl itaconate against rotenone-and MPP+-induced neurotoxicity in Parkinson’s disease|10.1038/s41598-023-42813-8
Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology|10.1093/clinchem/hvad139
Cortical Lewy body injections induce long-distance pathogenic alterations in the non-human primate brain|10.1038/s41531-023-00579-w
Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease|10.1038/s41467-023-40348-0
Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation|10.1093/brain/awad317
P2X7R influences tau aggregate burden in human tauopathies and shows distinct signalling in microglia and astrocytes|10.1016/j.bbi.2023.09.011
A safety mechanism enables tissue-specific resistance to protein aggregation during aging in C. elegans|10.1371/journal.pbio.3002284
Scalable Nanopore sequencing of human genomes provides a comprehensive view of haplotype-resolved variation and methylation|10.1038/s41592-023-01993-x
Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)|10.1038/s41531-023-00560-7
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease|10.1038/s41467-023-41122-y
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)|10.1038/s41531-023-00533-w
Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson’s disease|10.1038/s41531-023-00572-3
Parkinson's disease pathology is directly correlated to SIRT3 in human subjects and animal models: Implications for AAV.SIRT3-myc as a disease-modifying therapy|10.1016/j.nbd.2023.106287
Early and Accurate Diagnosis of Parkinson Disease May Be Rooted in Seed Amplification Assays|10.1093/clinchem/hvad111
First-in-Human PET Imaging of [18F]SDM-4MP3: A Cautionary Tale|10.1155/2023/8826977
Functional Brain Networks to Evaluate Treatment Responses in Parkinson's Disease|10.1007/s13311-023-01433-w
The Effects of Subthalamic Nucleus Deep Brain Stimulation and Retention Delay on Memory-Guided Reaching Performance in People with Parkinson’s Disease|10.3233/jpd-225041
CXCR6 orchestrates brain CD8+ T cell residency and limits mouse Alzheimer’s disease pathology|10.1038/s41590-023-01604-z
Measuring Up: A Comparison of TapeStation 4200 and Bioanalyzer 2100 as Measurement Tools for RNA Quality in Postmortem Human Brain Samples|10.3390/ijms241813795
Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort|10.1002/mds.29602
Functional alterations in resting‐state networks for Theory of Mind in Parkinson's disease|10.1111/ejn.16145
Impaired pre-synaptic plasticity and visual responses in auxilin-knockout mice|10.1016/j.isci.2023.107842
Disrupted‐in‐schizophrenia 1 protein aggregates in cerebrospinal fluid are elevated in patients with first‐episode psychosis|10.1111/pcn.13594
Image-encoded biological and non-biological variables may be used as shortcuts in deep learning models trained on multisite neuroimaging data|10.1093/jamia/ocad171
MerTK is a mediator of alpha-synuclein fibril uptake by human microglia|10.1093/brain/awad298
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease|10.1186/s40035-023-00374-w
A predictive algorithm to identify ever smoking in medical claims-based epidemiologic studies|10.1016/j.annepidem.2023.04.019
Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling|10.1016/j.molcel.2023.08.005
Leucine-rich repeat kinase 2 at a glance|10.1242/jcs.259724
No laughing white matter: Reduced integrity of the cortical cholinergic pathways in Parkinson's disease-related cognitive impairment|10.1016/j.nbd.2023.106243
Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment|10.2147/ppa.s420051
A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy|10.1021/acs.jmedchem.3c00779
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease|10.1038/s41531-023-00573-2
NeuroBridge: a prototype platform for discovery of the long-tail neuroimaging data|10.3389/fninf.2023.1215261
A blood-based marker of mitochondrial DNA damage in Parkinson’s disease|10.1126/scitranslmed.abo1557
Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson’s Disease|10.3390/ijms241713435
Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes|10.1073/pnas.2302720120
A Fixable Fluorescence‐Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells|10.1002/anie.202309306
Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils|10.1021/acschemneuro.3c00437
Neuron-derived extracellular vesicles to examine brain mTOR target engagement with sirolimus in patients with multiple system atrophy|10.1016/j.parkreldis.2023.105821
The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson’s Disease|10.3390/biom13091303
Lifespan neurodegeneration of the human brain in multiple sclerosis|10.1002/hbm.26464
Reference LINE-1 insertion polymorphisms correlate with Parkinson’s disease progression and differential transcript expression in the PPMI cohort|10.1038/s41598-023-41052-1
Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis|10.1371/journal.pone.0277718
Transdermal Nicotine Treatment and Progression of Early Parkinson’s Disease|10.1056/evidoa2200311
Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study|10.1007/s10286-023-00974-6
Scalable, flexible carbon fiber electrode thread arrays for three-dimensional probing of neurochemical activity in deep brain structures of rodents|10.1016/j.bios.2023.115625
Tau protein aggregation associated with SARS-CoV-2 main protease|10.1371/journal.pone.0288138
Interaction of an α-synuclein epitope with HLA-DRB1∗15:01 triggers enteric features in mice reminiscent of prodromal Parkinson’s disease|10.1016/j.neuron.2023.07.015
Super-Resolution-Chip: an in-vitro platform that enables super-resolution microscopy of co-cultures and 3D systems|10.1364/boe.498038
Pharmacological Inhibition of PTEN Rescues Dopaminergic Neurons by Attenuating Apoptotic and Neuroinflammatory Signaling Events|10.1007/s11481-023-10077-8
Seed amplification assay results illustrate discrepancy in Parkinson’s disease clinical diagnostic accuracy and error rates|10.1007/s00415-023-11810-2
A Fixable Fluorescence‐Quenched Substrate for Quantitation of Lysosomal Glucocerebrosidase Activity in Both Live and Fixed Cells|10.1002/ange.202309306
Atlas of the aging mouse brain reveals white matter as vulnerable foci|10.1016/j.cell.2023.07.027
High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression|10.1212/wnl.0000000000207725
Associations of Apolipoprotein ε4 Genotypes with Motor and Nonmotor Symptoms in Parkinson's Disease: A Cross‐Sectional Study|10.1002/mdc3.13862
Frequency and phenotypic spectrum of spinocerebellar ataxia 27B and other genetic ataxias in a Spanish cohort of late‐onset cerebellar ataxia|10.1111/ene.16039
Machine learning-based prediction of longitudinal cognitive decline in early Parkinson’s disease using multimodal features|10.1038/s41598-023-37644-6
Prediction of Parkinson’s disease pathogenic variants using hybrid Machine learning systems and radiomic features|10.1016/j.ejmp.2023.102647
American Football Play and Parkinson Disease Among Men|10.1001/jamanetworkopen.2023.28644
Neuromelanin-sensitive MRI correlates of cognitive and motor function in Parkinson's disease with freezing of gait|10.3389/frdem.2023.1215505
Preliminary Assessment of Reference Region Quantification and Reduced Scanning Times for [18F]SynVesT-1 PET in Parkinson’s Disease|10.1155/2023/1855985
Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathy|10.1038/s41531-023-00561-6
Human upper extremity motor cortex activity shows distinct oscillatory signatures for stereotyped arm and leg movements|10.3389/fnhum.2023.1212963
Sarkosyl differentially solubilizes patient-derived alpha-synuclein fibril strains|10.3389/fmolb.2023.1177556
The Impact of Head-Up Tilt Sleeping on Orthostatic Tolerance: A Scoping Review|10.3390/biology12081108
Genome-wide Analysis of Motor Progression in Parkinson Disease|10.1212/nxg.0000000000200092
Parkinson’s disease neurons exhibit alterations in mitochondrial quality control proteins|10.1038/s41531-023-00564-3
Pure cerebellar ataxia due to bi‐allelic PRDX3 variants including recurring p.Asp202Asn|10.1002/acn3.51874
Inflammation and the pathological progression of Alzheimer’s disease are associated with low circulating choline levels|10.1007/s00401-023-02616-7
Post‐Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery|10.1002/mds.29518
Aging, Parkinson’s Disease, and Models: What Are the Challenges?|10.59368/agingbio.20230010
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?|10.1093/brain/awad265
Novel human pluripotent stem cell-derived hypothalamus organoids demonstrate cellular diversity|10.1016/j.isci.2023.107525
Unique functional responses differentially map onto genetic subtypes of dopamine neurons|10.1038/s41593-023-01401-9
Bridging a mechanistic gap from diet to synapses|10.1073/pnas.2309992120
Urinary incontinence‐related effects on functional connectivity circuits in persons with Parkinson's disease|10.1002/nau.25258
Accuracy of the Early Diagnosis of Parkinson's Disease|10.1002/mds.29556
Chromosomal inversion polymorphisms shape human brain morphology|10.1016/j.celrep.2023.112896
Dissecting Detergent-Insoluble Proteome in Alzheimer's Disease by TMTc-Corrected Quantitative Mass Spectrometry|10.1016/j.mcpro.2023.100608
Preface to the 4th MDS Video Challenge Case Supplement for Movement Disorders Clinical Practice|10.1002/mdc3.13832
Race and Ethnicity in Lewy Body Dementia: A Narrative Review|10.3233/jad-230207
Reply to: Comment on “Summing MDS‐UPDRS Parts 1 + 2 (Non‐motor and Motor Experience of Daily Living): The Patient's Voice”|10.1002/mds.29513
Unanswered Questions in Clinical Practice|10.1002/mdc3.13837
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease|10.1001/jamaneurol.2023.2338
Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy|10.3390/pharmaceutics15082051
The Genetic Basis of Probable REM Sleep Behavior Disorder in Parkinson’s Disease|10.3390/brainsci13081146
Externally validated deep learning model to identify prodromal Parkinson’s disease from electrocardiogram|10.1038/s41598-023-38782-7
Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease|10.1016/j.heliyon.2023.e18443
The Clinical Profile of Tremor in Parkinson's Disease|10.1002/mdc3.13845
Long-term trajectories of ambulatory impairment in multiple sclerosis|10.1177/13524585231187521
The 5‐HT2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset|10.1111/ejn.16104
α-Synuclein Strains and Their Relevance to Parkinson’s Disease, Multiple System Atrophy, and Dementia with Lewy Bodies|10.3390/ijms241512134
Ageing-associated small RNA cargo of extracellular vesicles|10.1080/15476286.2023.2234713
Cough and Swallowing Therapy and Their Effects on Vocal Fold Bowing and Laryngeal Lesions|10.1002/lary.30922
Predicting dichotomised outcomes from high-dimensional data in biomedicine|10.1080/02664763.2023.2233057
Antihypertensive drugs may not delay the symptom progression of Parkinson’s disease: A 2-year follow-up study|10.1016/j.heliyon.2023.e18538
Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson’s disease patients and healthy controls|10.1186/s12916-023-02994-5
Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson’s Disease and Asymptomatic Carriers of Related Genes: A Brief Report|10.3390/medicina59081360
Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic|10.1038/s41398-023-02558-4
A Biological Definition and Integrated Staging System of Neuronal alpha-Synuclein Disease|10.5281/zenodo.8178862
Alpha‐synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain|10.1111/bpa.13196
In Silico Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers|10.1021/acs.jmedchem.3c00775
LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition|10.1073/pnas.2303789120
Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism|10.1002/mds.29563
Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer’s disease-associated biomarkers alterations among de novo Parkinson’s disease patients: a prospective cohort study|10.1186/s12974-023-02843-5
Style transfer generative adversarial networks to harmonize multisite MRI to a single reference image to avoid overcorrection|10.1002/hbm.26422
X‐Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease|10.1002/mds.29508
Cryptic exon detection and transcriptomic changes revealed in single-nuclei RNA sequencing of C9ORF72 patients spanning the ALS-FTD spectrum|10.1007/s00401-023-02599-5
PTPA variants and the risk for Parkinson’s disease in diverse ancestry populations|10.1093/brain/awad247
NIDM-Terms: community-based terminology management for improved neuroimaging dataset descriptions and query|10.3389/fninf.2023.1174156
Is REM Sleep Behavior Disorder Changing? Secular Changes Versus Referral Patterns|10.1002/mdc3.13842
Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study|10.1002/alz.13386
LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner|10.1038/s41419-023-05964-0
Longitudinal in vivo metabolic labeling reveals tissue-specific mitochondrial proteome turnover rates and proteins selectively altered by parkin deficiency|10.1038/s41598-023-38484-0
MAPT allele and haplotype frequencies in Nigerian Africans: Population distribution and association with Parkinson's disease risk and age at onset|10.1016/j.parkreldis.2023.105517
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression|10.3233/jpd-223433
Predictors of dopamine dysregulation syndrome in patients with early Parkinson’s disease|10.1007/s10072-023-06956-w
PTPA variants are rare in early-onset and familial Parkinson’s disease|10.1093/brain/awad244
Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons|10.1038/s41593-023-01390-9
Cerebral chemoarchitecture shares organizational traits with brain structure and function|10.7554/elife.83843
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease|10.1038/s41531-023-00535-8
Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial|10.1016/j.parkreldis.2023.105511
Spatially heterogeneous structure-function coupling in haemodynamic and electromagnetic brain networks|10.1016/j.neuroimage.2023.120276
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease|10.1038/s41531-023-00556-3
Artificial intelligence–coupled plasmonic infrared sensor for detection of structural protein biomarkers in neurodegenerative diseases|10.1126/sciadv.adg9644
Elevated ApoE, ApoJ and lipoprotein-bound α-synuclein levels in cerebrospinal fluid from Parkinson's disease patients – Validation in the BioFIND cohort|10.1016/j.parkreldis.2023.105765
Neuroinflammation and Mitochondrial Dysfunction in Parkinson’s Disease: Connecting Neuroimaging with Pathophysiology|10.3390/antiox12071411
An ankyrin repeat chaperone targets toxic oligomers during amyloidogenesis|10.1002/pro.4728
Network Connectivity Alterations across the MAPT Mutation Clinical Spectrum|10.1002/ana.26738
Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice|10.1038/s41467-023-39805-7
Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain|10.1038/s41565-023-01419-x
Care access and utilization among medicare beneficiaries living with Parkinson’s disease|10.1038/s41531-023-00523-y
Nerve growth factor receptor (Ngfr) induces neurogenic plasticity by suppressing reactive astroglial Lcn2/Slc22a17 signaling in Alzheimer’s disease|10.1038/s41536-023-00311-5
Prevalence and impact of neuropsychiatric symptoms in normal aging and neurodegenerative syndromes: A population‐based study from Latin America|10.1002/alz.13384
Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort|10.1002/alz.13357
Proteome wide association studies of LRRK2 variants identify novel causal and druggable proteins for Parkinson’s disease|10.1038/s41531-023-00555-4
A beginner’s guide into curated analyses of open access datasets for biomarker discovery in neurodegeneration|10.1038/s41597-023-02338-1
A simulative deep learning model of SNP interactions on chromosome 19 for predicting Alzheimer's disease risk and rates of disease progression|10.1002/alz.13319
Body composition and physical performance one year after COVID-19|10.1097/phm.0000000000002314
Genetic Investigation of Consanguineous Pakistani Families Segregating Rare Spinocerebellar Disorders|10.3390/genes14071404
Locus specific endogenous retroviral expression associated with Alzheimer’s disease|10.3389/fnagi.2023.1186470
A cholinergic contribution to postural control and freezing of gait in Parkinson’s disease|10.1093/brain/awad223
Alternative splicing impacts microRNA regulation within coding regions|10.1093/nargab/lqad081
Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson’s disease|10.1038/s41467-023-39652-6
HLA in isolated REM sleep behavior disorder and Lewy body dementia|10.1002/acn3.51841
Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study|10.3233/jpd-230007
Biochemical analyses of tau and other neuronal markers in the submandibular gland and frontal cortex across stages of Alzheimer disease|10.1016/j.neulet.2023.137330
Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain|10.1016/j.bbi.2023.04.008
Parallel development of Parkinson's-specific competencies for exercise professionals and criteria for exercise education programs|10.1016/j.parkreldis.2023.105407
Perspective on the current state of the LRRK2 field|10.1038/s41531-023-00544-7
Subsensory stochastic electrical stimulation targeting muscle afferents alters gait control during locomotor adaptations to haptic perturbations|10.1016/j.isci.2023.107038
Genome-wide case-only analysis of gene-gene interactions with known Parkinson’s disease risk variants reveals link between LRRK2 and SYT10|10.1038/s41531-023-00550-9
PINK1: From Parkinson’s disease to mitophagy and back again|10.1371/journal.pbio.3002196
Single-cell multiomic analyses sheds light on mitochondrial mutational selection|10.1038/s41588-023-01436-5
Association of Rare Variants in ARSA with Parkinson's Disease|10.1002/mds.29521
Comparison of Monoamine Oxidase-A, Aβ Plaques, Tau, and Translocator Protein Levels in Postmortem Human Alzheimer’s Disease Brain|10.3390/ijms241310808
Determinants of coping styles of people with Parkinson’s Disease|10.1038/s41531-023-00548-3
Effects of Parkin on the Mitochondrial Genome in the Heart and Brain of Mitochondrial Mutator Mice|10.1002/adbi.202300154
Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)|10.1038/s41531-023-00526-9
Genetic Testing in Parkinson's Disease|10.1002/mds.29500
Modeling of mitochondrial genetic polymorphisms reveals induction of heteroplasmy by pleiotropic disease locus 10398A>G|10.1038/s41598-023-37541-y
Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease|10.1038/s41467-023-39060-w
Original research: longitudinal evaluation of cognitively demanding daily function using performance-based functional assessment highlights heterogeneous trajectories in cognitive and functional abilities in people with Parkinson’s disease|10.3389/fnins.2023.1200347
Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design|10.1002/mds.29519
Whole proteome copy number dataset in primary mouse cortical neurons|10.1016/j.dib.2023.109336
Cerebellar functional connectivity change is associated with motor and neuropsychological function in early stage drug-naïve patients with Parkinson’s disease|10.3389/fnins.2023.1113889
Large-scale rare variant burden testing in Parkinson's disease|10.1093/brain/awad214
Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease|10.1002/mds.29510
History of high household pesticide use and Parkinson's disease in Brazil|10.1016/j.parkreldis.2023.105493
PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems|10.15252/embr.202256399
Reply to: Hypoxia treatment of Parkinson’s disease may disrupt the circadian system|10.1186/s12883-023-03281-9
Simultaneous Determination of the Size and Shape of Single α-Synuclein Oligomers in Solution|10.1021/acsnano.3c01393
Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden|10.1002/mds.29507
Corrigendum: Clinical and genetic analysis of Costa Rican patients with Parkinson's disease|10.3389/fneur.2023.1227084
Highly multiplexed bioactivity screening reveals human and microbiota metabolome-GPCRome interactions|10.1016/j.cell.2023.05.024
Proof-of-Principle Study of Inflammasome Signaling Proteins as Diagnostic Biomarkers of the Inflammatory Response in Parkinson’s Disease|10.3390/ph16060883
International Genetic Testing and Counseling Practices for Parkinson's Disease|10.1002/mds.29442
Nomogram for Early Prediction of Parkinson’s Disease Based on microRNA Profiles and Clinical Variables|10.3233/jpd-225080
What Patients Say: Large-Scale Analyses of Replies to the Parkinson’s Disease Patient Report of Problems (PD-PROP)|10.3233/jpd-225083
Lifestyle factors and clinical severity of Parkinson’s disease|10.1038/s41598-023-31531-w
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update|10.3233/jpd-239901
Pick’s Disease, Seeding an Answer to the Clinical Diagnosis Conundrum|10.3390/biomedicines11061646
Association of women-specific health factors in the severity of Parkinson’s disease|10.1038/s41531-023-00524-x
Severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies|10.1093/brain/awad192
Toward a standard model for autophagosome biogenesis|10.1083/jcb.202304011
Glycolipids in Parkinson's disease: beyond neuronal function|10.1002/2211-5463.13651
Targeted metabolomic analysis in Parkinson’s disease brain frontal cortex and putamen with relation to cognitive impairment|10.1038/s41531-023-00531-y
Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease|10.1212/wnl.0000000000207410
Neural cell state shifts and fate loss in ageing and age-related diseases|10.1038/s41582-023-00815-0
Sex differences for cognitive decline in progressive supranuclear palsy|10.1016/j.parkreldis.2023.105454
From Lysosomal Storage Disorders to Parkinson’s Disease – Challenges and Opportunities|10.1016/j.jmb.2022.167932
Multiscale model of primary motor cortex circuits predicts in vivo cell-type-specific, behavioral state-dependent dynamics|10.1016/j.celrep.2023.112574
Stability Changes in Fall-Prone Individuals With Parkinson Disease Following Reactive Step Training|10.1097/npt.0000000000000442
The Endo-lysosomal System in Parkinson’s Disease: Expanding the Horizon|10.1016/j.jmb.2023.168140
β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study|10.2147/clep.s405325
Bioinformatics pipeline to guide post‐GWAS studies in Alzheimer's: A new catalogue of disease candidate short structural variants|10.1002/alz.13168
PINK1-Dependent Mitophagy Inhibits Elevated Ubiquitin Phosphorylation Caused by Mitochondrial Damage|10.1021/acs.jmedchem.3c00555
The contributions of mitochondrial and nuclear mitochondrial genetic variation to neuroticism|10.1038/s41467-023-38480-y
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease|10.1002/mds.29450
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?|10.3389/fnmol.2023.1197853
Astrocyte Signature in Alzheimer’s Disease Continuum through a Multi-PET Tracer Imaging Perspective|10.3390/cells12111469
Methodological considerations in neuronal extracellular vesicle isolation for α-synuclein biomarkers|10.1093/brain/awad169
Sex and Gender Influence Urinary Symptoms and Management in Multiple System Atrophy|10.14802/jmd.23016
Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods|10.1007/s40120-023-00486-5
Longitudinal decline in striatal dopamine transporter binding in Parkinson’s disease: associations with apathy and anhedonia|10.1136/jnnp-2022-330790
Patterns of TDP‐43 Deposition in Brains with LRRK2 G2019S Mutations|10.1002/mds.29449
Association of sulfonylureas with the risk of dementia: A population‐based cohort study|10.1111/jgs.18397
Estimated glomerular filtration rate is a biomarker of cognitive impairment in Parkinson’s disease|10.3389/fnagi.2023.1130833
Brain Calcifications: Genetic, Molecular, and Clinical Aspects|10.3390/ijms24108995
Dopaminergic Dysfunction Is More Symmetric in Dementia with Lewy Bodies Compared to Parkinson’s Disease|10.3233/jpd-230001
Status of Current Biofluid Biomarkers in Parkinson's Disease|10.1002/mdc3.13753
Association of Cortical and Subcortical Microstructure With Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease|10.1212/wnl.0000000000207408
Assortative mixing in micro-architecturally annotated brain connectomes|10.1038/s41467-023-38585-4
Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization|10.1021/acschemneuro.3c00259
Galectin-3 shapes toxic alpha-synuclein strains in Parkinson’s disease|10.1007/s00401-023-02585-x
Valbenazine as treatment for Huntington's disease chorea|10.1016/s1474-4422(23)00163-1
Biologic targets of prescription medications and risk of neurodegenerative disease in United States Medicare beneficiaries|10.1371/journal.pone.0285011
Generation of gene-corrected isogenic controls from Parkinson's disease patient iPSC lines carrying the pathogenic SNCA p.A53T variant|10.1016/j.scr.2023.103125
A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides|10.1038/s41467-023-38215-z
Editorial: Brain stimulation in cognition and disease|10.3389/fnins.2023.1213272
Genetic risk factor clustering within and across neurodegenerative diseases|10.1093/brain/awad161
Impulse control disorder in Parkinson’s disease is associated with abnormal frontal value signalling|10.1093/brain/awad162
α-Synuclein fibril and synaptic vesicle interactions lead to vesicle destruction and increased lipid-associated fibril uptake into iPSC-derived neurons|10.1038/s42003-023-04884-1
miEAA 2023: updates, new functional microRNA sets and improved enrichment visualizations|10.1093/nar/gkad392
Alternating Magnetic Field-Promoted Nanoparticle Mixing: The On-Chip Immunocapture of Serum Neuronal Exosomes for Parkinson’s Disease Diagnostics|10.1021/acs.analchem.3c00357
FBXL4 suppresses mitophagy by restricting the accumulation of NIX and BNIP3 mitophagy receptors|10.15252/embj.2022112767
Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder|10.3233/jpd-223519
Prediction of Cognitive Decline in Parkinson’s Disease Using Clinical and DAT SPECT Imaging Features, and Hybrid Machine Learning Systems|10.3390/diagnostics13101691
Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson’s disease|10.1038/s43856-023-00294-w
Shared molecular genetic factors influence subcortical brain morphometry and Parkinson’s disease risk|10.1038/s41531-023-00515-y
Single-domain antibody–based noninvasive in vivo imaging of α-synuclein or tau pathology|10.1126/sciadv.adf3775
Trajectories of depressive symptoms over 20 years and subsequent lower urinary tract symptoms and impact among women|10.1097/gme.0000000000002193
Immunological Features of LRRK2 Function and Its Role in the Gut-Brain Axis Governing Parkinson’s Disease|10.3233/jpd-230021
Proposal for a Biologic Staging System of Parkinson’s Disease|10.3233/jpd-225111
Application of Aligned-UMAP to longitudinal biomedical studies|10.1016/j.patter.2023.100741
Digital technologies: Innovations that transform the face of drug development|10.1111/cts.13533
Golgi-IP, a tool for multimodal analysis of Golgi molecular content|10.1073/pnas.2219953120
Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease|10.1002/mds.29429
Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression|10.1002/mds.29424
Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias|10.1016/j.xgen.2023.100316
Moderating effects of uric acid and sex on cognition and psychiatric symptoms in asymmetric Parkinson’s disease|10.1186/s13293-023-00510-1
Need for personalized monitoring of Parkinson’s disease: the perspectives of patients and specialized healthcare providers|10.3389/fneur.2023.1150634
0908 Multi-modal Recruitment of Individuals with REM Sleep Behavior Disorder into a Longitudinal Prodromal Parkinson’s Study|10.1093/sleep/zsad077.0908
Basal ganglia neurons in healthy and parkinsonian primates generate recurring sequences of spikes|10.1152/jn.00265.2022
BKCa nitrosylation is associated with cerebral microvascular dysfunction in female 5x-FAD mice|10.1152/physiol.2023.38.s1.5731336
Future directions in psychiatric neurosurgery: Proceedings of the 2022 American Society for Stereotactic and Functional Neurosurgery meeting on surgical neuromodulation for psychiatric disorders|10.1016/j.brs.2023.05.011
Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease|10.1002/mds.29399
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease|10.1016/j.expneurol.2023.114370
Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes|10.1016/j.celrep.2023.112448
Unconventional initiation of PINK1/Parkin mitophagy by Optineurin|10.1016/j.molcel.2023.04.021
Neuroinflammation and white matter alterations in occupational manganese exposure assessed by diffusion basis spectrum imaging|10.1016/j.neuro.2023.04.013
Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats|10.1016/j.brainres.2023.148381
Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases|10.1038/s41531-023-00504-1
The identification of high-performing antibodies for Vacuolar protein sorting-associated protein 35 (hVPS35) for use in Western Blot, immunoprecipitation and immunofluorescence|10.12688/f1000research.133696.1
What does heritability of Alzheimer’s disease represent?|10.1371/journal.pone.0281440
Characterizing expression changes in noncoding RNAs during aging and heterochronic parabiosis across mouse tissues|10.1038/s41587-023-01751-6
CSF alpha‐synuclein aggregates by seed amplification and clinical presentation of AD|10.1002/alz.13109
Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease|10.1186/s40478-023-01563-4
Novel therapeutic approaches to target neurodegeneration|10.1111/bph.16078
The image and data archive at the laboratory of neuro imaging|10.3389/fninf.2023.1173623
The Sequence Effect Worsens Over Time in Parkinson’s Disease and Responds to Open and Closed-Loop Subthalamic Nucleus Deep Brain Stimulation|10.3233/jpd-223368
Cholinergic system correlates of postural control changes in Parkinson’s disease freezers|10.1093/brain/awad134
Astrocytic TDP-43 dysregulation impairs memory by modulating antiviral pathways and interferon-inducible chemokines|10.1126/sciadv.ade1282
Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders|10.3389/fncel.2023.1143319
Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson’s|10.1186/s41687-023-00577-9
Long-term exposure to low-level particulate air pollution and Parkinson's disease diagnosis - A Finnish register-based study|10.1016/j.envres.2023.115944
Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease|10.1038/s41467-023-37464-2
Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy|10.1093/jnen/nlad026
Episodic memory deficit in HIV infection: common phenotype with Parkinson’s disease, different neural substrates|10.1007/s00429-023-02626-x
Intermediate Deformable Image Registration Via Windowed Cross-Correlation|10.1109/isbi53787.2023.10230715
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study|10.1038/s41531-023-00497-x
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study|10.1016/s1474-4422(23)00109-6
Brain Structure Ages -- A new biomarker for multi-disease classification|10.48550/arxiv.2304.06591
In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson’s disease using neuromelanin-sensitive MRI: Replication in two cohorts|10.1371/journal.pone.0282684
Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord|10.3390/pharmaceutics15041230
USP8 Down-Regulation Promotes Parkin-Independent Mitophagy in the Drosophila Brain and in Human Neurons|10.3390/cells12081143
Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors|10.1021/acschembio.2c00868
Ethical and Responsible Use of AI/ML in the Earth, Space, and Environmental Sciences|10.22541/essoar.168132856.66485758
The effect of cardiovascular risk on disease progression in de novo Parkinson's disease patients: An observational analysis|10.3389/fneur.2023.1138546
The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study|10.3389/fneur.2023.1155669
Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study|10.1002/mdc3.13751
Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy|10.1093/jnen/nlad025
Predictors of Future Deep Brain Stimulation Surgery in de novo Parkinson's Disease|10.1002/mdc3.13747
Association of coffee consumption and striatal volume in patients with Parkinson's disease and healthy controls|10.1111/cns.14216
The effects of AQP4 rs162009 on resting‐state brain activity in Parkinson's disease|10.1111/cns.14208
Feasibility and patient acceptability of a commercially available wearable and a smart phone application in identification of motor states in parkinson’s disease|10.1371/journal.pdig.0000225
Neuroprotective actions of a fatty acid nitroalkene in Parkinson’s disease|10.1038/s41531-023-00502-3
Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson’s disease|10.1038/s41531-023-00496-y
Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism|10.1038/s41467-023-37454-4
Association of polygenic risk score with response to deep brain stimulation in Parkinson’s disease|10.1186/s12883-023-03188-5
Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges|10.1007/s00401-023-02557-1
Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease|10.1038/s41531-023-00482-4
Starburst amacrine cells, involved in visual motion perception, loose their synaptic input from dopaminergic amacrine cells and degenerate in Parkinson’s disease patients|10.1186/s40035-023-00348-y
Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism|10.1002/mds.29353
Remuneration and Recruitment of Study Participants for AD Cohort Studies From the General Public and From Minority Communities|10.1097/wad.0000000000000556
Olfactory Impairment Is the Main Predictor of Higher Scores at REM Sleep Behavior Disorder (RBD) Screening Questionnaire in Parkinson’s Disease Patients|10.3390/brainsci13040599
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force|10.1016/j.jval.2022.12.006
Workflows Community Summit 2022: A Roadmap Revolution|10.5281/zenodo.7750670
Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting|10.1038/s41598-023-32480-0
Sex differences in associations between APOE ε2 and longitudinal cognitive decline|10.1002/alz.13036
Identification of a Putative α-synuclein Radioligand Using an in silico Similarity Search|10.1007/s11307-023-01814-9
Developing better digital health measures of Parkinson’s disease using free living data and a crowdsourced data analysis challenge|10.1371/journal.pdig.0000208
Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay|10.1002/acn3.51753
Necroptosis inhibition counteracts neurodegeneration, memory decline, and key hallmarks of aging, promoting brain rejuvenation|10.1111/acel.13814
Modulating arousal to overcome gait impairments in Parkinson’s disease: how the noradrenergic system may act as a double-edged sword|10.1186/s40035-023-00347-z
Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis|10.1038/s41531-023-00491-3
Generation of two induced pluripotent stem cell lines and the corresponding isogenic controls from Parkinson’s disease patients carrying the heterozygous mutations c.1290A > G (p.T351A) or c.2067A > G (p.T610A) in the RHOT1 gene encoding Miro1|10.1016/j.scr.2023.103085
Long-term cognitive decline prediction based on multi-modal data using Multimodal3DSiameseNet: transfer learning from Alzheimer’s disease to Parkinson’s disease|10.1007/s11548-023-02866-6
Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred|10.1002/alz.13021
Structural connectivity and brain network analyses in Parkinson's disease: A cross-sectional and longitudinal study|10.3389/fneur.2023.1137780
Parkinson’s disease population-wide registries in the United States: Current and future opportunities|10.3389/fdgth.2023.1149154
Good vibrations: tactile cueing for freezing of gait in Parkinson’s disease|10.1007/s00415-023-11663-9
Lack of significant Lewy pathology in 237 essential tremor brains|10.1093/jnen/nlad022
Structure-based design and characterization of Parkin-activating mutations|10.26508/lsa.202201419
Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson’s disease and multiple system atrophy|10.1186/s40035-023-00346-0
Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease|10.1002/mdc3.13726
Genetics of Neurogenic Orthostatic Hypotension in Parkinson’s Disease, Results from a Cross-Sectional In Silico Study|10.3390/brainsci13030506
Abnormal dynamic functional connectivity changes correlated with non-motor symptoms of Parkinson’s disease|10.3389/fnins.2023.1116111
Longitudinal cognitive changes in patients with early Parkinson's disease and neuropsychiatric symptoms|10.1111/cns.14173
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation|10.1007/s40265-023-01838-z
Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser129 in Biological Samples|10.1021/acschemneuro.2c00676
Postmortem Cerebellar Volume Is Not Reduced in Essential Tremor: A Comparison with Multiple System Atrophy and Controls|10.3233/jpd-225033
Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay|10.3233/jpd-213085
Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD|10.1038/s41531-023-00476-2
Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11C]UCB‐J and [18F]FDG PET Study|10.1002/mds.29375
The Impact of the COVID‐19 Pandemic on Care Partners of People with Parkinson's Disease|10.1002/mdc3.13678
Self-Image in Women with Parkinson’s Disease|10.3233/jpd-230017
Reduction in GABAB on glia induce Alzheimer’s disease related changes|10.1016/j.bbi.2023.03.002
Age and sex differentially shape brain networks in Parkinson's disease|10.1111/cns.14149
Perceived Discrimination in Health Care for LGBTQIA+ People Living With Parkinson’s Disease|10.1093/geronb/gbad046
Imaging-based DBS programming help: Does it help?|10.1016/j.parkreldis.2023.105362
Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study|10.1093/brain/awad072
A comparative blind study between skin biopsy and seed amplification assay to disclose pathological α-synuclein in RBD|10.1038/s41531-023-00473-5
The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data|10.1038/s41531-023-00472-6
G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2|10.3390/biom13030473
Performance of machine learning algorithms for dementia assessment: impacts of language tasks, recording media, and modalities|10.1186/s12911-023-02122-6
Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease|10.1002/mds.29342
Addition to “Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders”|10.1021/acsami.3c02300
B lymphocyte responses in Parkinson’s disease and their possible significance in disease progression|10.1093/braincomms/fcad060
Impaired dopamine release in Parkinson’s disease|10.1093/brain/awad064
Methods and applications for single-cell and spatial multi-omics|10.1038/s41576-023-00580-2
Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment|10.3389/fneur.2023.1069411
Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease|10.1080/10543406.2023.2170400
Dementia prevention in memory clinics: recommendations from the European task force for brain health services|10.1016/j.lanepe.2022.100576
Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease|10.1016/j.celrep.2023.112231
Letter in response to Cole-Hunter et al., 2023: What does “Parkinson’s disease mortality” mean?|10.1016/j.envint.2023.107852
Protocol to measure centrosome cohesion deficits mediated by pathogenic LRRK2 in cultured cells using confocal microscopy|10.1016/j.xpro.2022.102024
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts|10.1038/s41531-023-00468-2
Duodenal alpha‐Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease|10.1002/mds.29358
Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson's Disease|10.5281/zenodo.7679354
Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older|10.1212/wnl.0000000000207077
A call for clinical trial globalization in Alzheimer's disease and related dementia|10.1002/alz.12995
Voltage-Gated Proton Channel Hv1 Regulates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease Models|10.3390/antiox12030582
Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies|10.1093/brain/awad044
Single‐cell sequencing of entorhinal cortex reveals widespread disruption of neuropeptide networks in Alzheimer's disease|10.1002/alz.12979
Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases|10.1038/s41588-023-01300-6
A progression analysis of motor features in Parkinson's disease based on the mapper algorithm|10.3389/fnagi.2023.1047017
Childhood Trauma and Parkinson Disease|10.1212/cpj.0000000000200124
Artificial intelligence-based clustering and characterization of Parkinson's disease trajectories|10.1038/s41598-023-30038-8
Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging|10.1002/mdc3.13687
Two-year clinical progression in focal and diffuse subtypes of Parkinson’s disease|10.1038/s41531-023-00466-4
A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease|10.1016/j.parkreldis.2023.105325
Macroscopic dynamics of neural networks with heterogeneous spiking thresholds|10.1103/physreve.107.024306
Brain Degeneration in Synucleinopathies Based on Analysis of Cognition and Other Nonmotor Features: A Multimodal Imaging Study|10.3390/biomedicines11020573
Lewy Body-like Pathology and Loss of Dopaminergic Neurons in Midbrain Organoids Derived from Familial Parkinson’s Disease Patient|10.3390/cells12040625
Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology|10.1038/s41531-023-00465-5
Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation|10.1126/sciadv.adg2997
ATP and NAD+ Deficiency in Parkinson’s Disease|10.3390/nu15040943
Guanylyl cyclase C ameliorates visceral pain: an unsuspected link|10.1172/jci166703
Statin Use and Incidence of Parkinson's Disease in Women from the FrenchE3NCohort Study|10.1002/mds.29349
Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort|10.1002/mds.29329
AI reveals insights into link between CD33 and cognitive impairment in Alzheimer’s Disease|10.1371/journal.pcbi.1009894
Machine learning within the Parkinson’s progression markers initiative: Review of the current state of affairs|10.3389/fnagi.2023.1076657
A proteogenomic view of Parkinson’s disease causality and heterogeneity|10.1038/s41531-023-00461-9
Two‐Year observational study of autonomic skin function in patients with Parkinson's disease compared to healthy individuals|10.1111/ene.15733
Data Archive for the BRAIN Initiative (DABI)|10.1038/s41597-023-01972-z
Novel Green Fluorescent Polyamines to Analyze ATP13A2 and ATP13A3 Activity in the Mammalian Polyamine Transport System|10.3390/biom13020337
Novel LRR-ROC Motif That Links the N- and C-terminal Domains in LRRK2 Undergoes an Order–Disorder Transition Upon Activation|10.1016/j.jmb.2023.167999
SOD1-Related Cerebellar Ataxia and Motor Neuron Disease: Cp Variant as Functional Modifier?|10.1007/s12311-023-01527-3
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease|10.1093/hmg/ddad025
Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers|10.1038/s41531-023-00445-9
Expert Consensus on the Use of On‐Demand Treatments for OFF Episodes in Parkinson's Disease: A Modified Delphi Panel|10.1002/mdc3.13690
Regulators of proteostasis are translationally repressed in fibroblasts from patients with sporadic and LRRK2-G2019S Parkinson’s disease|10.1038/s41531-023-00460-w
The Foundational Data Initiative for Parkinson Disease: Enabling efficient translation from genetic maps to mechanism|10.1016/j.xgen.2023.100261
The relationship between hippocampal amyloid beta burden and spatial distribution of neurofibrillary degeneration|10.1002/alz.12966
Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease|10.1038/s41531-023-00451-x
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system|10.1038/s41467-023-36058-2
Composite measures of motor performance and self-efficacy are better determinants of postural instability and gait difficulties than individual clinical measures in Parkinson's disease|10.1016/j.parkreldis.2022.105251
NLRP3 inflammasome in neurodegenerative disease|10.1016/j.trsl.2022.08.006
Linear ubiquitination induces NEMO phase separation to activate NF-κB signaling|10.26508/lsa.202201607
Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease|10.1038/s41531-023-00457-5
In vivoreduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease|10.1093/brain/awac445
New protocol for kinetic assay seeding ability recovery “KASAR” from formalin-fixed paraffin-embedded tissues|10.3389/fmolb.2023.1087982
Tissue specific LRRK2 interactomes reveal a distinct striatal functional unit|10.1371/journal.pcbi.1010847
Distribution of cholinergic nerve terminals in the aged human brain measured with [18F]FEOBV PET and its correlation with histological data|10.1016/j.neuroimage.2023.119908
Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation|10.3389/fnhum.2022.1084782
Frequency of and factors associated with antiseizure medication discontinuation discussions and decisions in patients with epilepsy: A multicenter retrospective chart review|10.1002/epi4.12695
Genome‐Wide Analysis of Structural Variants in Parkinson Disease|10.1002/ana.26608
Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease|10.1002/ana.26596
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort|10.1002/mds.29288
Integrated Multi‐Cohort Analysis of the Parkinson's Disease Gut Metagenome|10.1002/mds.29300
Parkin coregulates glutathione metabolism in adult mammalian brain|10.1186/s40478-022-01488-4
The SMN Complex at the Crossroad between RNA Metabolism and Neurodegeneration|10.3390/ijms24032247
Time-resolved RNA signatures of CD4+ T cells in Parkinson’s disease|10.1038/s41420-023-01333-0
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?|10.1261/rna.079507.122
Genetic Testing for GBA and LRRK2 Mutations: Is it Time for Routine Use?|10.1002/mdc3.13619
Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia|10.1186/s40035-022-00328-8
Why Therapeutic Trials Fail in Primary Tauopathies|10.1002/mds.29322
Loss of parkin causes endoplasmic reticulum calcium dyshomeostasis by upregulation of reticulocalbin 1|10.1111/ejn.15917
Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid|10.1038/s41596-022-00787-3
α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin|10.1523/jneurosci.1922-22.2022
New Tools for Lineage Tracing in Cancer In Vivo|10.1146/annurev-cancerbio-061421-123301
Sex-Specific Microglial Responses to Glucocerebrosidase Inhibition: Relevance to GBA1-Linked Parkinson’s Disease|10.3390/cells12030343
The Potent and Paradoxical Biology of Cellular Senescence in Cancer|10.1146/annurev-cancerbio-061421-124434
Ethnicity and Parkinson’s Disease: Motor and Nonmotor Features and Disease Progression in Latino Patients Living in Rural California|10.1093/gerona/glad016
Bradykinesia and Its Progression Are Related to Interhemispheric Beta Coherence|10.1002/ana.26605
EEG Entropy in REM Sleep as a Physiologic Biomarker in Early Clinical Stages of Alzheimer’s Disease|10.3233/jad-221152
Enhancing Diversity and Inclusion in Clinical Trials|10.1002/cpt.2819
Protective Effects of Lovastatin in a Population‐BasedALSStudy and Mouse Model|10.1002/ana.26600
Serotonergic and dopaminergic control of impulsivity in gambling disorder|10.1111/adb.13264
Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers|10.7554/elife.85837
In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease|10.1002/mds.29315
Mitochondrial and Endoplasmic Reticulum Stress Trigger Triglyceride Accumulation in Models of Parkinson’s Disease Independent of Mutations in MAPT|10.3390/metabo13010112
Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins|10.1186/s13024-022-00592-2
Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder|10.1002/mds.29306
Classification of GBA1 Variants in Parkinson's Disease: The GBA1‐PD Browser|10.1002/mds.29314
High-content phenotypic screen to identify small molecule enhancers of Parkin-dependent ubiquitination and mitophagy|10.1016/j.slasd.2022.12.004
Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta|10.1002/mds.29311
A comprehensive cognitive analysis of cervical dystonia: A single centre study|10.1016/j.prdoa.2023.100226
Anatomical substrates and connectivity for bradykinesia motor features in Parkinson’s disease after subthalamic nucleus deep brain stimulation|10.1093/braincomms/fcad337
Development and Pilot Testing of the Tremor Retrainer Smartphone Application for the Treatment of Functional Tremor|10.5334/tohm.823
Diversity of dynamic voltage patterns in neuronal dendrites revealed by nanopipette electrophysiology|10.1039/d2nr03475a
Erythroid Differentiation Dependent Interaction of VPS13A with XK at the Plasma Membrane of K562 Cells|10.1177/25152564231215133
escheR: unified multi-dimensional visualizations with Gestalt principles|10.1093/bioadv/vbad179
Explainable classification of Parkinson’s disease using deep learning trained on a large multi-center database of T1-weighted MRI datasets|10.1016/j.nicl.2023.103405
Eye-Closure Rate Modulation in Blepharospasm|10.5334/tohm.748
Higher Health Service Costs Associated With Delayed Diagnosis of Functional Neurological Disorder|10.1176/appi.neuropsych.21110288
How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature|10.1016/j.prdoa.2022.100174
Identification and Management of Persistent Stimulation-Induced Dyskinesia Associated with STN DBS: The See-Saw Dilemma|10.5334/tohm.780
Internal tremor in people with Parkinson’s Disease: Demographic characteristics and comorbid symptoms|10.1016/j.prdoa.2023.100229
Keystroke-Dynamics for Parkinson's Disease Signs Detection in an At-Home Uncontrolled Population: A New Benchmark and Method|10.1109/tbme.2022.3187309
Kv1.3 K+Channel Physiology Assessed by Genetic and Pharmacological Modulation|10.1152/physiol.00010.2022
Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel|10.1002/trc2.12375
Longitudinal hippocampal subfields, CSF biomarkers, and cognition in patients with Parkinson disease|10.1016/j.prdoa.2023.100199
Lunapark deficiency leads to an autosomal recessive neurodevelopmental phenotype with a degenerative course, epilepsy and distinct brain anomalies|10.1093/braincomms/fcad222
Multiclass prediction of different dementia syndromes based on multi-centric volumetric MRI imaging|10.1016/j.nicl.2023.103320
Network connectivity and local transcriptomic vulnerability underpin cortical atrophy progression in Parkinson’s disease|10.1016/j.nicl.2023.103523
Neural correlates of impulse control behaviors in Parkinson’s disease: Analysis of multimodal imaging data|10.1016/j.nicl.2023.103315
Protein network analysis links the NSL complex to Parkinson’s disease via mitochondrial and nuclear biology|10.1039/d2mo00325b
Resolving inter-regional communication capacity in the human connectome|10.1162/netn_a_00318
State, trait, and accumulated features of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS‐Cog) in mild Alzheimer's disease|10.1002/trc2.12376
Synergistic associations of depressive symptoms and aging on cognitive decline in early Parkinson’s disease|10.1016/j.prdoa.2023.100192
Testing for Allele-specific Expression from Human Brain Samples|10.21769/bioprotoc.4832
The complex role of inflammation and gliotransmitters in Parkinson's disease|10.1016/j.nbd.2022.105940
UniProtExtractR: an app and R package for easily extracting protein-specific UniProtKB information and fine-tuning organelle resolution|10.1093/bioadv/vbad157
Updated Parkinson's disease motor subtypes classification and correlation to cerebrospinal homovanillic acid and 5-hydroxyindoleacetic acid levels|10.1016/j.prdoa.2023.100187
α-Synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells: an in vitro proof of concept study|10.1093/braincomms/fcad285
Journal Production Guidance for Software and Data Citations|10.22541/essoar.167252601.17695321
A Collaboration for Guiding the Rational Design of Multielement Solid Catalysts|10.1002/ange.202216327
A Collaboration for Guiding the Rational Design of Multielement Solid Catalysts|10.1002/anie.202216327
Cognitive Behavioral Therapy for Anxiety in Parkinson’s Disease Induces Functional Brain Changes|10.3233/jpd-223527
Soluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke|10.1161/jaha.122.026901
Transcriptome Analysis Reveals a Two-Gene Signature Links to Motor Progression and Alterations of Immune Cells in Parkinson’s Disease|10.3233/jpd-223454
Genome-wide evaluation of the effect of short tandem repeat variation on local DNA methylation|10.1101/gr.277057.122
Golgi apparatus, endoplasmic reticulum and mitochondrial function implicated in Alzheimer’s disease through polygenic risk and RNA sequencing|10.1038/s41380-022-01926-8
High-speed imaging reveals the bimodal nature of dense core vesicle exocytosis|10.1073/pnas.2214897120
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy–Richardson Syndrome|10.1002/mds.29299
ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease|10.1186/s13195-022-01119-z
Cardiovascular Risk Factors and Risk of Alzheimer Disease and Mortality: A Latent Class Approach|10.1161/jaha.122.025724
Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes|10.2217/nmt-2022-0038
Multishank Thin‐Film Neural Probes and Implantation System for High‐Resolution Neural Recording Applications|10.1002/aelm.202200883
Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications|10.1124/pharmrev.122.000654
Progranulin loss results in sex-dependent dysregulation of the peripheral and central immune system|10.3389/fimmu.2022.1056417
Blood RNA transcripts reveal similar and differential alterations in fundamental cellular processes in Alzheimer's disease and other neurodegenerative diseases|10.1002/alz.12880
Motor symptoms in Parkinson’s disease are related to the interplay between cortical curvature and thickness|10.1016/j.nicl.2022.103300
Novel therapeutic approaches to target neurodegeneration|10.22541/au.167164898.84768756
Spatially resolved transcriptomics reveals genes associated with the vulnerability of middle temporal gyrus in Alzheimer’s disease|10.1186/s40478-022-01494-6
Editorial: Cannabinoids in neuroinflammation, neurodegeneration and pain: Focus on non-neuronal cells|10.3389/fnins.2022.1114775
Functional brain networks in the evaluation of patients with neurodegenerative disorders|10.1038/s41582-022-00753-3
How to unblur the vasovagal evidence?|10.1007/s10286-022-00915-9
Microglia ferroptosis is regulated by SEC24B and contributes to neurodegeneration|10.1038/s41593-022-01221-3
Presynaptic Hemiparkinsonism Following Cerebral Toxoplasmosis: Case Report and Literature Review|10.1002/mdc3.13631
The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”|10.1016/j.prdoa.2022.100177
A Combined α-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System|10.3233/jpd-223452
Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson’s disease|10.3389/fnagi.2022.1061096
Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats|10.1016/j.crneur.2022.100065
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder|10.3233/jpd-223380
Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts|10.1038/s41531-022-00439-z
Incidence of Parkinson disease in North America|10.1038/s41531-022-00410-y
Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs|10.1021/acschemneuro.2c00597
Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease|10.1111/ejn.15899
Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery|10.1126/sciadv.add1436
Plasma phosphorylated tau181 predicts cognitive and functional decline|10.1002/acn3.51695
Proximity to residential and workplace pesticides application and the risk of progression of Parkinson's diseases in Central California|10.1016/j.scitotenv.2022.160851
Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease|10.3233/jpd-223501
Predicting longitudinal brain atrophy in Parkinson’s disease using a Susceptible-Infected-Removed agent-based model|10.1162/netn_a_00296
Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study|10.2337/dc22-1705
Isolated Jaw and Tongue Tremor in a Definite Case of Progressive Supranuclear Palsy|10.1002/mdc3.13640
LRRK2-targeted Parkinson disease drug advances into phase III|10.1038/d41573-022-00212-0
Predictive modelling of Parkinson’s disease progression based on RNA-Sequence with densely connected deep recurrent neural networks|10.1038/s41598-022-25454-1
The genetic regulation of protein expression in cerebrospinal fluid|10.15252/emmm.202216359
Video-Based Facial Movement Analysis in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Clinical Validation|10.1044/2022_jslhr-22-00072
Chemosensory Dysfunction 3-Months After COVID-19, Medications and Factors Associated with Complete Recovery|10.1177/00034894221138485
It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum|10.1002/mds.29279
Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose Adjustment|10.33590/emj/10022165
Brain vitamin D forms, cognitive decline, and neuropathology in community‐dwelling older adults|10.1002/alz.12836
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease|10.1021/acs.jmedchem.2c01605
Spectrum of Pediatric to Early Adulthood POLR3A‐Associated Movement Disorders|10.1002/mdc3.13635
A Severe Case of Lupus Cerebritis|10.1212/01.wnl.0000903100.95793.8a
An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 Therapies|10.1212/01.wnl.0000903428.98962.0a
Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD|10.1002/mds.29284
Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls|10.1212/01.wnl.0000903096.36040.1d
Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects|10.1038/s41467-022-34732-5
Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences|10.1212/01.wnl.0000903160.72715.2d
Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)|10.1212/01.wnl.0000903320.23411.f9
Substitution of PINK1 Gly411 modulates substrate receptivity and turnover|10.1080/15548627.2022.2151294
The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis|10.1212/01.wnl.0000903316.50895.83
Understanding Correlation of Electroclinical Findings With Functional and Neuropsychiatric Outcomes in Patients with LGI1-Encephalitis|10.1212/01.wnl.0000903424.19914.85
Persistent depressive symptoms are associated with frontal regional atrophy in patients with Alzheimer's disease|10.1002/gps.5858
Synapsin III Regulates Dopaminergic Neuron Development in Vertebrates|10.3390/cells11233902
Bile acids and neurological disease|10.1016/j.pharmthera.2022.108311
Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic|10.1242/dmm.049755
Impairment of amacrine starburst cells and their synaptic contacts with dopaminergic cells could explain motion perception disturbances in Parkinson's disease|10.1111/j.1755-3768.2022.0786
Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease|10.1016/j.stem.2022.11.010
Machine learning‐based prediction of cognitive outcomes in de novo Parkinson's disease|10.1002/alz.067067
Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology|10.1016/j.nbd.2022.105925
Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics|10.1016/j.jconrel.2022.10.050
Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigation|10.1016/j.sleep.2022.09.025
Orchestration of selective autophagy by cargo receptors|10.1016/j.cub.2022.11.002
P5B-ATPases in the mammalian polyamine transport system and their role in disease|10.1016/j.bbamcr.2022.119354
Parkinson’s disease drug hunters think outside the α-synuclein box|10.1038/s41587-022-01610-w
Pompe disease treated before birth|10.1038/s41587-022-01621-7
Precision medicine for Parkinson’s disease: The subtyping challenge|10.3389/fnagi.2022.1064057
REM sleep behavior and olfactory dysfunction: Enhancing the utility and translation of animal models in the search for precision medicines for Parkinson's disease|10.1016/j.neubiorev.2022.104897
Roc, the G-domain of the Parkinson’s disease-associated protein LRRK2|10.1016/j.tibs.2022.06.009
Structural basis for Parkinson’s disease-linked LRRK2’s binding to microtubules|10.1038/s41594-022-00863-y
Volitional Control of Brain Motor Activity and Its Therapeutic Potential|10.1016/j.neurom.2022.01.007
Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains|10.1038/s41380-022-01875-2
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration|10.1002/mds.29262
Regulation of Αlpha-Synuclein Gene (SNCA) by Epigenetic Modifier TET1 in Parkinson Disease|10.5213/inj.2222206.103
Implications of DNA Methylation in Lewy Body Pathology|10.1002/mds.29290
Movement disorders in hereditary spastic paraplegia (HSP): a systematic review and individual participant data meta-analysis|10.1007/s10072-022-06516-8
Spatially informed Bayesian neural network for neurodegenerative diseases classification|10.1002/sim.9604
Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules|10.1186/s40035-022-00326-w
LRP1: a novel receptor for the transmission of pathological α-Synuclein|10.1186/s13024-022-00582-4
Transparent Exploration of Machine Learning for Biomarker Discovery from Proteomics and Omics Data|10.1021/acs.jproteome.2c00473
Unaltered T cell responses to common antigens in individuals with Parkinson's disease|10.1016/j.jns.2022.120510
Anti‐IgLON5 Disease with Isolated Hemichorea: A Case Report and Review of the Literature|10.1002/mdc3.13614
Multiregion transcriptomic profiling of the primate brain reveals signatures of aging and the social environment|10.1038/s41593-022-01197-0
Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit|10.3389/fnins.2022.1048945
Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons|10.1038/s41531-022-00423-7
Specialized Versus Generic Allied Health Therapy and the Risk of Parkinson's Disease Complications|10.1002/mds.29274
Longitudinal IgG antibody responses to Plasmodium vivax blood-stage antigens during and after acute vivax malaria in individuals living in the Brazilian Amazon|10.1371/journal.pntd.0010773
Motor cortex excitability is reduced during freezing of upper limb movement in Parkinson’s disease|10.1038/s41531-022-00420-w
Nicotine‐Mediated Rescue of α‐Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila|10.1002/mds.29283
Preventing Surgery-Induced NK Cell Dysfunction Using Anti-TGF-β Immunotherapeutics|10.3390/ijms232314608
The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson’s disease|10.3389/fnins.2022.1049118
Cerebrospinal fluid and blood profiles of transfer RNA fragments show age, sex, and Parkinson's disease‐related changes|10.1111/jnc.15723
Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential|10.1038/s42003-022-03965-x
Millisecond Hydrogen/Deuterium-Exchange Mass Spectrometry Approach to Correlate Local Structure and Aggregation in α-Synuclein|10.1021/acs.analchem.2c03183
Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy|10.3390/ijms232314554
Spillover: The Approval of New Medications for Alzheimer’s Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants|10.3233/jad-220113
The Effects of Deep Brain Stimulation in Patients with Multiple System Atrophy|10.3233/jpd-223504
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis|10.1007/s40263-022-00963-9
Screening performances of an 8-item UPSIT Italian version in the diagnosis of Parkinson’s disease|10.1007/s10072-022-06457-2
Human pericytes degrade diverse α-synuclein aggregates|10.1371/journal.pone.0277658
Isolation of Human Microglia from Neuropathologically Diagnosed Cases in the Single-Cell Era|10.1007/978-1-0716-2655-9_3
LUBAC assembles a ubiquitin signaling platform at mitochondria for signal amplification and transport of NF‐κB to the nucleus|10.15252/embj.2022112006
Somatic CNV Detection by Single-Cell Whole-Genome Sequencing in Postmortem Human Brain|10.1007/978-1-0716-2655-9_11
Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy|10.3390/ijms232214340
BDNF rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's disease|10.3389/fneur.2022.1053591
Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome|10.1186/s13195-022-01113-5
Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline|10.1016/j.parkreldis.2022.11.013
Major advances in Parkinson's disease over the past two decades and future research directions|10.1016/s1474-4422(22)00448-3
Revisiting levodopa for advanced Parkinson's disease|10.1016/s1474-4422(22)00435-5
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial|10.1016/s1474-4422(22)00400-8
Universal clinical Parkinson’s disease axes identify a major influence of neuroinflammation|10.1186/s13073-022-01132-9
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease|10.1007/s40263-022-00973-7
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms|10.1038/s41467-022-34667-x
Altered Cortical Palmitoylation Induces Widespread Molecular Disturbances in Parkinson’s Disease|10.3390/ijms232214018
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review|10.1002/mds.29278
Movement Disorders andSARS‐CoV‐2|10.1002/mdc3.13615
APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson’s disease|10.1038/s41531-022-00411-x
Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s Disease|10.3390/ijms232213985
Biomarkers and non-motor symptoms as a function of motor symptom asymmetry in early Parkinson's disease|10.1016/j.neuropsychologia.2022.108419
Digitizing a Therapeutic: Development of an Augmented Reality Dual-Task Training Platform for Parkinson’s Disease|10.3390/s22228756
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease|10.1186/s13195-022-01116-2
Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders|10.1186/s40478-022-01468-8
Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose|10.1002/alz.12835
Compensation Strategies for Gait Impairments in Parkinson's Disease: From Underlying Mechanisms to Daily Clinical Practice|10.1002/mdc3.13616
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease|10.1093/brain/awac413
The Existential Essentialism in Tremor Nosology − 7 Pitfalls, 2 Remedies, and a Path Ahead|10.1002/mdc3.13622
CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers|10.1136/jnnp-2022-330052
Epidemiology meets toxicogenomics: Mining toxicologic evidence in support of an untargeted analysis of pesticides exposure and Parkinson’s disease|10.1016/j.envint.2022.107613
Older patients with COVID‐19 and neuropsychiatric conditions: A study of risk factors for mortality|10.1002/brb3.2787
R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations|10.1038/s42003-022-04136-8
Stability of motor-nonmotor subtype in early-stage Parkinson’s disease|10.3389/fnagi.2022.1040405
The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program|10.3389/fneur.2022.1036068
Association between theLRP1BandAPOEloci and the development of Parkinson’s disease dementia|10.1093/brain/awac414
Genome-wide contribution of common short-tandem repeats to Parkinson’s disease genetic risk|10.1093/brain/awac301
Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation|10.1021/acschemneuro.2c00342
A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice|10.7554/elife.81453
Iron- and Neuromelanin-Weighted Neuroimaging to Study Mitochondrial Dysfunction in Patients with Parkinson’s Disease|10.3390/ijms232213678
Mitochondrial haplogroups and cognitive progression in Parkinson’s disease|10.1093/brain/awac327
A connectomics-based taxonomy of mammals|10.7554/elife.78635
Bootstrap-adjusted quasi-likelihood information criteria for mixed model selection|10.1080/02664763.2022.2143484
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease|10.1038/s41531-022-00409-5
Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial|10.1002/mds.29268
Disease specific and nonspecific metabolic brain networks in behavioral variant of frontotemporal dementia|10.1002/hbm.26140
Home Wireless Device Tracks Body Movements in People with Parkinson's Disease|10.1097/01.nt.0000899540.26889.fc
Rapid ex vivo reverse genetics identifies the essential determinants of prion protein toxicity|10.1111/bpa.13130
Progression of regional cortical cholinergic denervation in Parkinson’s disease|10.1093/braincomms/fcac320
Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease|10.1016/j.nbd.2022.105885
Decreased Water Mobility Contributes To Increased α‐Synuclein Aggregation**|10.1002/anie.202212063
Decreased Water Mobility Contributes To Increased α‐Synuclein Aggregation**|10.1002/ange.202212063
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease|10.1002/mds.29251
Tracer development for PET imaging of proteinopathies|10.1016/j.nucmedbio.2022.04.001
Diagnosis and Management of Functional Tic-Like Phenomena|10.3390/jcm11216470
Functional Movement Disorders and Deep Brain Stimulation: A Multi‐Center Study|10.1002/mdc3.13609
Using FRET-Based Biosensor Cells to Study the Seeding Activity of Tau and α-Synuclein|10.1007/978-1-0716-2597-2_10
LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease|10.3390/biom12111597
Vertical Supranuclear Gaze Palsy in Primary Familial Brain Calcification Associated with a Novel SLC20A2 Mutation|10.1002/mdc3.13604
Brain network characteristics and cognitive performance in motor subtypes of Parkinson's disease: A resting state fMRI study|10.1016/j.parkreldis.2022.10.027
Parkinson's disease resting tremor severity classification using machine learning with resampling techniques|10.3389/fnins.2022.955464
Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: The PPMI dataset|10.1016/j.parkreldis.2022.10.019
The plight of loneliness in Parkinson's disease: New opportunities|10.1016/j.parkreldis.2022.10.029
Analysis of Y chromosome haplogroups in Parkinson’s disease|10.1093/braincomms/fcac277
Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites|10.1126/science.abm3233
Adult-onset KMT2B-related dystonia|10.1093/braincomms/fcac276
Common signatures of differential microRNA expression in Parkinson’s and Alzheimer’s disease brains|10.1093/braincomms/fcac274
Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation|10.1083/jcb.202207022
The protean roles of neuroinflammation in trauma, infections, autoimmunity and neurodegeneration|10.1016/j.smim.2022.101655
Comparison of manual and automated measures of walking speed: Distance and pace matter|10.1016/j.exger.2022.111987
Management of psychiatric and cognitive complications in Parkinson’s disease|10.1136/bmj-2021-068718
Photoreceptor Enhanced Light Therapy (PELT): A Framework for Implementing BiologicallyDirected Integrative Lighting|10.1080/15502724.2022.2123816
Rehabilitation of Airway Protection in Individuals With Movement Disorders: A Telehealth Feasibility Study|10.1044/2022_ajslp-22-00063
Promoting Physical Activity Among Immigrant Asian Americans: Results from Four Community Health Worker Studies|10.1007/s10903-022-01411-y
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort|10.1038/s41531-022-00404-w
Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson’s disease|10.1016/j.biopha.2022.113908
The ADORA1 mutation linked to early-onset Parkinson’s disease alters adenosine A1-A2A receptor heteromer formation and function|10.1016/j.biopha.2022.113896
Cortico-Subthalamic Field Potentials Support Classification of the Natural Gait Cycle in Parkinson’s Disease and Reveal Individualized Spectral Signatures|10.1523/eneuro.0325-22.2022
Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson’s disease|10.1038/s41531-022-00405-9
A Pilot Trial of Dopamine Replacement for Dynamic Facial Expressions in Parkinson's Disease|10.1002/mdc3.13603
Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease|10.1002/mds.29257
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia|10.3389/fneur.2022.846126
Cognitive dysfunction 1 year after COVID‐19: evidence from eye tracking|10.1002/acn3.51675
Genetic architecture of Parkinson’s disease subtypes – Review of the literature|10.3389/fnagi.2022.1023574
Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson’s disease: Results from a data-driven approach|10.3389/fnagi.2022.1006567
Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity|10.1038/s41531-022-00388-7
State-of-the-art review of the clinical research on menopause and hormone replacement therapy association with Parkinson’s disease: What meta-analysis studies cannot tell us|10.3389/fnagi.2022.971007
Association of Early Weight Change With Cognitive Decline in Patients With Parkinson Disease|10.1212/wnl.0000000000201404
Editorial: Non-neuronal cell heterogeneity in the nervous system during health and disease|10.3389/fncel.2022.1047296
Functional Interaction Between α-Synuclein and Nurr1 in Dopaminergic Neurons|10.1016/j.neuroscience.2022.10.011
QEEG abnormalities in cognitively unimpaired patients with delirium|10.1136/jnnp-2022-330010
Druggable transcriptomic pathways revealed in Parkinson’s patient-derived midbrain neurons|10.1038/s41531-022-00400-0
Longitudinal evaluation of olfactory function in individuals with Gaucher disease and GBA1 mutation carriers with and without Parkinson's disease|10.3389/fneur.2022.1039214
DBSegment: Fast and robust segmentation of deep brain structures considering domain generalization|10.1002/hbm.26097
Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers|10.1002/mds.29253
Rating Scales for Medication Adherence in Parkinson's Disease: A Systematic Review for Critique and Recommendations|10.1002/mdc3.13586
Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs|10.3389/fbioe.2022.1035543
Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics|10.1038/s41467-022-33881-x
Pericytes take up and degrade α-synuclein but succumb to apoptosis under cellular stress|10.1038/s41598-022-20261-0
Using former carers’ expertise in peer support for carers of people with Parkinson’s Disease|10.1038/s41531-022-00381-0
A Guide for the Differential Diagnosis of Multiple System Atrophy in Clinical Practice|10.3233/jpd-223392
Boxing with and without Kicking Techniques for People with Parkinson’s Disease: An Explorative Pilot Randomized Controlled Trial|10.3233/jpd-223447
Cellular Senescence in Obesity and Associated Complications: a New Therapeutic Target|10.1007/s11892-022-01493-w
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up|10.3233/jpd-223295
How Vacations Affect Parkinson's Disease|10.1002/mdc3.13597
Split‐Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease|10.1002/mds.29238
A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk|10.3390/ijms232012211
Alzheimer’s disease large-scale gene expression portrait identifies exercise as the top theoretical treatment|10.1038/s41598-022-22179-z
Chronotype, sleep, and sleepiness in Parkinson's disease|10.1016/j.parkreldis.2022.10.011
Motor and psychiatric features in idiopathic blepharospasm: A data-driven cluster analysis|10.1016/j.parkreldis.2022.10.008
Suitability of Automated Writing Measures for Clinical Trial Outcome in Writer's Cramp|10.1002/mds.29237
The effect of limb selection methods on gait analysis in Parkinson's disease|10.1016/j.parkreldis.2022.10.013
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?|10.1186/s40035-022-00317-x
Alzheimer’s disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment|10.1038/s43587-022-00290-0
Differential cholinergic systems’ changes in progressive supranuclear palsy versus Parkinson’s disease: an exploratory analysis|10.1007/s00702-022-02547-9
Targeting the inflammasome in Parkinson’s disease|10.3389/fnagi.2022.957705
Interfacility Transfers for Seizure-Related Emergencies in the United States|10.1212/wnl.0000000000201319
Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders|10.1021/acsami.2c14220
The interplay between structural and functional connectivity in early stage Parkinson's disease patients|10.1016/j.jns.2022.120452
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers|10.1001/jamaneurol.2022.3265
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease|10.1038/s41531-022-00395-8
The impact of harmonization on radiomic features in Parkinson’s disease and healthy controls: A multicenter study|10.3389/fnins.2022.1012287
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4|10.1002/alz.12797
Gender Differences in the Prevalence of Parkinson's Disease|10.1002/mdc3.13584
Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis|10.1038/s41467-022-33500-9
Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors|10.1001/jamanetworkopen.2022.35068
Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology|10.1038/s41531-022-00397-6
neuromaps: structural and functional interpretation of brain maps|10.1038/s41592-022-01625-w
Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutants|10.1016/j.jbc.2022.102565
Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis|10.3389/fneur.2022.919778
Recruitment and Retention in Remote Research: Learnings From a Large, Decentralized Real-world Study|10.2196/40765
Assessment of Bioenergetic Deficits in Patients With Parkinson Disease and Progressive Supranuclear Palsy Using 31 P-MRSI|10.1212/wnl.0000000000201288
Body Mass Index, Abdominal Adiposity, and Incidence of Parkinson Disease in French Women From the E3N Cohort Study|10.1212/wnl.0000000000201468
Genetics in parkinson’s disease: From better disease understanding to machine learning based precision medicine|10.3389/fmmed.2022.933383
Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study|10.1177/13524585221125381
Progressive Supranuclear Palsy Syndrome Associated With a Novel Tauopathy|10.1212/wnl.0000000000201485
147th Annual Meeting American Neurological Association|10.1002/ana.26484
33RD International Symposium on the Autonomic Nervous System|10.1007/s10286-022-00892-z
Atypical antipsychotic use and mortality risk in Parkinson disease|10.1016/j.parkreldis.2022.08.013
Delivery of RNA Therapeutics: The Great Endosomal Escape!|10.1089/nat.2022.0004
Diagnosis and Medical Management of Parkinson Disease|10.1212/con.0000000000001152
Diagnosis and Treatment of Cognitive and Neuropsychiatric Symptoms in Parkinson Disease and Dementia With Lewy Bodies|10.1212/con.0000000000001151
ECTRIMS 2022 – Poster|10.1177/13524585221123687
Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation|10.1016/j.drudis.2022.06.005
Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker|10.1038/s41594-022-00837-0
Identification of Drugs Associated with Lower Risk of Parkinson’s Disease Using a Systematic Screening Approach in a Nationwide Nested Case–Control Study|10.2147/clep.s381289
Intermuscular coherence as a biomarker of subthalamic nucleus deep brain stimulation efficacy in Parkinson’s disease|10.1016/j.clinph.2022.07.489
Issue Overview|10.1212/01.con.0000892540.33029.c0
Mechanisms of NLRP3 activation and pathology during neurodegeneration|10.1016/j.biocel.2022.106273
Neurodegenerative Cerebellar Ataxia|10.1212/con.0000000000001180
Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina|10.1002/jex2.59
Prodromal α-Synucleinopathies|10.1212/con.0000000000001153
Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: A systematic review and meta-analysis|10.1016/j.cyto.2022.156006
Triplication of Synaptojanin 1 in Alzheimer’s Disease Pathology in Down Syndrome|10.2174/1567205020666221202102832
[18F]NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinson’s Disease|10.3390/cells11193081
Artificial intelligence for detection of Alzheimer's disease: demonstration of real-world value is required to bridge the translational gap|10.1016/s2589-7500(22)00190-x
ATP1A3‐Related Relapsing Encephalopathy with Cerebellar Ataxia (RECA): A Genetic Disorder with an Inflammatory Basis?|10.1002/mdc3.13564
Ca 2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons|10.1126/sciadv.abp8701
Daily-Living Freezing of Gait as Quantified Using Wearables in People With Parkinson Disease: Comparison With Self-Report and Provocation Tests|10.1093/ptj/pzac129
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release|10.1002/mds.29235
Movement Disorder Society Unified Parkinson's Disease Rating Scale Motor Examination Retains Its 2‐Domain Profile in Both On and Off States|10.1002/mdc3.13566
Safety of deep brain stimulation in pregnancy: A comprehensive review|10.3389/fnhum.2022.997552
Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiology|10.1016/j.ebiom.2022.104290
Radiolabeled Aminopyrazoles as Novel Isoform Selective Probes for pJNK3 Quantification|10.1021/acsmedchemlett.2c00278
Serum peroxiredoxin 3 is reduced in genetic carriers of Parkinson’s disease|10.1136/jnnp-2022-329433
Age-Related Adaptive Immune Changes in Parkinson’s Disease|10.3233/jpd-223228
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease|10.3233/jpd-223277
Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease|10.3233/jpd-223241
Epidemiological Evidence for an Immune Component of Parkinson’s Disease|10.3233/jpd-223180
Freezing of gait is a risk factor for cognitive decline in Parkinson’s disease|10.1007/s00415-022-11371-w
GBA1 and The Immune System: A Potential Role in Parkinson’s Disease?|10.3233/jpd-223423
Genomics transformer for diagnosing Parkinson's disease|10.1109/bhi56158.2022.9926815
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies|10.3233/jpd-223245
Neuronal Presentation of Antigen and Its Possible Role in Parkinson’s Disease|10.3233/jpd-223153
Blood based biomarkers for movement disorders|10.1111/ane.13700
LRRK2 phosphorylation of Rab GTPases in Parkinson's disease|10.1002/1873-3468.14492
Quantification of the purinergic P2X7 receptor with [11C]SMW139 improves through correction for brain-penetrating radiometabolites|10.1177/0271678x221126830
Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players|10.1007/s00259-022-05963-x
Effect Modification between Genes and Environment and Parkinson's Disease Risk|10.1002/ana.26467
Glycolysis: The Next Big Breakthrough in Parkinson’s Disease|10.1007/s12640-022-00579-3
Relationship between Substantia Nigra Neuromelanin Imaging and Dual Alpha-Synuclein Labeling of Labial Minor in Salivary Glands in Isolated Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease|10.3390/genes13101715
A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation|10.7554/elife.79771
Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease|10.1002/mds.29212
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study|10.1002/mds.29221
Parkinson’s disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2β), and NR4A2 (NURR1) in cortical neurons|10.1038/s41531-022-00355-2
DORIS: A diffusion MRI-based 10 tissue class deep learning segmentation algorithm tailored to improve anatomically-constrained tractography|10.3389/fnimg.2022.917806
Large-scale biophysically detailed model of somatosensory thalamocortical circuits in NetPyNE|10.3389/fninf.2022.884245
Temporal order of clinical and biomarker changes in familial frontotemporal dementia|10.1038/s41591-022-01942-9
Concerns about the European Academy's Recommendations and Guidelines Regarding Pallidotomy for Parkinson's Disease|10.1111/ene.15569
Cumulative Effect of Head Injuries on Nonmotor Outcomes in Parkinson’s Disease|10.1176/appi.neuropsych.21100257
Monitoring gait at home with radio waves in Parkinson’s disease: A marker of severity, progression, and medication response|10.1126/scitranslmed.adc9669
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration|10.1038/s41467-022-32944-3
Relationship of serum beta‐synuclein with blood biomarkers and brain atrophy|10.1002/alz.12790
Association of Total Bilirubin with Motor Signs in Early Parkinson’s Disease in LRRK2 Variant Carriers|10.1007/s12031-022-02067-x
Botulinum Toxin in the Treatment of Cervical Dystonia: Evidence-Based Review|10.3389/dyst.2022.10655
Clinical autonomic nervous system laboratories in Europe|10.1111/ene.15538
Interpretable deep learning of myelin histopathology in age-related cognitive impairment|10.1186/s40478-022-01425-5
The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines|10.1093/hmg/ddac233
In situ structural analysis reveals membrane shape transitions during autophagosome formation|10.1073/pnas.2209823119
Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivo|10.1007/s00401-022-02491-8
Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities|10.3390/cells11182908
Serial olfactory testing for the diagnosis of prodromal Parkinson's disease in the PARS study|10.1016/j.parkreldis.2022.09.007
Automatic Assessment of Intelligibility in Noise in Parkinson Disease: Validation Study|10.2196/40567
Atypical Parkinsonism with Pathological Dopamine Transporter Imaging in Neuronal Ceroid Lipofuscinosis Type 5|10.1002/mdc3.13562
Soft, biocompatible materials and skin-like electronics as wearable devices: an interview with John A. Rogers|10.1093/nsr/nwac191
Brain-restricted mTOR inhibition with binary pharmacology|10.1038/s41586-022-05213-y
Gaps, Controversies, and Proposed Roadmap for Research in Poststroke Movement Disorders|10.1002/mds.29218
Is Pathology Always the Diagnostic Gold Standard in Neurodegeneration?|10.1002/mdc3.13570
Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease|10.1002/mds.29220
Subcellular Fractionation for the Isolation of Synaptic Components from the Murine Brain|10.3791/64574
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?|10.1002/mds.29224
Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort|10.1186/s13041-022-00964-1
BLENDS: Augmentation of Functional Magnetic Resonance Images for Machine Learning Using Anatomically Constrained Warping|10.1089/brain.2021.0186
Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques|10.3390/ijms231810651
Integrating multi-omics summary data using a Mendelian randomization framework|10.1093/bib/bbac376
Timing of Physical Therapy Sessions for Individuals With Parkinson Disease May Unlock Benefits|10.1001/jamaneurol.2022.2649
Prion 2022 Conference abstracts: pushing the boundaries|10.1080/19336896.2022.2091286
Age Cutoff for Early‐Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease|10.1002/mdc3.13523
Joint Modeling Study Identifies Blood‐Based Transcripts Link to Cognitive Decline in Parkinson's Disease|10.1002/mds.29213
Clinicopathologic Correlations of Jaw Tremor in a Longitudinal Aging Study|10.1212/cpj.0000000000200072
Contextual in situ help for visual data interfaces|10.1177/14738716221120064
Cytosolic sequestration of spatacsin by Protein Kinase A and 14-3-3 proteins|10.1016/j.nbd.2022.105858
Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors|10.3390/s22186831
Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks|10.1038/s41746-022-00674-x
Does Head Tremor Predict Postural Instability After Bilateral Thalamic Stimulation in Essential Tremor?|10.1007/s12311-022-01477-2
Effective R2 relaxation rate, derived from dual-contrast fast-spin-echo MRI, enables detection of hemisphere differences in iron level and dopamine function in Parkinson’s disease and healthy individuals|10.1016/j.jneumeth.2022.109708
Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at 16q11.2 and MAPT H1 loci|10.1093/brain/awac325
The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations|10.1002/mds.29215
Highly efficient generation of isogenic pluripotent stem cell models using prime editing|10.7554/elife.79208
Paper Spray Ionization Ion Mobility Mass Spectrometry of Sebum Classifies Biomarker Classes for the Diagnosis of Parkinson’s Disease|10.1021/jacsau.2c00300
Frontostriatal and limbic contributions to cognitive decline in Parkinson's disease|10.1111/jon.13045
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts|10.1002/mds.29216
Selected autonomic signs and symptoms as risk markers for phenoconversion and functional dependence in prodromal Parkinson’s disease|10.1007/s10286-022-00889-8
A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson’s Disease|10.3233/jpd-223262
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies|10.3233/jpd-212986
Adaptive structural changes in the motor cortex and white matter in Parkinson’s disease|10.1007/s00401-022-02488-3
Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease|10.1212/wnl.0000000000201201
The Gray Area of Freezing of Gait Annotation: A Guideline and Open‐Source Practical Tool|10.1002/mdc3.13556
The Role of Parkinson Nurses for Personalizing Care in Parkinson’s Disease: A Systematic Review and Meta-Analysis|10.3233/jpd-223215
Abstracts|10.1002/mds.29223
ABSTRACTS of ICPE 2022, the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Copenhagen, Denmark, 26–28 August, 2022|10.1002/pds.5518
Autonomic changes in Huntington’s disease correlate with altered central autonomic network connectivity|10.1093/braincomms/fcac253
Concerns About the European Academy's Recommendations and Guidelines Regarding Pallidotomy for Parkinson's Disease|10.1002/mds.29210
Decreased vestibular efficacy contributes to abnormal balance in Parkinson's disease|10.1016/j.jns.2022.120357
Early‐Onset Neurodevelopmental Movement Disorder Secondary to Novel Mutation in KCNN2|10.1002/mdc3.13535
Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data|10.1016/j.neurobiolaging.2022.03.019
Identification of risk genes for Alzheimer’s disease by gene embedding|10.1016/j.xgen.2022.100162
Intraindividual variability in neuropsychological performance predicts longitudinal cortical volume loss in early Parkinson’s disease.|10.1037/neu0000809
Levodopa Responsive Dystonia Parkinsonism, Intellectual Disability, and Optic Atrophy Due to a Heterozygous Missense Variant in AFG3L2|10.1002/mdc3.13538
Microglia: Friend and foe in tauopathy|10.1016/j.pneurobio.2022.102306
Neurofilament light as a biomarker for motor decline in Parkinson’s disease|10.3389/fnins.2022.959261
Olfactory dysfunction in COVID-19: pathology and long-term implications for brain health|10.1016/j.molmed.2022.06.005
Remodeling of the Cortical Structural Connectome in Posttraumatic Stress Disorder: Results From the ENIGMA-PGC Posttraumatic Stress Disorder Consortium|10.1016/j.bpsc.2022.02.008
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease|10.1002/mds.29193
Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading|10.1126/sciadv.abn0356
“Stretched Slinky” Sign|10.1212/cpj.0000000000200075
Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson’s disease phenotypes|10.1038/s41531-022-00373-0
Mechanisms controlling selective elimination of damaged lysosomes|10.1016/j.cophys.2022.100590
Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity|10.1038/s41593-022-01140-3
PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain|10.1042/bcj20220308
Identifying Protective Drugs for Parkinson's Disease in Health‐Care Databases Using Machine Learning|10.1002/mds.29205
Longitudinal corpus callosum microstructural decline in early-stage Parkinson’s disease in association with akinetic-rigid symptom severity|10.1038/s41531-022-00372-1
Neuropathologic validation of the Alzheimer’s Questionnaire|10.1007/s40520-022-02222-9
Patient‐Reported Symptoms in the Global Multiple System Atrophy Registry|10.1002/mdc3.13544
Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism|10.1002/mds.29197
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?|10.1002/mds.29202
Leveraging Patient Preference Information in Medical Device Clinical Trial Design|10.1007/s43441-022-00450-9
Multi-predictor modeling for predicting early Parkinson’s disease and non-motor symptoms progression|10.3389/fnagi.2022.977985
Analysis of sleep, daytime sleepiness, and autonomic function in multiple system atrophy and Parkinson disease: a prospective study|10.5664/jcsm.10268
Evaluation of Compensation Strategies for Gait Impairment in Patients With Parkinson Disease|10.1212/wnl.0000000000201159
Multiple system atrophy|10.1038/s41572-022-00382-6
Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients|10.3390/ijms23179639
Hypermobile Ehlers‐Danlos Syndrome: A Prodromal Subtype of Functional Movement Disorders?|10.1002/mdc3.13545
Untwisted α-Synuclein Filaments Formed in the Presence of Lipid Vesicles|10.1021/acs.biochem.2c00283
Beyond ATP, new roles of mitochondria|10.1042/bio_2022_119
Childhood‐Onset Choreo‐Dystonia Due to a Recurrent Novel Homozygous Nonsense HPCA Variant: Case Series and Literature Review|10.1002/mdc3.13529
Common Variants Near ZIC1 and ZIC4 in Autopsy‐Confirmed Multiple System Atrophy|10.1002/mds.29164
Non-reference genome transposable elements (TEs) have a significant impact on the progression of the Parkinson’s disease|10.1177/15353702221117147
Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease|10.1002/mds.29188
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II|10.3389/fneur.2022.994114
Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals|10.1038/s41591-022-01932-x
Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease|10.1002/mds.29184
Generation of realistic synthetic data using Multimodal Neural Ordinary Differential Equations|10.1038/s41746-022-00666-x
Catechol-containing compounds are a broad class of protein aggregation inhibitors: Redox state is a key determinant of the inhibitory activities|10.1016/j.phrs.2022.106409
Low Frequency of p.S510G in PIAS1 Challenges its Relevance for Modifying Repeat Expansion Disorders|10.1002/mds.29191
Magnetic Resonance T1w/T2w Ratio in the Putamen and Cerebellum as a Marker of Cognitive Impairment in MSA: a Longitudinal Study|10.1007/s12311-022-01455-8
Estrogen-related receptor gamma regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy|10.1038/s41531-022-00369-w
GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein|10.1126/science.abk0637
Toward preventing Parkinson’s disease|10.1126/science.add7162
Transition Services for Children and Young Adults with Movement Disorders: A Survey by the MDS Task Force on Pediatrics|10.1002/mdc3.13549
Unveiling the B cell receptor structure|10.1126/science.add8065
An economic evaluation of the NightWatch for children with refractory epilepsy: Insight into the cost-effectiveness and cost-utility|10.1016/j.seizure.2022.08.003
Deciphering the molecular mechanism and crosstalk between Parkinson's disease and breast cancer through multi-omics and drug repurposing approach|10.1016/j.npep.2022.102283
Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS)|10.1016/j.parkreldis.2022.08.002
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease|10.1186/s13024-022-00554-8
Endosomal-Lysosomal and Autophagy Pathway in Alzheimer’s Disease: A Systematic Review and Meta-Analysis|10.3233/jad-220360
Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease|10.1212/wnl.0000000000200699
Neuroprotective Trials in REM Sleep Behavior Disorder|10.1212/wnl.0000000000200235
Outcome Assessment in Parkinson Disease Prevention Trials|10.1212/wnl.0000000000200236
Path to Parkinson Disease Prevention|10.1212/wnl.0000000000200793
Repeat‐Associated Non‐AUG Translation of AGAGGG Repeats that Cause X‐Linked Dystonia‐Parkinsonism|10.1002/mds.29183
Who to Enroll in Parkinson Disease Prevention Trials?|10.1212/wnl.0000000000200812
Lifestyle Interventions for the Prevention of Parkinson Disease|10.1212/wnl.0000000000200787
Planning for Prevention of Parkinson Disease|10.1212/wnl.0000000000200789
Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease|10.1002/mds.29189
What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?|10.1212/wnl.0000000000200786
Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease|10.3389/fneur.2022.971252
Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model|10.1016/j.neuropharm.2022.109213
Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases|10.1002/mds.29171
A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease|10.1212/nxg.0000000000200008
Aberrant splicing of PSEN2, but not PSEN1, in individuals with sporadic Alzheimer’s disease|10.1093/brain/awac294
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding|10.1042/bcj20220161
Longitudinal Mediating Effect of Depression on the Relationship between Excessive Daytime Sleepiness and Activities of Daily Living in Parkinson’s Disease|10.1080/07317115.2022.2111014
Management of dysphagia and gastroparesis in Parkinson’s disease in real-world clinical practice – Balancing pharmacological and non-pharmacological approaches|10.3389/fnagi.2022.979826
Structural Insights and Development of LRRK2 Inhibitors for Parkinson’s Disease in the Last Decade|10.3390/genes13081426
Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson’s disease patients|10.1038/s41531-022-00366-z
The Role of Rab Proteins in Parkinson’s Disease Synaptopathy|10.3390/biomedicines10081941
Gray Matter Volume Loss in Proposed Brain‐First and Body‐First Parkinson's Disease Subtypes|10.1002/mds.29172
Scalable approaches for functional analyses of whole-genome sequencing non-coding variants|10.1093/hmg/ddac191
Parkinson’s Disease and Sugar Intake—Reasons for and Consequences of a Still Unclear Craving|10.3390/nu14153240
Views of in‐person and virtual group exercise before and during the pandemic in people with Parkinson disease|10.1002/pmrj.12848
Endolysosomal cholesterol export: More than just NPC1|10.1002/bies.202200111
Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation|10.1038/s41531-022-00363-2
Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysis|10.3389/fneur.2022.927573
Increased Phospho‐AKT in Blood Cells from LRRK2 G2019S Mutation Carriers|10.1002/ana.26469
Increasing Computational Protein Design Literacy through Cohort-Based Learning for Undergraduate Students|10.1021/acs.jchemed.2c00500
Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease|10.1002/mdc3.13533
Systematic Functional Analysis of PINK1 and PRKN Coding Variants|10.3390/cells11152426
The Role of Transportation in the Enrollment of Elderly African Americans into Exercise and Memory Study: GEMS Study|10.1007/s40615-022-01367-7
Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease|10.1002/mds.29157
The economic imperatives for technology enabled wellness centered healthcare|10.1057/s41271-022-00356-8
Clinical trajectories and biomarkers for weight variability in early Parkinson’s disease|10.1038/s41531-022-00362-3
Putting participants and study partners FIRST when clinical trials end early|10.1002/alz.12732
An overview of the active clinical trials for Parkinson’s disease psychosis|10.2217/nmt-2022-0020
Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis|10.1016/j.parkreldis.2022.06.004
Cellular senescence: a key therapeutic target in aging and diseases|10.1172/jci158450
Diagnosis and treatment of orthostatic hypotension|10.1016/s1474-4422(22)00169-7
Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease|10.1016/j.nbd.2022.105744
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic|10.2217/nmt-2021-0055
Isotope tracing in health and disease|10.1016/j.copbio.2022.102739
Late Breaking Orals|10.1002/jev2.12252
Microbes and Parkinson’s disease: from associations to mechanisms|10.1016/j.tim.2022.01.004
Mitochondrial hyperfusion via metabolic sensing of regulatory amino acids|10.1016/j.celrep.2022.111198
Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis|10.1016/j.cell.2022.06.038
Parkinson’s Disease Severity Estimation using Deep Learning and Cloud Technology|10.1109/coins54846.2022.9854945
Peripheral tau as a biomarker for neurodegenerative diseases: is life on Earth, life on Mars?|10.1093/brain/awac281
PLA2G6-associated neurodegeneration in four different populations-case series and literature review|10.1016/j.parkreldis.2022.06.016
Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”?|10.1002/mds.29136
Reply to: “Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1‐Associated Parkinson's Disease”|10.1002/mds.29131
Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism|10.1016/j.phrs.2022.106338
The frontostriatal subtype of mild cognitive impairment in Parkinson's disease, but not the posterior cortical one, is associated with specific EEG alterations|10.1016/j.cortex.2022.04.015
What have we learned from genome-wide association studies (GWAS) in Parkinson's disease?|10.1016/j.arr.2022.101648
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein|10.3791/63313
Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination|10.1038/s41531-022-00360-5
Movement disorders of the mouth: a review of the common phenomenologies|10.1007/s00415-022-11299-1
Neurofilament light levels predict clinical progression and death in multiple system atrophy|10.1093/brain/awac253
Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel|10.1007/s40120-022-00388-y
FDG-PET combined with learning vector quantization allows classification of neurodegenerative diseases and reveals the trajectory of idiopathic REM sleep behavior disorder|10.1016/j.cmpb.2022.107042
Measurement Properties of Clinical Scales Rating the Severity of Blepharospasm: A Multicenter Observational Study|10.1002/mdc3.13530
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living|10.3791/63978
Application of longitudinal item response theory models to modeling Parkinson’s disease progression|10.1002/psp4.12853
Association of a common genetic variant with Parkinson’s disease is mediated by microglia|10.1126/scitranslmed.abp8869
Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson's Disease Dementia: A 36 Months Follow Up Study|10.1002/mdc3.13510
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways|10.1186/s13195-022-01044-1
Exogenous Tetranectin Alleviates Pre-formed-fibrils-induced Synucleinopathies in SH-SY5Y Cells by Activating the Plasminogen Activation System|10.1007/s11064-022-03673-2
Influence of Age on Magnitude and Timing of Vasodepression and Cardioinhibition in Tilt-Induced Vasovagal Syncope|10.1016/j.jacep.2022.05.009
Recent advances in establishing fluid biomarkers for the diagnosis and differentiation of alpha-synucleinopathies – a mini review|10.1007/s10286-022-00882-1
Table for One|10.1097/01.nnn.0000856280.92010.9b
Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease|10.1001/jamanetworkopen.2022.23821
Disruption of Dopamine Receptor 1 Localization to Primary Cilia Impairs Signaling in Striatal Neurons|10.1523/jneurosci.0497-22.2022
Shared mechanisms across the major psychiatric and neurodegenerative diseases|10.1038/s41467-022-31873-5
Chemical Replacement of Noggin with Dorsomorphin Homolog 1 for Cost-Effective Direct Neuronal Conversion|10.1089/cell.2021.0200
Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis|10.1002/ana.26462
Studying cognitive function in patients with a long-standing diagnosis of SWEDD|10.1016/j.jns.2022.120353
Association between Functional Connectivity of Entorhinal Cortex and Olfactory Performance in Parkinson’s Disease|10.3390/brainsci12080963
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies|10.1038/s41531-022-00357-0
Profiling the NOTCH2NLC GGC Repeat Expansion in Parkinson's Disease in the European Population|10.1002/mds.29155
Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions|10.1002/mds.29126
Reliability of Automatic Computer Vision-Based Assessment of Orofacial Kinematics for Telehealth Applications|10.1159/000525698
Targeting retinoic acid receptor alpha-corepressor interaction activates chaperone-mediated autophagy and protects against retinal degeneration|10.1038/s41467-022-31869-1
Patients with Parkinson's disease and a history of falls have decreased cerebellar grey matter volumes in the cognitive cerebellum|10.1016/j.neurol.2022.05.002
Disrupted Brain Structural Network Connection in de novo Parkinson's Disease With Rapid Eye Movement Sleep Behavior Disorder|10.3389/fnhum.2022.902614
Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age|10.1016/j.ebiom.2022.104179
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease|10.1038/s41531-022-00354-3
Neural correlates of risky decision making in Parkinson’s disease patients with impulse control disorders|10.1007/s00221-022-06423-6
2022 Emerging Science Abstracts|10.1212/wnl.0000000000200917
Characterization of Non‐Motor Fluctuations Using the Movement Disorder Society Non‐Motor Rating Scale|10.1002/mdc3.13520
Heterogeneous pain trajectories in persons with Parkinson's disease|10.1016/j.parkreldis.2022.07.006
Increased Subcortical Sodium Levels in Patients with Progressive Supranuclear Palsy|10.3390/biomedicines10071728
Sex and Race Reporting and Representation in Noncancerous Voice Clinical Trials: A Meta-Analysis of National Institutes of Health–Registered Research Between 1988 and 2021|10.1044/2022_jslhr-22-00141
17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes|10.1186/s13024-022-00551-x
Agglomerative and divisive hierarchical Bayesian clustering|10.1016/j.csda.2022.107566
Deep brain stimulation for obsessive–compulsive disorder: a crisis of access|10.1038/s41591-022-01879-z
Feedforward activation of PRKN/parkin|10.1080/15548627.2022.2100615
From the prodromal stage of multiple sclerosis to disease prevention|10.1038/s41582-022-00686-x
Identifying and characterising sources of variability in digital outcome measures in Parkinson’s disease|10.1038/s41746-022-00643-4
Mapping microstructural gradients of the human striatum in normal aging and Parkinson’s disease|10.1126/sciadv.abm1971
Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson’s disease|10.1038/s41598-022-15874-4
Mitochondrial DNA variation in Parkinson’s disease: Analysis of “out-of-place” population variants as a risk factor|10.3389/fnagi.2022.921412
Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures|10.1186/s40478-022-01399-4
Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: study rationale and protocol|10.1186/s12883-022-02770-7
Characterization of Early Stage Parkinson's Disease From Resting-State fMRI Data Using a Long Short-Term Memory Network|10.3389/fnimg.2022.952084
In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts|10.1073/pnas.2203769119
Studying the Parkinson’s disease metabolome and exposome in biological samples through different analytical and cheminformatics approaches: a pilot study|10.1007/s00216-022-04207-z
Within-host evolution of a gut pathobiont facilitates liver translocation|10.1038/s41586-022-04949-x
A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism|10.1111/neup.12848
A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells|10.1073/pnas.2200553119
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity|10.1002/alz.12697
Isolated Craniocervical Dystonia Without Initial Neuropsychiatric Manifestations Associated with NMDA‐Receptor Antibodies|10.1002/mdc3.13517
Analysis of EEG for Parkinson’s Disease Detection|10.1109/spcom55316.2022.9840776
Height and nigral neuron density in Parkinson’s disease|10.1186/s12883-022-02775-2
Six Action Steps to Address Global Disparities in Parkinson Disease|10.1001/jamaneurol.2022.1783
Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity|10.3389/fnagi.2022.930315
Viewpoint on Milestones for Fellowship Training in Movement Disorders|10.1002/mds.29146
GRN Mutations Are Associated with Lewy Body Dementia|10.1002/mds.29144
The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited|10.1002/mds.29133
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?|10.3233/jpd-223183
Exosomes in Alpha-Synucleinopathies: Propagators of Pathology or Potential Candidates for Nanotherapeutics?|10.3390/biom12070957
Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons|10.1016/j.neuron.2022.06.006
Pedunculopontine Nucleus Dysconnectivity Correlates With Gait Impairment in Parkinson’s Disease: An Exploratory Study|10.3389/fnagi.2022.874692
Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson’s disease-associated GBA gene|10.1038/s42003-022-03610-7
Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations?|10.1002/mds.29132
European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies|10.1111/ene.15386
Structural connectivity alterations in the motor network of patients with scans without evidence of dopaminergic deficit (SWEDD)|10.1007/s00415-022-11259-9
A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson’s disease with dementia|10.1093/braincomms/fcac175
Gut instincts in neuroimmunity from the eighteenth to twenty-first centuries|10.1007/s00281-022-00948-2
Neural Correlates of Optimal Deep Brain Stimulation for Cervical Dystonia|10.1002/ana.26450
Power and Sample Size for Longitudinal Models in R -- The longpower Package and Shiny App|10.32614/rj-2022-022
Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice|10.7554/elife.75253
A biological classification of Huntington's disease: the Integrated Staging System|10.1016/s1474-4422(22)00120-x
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases|10.1016/j.pneurobio.2022.102270
An MDS Evidence‐Based Review on Treatments for Huntington's Disease|10.1002/mds.29059
CD11b agonists offer a novel approach for treating lupus nephritis|10.1016/j.trsl.2022.03.001
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply|10.1001/jamaneurol.2022.1604
Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson’s disease|10.1016/j.nbd.2022.105721
Diabetes and Neuroaxonal Damage in Parkinson's Disease|10.1002/mds.29067
Editor's Note|10.1002/mds.29149
European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies|10.1002/mds.29066
ID:16203 Brachial Plexus Stimulation for Refractory Neuropathic Upper Limb Pain in a Traumatic Brain Injury Patient|10.1016/j.neurom.2022.02.011
ID:16220 Visualization Tool for DBS Programming Used With a Multiple-Source, Constant-Current System Reduces Initial Programming Time|10.1016/j.neurom.2022.02.012
Inconsistency and incongruence: the two diagnostic pillars of functional movement disorder|10.1016/s0140-6736(22)01184-9
Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios|10.2147/dnnd.s245197
L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome|10.1016/j.parkreldis.2022.05.023
Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy|10.1186/s40035-022-00309-x
LRRK2 as a target for modulating immune system responses|10.1016/j.nbd.2022.105724
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease|10.1007/s40265-022-01747-7
Parkinson's Progression Markers Initiative brain autopsy program|10.1016/j.parkreldis.2022.06.017
Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment|10.1007/s40120-022-00375-3
Reply to: “Diabetes and Neuroaxonal Damage in Parkinson's Disease”|10.1002/mds.29064
Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala|10.7554/elife.78055
The emerging role of LRRK2 in tauopathies|10.1042/cs20220067
The LRRK2 signaling network converges on a centriolar phospho-Rab10/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization|10.1242/bio.059468
Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants|10.1016/j.parkreldis.2022.06.021
Editorial: Digital Innovation and Data-Driven Research in Neurodegenerative Diseases|10.3389/fneur.2022.961847
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat|10.1016/j.ejphar.2022.175090
OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE|10.3389/fneur.2022.914486
A Ranking-based Weakly Supervised Learning model for telemonitoring of Parkinson’s disease|10.1080/24725579.2022.2091065
Geometric framework to predict structure from function in neural networks|10.1103/physrevresearch.4.023255
Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's disease|10.1016/j.parkreldis.2022.06.013
A late-onset neurological disorder: is progression inevitable?|10.1016/j.parkreldis.2022.06.014
Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism|10.1016/j.parkreldis.2022.06.019
Telemedicine as an Untapped Opportunity for Parkinson’s Nurses Training in Personalized Care Approaches|10.3390/jpm12071057
Aromaticity at position 39 in α‐synuclein: A modulator of amyloid fibril assembly and membrane‐bound conformations|10.1002/pro.4360
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease|10.1001/jamaneurol.2022.1601
Dopamine transporter single-photon emission computed tomography-derived radiomics signature for detecting Parkinson’s disease|10.1186/s13550-022-00910-1
Evaluation of the effects of the mGlu2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset|10.1007/s43440-022-00378-9
Genetic prediction of impulse control disorders in Parkinson's disease|10.1002/acn3.51569
Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson’s disease: correlation with postural and gait deficits|10.1007/s00702-022-02523-3
Cathepsin B p.Gly284Val Variant in Parkinson’s Disease Pathogenesis|10.3390/ijms23137086
ggtranscript: an R package for the visualization and interpretation of transcript isoforms usingggplot2|10.1093/bioinformatics/btac409
Olfactory Bulb Amyloid-β Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment|10.1093/jnen/nlac042
ePosters|10.1111/ene.15466
Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis|10.1016/j.molcel.2022.06.005
Plcg2M28L Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice|10.3389/fnagi.2022.886575
Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder|10.3233/jpd-223201
Symposia|10.1111/ene.15461
Abnormal DaTscan in GM1‐Gangliosidosis Type III Manifesting with Dystonia‐Parkinsonism|10.1002/mdc3.13512
Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor|10.1002/mds.29130
Impact of the COVID-19 Pandemic on the Behavioral Health of People With Intellectual and Developmental Disabilities|10.1176/appi.ps.202100524
Physical inactivity is associated with Parkinson's disease mild cognitive impairment and dementia|10.1016/j.mhpa.2022.100461
Physical inactivity links depressive symptoms and cognitive functioning among individuals with Parkinson’s disease.|10.1037/neu0000837
Association of Concurrent Olfactory Dysfunction and Probable Rapid Eye Movement Sleep Behavior Disorder with Early Parkinson's Disease Progression|10.1002/mdc3.13511
Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts|10.1136/jnnp-2021-327376
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease|10.1186/s40478-022-01388-7
Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites|10.3389/fnins.2022.900338
Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms|10.1002/mds.29128
Genome Sequencing in the Parkinson Disease Clinic|10.1212/nxg.0000000000200002
Measuring evolution learning: impacts of student participation incentives and test timing|10.1186/s12052-022-00166-2
Multimodal deep learning for Alzheimer’s disease dementia assessment|10.1038/s41467-022-31037-5
Satellite repeat transcripts modulate heterochromatin condensates and safeguard chromosome stability in mouse embryonic stem cells|10.1038/s41467-022-31198-3
Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study|10.1002/alz.12696
Moving the Dial Toward Equity in Parkinson’s Disease Clinical Research: a Review of Current Literature and Future Directions in Diversifying PD Clinical Trial Participation|10.1007/s11910-022-01212-8
Differential impact of individual autonomic domains on clinical outcomes in Parkinson’s disease|10.1007/s00415-022-11221-9
Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease|10.1002/mds.29124
Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial|10.1007/s40120-022-00371-7
Racial Disparities Remain in Access to Deep Brain Stimulation|10.1097/01.nt.0000840588.90259.50
The Association of CSF sTREM2 With Cognitive Decline and Its Dynamic Change in Parkinson's Disease: Analysis of the PPMI Cohort|10.3389/fnagi.2022.892493
Racial disparities in hypertension management among multiple sclerosis patients|10.1016/j.msard.2022.103972
Relationships of self-reported and objective measures of sleep, sleepiness, and sleep quality in Parkinson's disease|10.1016/j.parkreldis.2022.06.009
Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia|10.1002/mds.29057
Integrating Data Directly into Publications with Augmented Reality and Web-Based Technologies – Schol-AR|10.1038/s41597-022-01426-y
Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment|10.1093/braincomms/fcac155
Investigational therapeutics for the treatment of progressive supranuclear palsy|10.1080/13543784.2022.2087179
Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease|10.1016/j.parkreldis.2022.06.007
Association Between Dopaminergic Medications and the Evolution of REM Sleep Behavior Disorder in Parkinson's Disease|10.3389/fneur.2022.880583
Associations of Sleep Disorders With Depressive Symptoms in Early and Prodromal Parkinson’s Disease|10.3389/fnagi.2022.898149
Breakthrough News in Adenoviral Vector‐Mediated AADC Gene Therapy: Lessons from the Success in AADC Deficiency and Possible Future Applications|10.1002/mdc3.13503
Quantitative determination of LY‐404,039, a metabotropic glutamate 2/3 receptor agonist, in rat plasma using chemical derivatization and HPLC–MRM/MS|10.1002/bmc.5423
Closing the loop for patients with Parkinson disease: where are we?|10.1038/s41582-022-00674-1
Incidence of amyotrophic lateral sclerosis in older adults|10.1002/mus.27652
Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy|10.1038/s41531-022-00335-6
WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson’s Disease Monocytes|10.3389/fncel.2022.892899
A step forward for LRRK2 inhibitors in Parkinson’s disease|10.1126/scitranslmed.abq7374
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts|10.1038/s41531-022-00336-5
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop|10.1007/s11910-022-01207-5
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease|10.1126/scitranslmed.abj2658
Structure of the second phosphoubiquitin–binding site in parkin|10.1016/j.jbc.2022.102114
The immunology of Parkinson’s disease|10.1007/s00281-022-00947-3
Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia|10.3233/jpd-213126
Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson’s Disease Trials|10.3233/jpd-223274
Predicting the onset of freezing of gait in Parkinson’s disease|10.1186/s12883-022-02713-2
PRKRAP1 and Other Pseudogenes in Movement Disorders: The Troublemakers in Genetic Analyses Are More Than Genomic Fossils|10.1002/mdc3.13499
Quantitative Digitography Measures Motor Symptoms and Disease Progression in Parkinson’s Disease|10.3233/jpd-223264
Association of Structural Measurements of Brain Reserve With Motor Progression in Patients With Parkinson Disease|10.1212/wnl.0000000000200814
Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive Factors|10.1002/mds.29077
Interventions for preventing falls in Parkinson's disease|10.1002/14651858.cd011574.pub2
Long‐term independence and quality of life after subthalamic stimulation in Parkinson disease|10.1111/ene.15436
Structure–Functional Selectivity Relationship Studies on A-86929 Analogs and Small Aryl Fragments toward the Discovery of Biased Dopamine D1 Receptor Agonists|10.1021/acschemneuro.2c00235
Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease|10.3389/fneur.2022.889647
Unraveling trajectories of diffusive particles on networks|10.1103/physrevresearch.4.023182
Olfaction and apathy in early idiopathic Parkinson's disease|10.1016/j.jns.2022.120314
Are Virtual Objective Assessments of Fall‐Risk Feasible and Safe for People with Parkinson's Disease?|10.1002/mdc3.13494
Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant|10.1212/wnl.0000000000200737
ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling|10.1083/jcb.202106046
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease|10.1080/14737175.2022.2091436
Subacute tremor and ataxia: Diligence in pursuit of a diagnosis|10.1016/j.parkreldis.2022.05.016
Targeted copy number variant identification across the neurodegenerative disease spectrum|10.1002/mgg3.1986
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting|10.1038/s41531-022-00330-x
A unifying model for the role of the ATG8 system in autophagy|10.1242/jcs.258997
Abstracts|10.1002/mds.29002
Back to the Office|10.1097/01.nnn.0000834412.51769.b3
Cellular mechanism of action of 2-nitroimidazoles as hypoxia-selective therapeutic agents|10.1016/j.redox.2022.102300
Coaching About Parkinson's Disease|10.1097/01.nnn.0000834388.63255.a1
Cognitive Syndromes Associated With Movement Disorders|10.1212/con.0000000000001134
Coping Styles in Patients with Parkinson’s Disease: Consideration in the Co-Designing of Integrated Care Concepts|10.3390/jpm12060921
Emerging roles of endoplasmic reticulum proteostasis in brain development|10.1016/j.cdev.2022.203781
Exploration of whether socioeconomic factors affect the results of priority setting partnerships: updating the top 10 research priorities for the management of Parkinson’s in an international setting|10.1136/bmjopen-2021-049530
Glucose-lowering drugs, cognition, and dementia: The clinical evidence|10.1016/j.neubiorev.2022.104654
Group Exercise Classes Are Fun and Motivating|10.1097/01.nnn.0000834396.10260.d4
Immune responses in the Parkinson's disease brain|10.1016/j.nbd.2022.105700
Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson’s disease|10.1016/j.xpro.2022.101445
Issue Overview|10.1212/01.con.0000840008.09408.75
Molecular mechanisms defining penetrance of LRRK2-associated Parkinson’s disease|10.1515/medgen-2022-2127
Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies|10.3390/ijms23116216
Pets May Be Good for Brain Health|10.1097/01.nnn.0000834384.40968.7e
Pre‐existing humoral immune comebacks control the development of the severe form of coronavirus disease 2019 in Gaucher patients|10.1002/ctd2.96
Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s disease|10.1016/j.xcrm.2022.100661
Tageslichtlenksysteme mittels Spiegeloptiken|10.1002/bapi.202200011
The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability|10.1016/j.cell.2022.05.008
The Regulation of Immunity|10.4049/jimmunol.2290007
The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease|10.1016/j.nbd.2022.105687
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease|10.1001/jamaneurol.2022.1166
GBA-associated PD: chances and obstacles for targeted treatment strategies|10.1007/s00702-022-02511-7
Mutation Screening of TFG in α‐Synucleinopathy and Amyotrophic Lateral Sclerosis|10.1002/mds.29079
Quality of Life for Patients With Parkinson Disease|10.1212/wnl.0000000000200741
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis|10.1212/wnl.0000000000200745
Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status|10.1007/s10072-022-06129-1
Heart-brain synchronization breakdown in Parkinson’s disease|10.1038/s41531-022-00323-w
Immune Senescence, Immunosenescence and Aging|10.3389/fragi.2022.900028
Inhibition of autophagic flux by S-nitrosylation of SQSTM1/p62 promotes neuronal secretion and cell-to-cell transmission of SNCA/α-synuclein in Parkinson disease and Lewy body dementia|10.1080/27694127.2022.2076770
Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement|10.1016/j.isci.2022.104476
Deep learning architectures for Parkinson's disease detection by using multi-modal features|10.1016/j.compbiomed.2022.105610
Electrocorticography is superior to subthalamic local field potentials for movement decoding in Parkinson’s disease|10.7554/elife.75126
Elucidating the importance and regulation of key enhancers for human MEIS1 expression|10.1038/s41375-022-01602-4
Experienced Respiratory Symptoms and the Impact on Daily Life from the Perspective of People with Parkinson’s Disease: A Grounded Theory|10.3233/jpd-213121
Genome-wide analysis furthers decoding of Alzheimer disease genetics|10.1038/s41582-022-00678-x
Biallelic variants in ZNF142 lead to a syndromic neurodevelopmental disorder|10.1111/cge.14165
Corticobasal Syndrome with TAR Binding Protein 43–Positive Oligodendrocyte Inclusions|10.1002/mds.29070
Explainable machine learning with pairwise interactions for the classification of Parkinson’s disease and SWEDD from clinical and imaging features|10.1007/s11682-022-00688-9
Intracellular Aβ42 Aggregation Leads to Cellular Thermogenesis|10.1021/jacs.2c03599
The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged Humans|10.3389/fnagi.2022.902191
Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage|10.1002/mds.29062
How Flavonoids Affect Parkinson's Disease|10.1097/01.nnn.0000834392.64279.cf
Library-Derived Peptide Aggregation Modulators of Parkinson’s Disease Early-Onset α-Synuclein Variants|10.1021/acschemneuro.2c00190
The Role of Ubiquitin in Regulating Stress Granule Dynamics|10.3389/fphys.2022.910759
Automatic Facial Asymmetry Analysis for Elderly Stroke Detection by using Cosine Similarity|10.1109/ecti-con54298.2022.9795508
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein|10.1038/s41531-022-00322-x
Brain atrophy pattern in de novo Parkinson’s disease with probable RBD associated with cognitive impairment|10.1038/s41531-022-00326-7
Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action|10.3233/jpd-223190
Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE‐PD observational study|10.1111/ane.13648
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update|10.3233/jpd-229002
Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease|10.1002/alz.12684
Structural Connectivity of Subthalamic Nucleus Stimulation for Improving Freezing of Gait|10.3233/jpd-212997
Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function|10.1186/s40478-022-01374-z
Combining Neuroimaging and Omics Datasets for Disease Classification Using Graph Neural Networks|10.3389/fnins.2022.866666
Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson’s disease patients|10.1080/00207454.2022.2079501
Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism|10.3390/ijms23105842
Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia|10.1212/wnl.0000000000200582
Virtual exam for Parkinson’s disease enables frequent and reliable remote measurements of motor function|10.1038/s41746-022-00607-8
How to proceed after “negative” exome: A review on genetic diagnostics, limitations, challenges, and emerging new multiomics techniques|10.1002/jimd.12507
A History of Senile Plaques: From Alzheimer to Amyloid Imaging|10.1093/jnen/nlac030
Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression|10.1093/brain/awac187
Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity|10.3233/jpd-213128
Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease|10.1002/ana.26410
Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study|10.3390/brainsci12050661
Association between probable REM sleep behavior disorder and increased dermal alpha-synuclein deposition in Parkinson's disease|10.1016/j.parkreldis.2022.05.010
Personalized Care in Late-Stage Parkinson’s Disease: Challenges and Opportunities|10.3390/jpm12050813
Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?|10.1002/mds.29058
Symptomatic Care in Multiple System Atrophy: State of the Art|10.1007/s12311-022-01411-6
Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review|10.3389/dyst.2022.10359
Combining biomarkers for prognostic modelling of Parkinson’s disease|10.1136/jnnp-2021-328365
Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study|10.1002/mdc3.13471
Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension|10.1016/j.parkreldis.2022.05.002
Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease|10.1093/brain/awac176
Path analysis of biomarkers for cognitive decline in early Parkinson’s disease|10.1371/journal.pone.0268379
Sex differences in the genetic architecture of cognitive resilience to Alzheimer’s disease|10.1093/brain/awac177
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?|10.1002/mds.29052
Periodic Limb Movements while Awake (PLMA) as a Manifestation of Wearing‐Off in Parkinson's Disease: A Case Series and Review of the Literature|10.1002/mdc3.13487
Diagnostic accuracy of keystroke dynamics as digital biomarkers for fine motor decline in neuropsychiatric disorders: a systematic review and meta-analysis|10.1038/s41598-022-11865-7
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease|10.1038/s41531-022-00317-8
Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer’s Disease and Primary Tauopathy Postmortem Brains|10.3233/jad-220125
Perry Syndrome with Intrafamilial Heterogeneity in Presentation and Survival Including Acute Respiratory Failure: Case Series|10.1002/mdc3.13473
Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology|10.1002/mds.29044
TDP‐43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease|10.1002/mds.29048
Dopaminergic Positron Emission Tomography Imaging in the Alpha‐Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease|10.1002/mds.29051
Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method|10.3390/diagnostics12051161
Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease|10.1002/mds.29041
Diagnostic classification of Parkinson’s disease based on non-motor manifestations and machine learning strategies|10.1007/s00521-022-07256-8
Early Parkinson’s Disease Phenotypes Tailored by Personality, Behavior, and Motor Symptoms|10.3233/jpd-213070
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease|10.1002/mds.29043
Patterns of Beginning of Dose Motor Deterioration: A New Look at an Old Phenomenon|10.1002/mdc3.13470
The chaperone Clusterin in neurodegeneration−friend or foe?|10.1002/bies.202100287
A Markov random field model-based approach for differentially expressed gene detection from single-cell RNA-seq data|10.1093/bib/bbac166
ATXN2 intermediate expansions in amyotrophic lateral sclerosis|10.1093/brain/awac167
Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative|10.1002/gps.5727
Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord|10.1093/brain/awac165
Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes|10.1002/pds.5448
Generation of homozygous PRKN, PINK1 and double PINK1/PRKN knockout cell lines from healthy induced pluripotent stem cells using CRISPR/Cas9 editing|10.1016/j.scr.2022.102806
Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease|10.1007/s10072-022-06110-y
Vocal changes in a zebra finch model of Parkinson’s disease characterized by alpha-synuclein overexpression in the song-dedicated anterior forebrain pathway|10.1371/journal.pone.0265604
Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes|10.1186/s13195-022-00983-z
Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms|10.3233/jpd-223285
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions|10.1080/14740338.2022.2069240
Incidence of Parkinson Disease in North America (P1-1.Virtual)|10.1212/wnl.98.18_supplement.2665
Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD) (P9-11.006)|10.1212/wnl.98.18_supplement.1529
The Huntington’s Disease Health Index: Initial Evaluation of a Disease-Specific Patient Reported Outcome Measure|10.3233/jhd-210506
SHIP164 is a chorein motif lipid transfer protein that controls endosome–Golgi membrane traffic|10.1083/jcb.202111018
Sleep, Pain, and Neurodegeneration: A Mendelian Randomization Study|10.3389/fneur.2022.765321
Structural basis for feedforward control in the PINK1/Parkin pathway|10.15252/embj.2021109460
Abstracts|10.1002/mdc3.13411
Alternative protective group strategy for the radiosynthesis of Flortaucipir 18F|10.1016/s0969-8051(22)00208-6
Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo|10.1016/j.xcrm.2022.100630
Die Folgen der Schulgeldfreiheit – Wissenschaft nachgefragt|10.1055/a-1815-6034
Exposure to Pesticides Predicts Prodromal Feature of Parkinson's Disease: Public Health Implications|10.1002/mds.29012
Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: A randomized controlled trial|10.1016/j.brs.2022.05.012
Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursors|10.1016/s0969-8051(22)00209-8
Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synuclein|10.1016/s0969-8051(22)00207-4
Physical activity and exercise for people with Parkinson’s|10.47795/fenh4822
Schwungvolles Gehen – Musikalisches Feedback in der Parkinsontherapie|10.1055/a-1788-9184
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease|10.1186/s40035-022-00298-x
The role of primary and secondary delays in the effective resonance frequency of acoustically interacting microbubbles|10.1016/j.ultsonch.2022.106033
Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics|10.1002/mds.29042
The path linking excessive daytime sleepiness and activity of daily living in Parkinson’s disease: the longitudinal mediation effect of autonomic dysfunction|10.1007/s10072-022-06081-0
A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity|10.1126/sciadv.abn0044
Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease|10.3233/jpd-223223
DARQ: Deep learning of quality control for stereotaxic registration of human brain MRI to the T1w MNI-ICBM 152 template|10.1016/j.neuroimage.2022.119266
Effect of olfactory bulb pathology on olfactory function in normal aging|10.1111/bpa.13075
Level I PD‐MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia|10.1002/mdc3.13451
Pathway‐Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease|10.1002/mds.29030
Recurrent Biallelic p.L347P PINK1 Variant in Polynesians with Parkinsonism and Isolated Dopa‐Responsive Dystonia|10.1002/mdc3.13467
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial|10.1016/j.ebiom.2022.104021
DYT‐TUBB4A (DYT4 Dystonia): Clinical Anthology of 11 Cases and Systematized Review|10.1002/mdc3.13452
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update|10.1002/mds.28982
Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion|10.1136/jnnp-2021-328547
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease|10.3389/fnins.2022.848215
Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy|10.1212/wnl.0000000000200136
Sudden Death and Cardiac Arrythmia With Lamotrigine|10.1212/wnl.0000000000200164
Lipid level alteration in human and cellular models of alpha synuclein mutations|10.1038/s41531-022-00313-y
Deep Brain Stimulation for Parkinson’s Disease: Why Earlier Use Makes Shared Decision Making Important|10.1007/s12152-022-09496-w
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation|10.1002/mds.29025
Signaling cascades in the failing heart and emerging therapeutic strategies|10.1038/s41392-022-00972-6
Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s disease|10.1038/s41531-022-00308-9
A Machine Learning Approach to Parkinson’s Disease Blood Transcriptomics|10.3390/genes13050727
Impaired bed mobility in prediagnostic and de novo Parkinson's disease|10.1016/j.parkreldis.2022.04.007
Integrating human brain proteomes with genome-wide association data implicates novel proteins in post-traumatic stress disorder|10.1038/s41380-022-01544-4
Lyso-IP: Uncovering Pathogenic Mechanisms of Lysosomal Dysfunction|10.3390/biom12050616
Protracted course progressive supranuclear palsy|10.1111/ene.15346
Symptom Severity Mixity in Older-Age Bipolar Disorder: Analyses From the Global Aging and Geriatric Experiments in Bipolar Disorder Database (GAGE-BD)|10.1016/j.jagp.2022.03.007
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy|10.1002/mds.29005
Women Caring for Husbands Living with Parkinson’s Disease: A Phenomenological Study Protocol|10.3390/jpm12050659
Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study|10.1016/j.parkreldis.2022.04.001
Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson’s Disease|10.3233/jpd-213143
Lipid Peroxidation Induced ApoE Receptor-Ligand Disruption as a Unifying Hypothesis Underlying Sporadic Alzheimer’s Disease in Humans|10.3233/jad-220071
Redefining the hypotheses driving Parkinson’s diseases research|10.1038/s41531-022-00307-w
Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?|10.3233/jpd-223170
Allele-specific analysis reveals exon- and cell-type-specific regulatory effects of Alzheimer’s disease-associated genetic variants|10.1038/s41398-022-01913-1
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease|10.1001/jamaneurol.2022.0676
Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis|10.1002/mdc3.13459
Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children|10.1002/mds.29027
Task Force Consensus on Nosology and Cut‐Off Values for Axial Postural Abnormalities in Parkinsonism|10.1002/mdc3.13460
Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer|10.1155/2022/5899728
Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer’s Disease to Parkinson’s Disease|10.3233/jpd-212989
Conditions Associated with On‐State Freezing of Gait|10.1002/mdc3.13445
REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study|10.1007/s00415-022-11120-z
A data-driven model of brain volume changes in progressive supranuclear palsy|10.1093/braincomms/fcac098
Analysis of modular gene co-expression networks reveals molecular pathways underlying Alzheimer’s disease and progressive supranuclear palsy|10.1371/journal.pone.0266405
The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models|10.1242/dmm.049192
Advanced‐Stage Parkinson's Disease: From Identification to Characterization Using a Nationwide Database|10.1002/mdc3.13458
Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease|10.1212/wnl.0000000000200113
Machine Learning Models for Diagnosis of Parkinson’s Disease Using Multiple Structural Magnetic Resonance Imaging Features|10.3389/fnagi.2022.808520
Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase|10.1016/j.neuropharm.2022.109058
Does Prefrontal Glutamate Index Cognitive Changes in Parkinson’s Disease?|10.3389/fnhum.2022.809905
Palladium-Catalyzed α-Arylation of Cyclic β-Dicarbonyl Compounds for the Synthesis of CaV1.3 Inhibitors|10.1021/acsomega.2c00889
Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease|10.1002/mds.28992
Editorial: LRRK2—Fifteen Years From Cloning to the Clinic|10.3389/fnins.2022.880914
Effect of Exercise and Rehabilitation Therapy on Risk of Hospitalization in Parkinson's Disease|10.1002/mdc3.13456
Multiomics implicate gut microbiota in altered lipid and energy metabolism in Parkinson’s disease|10.1038/s41531-022-00300-3
Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables|10.1007/s10072-022-06061-4
Tumor suppressor PALB2 maintains redox and mitochondrial homeostasis in the brain and cooperates with ATG7/autophagy to suppress neurodegeneration|10.1371/journal.pgen.1010138
Distinct CholinomiR Blood Cell Signature as a Potential Modulator of the Cholinergic System in Women with Fibromyalgia Syndrome|10.3390/cells11081276
Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia|10.1016/j.neurobiolaging.2022.03.018
Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson’s disease (randomized controlled trial)|10.1186/s13063-022-06160-9
GBA Variants and Parkinson Disease: Mechanisms and Treatments|10.3390/cells11081261
Wolframin is a novel regulator of tau pathology and neurodegeneration|10.1007/s00401-022-02417-4
Neuropsychological Functioning in Primary Dystonia: Updated and Expanded Multidomain Meta‐Analysis|10.1002/mds.29022
Transcriptional landscape of human microglia implicates age, sex, and APOE ‐related immunometabolic pathway perturbations|10.1111/acel.13606
Evolution patterns of probable REM sleep behavior disorder predicts Parkinson’s disease progression|10.1038/s41531-022-00303-0
Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes|10.1038/s41467-022-29444-9
Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson’s Disease|10.3233/jpd-212787
Tele-Yoga for the Management of Cervical Dystonia: A Safety and Feasibility Trial|10.3389/dyst.2021.10015
A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity|10.1007/s13311-022-01199-7
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments|10.1002/mds.28991
A randomized clinical trial of burst vs. spaced physical therapy for Parkinsons disease|10.1016/j.parkreldis.2022.02.021
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches|10.1016/s1474-4422(21)00377-x
Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson’s Disease — The RESISTA-PD Trial|10.1016/j.gpb.2021.08.009
Functional tremor|10.1016/j.jns.2022.120208
Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology|10.1016/j.jns.2022.120197
La thérapie comportementale et cognitive pour l’anxiété dans la maladie de Parkinson induit des modifications cérébrales fonctionnelles|10.1016/j.neurol.2022.02.152
Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials|10.2217/nmt-2021-0051
Mechanisms underlying ubiquitin-driven selective mitochondrial and bacterial autophagy|10.1016/j.molcel.2022.03.012
Multi-modality machine learning predicting Parkinson’s disease|10.1038/s41531-022-00288-w
New insights into the genetic etiology of Alzheimer’s disease and related dementias|10.1038/s41588-022-01024-z
The clinical and electrophysiological investigation of tremor|10.1016/j.clinph.2022.01.004
The Faces of Parkinson's Disease: Helping Students Realize It Is More Than Tremors|10.3928/01484834-20220209-08
Une valine 11 codée par le gène HLA-DRB1 est associée inversement au risque de maladie de Parkinson et interagit avec l’initiation du tabagisme|10.1016/j.neurol.2022.02.151
Methylated Cytochrome P450 and the Solute Carrier Family of Genes Correlate With Perturbations in Bile Acid Metabolism in Parkinson’s Disease|10.3389/fnins.2022.804261
Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson’s disease|10.1038/s41598-022-09506-0
Structural and biochemical insights into lipid transport by VPS13 proteins|10.1083/jcb.202202030
Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort|10.1002/alz.12632
Generation of two human induced pluripotent stem cell lines from fibroblasts of Parkinson’s disease patients carrying the ILE368ASN mutation in PINK1 (LCSBi002) and the R275W mutation in Parkin (LCSBI004)|10.1016/j.scr.2022.102765
Hierarchical Denoising of Ordinal Time Series of Clinical Scores|10.1109/jbhi.2022.3163126
Transmembrane protein ATG-9 links presynaptic autophagy with the synaptic vesicle cycle|10.1080/15548627.2022.2049151
Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages|10.1038/s41531-022-00297-9
Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study|10.1002/mds.28990
Comparison of Chinese and American subjects on the self‐administered Waterless Empirical Taste Test|10.1111/joss.12745
CRISPR/Cas9‐Based Functional Genomics in Human Induced Pluripotent Stem Cell–Derived Models: Can “the Stars Align” for Neurodegenerative Diseases?|10.1002/mds.28998
Initiation and progression of α-synuclein pathology in Parkinson’s disease|10.1007/s00018-022-04240-2
Label-Free Characterization of Amyloids and Alpha-Synuclein Polymorphs by Exploiting Their Intrinsic Fluorescence Property|10.1021/acs.analchem.1c05651
Sensitivity to Change and Patient‐Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data‐Driven Analysis|10.1002/mds.28993
Smoking is associated with age at disease onset in Parkinson's disease|10.1016/j.parkreldis.2022.03.005
Foundations of circadian medicine|10.1371/journal.pbio.3001567
Sensor Measurements Can Characterize Fluctuations and Wearing Off in Parkinson’s Disease and Guide Therapy to Improve Motor, Non-motor and Quality of Life Scores|10.3389/fnagi.2022.852992
Uncovering Essential Tremor Genetics: The Promise of Long-Read Sequencing|10.3389/fneur.2022.821189
Brain health: The hidden casualty of a humanitarian crisis|10.1016/j.lanepe.2022.100374
Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease|10.1212/wnl.0000000000013303
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma|10.1158/1535-7163.mct-21-0836
Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease|10.2217/nmt-2021-0057
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England|10.1007/s40273-022-01132-y
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures|10.1038/s41531-022-00282-2
Structure-constrained combination-based nonlinear association analysis between incomplete multimodal imaging and genetic data for biomarker detection of neurodegenerative diseases|10.1016/j.media.2022.102419
Co-evolution of machine learning and digital technologies to improve monitoring of Parkinson’s disease motor symptoms|10.1038/s41746-022-00568-y
Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells|10.1002/2211-5463.13398
Serine/Threonine Protein Phosphatase 2A Regulates the Transport of Axonal Mitochondria|10.3389/fncel.2022.852245
The emerging postural instability phenotype in idiopathic Parkinson disease|10.1038/s41531-022-00287-x
A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively|10.3390/cells11061018
Adaptive and pathological connectivity responses in Parkinson’s disease brain networks|10.1093/cercor/bhac110
Large-scale societal dynamics are reflected in human mood and brain|10.1038/s41598-022-08569-3
Roles of Insect Oenocytes in Physiology and Their Relevance to Human Metabolic Diseases|10.3389/finsc.2022.859847
Tracking cortical excitability dynamics with transcranial magnetic stimulation in focal epilepsy|10.1002/acn3.51535
Influence of Adding Nano Particles on Dissipation Factor and Volume Resistivity of Polymer|10.1109/micest54286.2022.9790233
Multi-Class Classifier in Parkinson’s Disease Using an Evolutionary Multi-Objective Optimization Algorithm|10.3390/app12063048
Neurofunctional characteristics of executive control in older people with HIV infection: a comparison with Parkinson’s disease|10.1007/s11682-022-00645-6
Longitudinal intronic RNA-Seq analysis of Parkinson’s disease patients reveals disease-specific nascent transcription|10.1177/15353702221081027
Pitfalls and Recommended Strategies and Metrics for Suppressing Motion Artifacts in Functional MRI|10.1007/s12021-022-09565-8
Restless Legs Symptoms and Periodic Leg Movements in Sleep Among Patients with Parkinson’s Disease|10.3233/jpd-213100
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives|10.1002/mds.28984
Gait‐Related Metabolic Covariance Networks at Rest in Parkinson's Disease|10.1002/mds.28977
Incidence of Parkinson’s disease in French women from the E3N cohort study over 27 years of follow-up|10.1007/s10654-022-00851-y
Integrating whole-genome sequencing with multi-omic data reveals the impact of structural variants on gene regulation in the human brain|10.1038/s41593-022-01031-7
Single Molecule Fingerprinting Reveals Different Amplification Properties of α-Synuclein Oligomers and Preformed Fibrils in Seeding Assay|10.1021/acschemneuro.1c00553
Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia|10.1002/mdc3.13437
Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease|10.1002/mds.28986
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease|10.1007/s12325-022-02097-2
The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity|10.1083/jcb.202010065
Aquaporin-4 Polymorphisms Are Associated With Cognitive Performance in Parkinson’s Disease|10.3389/fnagi.2021.740491
Characterisation of the Function of a SINE-VNTR-Alu Retrotransposon to Modulate Isoform Expression at the MAPT Locus|10.3389/fnmol.2022.815695
Implementation and Outcomes of a Movement Disorder Society‐Sponsored Peer Reviewing Education and Mentoring Program|10.1002/mds.28978
Metadata Framework to Support Deployment of Digital Health Technologies in Clinical Trials in Parkinson’s Disease|10.3390/s22062136
Role of Lysosomal Gene Variants in Modulating GBA‐Associated Parkinson's Disease Risk|10.1002/mds.28987
Undetected ophthalmological disorders in Parkinson’s disease|10.1007/s00415-022-11014-0
Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein|10.1038/s41598-022-07706-2
Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration|10.1073/pnas.2121609119
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population|10.1001/jamaneurol.2022.0003
Monogenic Parkinson’s Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing|10.3390/genes13030471
Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson’s Disease and Multiple System Atrophy|10.3390/cells11050906
Unique Astrocyte Cytoskeletal and Nuclear Morphology in a Three-Dimensional Tissue-Engineered Rostral Migratory Stream|10.3390/neuroglia3010003
Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson’s Disease|10.1007/s12325-022-02072-x
A Novel Tissue Atlas and Online Tool for the Interrogation of Small RNA Expression in Human Tissues and Biofluids|10.3389/fcell.2022.804164
Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing|10.1126/sciadv.abm5386
Inflammation and immune dysfunction in Parkinson disease|10.1038/s41577-022-00684-6
Managing freezing of gait in Parkinson’s disease: a systematic review and network meta-analysis|10.1007/s00415-022-11031-z
Overcoming congressional inertia on obesity requires better literacy in obesity science|10.1002/oby.23405
Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury|10.3389/fnhum.2022.813387
Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers|10.1038/s41531-022-00285-z
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study|10.1111/ene.15307
SNCA rs3910105 Is Associated With Development of Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease|10.3389/fnins.2022.832550
The silver linings of Parkinson’s disease|10.1038/s41531-022-00283-1
Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson’s disease|10.1007/s00415-022-11041-x
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine|10.1016/j.parkreldis.2022.02.017
A possible role for VPS13-family proteins in bulk lipid transfer, membrane expansion and organelle biogenesis|10.1242/jcs.259357
Body-first Parkinson’s disease and variant Creutzfeldt–Jakob disease – similar or different?|10.1016/j.nbd.2022.105625
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology|10.1093/brain/awab374
Current Status of Next-Generation Sequencing Approaches for Candidate Gene Discovery in Familial Parkinson´s Disease|10.3389/fgene.2022.781816
Evaluation of the Impact of Integrated Care and Self-Management After Deep Brain Stimulation in Parkinson’s Disease|10.3233/jpd-212911
Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson’s disease|10.1016/j.scr.2022.102733
L1CAM‐associated extracellular vesicles: A systematic review of nomenclature, sources, separation, and characterization|10.1002/jex2.35
Lessons from metabolic perturbations in lysosomal storage disorders for neurodegeneration|10.1016/j.coisb.2021.100408
LRRK2 and idiopathic Parkinson’s disease|10.1016/j.tins.2021.12.002
Lysosomal dysfunction in neurodegeneration: emerging concepts and methods|10.1016/j.tins.2021.12.004
More of less: Novel multi-ome profiling of single human neurons|10.1016/j.xgen.2022.100110
Polygenic burden of Parkinson's disease risk stratifies the prognosis of isolated rapid-eye-movement disorder: A preliminary observational study|10.1016/j.parkreldis.2022.02.005
Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9|10.1016/j.neuron.2021.12.031
Stimulation of the pedunculopontine and cuneiform nuclei for freezing of gait and falls in Parkinson disease: Cross-over single-blinded study and long-term follow-up|10.1016/j.parkreldis.2022.01.010
Targeted Metabolomic Analysis in Alzheimer’s Disease Plasma and Brain Tissue in Non-Hispanic Whites|10.3233/jad-215448
The Role of Insular Cortex in Gut‐Inflammation Memory: What Does It Mean for Parkinson's Disease?|10.1002/mds.28975
A novel risk calculator predicting surgical site infection after spinal surgery in patients with cerebral palsy|10.1111/dmcn.15193
The Disease Modification Conundrum in Parkinson’s Disease: Failures and Hopes|10.3389/fnagi.2022.810860
NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation|10.1155/2022/2337363
A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease|10.1002/mds.28970
Additive Effect of Dopaminergic Medication on Gait Under Single and Dual-Tasking Is Greater Than of Deep Brain Stimulation in Advanced Parkinson Disease With Long-Duration Deep Brain Stimulation|10.1016/j.neurom.2022.01.015
Physician‐Assisted Dying: Access and Utilization in Patients with Movement Disorders|10.1002/mds.28964
Validation of the Arabic Version of the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale|10.1002/mds.28905
CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers|10.3389/fneur.2022.834580
Etiology, pathological characteristics, and clinical management of black pleural effusion|10.1097/md.0000000000028130
Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2|10.1073/pnas.2112712119
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies|10.1007/s40263-022-00903-7
Combining Multimodal Biomarkers to Guide Deep Brain Stimulation Programming in Parkinson Disease|10.1016/j.neurom.2022.01.017
Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes|10.1016/j.nbd.2022.105668
Defining Utility Values for Chorea Health States in Patients with Huntington’s Disease|10.1007/s12325-022-02046-z
Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads|10.7554/elife.73971
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study|10.3389/fneur.2022.773999
Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease|10.1186/s13024-022-00520-4
Correction to Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain|10.1021/acschemneuro.2c00110
Designing the Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson's Disease study|10.1016/j.cct.2022.106713
Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism|10.1002/mds.28961
LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains|10.1371/journal.pbio.3001427
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses|10.1007/s40120-022-00332-0
Prodromal Parkinson's disease: hype or hope for disease-modification trials?|10.1186/s40035-022-00286-1
Qigong Training Positively Impacts Both Posture and Mood in Breast Cancer Survivors With Persistent Post-surgical Pain: Support for an Embodied Cognition Paradigm|10.3389/fpsyg.2022.800727
The Classification Power of Classical and Intra-voxel Incoherent Motion (IVIM) Fitting Models of Diffusion-weighted Magnetic Resonance Images: An Experimental Study|10.1007/s10278-022-00604-z
Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation|10.1093/hmg/ddac035
Prevalence of Prodromal Symptoms of Parkinson’s Disease in the Late Middle-Aged Population|10.3233/jpd-213007
Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight|10.3390/biom12020324
Dynamic interplay of cognitive functioning and depressive symptoms in patients with Parkinson’s disease.|10.1037/neu0000795
Long-term adherence of human brain cells in vitro is enhanced by charged amine-based plasma polymer coatings|10.1016/j.stemcr.2022.01.013
Astrocytic α2-Na + /K + ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model|10.1126/scitranslmed.abm4107
Subtle anomaly detection: Application to brain MRI analysis of de novo Parkinsonian patients|10.1016/j.artmed.2022.102251
Determinants of Self-Stigma in People with Parkinson’s Disease: A Mixed Methods Scoping Review|10.3233/jpd-212869
Neuromelanin‐MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template‐Based Standardized Analysis|10.1002/mds.28934
Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease|10.1007/s10072-022-05952-w
S-Nitrosylation of p62 Inhibits Autophagic Flux to Promote α-Synuclein Secretion and Spread in Parkinson's Disease and Lewy Body Dementia|10.1523/jneurosci.1508-21.2022
Antemortem detection of Parkinson’s disease pathology in peripheral biopsies using artificial intelligence|10.1186/s40478-022-01318-7
Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial|10.1002/mds.28953
De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia|10.1002/mds.28959
Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson’s disease|10.1016/j.omtn.2022.02.007
Cardiac sympathetic innervation in Parkinson’s disease versus multiple system atrophy|10.1007/s10286-022-00853-6
Divergence Between Informant and Self-Ratings of Activities of Daily Living Impairments in Parkinson’s Disease|10.3389/fnagi.2022.838674
Impact of Surgical History on Parkinson's Disease Progression|10.1109/delcon54057.2022.9753658
Trends in the Utilization of Teleneurology and Other Healthcare Resources Prior to and During the COVID-19 Pandemic in an Urban, Tertiary Health System|10.3389/fneur.2022.834708
Semantic Integration of Multi-Modal Data and Derived Neuroimaging Results Using the Platform for Imaging in Precision Medicine (PRISM) in the Arkansas Imaging Enterprise System (ARIES)|10.3389/frai.2021.649970
Special Issue on new therapeutic approaches to Parkinson disease|10.1016/j.neuropharm.2022.108998
Assessing Gq-GPCR–induced human astrocyte reactivity using bioengineered neural organoids|10.1083/jcb.202107135
Autonomic and Depression Symptoms in Parkinson’s Disease: Clinical Evidence for Overlapping Physiology|10.3233/jpd-213075
How Prolonged Isolation Affects People With Parkinson Disease During the COVID-19 Pandemic|10.1001/jama.2022.1510
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies|10.1016/j.parkreldis.2022.01.022
Multi-transcriptomic analysis points to early organelle dysfunction in human astrocytes in Alzheimer's disease|10.1016/j.nbd.2022.105655
The Neuroinflammatory Acute Phase Response in Parkinsonian‐Related Disorders|10.1002/mds.28958
The Utility of Breath Analysis in the Diagnosis and Staging of Parkinson’s Disease|10.3233/jpd-213133
Enhancing clinical information display to improve patient encounters: human-centered design and evaluation of the Parkinson’s Disease-BRIDGE platform (Preprint)|10.2196/33967
Implementation Experience with a 30-Day Hospital Readmission Risk Score in a Large, Integrated Health System: A Retrospective Study|10.1007/s11606-021-07277-4
White Matter Microstructural Alterations in Newly Diagnosed Parkinson’s Disease: A Whole-Brain Analysis Using dMRI|10.3390/brainsci12020227
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers|10.1002/mds.28941
Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients|10.3390/metabo12020149
Automated Video Monitoring of Unmarked and Marked Honey Bees at the Hive Entrance|10.3389/fcomp.2021.769338
Blood GFAP as an emerging biomarker in brain and spinal cord disorders|10.1038/s41582-021-00616-3
Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy|10.1073/pnas.2113489119
Invariable Ribosome Stoichiometry During Murine Erythroid Differentiation: Implications for Understanding Ribosomopathies|10.3389/fmolb.2022.805541
Mapping dopaminergic projections in the human brain with resting-state fMRI|10.7554/elife.71846
Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders|10.1002/mdc3.13412
Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders|10.1002/mdc3.13415
An open-label prospective pilot trial of nucleus accumbens deep brain stimulation for children with autism spectrum disorder and severe, refractory self-injurious behavior: study protocol|10.1186/s40814-022-00988-3
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment|10.1007/s40120-021-00317-5
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study|10.1002/mds.28932
Transition and Sustainability of an Online Care Model for People With Parkinson's Disease in Response to the COVID-19 Pandemic|10.3389/fpubh.2021.772805
Association of Essential Tremor With Novel Risk Loci|10.1001/jamaneurol.2021.4781
Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)|10.1136/bmjopen-2021-052032
Competitive Displacement of De Novo Designed HeteroDimers Can Reversibly Control Protein–Protein Interactions and Implement Feedback in Synthetic Circuits|10.1089/genbio.2021.0011
Deep Learning‐Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder|10.1002/mds.28933
Functional neurological disorder and somatic symptom disorder in Parkinson's disease|10.1016/j.jns.2021.120017
GBA mutations, glucosylceramide and Parkinson's disease|10.1016/j.conb.2021.11.004
Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level|10.1038/s41593-021-00999-y
Model-Protected Multi-Task Learning|10.1109/tpami.2020.3015859
Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms|10.1016/j.nbd.2021.105580
New dopaminergic therapies for PD motor complications|10.1016/j.neuropharm.2021.108869
Parkinsonism and tremor syndromes|10.1016/j.jns.2021.120018
PARkinson's: From cellular mechanisms to potential therapeutics|10.1016/j.pharmthera.2021.107968
PTEN-induced kinase 1 (PINK1) and Parkin: Unlocking a mitochondrial quality control pathway linked to Parkinson's disease|10.1016/j.conb.2021.09.005
Rapid global phaseout of animal agriculture has the potential to stabilize greenhouse gas levels for 30 years and offset 68 percent of CO2 emissions this century|10.1371/journal.pclm.0000010
Reply to: “Age‐Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK‐PD)”|10.1002/mds.28920
Rodent models based on endolysosomal genes involved in Parkinson's disease|10.1016/j.conb.2021.09.004
Targeting cellular senescence with senotherapeutics: senolytics and senomorphics|10.1111/febs.16350
The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life|10.1002/mds.28952
The potential utility of smell testing to screen for neurodegenerative disorders|10.1080/14737159.2022.2037424
ThX: a next generation probe for the early detection of amyloid aggregates|10.1016/j.bpj.2021.11.2608
Uncovering clinical and radiological asymmetry in progressive supranuclear palsy—Richardson’s syndrome|10.1007/s10072-022-05919-x
Archaeological Recovery of Late Pleistocene Hair and Environmental DNA from Interior Alaska|10.1080/14614103.2022.2031836
Dancing Feet Dyskinesia in a Patient with GBA-PD|10.14802/jmd.20169
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium|10.3389/fneur.2021.805135
Magnetic Resonance Parkinsonism Index Is Associated with REM Sleep Behavior Disorder in Parkinson’s Disease|10.3390/brainsci12020202
Prodromal Cognitive Deficits and the Risk of Subsequent Parkinson’s Disease|10.3390/brainsci12020199
Subcellular proteomics of dopamine neurons in the mouse brain|10.7554/elife.70921
Establishing gene regulatory networks from Parkinson’s disease risk loci|10.1093/brain/awac022
Anxiety predicts impulsive-compulsive behaviours in Parkinson's disease: Clinical relevance and theoretical implications|10.1016/j.jpsychires.2022.01.052
One-Carbon Metabolism in Alzheimer’s Disease and Parkinson’s Disease Brain Tissue|10.3390/nu14030599
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease|10.1002/mds.28936
Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective|10.1002/ame2.12209
Investigating Simultaneity for Deep Learning–Enhanced Actual Ultra-Low-Dose Amyloid PET/MR Imaging|10.3174/ajnr.a7410
Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α-Synuclein Converge on Fatty Acid Homeostasis|10.1523/jneurosci.1881-21.2022
Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations|10.1038/s41467-022-28087-0
Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 Pandemic|10.14802/jmd.20126
Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective|10.1080/13696998.2022.2033493
Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study|10.3233/jpd-213039
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial|10.1016/s2666-5247(21)00239-1
Lamina-specific immunohistochemical signatures in the olfactory bulb of healthy, Alzheimer’s and Parkinson’s disease patients|10.1038/s42003-022-03032-5
Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease|10.1016/j.parkreldis.2022.01.017
No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance|10.1002/mds.28935
Down‐Regulation of Dopamine Transporter in Early Premotor Phases|10.1002/mds.28924
Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity|10.1002/mds.28929
Head tremor in cervical dystonia: Quantifying severity with computer vision|10.1016/j.jns.2022.120154
Preventing Parkinson’s Disease: An Environmental Agenda|10.3233/jpd-212922
Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia|10.1002/acn3.51482
Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease|10.1002/mds.28927
Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson’s Disease|10.1155/2022/5597503
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration|10.1016/j.cell.2021.12.041
Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies|10.1002/mds.28921
Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson’s Disease|10.3390/ijms23031089
Alzheimer’s Disease Variant Portal: A Catalog of Genetic Findings for Alzheimer’s Disease|10.3233/jad-215055
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis|10.1002/mds.28923
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment|10.1002/mds.28913
Heterogeneous digital biomarker integration out-performs patient self-reports in predicting Parkinson’s disease|10.1038/s42003-022-03002-x
Higher Risk, Higher Reward? Self‐Reported Effects of Real‐World Cannabis Use in Parkinson's Disease|10.1002/mdc3.13414
Anxiety in Parkinson's disease: A resting-state high density EEG study|10.1016/j.neucli.2022.01.001
Preserved motor memory in Parkinson's disease|10.1016/j.neuropsychologia.2022.108161
FILER: a framework for harmonizing and querying large-scale functional genomics knowledge|10.1093/nargab/lqab123
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype|10.1016/j.ymthe.2022.01.021
Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain|10.3390/molecules27020507
Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels|10.1503/jpn.210113
Movement disorders associated with neuronal antibodies: a data-driven approach|10.1007/s00415-021-10934-7
Novel lower-extremity dexterity assessment for Parkinson’s disease: validation against measures of arm dexterity and general mobility|10.1080/09638288.2021.2025273
Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson’s disease|10.1038/s42003-021-02973-7
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease|10.1002/mds.28912
Editorial introductions|10.1097/wco.0000000000001027
Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease|10.1212/wnl.0000000000013218
Quantum diamond biomarker detection|10.1002/phvs.202270107
Functional characterization of the biogenic amine transporters on human macrophages|10.1172/jci.insight.151892
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries|10.1007/s40120-021-00313-9
A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson’s Disease Clinical Trial: A Pilot Study|10.1159/000521232
Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson’s disease and cognition|10.1016/j.bbi.2022.01.005
Holocue: A Wearable Holographic Cueing Application for Alleviating Freezing of Gait in Parkinson's Disease|10.3389/fneur.2021.628388
Multidimensional nonadditivity in one-facet g-theory designs: A profile analytic approach.|10.1037/met0000452
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain|10.1186/s13024-021-00509-5
Progressive Prefrontal Cortex Dysfunction in Parkinson's Disease With Probable REM Sleep Behavior Disorder: A 3-Year Longitudinal Study|10.3389/fnagi.2021.750767
The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation|10.1016/j.brainres.2022.147781
Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease|10.1002/mds.28897
Sleep and circadian rhythms in Parkinson’s disease and preclinical models|10.1186/s13024-021-00504-w
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study|10.1002/mds.28902
Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline|10.1016/j.parkreldis.2022.01.002
Cardiovascular Risk Factors and Phenoconversion to Neurodegenerative Synucleinopathies in Idiopathic REM Sleep Behavior Disorder|10.3233/jpd-212984
More than Just a Brain Disorder: A Five-Point Manifesto for Psychological Care for People with Huntington’s Disease|10.3390/jpm12010064
A Sensor-Based Perspective in Early-Stage Parkinson’s Disease: Current State and the Need for Machine Learning Processes|10.3390/s22020409
Annexins Bridging the Gap: Novel Roles in Membrane Contact Site Formation|10.3389/fcell.2021.797949
Can Legislation Save the Day for Challenges Related to Prior Authorization?|10.1097/01.nt.0000817608.36002.47
Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels|10.1186/s40478-021-01307-2
Facial Analysis Software Helps Screen for Parkinson's Disease|10.1097/01.nt.0000817640.88538.ff
Sex Differences in Brain and Cognition in de novo Parkinson's Disease|10.3389/fnagi.2021.791532
LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights|10.3390/cells11010169
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers|10.1002/ana.26302
A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration|10.1016/j.nbd.2022.105612
Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease|10.1001/jama.2021.21008
Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease—Reply|10.1001/jama.2021.21011
Error in Figure|10.1001/jama.2021.16187
Error in Figures|10.1001/jama.2021.21948
Imprecise Language|10.1001/jama.2021.22816
Incorrect Affiliation and Address|10.1001/jama.2021.22611
Machine Learning Identifies Six Genetic Variants and Alterations in the Heart Atrial Appendage as Key Contributors to PD Risk Predictivity|10.3389/fgene.2021.785436
Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes|10.1007/s11060-021-03939-9
The National Institute on Aging Late‐Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery|10.1002/alz.12514
A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potential|10.1002/trc2.12274
Advanced diffusion imaging to track progression in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy|10.1016/j.nicl.2022.103022
Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function|10.1016/j.celrep.2021.110090
An atypical ubiquitin ligase at the heart of neural development and programmed axon degeneration|10.4103/1673-5374.338992
Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study|10.1016/j.parkreldis.2021.11.027
Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases|10.1016/j.jbc.2021.101478
Association between cigarette smoking and Parkinson’s disease: a neuroimaging study|10.1177/17562864221092566
Association of vitamin K with cognitive decline and neuropathology in community‐dwelling older persons|10.1002/trc2.12255
At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer’s Disease and Related Research|10.14283/jpad.2022.7
Auto-annotating sleep stages based on polysomnographic data|10.1016/j.patter.2021.100371
c‐Abl Inhibitors as Disease‐Modifying Therapies for Parkinson's Disease: Gaps and Opportunities|10.1002/mds.28907
Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study|10.1016/j.nbas.2022.100039
Characterization of Axon Guidance Phenotypes in Wnt/PCP Mutant Mice|10.1007/978-1-0716-2035-9_17
Clinical neurophysiology of Parkinson’s disease and parkinsonism|10.1016/j.cnp.2022.06.002
Concurrent validity of Zeno instrumented walkway and video-based gait features in adults with Parkinson’s disease|10.1109/jtehm.2022.3180231
Considerations for clinical trial design and conduct in the evaluation of novel advanced therapeutics in neurodegenerative disease|10.1016/bs.irn.2022.09.006
Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset|10.1016/j.neuroscience.2021.11.009
Deep learning for Parkinson’s disease symptom detection and severity evaluation using accelerometer signal|10.14428/esann/2022.es2022-107
Define and visualize pathological architectures of human tissues from spatially resolved transcriptomics using deep learning|10.1016/j.csbj.2022.08.029
Depression and Parkinson's disease: a Chicken-Egg story|10.3934/neuroscience.2022027
Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling|10.1016/j.nicl.2022.103144
Distinct atrophy of septal nuclei in Parkinson’s disease|10.1016/j.prdoa.2022.100171
DNA Sequence Analysis for Brain Disorder Using Deep Learning and Secure Storage|10.32604/cmc.2022.022028
Drug News|10.1097/01.nurse.0000803500.30920.0c
Early Autonomic Symptoms Predict Functional Decline in Parkinson’s Disease Independent of Dopaminergic Therapy|10.1159/000525664
Environmental neurotoxicants and inflammasome activation in Parkinson’s disease – A focus on the gut-brain axis|10.1016/j.biocel.2021.106113
Evaluation of morning bradykinesia in Parkinson’s disease in a United States cohort using continuous objective monitoring|10.1016/j.prdoa.2022.100145
Evaluation of the Dementia Apraxia Test in Parkinson’s Disease Patients|10.1159/000525618
Exploration of Protein Aggregations in Parkinson’s Disease Through Computational Approaches and Big Data Analytics|10.1007/978-1-0716-1546-1_19
Extracellular vesicles in pharmacology: Novel approaches in diagnostics and therapy|10.1016/j.phrs.2021.105980
Extracranial carotid atherosclerosis is associated with increased neurofibrillary tangle accumulation|10.1016/j.jvs.2021.07.238
GaitForeMer: Self-supervised Pre-training of Transformers via Human Motion Forecasting for Few-Shot Gait Impairment Severity Estimation|10.1007/978-3-031-16452-1_13
Gastric acid suppressants and cognitive decline in people with or without cognitive impairment|10.1002/trc2.12243
Hippocampal Functional Connectivity in Parkinson’s Disease|10.1159/000526377
Inclusionary Trials: A Review of Lessons Not Learned|10.1093/epirev/mxac007
Integrating Multimorbidity into a Whole-Body Understanding of Disease Using Spatial Genomics|10.1007/978-3-031-06573-6_5
Machine Learning-Based Prediction of Impulse Control Disorders in Parkinson’s Disease From Clinical and Genetic Data|10.1109/ojemb.2022.3178295
Mapping of a N-terminal α-helix domain required for human PINK1 stabilization, Serine228 autophosphorylation and activation in cells|10.1098/rsob.210264
Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer’s disease topography|10.1016/j.nicl.2022.103080
NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson’s disease using convolutional neural network|10.1016/j.nicl.2022.103250
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study|10.1002/trc2.12329
Poster Session|10.5692/clinicalneurol.62_supplement_s247
POSTERS - 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA|10.14283/jpad.2022.97
Profiles of women in science: Malú Gámez Tansey, Norman and Susan Fixel Professor of Neuroscience and Neurology, Co‐Director of the Center for Translational Research in Neurodegenerative Disease and Director of the Parkinson's Foundation Research Center of Excellence, University of Florida College of Medicine|10.1111/ejn.15578
Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?|10.1016/j.prdoa.2022.100161
Sorting (Nexin-13) out Novel Insights into Endolysosomal Cholesterol Export|10.1177/25152564221114513
Subcellular and regional localization of mRNA translation in midbrain dopamine neurons|10.1016/j.celrep.2021.110208
The many genomes of Parkinson's disease|10.1016/bs.irn.2022.07.007
The neuropsychiatry of Parkinson's disease: advances and challenges|10.1016/s1474-4422(21)00330-6
Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease|10.1124/pharmrev.120.000133
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders|10.1016/j.pharmthera.2021.107937
Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore®|10.1007/s00330-021-08385-9
Vascular risk profile and white matter hyperintensity volume among Mexican Americans and non‐Hispanic Whites: The HABLE study|10.1002/dad2.12263
Western diet associated with increased post-stroke depressive symptoms|10.1017/jns.2022.38
What's New at the Journal in 2022|10.1002/mds.28906
Impact of COVID-19 Pandemic on (Health) Care Situation of People with Parkinson’s Disease in Germany (Care4PD)|10.3390/brainsci12010062
Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel|10.3233/jpd-212979
Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma|10.3390/cancers14010205
Rapid motor progression of Parkinson’s disease associates with clinical and genetic variants|10.52586/5044
Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms|10.3390/ijerph19010364
A Predictive Visual Analytics System for Studying Neurodegenerative Disease Based on DTI Fiber Tracts|10.1109/tvcg.2021.3137174
Multiple Chemical Sensitivity|10.3390/brainsci12010046
Adjunctive Therapies in Parkinson Disease—Have We Made Meaningful Progress?|10.1001/jamaneurol.2021.4140
Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study|10.1159/000520959
Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?|10.3390/biom12010040
Subcortical Iron Accumulation Pattern May Predict Neuropsychological Outcomes After Subthalamic Nucleus Deep Brain Stimulation: A Pilot Study|10.3233/jpd-212833
Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brain|10.1016/j.neures.2021.12.004
Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration|10.1111/acel.13541
Parkinson’s Disease Progression and Statins: Hydrophobicity Matters|10.3233/jpd-212819
Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease|10.1002/mds.28837
Automatic Speech Recognition in Noise for Parkinson's Disease: A Pilot Study|10.3389/frai.2021.809321
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease|10.1002/mds.28883
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait|10.1002/mds.28887
Profiling Parkinson’s disease cognitive phenotypes via resting-state magnetoencephalography|10.1152/jn.00316.2021
Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease|10.1002/mds.28886
The Myelin‐Weighted Connectome in Parkinson's Disease|10.1002/mds.28891
Activation mechanism of PINK1|10.1038/s41586-021-04340-2
Disrupted functional connectivity in PD with probable RBD and its cognitive correlates|10.1038/s41598-021-03751-5
Low plasma serotonin linked to higher nigral iron in Parkinson’s disease|10.1038/s41598-021-03700-2
Targeting KRAS G12C with Covalent Inhibitors|10.1146/annurev-cancerbio-041621-012549
4R-cembranoid protects neuronal cells from oxygen–glucose deprivation by modulating microglial cell activation|10.1016/j.brainresbull.2021.12.007
Movement disorders research in 2021: cracking the paradigm|10.1016/s1474-4422(21)00413-0
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study|10.1016/s1474-4422(21)00368-9
Trajectory Analysis of Orthostatic Hypotension in Parkinson’s Disease: Results From Parkinson’s Progression Markers Initiative Cohort|10.3389/fnagi.2021.762759
Parkinson’s Disease Classification from Magnetic Resonance Images (MRI) using Deep Transfer Learned Convolutional Neural Networks|10.1109/indicon52576.2021.9691745
Practical Application of DaTQUANT with Optimal Threshold for Diagnostic Accuracy of Dopamine Transporter SPECT|10.3390/tomography7040081
Predictors of multi-domain cognitive decline following DBS for treatment of Parkinson's disease|10.1016/j.parkreldis.2021.12.011
Deep Learning-based Parkinson disease Classification using PET Scan Imaging Data|10.1109/iccca52192.2021.9666251
Resting‐State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease‐Mild Cognitive Impairment|10.1002/mds.28888
Contributions of sex, depression, and cognition on brain connectivity dynamics in Parkinson’s disease|10.1038/s41531-021-00257-9
Genetic Evidence Supporting a Causal Role of Depression in Alzheimer’s Disease|10.1016/j.biopsych.2021.11.025
Possible EIF2AK2 ‐Associated Stress‐Related Neurological Decompensation with Combined Dystonia and Striatal Lesions|10.1002/mdc3.13384
What the VaP? The meaning of “vascular parkinsonism”|10.1016/j.parkreldis.2021.12.008
Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease|10.1038/s41531-021-00260-0
Relationship of Genotype, Phenotype, and Treatment in Dopa‐Responsive Dystonia: MDSGene Review|10.1002/mds.28874
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?|10.1038/s41583-021-00542-9
Mutation in protein disulfide isomerase A3 causes neurodevelopmental defects by disturbing endoplasmic reticulum proteostasis|10.15252/embj.2020105531
Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington’s Disease: A Retrospective Database Analysis|10.1007/s40120-021-00309-5
Change in the Parkinson Anxiety Scale correlates with change in other clinical measures of anxiety over time|10.1016/j.prdoa.2021.100126
Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns|10.1093/brain/awab440
Heterozygous PRKN mutations are common but do not increase the risk of Parkinson’s disease|10.1093/brain/awab456
Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression|10.3389/fnins.2021.765765
Self‐Report versus Clinician Examination in Early Parkinson's Disease|10.1002/mds.28884
Leucine rich repeat kinase 2 (LRRK2) peptide modulators: Recent advances and future directions|10.1002/pep2.24251
3D convolutional neural networks for classification of Alzheimer’s and Parkinson’s disease with T1-weighted brain MRI|10.1117/12.2606297
Clinical profiles and outcomes of deep brain stimulation in G2019S LRRK2 Parkinson disease|10.3171/2021.7.jns21190
Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer’s disease|10.1093/braincomms/fcab293
Llamanade: An open-source computational pipeline for robust nanobody humanization|10.1016/j.str.2021.11.006
Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study|10.1016/j.lana.2021.100136
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial|10.3233/jpd-212714
Systematic analysis of PINK1 variants of unknown significance shows intact mitophagy function for most variants|10.1038/s41531-021-00258-8
A Comparative Study of High-Contrast Fluorescence Lifetime Probes for Imaging Amyloid in Tissue|10.1021/acs.jpcb.1c07762
Self-normalized Classification of Parkinson’s Disease DaTscan Images|10.1109/bibm52615.2021.9669820
The effect of polygenic risk on white matter microstructural degeneration in Parkinson's disease: A longitudinal Diffusion Tensor Imaging study|10.1111/ene.15201
Integrated Genomic, Transcriptomic and Proteomic Analysis for Identifying Markers of Alzheimer’s Disease|10.3390/diagnostics11122303
PhosPiR: an automated phosphoproteomic pipeline in R|10.1093/bib/bbab510
Protein Profiling of RGS6, a Pleiotropic Gene Implicated in Numerous Neuropsychiatric Disorders, Reveals Multi-Isoformic Expression and a Novel Brain-Specific Isoform|10.1523/eneuro.0379-21.2021
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies|10.1093/brain/awab431
Radiomics in predicting recurrence for patients with locally advanced breast cancer using quantitative ultrasound|10.18632/oncotarget.28139
Trait Anxiety as a Risk Factor for Impulse Control Disorders in de novo Parkinson’s Disease|10.3233/jpd-212959
Mechanism of PINK1 activation by autophosphorylation and insights into assembly on the TOM complex|10.1016/j.molcel.2021.11.012
Pathological α-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of α-syn in vivo|10.1073/pnas.2108489118
[18F]Nifene PET/CT Imaging in Mice: Improved Methods and Preliminary Studies of α4β2* Nicotinic Acetylcholinergic Receptors in Transgenic A53T Mouse Model of α-Synucleinopathy and Post-Mortem Human Parkinson’s Disease|10.3390/molecules26237360
GPi‐DBS for KMT2B‐Associated Dystonia: Systematic Review and Meta‐Analysis|10.1002/mdc3.13374
How Parkinson’s patients in the USA perceive deep brain stimulation in the 21st century: Results of a nationwide survey|10.1016/j.jocn.2021.11.017
The Human Tic Detector: An automatic approach to tic characterization using wearable sensors|10.1016/j.clinph.2021.10.017
White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia|10.1016/j.neurobiolaging.2021.11.007
Atlas of RNA editing events affecting protein expression in aged and Alzheimer’s disease human brain tissue|10.1038/s41467-021-27204-9
Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease|10.1002/alz.12505
For Some Neurologists, COVID-19 Has Prompted an ‘Existential Crisis’|10.1097/01.nt.0000805196.94665.be
How to Increase Diverse Representation in Parkinson's Disease Trials|10.1097/01.nt.0000805216.68841.48
Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on Neuroinflammation|10.1007/s12035-021-02625-1
MS Study That Spans Decades Indicates Patients Benefit from Early Diagnosis and Treatment|10.1097/01.nt.0000805208.98399.94
Multiplexed Profiling of Extracellular Vesicles for Biomarker Development|10.1007/s40820-021-00753-w
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis|10.1212/wnl.0000000000013121
The contribution of behavioral features to caregiver burden in FTLD spectrum disorders|10.1002/alz.12494
A brief history of nearly EV‐erything – The rise and rise of extracellular vesicles|10.1002/jev2.12144
A Downsized and Optimised Intracellular Library-Derived Peptide Prevents Alpha-Synuclein Primary Nucleation and Toxicity Without Impacting Upon Lipid Binding|10.1016/j.jmb.2021.167323
Amantadine in the treatment of Parkinson's disease and other movement disorders|10.1016/s1474-4422(21)00249-0
Autophagy and the hallmarks of aging|10.1016/j.arr.2021.101468
Corrigendum to “Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys” [EBioMedicine 2020; 59:102944]|10.1016/j.ebiom.2021.103731
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories|10.1186/s13024-021-00491-y
Disease modifying therapies for Parkinson's disease: Novel targets|10.1016/j.neuropharm.2021.108839
Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice|10.1016/j.xcrm.2021.100455
LRRK2 signaling in neurodegeneration: two decades of progress|10.1042/ebc20210013
Neuropathological evidence of body-first vs. brain-first Lewy body disease|10.1016/j.nbd.2021.105557
Programmed autophagy prevents excess organelle baggage during neurogenesis|10.1016/j.molcel.2021.11.034
Progression of Self-Perceived Speech and Swallowing Impairment in Early Stage Parkinson's Disease: Longitudinal Analysis of the Unified Parkinson's Disease Rating Scale|10.1044/2021_jslhr-21-00216
Protocol for the DeFOG trial: A randomized controlled trial on the effects of smartphone-based, on-demand cueing for freezing of gait in Parkinson's disease|10.1016/j.conctc.2021.100817
Soluble P‐tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau|10.1002/alz.050391
Systematic characterization of human gut microbiome-secreted molecules by integrated multi-omics|10.1038/s43705-021-00078-0
The East Asian Parkinson Disease Genomics Consortium|10.1016/s1474-4422(21)00373-2
Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles|10.1002/jev2.12182
Vesicular dysfunction and pathways to neurodegeneration|10.1042/ebc20210034
Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?|10.1093/ageing/afab242
Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults|10.1007/s10072-021-05784-0
A real-world study of wearable sensors in Parkinson’s disease|10.1038/s41531-021-00248-w
An MDS Evidence‐Based Review on Treatments for Huntington's Disease|10.1002/mds.28855
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis|10.1038/s41531-021-00247-x
Approach to Tremor Disorders|10.1055/s-0041-1726356
Correction to: High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease|10.1186/s40478-021-01292-6
Dysprosody in Isolated REM Sleep Behavior Disorder with Impaired Olfaction but Intact Nigrostriatal Pathway|10.1002/mds.28873
Flavaglines: Their Discovery from Plants Used in Traditional Chinese Medicine, Synthesis, and Drug Development Against Cancer and Immune Disorders|10.2174/2666001601666211126091737
Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease|10.1038/s41531-021-00250-2
Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson’s Disease Using a Wrist-Worn Accelerometer|10.3390/s21237876
Update From the Foundation|10.1177/15394492211059406
Silica-coated magnetic-nanoparticle-induced cytotoxicity is reduced in microglia by glutathione and citrate identified using integrated omics|10.1186/s12989-021-00433-y
Predictors of Spiritual Well-Being in Family Caregivers for Individuals with Parkinson's Disease|10.1089/jpm.2020.0797
Alzheimer’s disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions|10.1172/jci149904
Brain Repair by Cell Replacement via In Situ Neuronal Reprogramming|10.1146/annurev-genet-071719-023616
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity|10.1002/mds.28858
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies|10.1001/jamaneurol.2021.4222
Cellular Bioenergetics and AMPK and TORC1 Signalling in Blood Lymphoblasts Are Biomarkers of Clinical Status in FMR1 Premutation Carriers|10.3389/fpsyt.2021.747268
Generation of two human induced pluripotent stem cell lines (iPSCs) with mutations of the α-synuclein (SNCA) gene associated with Parkinson’s disease; the A53T mutation (LCSBi003) and a triplication of the SNCA gene (LCSBi007)|10.1016/j.scr.2021.102600
Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI|10.1038/s41531-021-00241-3
The complexities of CACNA1A in clinical neurogenetics|10.1007/s00415-021-10897-9
Apathy as a Within-Person Mediator of Depressive Symptoms and Cognition in Parkinson's Disease: Longitudinal Mediation Analyses|10.1016/j.jagp.2021.11.007
2021 AAPM&R Annual Assembly Abstracts|10.1002/pmrj.12735
Effect of data leakage in brain MRI classification using 2D convolutional neural networks|10.1038/s41598-021-01681-w
Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern|10.1002/mds.28859
Current Guidelines for Classifying and Diagnosing Cervical Dystonia: Empirical Evidence and Recommendations|10.1002/mdc3.13376
Protective Factors That Maintain Asymptomatic Longevity in Untreated Congenitally Corrected Transposition of Great Arteries|10.1016/j.cjco.2021.11.004
Cerebral Amyloid Angiopathy Is Associated With Emotional Dysregulation, Impulse Dyscontrol, and Apathy|10.1161/jaha.121.022089
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary|10.1212/wnl.0000000000012868
An integrated brain-specific network identifies genes associated with neuropathologic and clinical traits of Alzheimer’s disease|10.1093/bib/bbab522
Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease|10.1002/mds.28849
Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms|10.1002/mdc3.13354
Biofunctionalised bacterial cellulose scaffold supports the patterning and expansion of human embryonic stem cell-derived dopaminergic progenitor cells|10.1186/s13287-021-02639-5
Enhanced Parkinson’s Disease Tremor Severity Classification by Combining Signal Processing with Resampling Techniques|10.1007/s42979-021-00953-6
Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1|10.1126/sciadv.abj0722
Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease|10.1002/mds.28850
Spontaneous Graft‐Induced Dyskinesias Are Independent of 5‐HT Neurons and Levodopa Priming in a Model of Parkinson's Disease|10.1002/mds.28856
Tandem Ring Opening/Intramolecular [2 + 2] Cycloaddition Reaction for the Synthesis of Cyclobutane Fused Thiazolino-2-Pyridones|10.1021/acs.joc.1c01875
The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models|10.3390/biom11111685
Comparison of Transcranial Sonography and [18F]‐Fluorodopa PET Imaging in GBA1 Mutation Carriers|10.1002/mds.28852
Differential Effects of Pathological Beta Burst Dynamics Between Parkinson’s Disease Phenotypes Across Different Movements|10.3389/fnins.2021.733203
Disease Duration Influences Gene Expression in Neuromelanin-Positive Cells From Parkinson’s Disease Patients|10.3389/fnmol.2021.763777
The PINK1—Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells|10.1371/journal.pone.0259903
Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease|10.1007/s10719-021-10023-x
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model|10.1002/alz.12463
Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain|10.1021/acschemneuro.1c00641
Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity|10.1039/d1cb00103e
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis|10.1212/nxi.0000000000001104
Effects of Bolus Holding on Respiratory–Swallow Coordination in Parkinson's Disease|10.1044/2021_ajslp-21-00044
Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein|10.1186/s40478-021-01283-7
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease|10.1186/s40478-021-01282-8;
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease|10.1186/s40478-021-01282-8
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease|10.1002/mds.28846
Deep brain stimulation effect on anterior pallidum reduces motor impulsivity in Parkinson's disease|10.1016/j.brs.2021.11.006
Pedunculopontine and Cuneiform Nuclei Deep Brain Stimulation for Severe Gait and Balance Disorders in Parkinson’s Disease: Interim Results from a Randomized Double-Blind Clinical Trial|10.3233/jpd-212793
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease|10.3233/jpd-212892
Sleep Disorders and Future Diagnosis of Parkinsonism: A Prospective Study Using the Canadian Longitudinal Study on Aging|10.3233/jpd-212796
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II|10.3389/fneur.2021.754016
Bach1 derepression is neuroprotective in a mouse model of Parkinson’s disease|10.1073/pnas.2111643118
Neuroprotektive Therapien bei idiopathischen, genetischen und atypischen Parkinson-Syndromen mit α-Synuklein – Pathologie|10.1007/s00115-021-01220-y
Analysis of Discrepancies Between Pulse Oximetry and Arterial Oxygen Saturation Measurements by Race and Ethnicity and Association With Organ Dysfunction and Mortality|10.1001/jamanetworkopen.2021.31674
Disruption of mitochondrial complex I induces progressive parkinsonism|10.1038/s41586-021-04059-0
Falling down the digital divide: A cautionary tale|10.1016/j.parkreldis.2021.10.032
Longitudinal Analysis of Brain-Predicted Age in Amnestic and Non-amnestic Sporadic Early-Onset Alzheimer's Disease|10.3389/fnagi.2021.729635
Mitochondrial Defects in Fibroblasts of Pathogenic MAPT Patients|10.3389/fcell.2021.765408
Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis|10.1080/14789450.2021.2004890
Prevalence and characteristics of the aberrant anterior tibial artery: a single-center magnetic resonance imaging study and scoping review|10.1186/s12891-021-04801-9
Recruitment for Remote Decentralized Studies in Parkinson’s Disease|10.3233/jpd-212935
The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy|10.3233/jpd-212877
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders|10.1016/j.neubiorev.2021.08.011
Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease|10.1016/j.neurobiolaging.2021.06.005
Citius, Fortius, Altius—Understanding Which Components Drive Exercise Benefits in Parkinson Disease|10.1001/jamaneurol.2021.3744
Common and rare variants in HFE are not associated with Parkinson's disease in Europeans|10.1016/j.neurobiolaging.2021.05.019
Depression Level Prediction in People with Parkinson’s Disease during the COVID-19 Pandemic|10.1109/embc46164.2021.9630566
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo‐Controlled Trial of Rasagiline|10.1002/mds.28838
Early subthalamic nucleus deep brain stimulation in Parkinson’s disease reduces long-term medication costs|10.1016/j.clineuro.2021.106976
Effects of exergaming on hippocampal volume and brain‐derived neurotrophic factor levels in Parkinson’s disease|10.1111/ene.15165
Facial Landmark Tracking in Videos of Individuals with Neurological Impairments: Is There a Trade-off Between Smoothness and Accuracyƒ|10.1109/embc46164.2021.9630639
Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings|10.1016/j.nmd.2021.09.010
Genome-wide association study and functional validation implicates JADE1 in tauopathy|10.1007/s00401-021-02379-z
IL-10: A possible immunobiological component of positive mental health in refugees|10.1016/j.cpnec.2021.100097
NRM 2021 Abstract Booklet|10.1177/0271678x211061050
Quantifying Stridor Associated with Parkinsonism and Deep Brain Stimulation—A Case Report|10.1002/mdc3.13368
Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta‐analysis|10.1002/ehf2.13648
A systematic, concept‐based method of developing the exposure measure for drug safety and effectiveness studies|10.1002/pds.5372
Blood Neurofilament Light Chain in Parkinson’s Disease: Comparability between Parkinson’s Progression Markers Initiative (PPMI) and Asian Cohorts|10.3390/jcm10215085
Regulation of Blood Flow in the Cerebral Posterior Circulation by Parasympathetic Nerve Fibers: Physiological Background and Possible Clinical Implications in Patients With Vertebrobasilar Stroke|10.3389/fneur.2021.660373
Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members|10.5334/tohm.656
Closing the structure-to-function gap for LRRK2|10.1016/j.tibs.2021.10.003
Mental health in people with Parkinson’s disease during the COVID-19 pandemic: potential for targeted interventions?|10.1038/s41531-021-00238-y
Structural basis of polyamine transport by human ATP13A2 (PARK9)|10.1016/j.molcel.2021.08.017
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial|10.1002/mds.28840
Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based 123I-FP-CIT SPECT quantification method|10.1007/s00702-021-02434-9
Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches|10.1042/bcj20210508
MicroED for the study of protein–ligand interactions and the potential for drug discovery|10.1038/s41570-021-00332-y
Improving Patient Outreach by Defining Telehealth Suitability in a Tertiary Huntington’s Disease Clinic|10.3233/jhd-210498
Repeated Gait Perturbation Training in Parkinson's Disease and Healthy Older Adults: A Systematic Review and Meta-Analysis|10.3389/fnhum.2021.732648
Stability Evaluation of Brain Changes in Parkinson's Disease Based on Machine Learning|10.3389/fncom.2021.735991
Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson’s Disease?|10.3390/ijms222111522
MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region|10.1007/s11060-021-03866-9
Temporal proteomics during neurogenesis reveals large-scale proteome and organelle remodeling via selective autophagy|10.1016/j.molcel.2021.10.001
Associations of Body Mass Index-Metabolic Phenotypes with Cognitive Decline in Parkinson’s Disease|10.1159/000517538
Comparison of the Efficacy of Deep Brain Stimulation in Different Targets in Improving Gait in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-Analysis|10.3389/fnhum.2021.749722
The South African Parkinson's Disease Study Collection|10.1002/mds.28828
An initial exploration of the convergent and ecological validity of the UDS 3.0 neuropsychological battery in Parkinson’s Disease|10.1080/13803395.2022.2034753
Energy expenditure, body composition and dietary habits in progressive supranuclear palsy|10.1007/s00415-021-10846-6
Prefrontal Physiomarkers of Anxiety and Depression in Parkinson’s Disease|10.3389/fnins.2021.748165
Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family|10.1002/mds.28833
Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease|10.1002/mdc3.13360
Endoplasmic Reticulum-Based Calcium Dysfunctions in Synucleinopathies|10.3389/fneur.2021.742625
Interaction-Based Feature Selection Algorithm Outperforms Polygenic Risk Score in Predicting Parkinson’s Disease Status|10.3389/fgene.2021.744557
Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder|10.3233/jpd-212867
The commercial genetic testing landscape for Parkinson's disease|10.1016/j.parkreldis.2021.10.001
The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease|10.2217/nmt-2021-0032
North American survey on impact of the COVID-19 pandemic shutdown on DBS care|10.1016/j.parkreldis.2021.10.011
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases|10.1093/brain/awab404
White matter changes in drug-naïve Parkinson's disease patients with impulse control & probable REM sleep behavior disorders|10.1016/j.jns.2021.120032
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome|10.1001/jamanetworkopen.2021.29397
Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain|10.7554/elife.67900
Glucocerebrosidase 1 and leucine‐rich repeat kinase 2 in Parkinson disease and interplay between the two genes|10.1111/jnc.15524
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease|10.1212/wnl.0000000000012952
A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson’s Disease: A Qualitative Study|10.3233/jpd-202457
An Expanded Polyproline Domain Maintains Mutant Huntingtin Soluble in vivo and During Aging|10.3389/fnmol.2021.721749
Small Molecule Improvement of Trafficking Defects in Models of Neurodegeneration|10.1021/acschemneuro.1c00524
A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease|10.1038/s41531-021-00239-x
CD4 + T cells contribute to neurodegeneration in Lewy body dementia|10.1126/science.abf7266
Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum|10.1002/alz.12480
KYNA/Ahr Signaling Suppresses Neural Stem Cell Plasticity and Neurogenesis in Adult Zebrafish Model of Alzheimer’s Disease|10.3390/cells10102748
Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease|10.1016/j.parkreldis.2021.10.010
The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends|10.1038/s41467-021-25966-w
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications|10.1016/j.parkreldis.2021.10.009
Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes|10.1038/s41746-021-00513-5
Generation of two human induced pluripotent stem cell lines from fibroblasts of unrelated Parkinson’s patients carrying the G2019S mutation in the LRRK2 gene (LCSBi005, LCSBi006)|10.1016/j.scr.2021.102569
Lower Circulating Lymphocyte Count Predicts ApoEε4‐Related Cognitive Decline in Parkinson's Disease|10.1002/mds.28799
Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity|10.1002/mds.28829
T lymphocyte senescence is attenuated in Parkinson’s disease|10.1186/s12974-021-02287-9
A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model|10.3233/jpd-212847
Choroidal Thickness Correlates with Clinical and Imaging Metrics of Parkinson’s Disease: A Pilot Study|10.3233/jpd-212676
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials|10.3233/jpd-212672
Exploring the Use of Intracranial and Extracranial (Remote) Photobiomodulation Devices in Parkinson’s Disease: A Comparison of Direct and Indirect Systemic Stimulations|10.3233/jad-210052
Predicting PY motif-mediated protein-protein interactions in the Nedd4 family of ubiquitin ligases|10.1371/journal.pone.0258315
A Novel Variant of ATP5MC3 Associated with Both Dystonia and Spastic Paraplegia|10.1002/mds.28821
Lack of progression of beta dynamics after long‐term subthalamic neurostimulation|10.1002/acn3.51463
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease|10.3233/jpd-212851
Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?|10.1002/mdc3.13347
Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption|10.1038/s41467-021-26066-5
Platelet Behavior Contributes to Neuropathologies: A Focus on Alzheimer's and Parkinson's Disease|10.1055/s-0041-1733960
Population-specific neuromodulation prolongs therapeutic benefits of deep brain stimulation|10.1126/science.abi7852
Visual dysfunction is associated with cognitive impairment in Parkinson's disease|10.1016/j.parkreldis.2021.10.005
Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease|10.1371/journal.pone.0257372
Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models|10.1172/jci.insight.148649
New Insights from a Two-Country Study Comparing Escalation Strategies for MS Drugs|10.1097/01.nt.0000797988.61856.80
Then and Now: 20 Years of Monumental Strides in Movement Disorders|10.1097/01.nt.0000797984.85450.f1
Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease|10.1002/mds.28805
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity|10.1002/mds.28815
Genetic Stratification of Age‐Dependent Parkinson's Disease Risk by Polygenic Hazard Score|10.1002/mds.28808
Increased functional connectivity in a population at risk of developing Parkinson's disease|10.1016/j.parkreldis.2021.09.026
LGALS3 (galectin 3) mediates an unconventional secretion of SNCA/α-synuclein in response to lysosomal membrane damage by the autophagic-lysosomal pathway in human midbrain dopamine neurons|10.1080/15548627.2021.1967615
A novel approach to understanding Parkinsonian cognitive decline using minimum spanning trees, edge cutting, and magnetoencephalography|10.1038/s41598-021-99167-2
Fine-mapping of Parkinson’s disease susceptibility loci identifies putative causal variants|10.1093/hmg/ddab294
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11C]PBR28 and Machine Learning Analysis|10.1002/mds.28814
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome|10.1001/jamanetworkopen.2021.28204
Associations of sleep disorders with cerebrospinal fluid α-synuclein in prodromal and early Parkinson’s disease|10.1007/s00415-021-10812-2
European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part IV: deep brain stimulation|10.1007/s00787-021-01881-9
Early‐Onset Parkinson's Disease: A Novel Deletion Comprising the DJ‐1 and TNFRSF9 Genes|10.1002/mds.28812
T-cell based immunotherapies for Parkinson’s disease|10.37349/ent.2021.00007
Parkinson’s Disease Videos on YouTube: Types and Characteristics of Content on Communication and Cognition|10.1080/15398285.2021.1980692
Predicting Parkinson’s Disease and Its Pathology via Simple Clinical Variables|10.3233/jpd-212876
146th Annual Meeting American Neurological Association|10.1002/ana.26180
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data|10.3389/fneur.2021.705407
Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer’s disease|10.1093/braincomms/fcab281
Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers|10.1016/j.parkreldis.2021.08.008
Application of the mPSPRS to the Salerno Cohort and a Comparison Between PSP‐RS and vPSP|10.1002/mds.28757
Brain atrophy progression in Parkinson’s disease is shaped by connectivity and local vulnerability|10.1093/braincomms/fcab269
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations|10.1002/mds.28818
ECTRIMS 2021 – ePoster|10.1177/13524585211044667
ECTRIMS 2021 – Late Breaking News ePoster|10.1177/13524585211047080
Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease|10.1001/jamaneurol.2021.1312
Enhanced arm swing improves Parkinsonian gait with EEG power modulations resembling healthy gait|10.1016/j.parkreldis.2021.09.011
Enhancer-associated H3K4 methylation safeguards in vitro germline competence.|10.17863/cam.77657
Heat Shock Protein 70 as a Sex-Skewed Regulator of α-Synucleinopathy|10.1007/s13311-021-01114-6
In-Home Falls Risk Assessment in Parkinson Disease: A Guide for Clinicians|10.1016/j.apmr.2021.04.001
Insights into VPS13 properties and function reveal a new mechanism of eukaryotic lipid transport|10.1016/j.bbalip.2021.159003
Longitudinal risk factors for developing depressive symptoms in Parkinson's disease|10.1016/j.jns.2021.117615
Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?|10.1002/mds.28765
MicroRNA-7 Protects Against Neurodegeneration Induced by α-Synuclein Preformed Fibrils in the Mouse Brain|10.1007/s13311-021-01130-6
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study|10.1016/j.parkreldis.2021.09.024
Nigral diffusivity, but not free water, correlates with iron content in Parkinson’s disease|10.1093/braincomms/fcab251
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection|10.1124/pharmrev.120.000189
Restoring lost nigrostriatal fibers in Parkinson’s disease based on clinically-inspired design criteria|10.1016/j.brainresbull.2021.07.016
Small Molecule Metabolites at the Host–Microbiota Interface|10.4049/jimmunol.2100528
Tardive Dyskinesia in Older Persons Taking Antipsychotics|10.2147/ndt.s328301
Transcriptional signatures in iPSC-derived neurons are reproducible across labs when differentiation protocols are closely matched|10.1016/j.scr.2021.102558
Proposed research criteria for prodromal behavioural variant frontotemporal dementia|10.1093/brain/awab365
Salivary Lactoferrin Expression in a Mouse Model of Alzheimer’s Disease|10.3389/fimmu.2021.749468
Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation|10.1093/brain/awab371
Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study|10.3389/fneur.2021.723476
Cluster Analysis of Categorical Variables of Parkinson’s Disease Patients|10.3390/brainsci11101290
Kinetics of alpha-synuclein depletion in three brain regions following conditional pan-neuronal inactivation of the encoding gene (Snca) by tamoxifen-induced Cre-recombination in adult mice|10.1007/s11248-021-00286-3
Quantitative proteomics reveals the selectivity of ubiquitin-binding autophagy receptors in the turnover of damaged lysosomes by lysophagy|10.7554/elife.72328
Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease|10.1002/mds.28803
Screening of Parkinson’s Disease Using Geometric Features Extracted from Spiral Drawings|10.3390/brainsci11101297
Contribution of rare variant associations to neurodegenerative disease presentation|10.1038/s41525-021-00243-3
Current directions in tau research: Highlights from Tau 2020|10.1002/alz.12452
Factors associated with impaired quality of life three months after being diagnosed with COVID-19|10.1007/s11136-021-02998-9
Severity of Downgaze Palsy in the Context of Disease Duration Could Estimate Survival Duration in Patients With Progressive Supranuclear Palsy|10.3389/fneur.2021.736784
Structural basis for the specificity of PPM1H phosphatase for Rab GTPases|10.15252/embr.202152675
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease|10.1002/alz.12422
Relationships between Mitochondrial Function, AMPK, and TORC1 Signaling in Lymphoblasts with Premutation Alleles of the FMR1 Gene|10.3390/ijms221910393
The Power of Musification: Sensor‐Based Music Feedback Improves Arm Swing in Parkinson's Disease|10.1002/mdc3.13352
32nd International Symposium on the Autonomic Nervous System|10.1007/s10286-021-00822-5
Measuring Structural Racism: A Guide for Epidemiologists and Other Health Researchers|10.1093/aje/kwab239
Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency|10.1001/jamanetworkopen.2021.25584
Pandemic Tic‐like Behaviors Following Social Media Consumption|10.1002/mds.28800
Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration|10.1093/brain/awab356
SRCP: a comprehensive pipeline for accurate annotation and quantification of circRNAs|10.1186/s13059-021-02497-7
A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons|10.7554/elife.69795
Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset|10.1007/s00210-021-02162-7
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity|10.1002/mds.28792
Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems|10.3233/jpd-212662
Fine mapping of the HLA locus in Parkinson’s disease in Europeans|10.1038/s41531-021-00231-5
Pathways to Parkinson’s disease: a spotlight on 14-3-3 proteins|10.1038/s41531-021-00230-6
Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk|10.1002/mds.28787
Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views|10.1007/s11910-021-01140-z
Wearable sensor-driven responsive deep brain stimulation for essential tremor|10.1016/j.brs.2021.09.002
Age of Onset of Huntington's Disease in Carriers of Reduced Penetrance Alleles|10.1002/mds.28789
A Cross‐Sectional Comprehensive Assessment of the Profile and Burden of Non‐motor Symptoms in Relation to Motor Phenotype in the Nigeria Parkinson Disease Registry Cohort|10.1002/mdc3.13346
Alpha-Synuclein and Lipids: The Elephant in the Room?|10.3390/cells10092452
Comprehensive subtyping of Parkinson’s disease patients with similarity fusion: a case study with BioFIND data|10.1038/s41531-021-00228-0
Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition|10.1186/s13041-021-00848-w
Oromandibular Dystonia: A Clinical Examination of 2,020 Cases|10.3389/fneur.2021.700714
The intracellular milieu of Parkinson’s disease patient brain cells modulates alpha-synuclein protein aggregation|10.1186/s40478-021-01256-w
Longitudinal clustering analysis and prediction of Parkinson’s disease progression using radiomics and hybrid machine learning|10.21037/qims-21-425
Dysregulation of mitochondrial and proteolysosomal genes in Parkinson’s disease myeloid cells|10.1038/s43587-021-00110-x
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression|10.1001/jama.2021.10207
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus|10.1038/s41582-021-00549-x
Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders|10.1007/s00401-021-02367-3
echolocatoR: an automated end-to-end statistical and functional genomic fine-mapping pipeline|10.1093/bioinformatics/btab658
Rare variants in the endocytic pathway are associated with Alzheimer’s disease, its related phenotypes, and functional consequences|10.1371/journal.pgen.1009772
Low cost cloud based remote microscopy for biological sciences|10.1016/j.iot.2021.100454
The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagy|10.1016/j.jbc.2021.101191
A systematic review on exercise and training-based interventions for freezing of gait in Parkinson’s disease|10.1038/s41531-021-00224-4
Differentiation of multiple system atrophy subtypes by gray matter atrophy|10.1111/jon.12927
Genetic variants in progranulin upstream open reading frames increase downstream protein expression|10.1016/j.neurobiolaging.2021.09.007
Identification of Novel Single-Nucleotide Variants With Potential of Mediating Malfunction of MicroRNA in Congenital Heart Disease|10.3389/fcvm.2021.739598
SORL1 mutation in a Greek family with Parkinson's disease and dementia|10.1002/acn3.51433
Structural basis for membrane recruitment of ATG16L1 by WIPI2 in autophagy|10.7554/elife.70372
Task-Oriented Intelligent Solution to Measure Parkinson’s Disease Tremor Severity|10.1155/2021/9624386
Unified AI framework to uncover deep interrelationships between gene expression and Alzheimer’s disease neuropathologies|10.1038/s41467-021-25680-7
Cognitive Decline in Parkinson’s Disease: A Subgroup of Extreme Decliners Revealed by a Data-Driven Analysis of Longitudinal Progression|10.3389/fpsyg.2021.729755
MPTP Parkinsonism and Implications for Understanding Parkinson's Disease|10.1002/mdc3.13344
Synaptic tau: A pathological or physiological phenomenon?|10.1186/s40478-021-01246-y
Allosteric Inhibition of Parkinson’s-Linked LRRK2 by Constrained Peptides|10.1021/acschembio.1c00487
Diagnostic criteria for blepharospasm: A multicenter international study|10.1016/j.parkreldis.2021.09.004
Noninvasive vagus nerve stimulation in Parkinson’s disease: current status and future prospects|10.1080/17434440.2021.1969913
Perception and Use of Compensation Strategies for Gait Impairment by Persons With Parkinson Disease|10.1212/wnl.0000000000012633
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs|10.1002/mds.28722
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study|10.1002/mds.28758
Altered Brain Functional Network in Subtypes of Parkinson's Disease: A Dynamic Perspective|10.3389/fnagi.2021.710735
Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients|10.1038/s41531-021-00219-1
Psychometric properties of the Beck Depression Inventory‐II in progressive supranuclear palsy|10.1002/brb3.2344
Classification based levodopamine response prediction in parkinson’s disorder|10.1080/08839514.2021.1975881
Subthalamic and pallidal deep brain stimulation for Parkinson’s disease—meta-analysis of outcomes|10.1038/s41531-021-00223-5
Epigenomic features related to microglia are associated with attenuated effect of APOE ε4 on Alzheimer's disease risk in humans|10.1002/alz.12425
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease|10.1002/mds.28779
Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer’s dementia|10.1186/s13195-021-00892-7
Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study|10.3389/fneur.2021.711358
RETRACTED ARTICLE: Facial expressions can detect Parkinson’s disease: preliminary evidence from videos collected online|10.1038/s41746-021-00502-8
Could Soluble Amyloid Be Neuroprotective Rather Than Toxic?|10.1097/01.nt.0000792796.54034.5f
Measuring Tremor—A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating|10.1002/mds.28776
Neurodegenerative disorder diagnosis using support vector machine and Naive bayes algorithms|10.1109/icirca51532.2021.9545021
New Questions About a Mysterious Neurologic Cluster in Canada|10.1097/01.nt.0000792776.14362.2b
Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone|10.1080/14737175.2021.1968298
Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer|10.1038/s41467-021-25467-w
Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease|10.3390/cells10092286
A comparative and comprehensive study of prediction of Parkinson’s disease|10.11591/ijeecs.v23.i3.pp1748-1760
A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic „CERAD-Plus“ tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study|10.1016/j.parkreldis.2021.07.034
Allied Healthcare Professionals|10.1002/mds.28794
Carlos II of Spain, ‘The Bewitched’: cursed by aspartylglucosaminuria?|10.1136/bmjno-2020-000072
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience|10.1016/j.parkreldis.2021.08.018
Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset|10.1016/j.ejphar.2021.174452
Is there a special relationship between complex I activity and nigral neuronal loss in Parkinson’s disease? A critical reappraisal|10.1016/j.brainres.2021.147434
Limited-stage small cell lung cancer: Outcomes associated with prophylactic cranial irradiation over a 20-year period at the Princess Margaret Cancer Centre|10.1016/j.ctro.2021.06.009
Protein Transnitrosylation Signaling Networks Contribute to Inflammaging and Neurodegenerative Disorders|10.1089/ars.2021.0081
Reply to: “Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy”|10.1002/mds.28725
Reply to: “α‐Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism”|10.1002/mds.28742
Seeking progress in disease modification in Parkinson disease|10.1016/j.parkreldis.2021.09.006
Sex-Dependent Cortical Volume Changes in Patients with Degenerative Cervical Myelopathy|10.3390/jcm10173965
Tackling underrepresentation to aid understanding of Parkinson’s disease: Progress and further opportunities|10.36866/123.32
Tackling underrepresentation to aid understanding of Parkinson’s disease: Progress and further opportunities|10.36866/pn.123.32
Tau and MAPT genetics in tauopathies and synucleinopathies|10.1016/j.parkreldis.2021.09.008
Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils|10.1021/acschemneuro.1c00536
Graph Fusion Network-Based Multimodal Learning for Freezing of Gait Detection|10.1109/tnnls.2021.3105602
Modelling the functional genomics of Parkinson’s disease inCaenorhabditis elegans:LRRK2and beyond|10.1042/bsr20203672
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy|10.1002/cpt.2408
Teaching Video NeuroImage: “Weighing” in on an Unusual Tremor|10.1212/wnl.0000000000012141
Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging|10.1001/jamaneurol.2021.2876
A comparison of prediction approaches for identifying prodromal Parkinson disease|10.1371/journal.pone.0256592
Alpha-Synuclein PET Tracer Development—An Overview about Current Efforts|10.3390/ph14090847
Clinical, pathological and genetic characteristics of Perry disease—new cases and literature review|10.1111/ene.15048
Serum neurofilament light chain predicts future freezing of gait in Parkinson's disease|10.1016/j.parkreldis.2021.08.015
Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians|10.1002/mds.28773
Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?|10.3390/jpm11090834
Genotype–Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review|10.1002/mds.28753
Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways|10.1016/j.freeradbiomed.2021.08.230
Longitudinal observational study of boxing therapy in Parkinson’s disease, including adverse impacts of the COVID-19 lockdown|10.1186/s12883-021-02359-6
Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease|10.1002/mds.28745
Abnormal Topological Network in Parkinson’s Disease With Impulse Control Disorders: A Resting-State Functional Magnetic Resonance Imaging Study|10.3389/fnins.2021.651710
Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach|10.1002/mds.28760
Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?|10.1002/mds.28768
Structural Biology of LRRK2 and its Interaction with Microtubules|10.1002/mds.28755
The Discovery of α‐Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution|10.1002/mdc3.13312
Does MDS‐UPDRS Provide Greater Sensitivity to Mild Disease than UPDRS in De Novo Parkinson's Disease?|10.1002/mdc3.13329
Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging|10.1016/j.semarthrit.2021.08.004
Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1|10.1002/mds.28756
Rab GTPases in Parkinson's disease: a primer|10.1042/ebc20210016
Aducanumab: look before leaping|10.1038/s41591-021-01477-5
Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology|10.1186/s40478-021-01240-4
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study|10.1016/s1474-4422(21)00214-3
“Real‐Life” Remote Dystonia Assessment: Feasibility, Accuracy, and Practice Implications|10.1002/mdc3.13330
Multitarget Transcranial Electrical Stimulation for Freezing of Gait: A Randomized Controlled Trial|10.1002/mds.28759
Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood|10.1002/mds.28749
Estimating the Risk of Deep Brain Stimulation in the Modern Era: 2008 to 2020|10.1093/ons/opab261
Basal Synaptic Transmission and Long-Term Plasticity at CA3-CA1 Synapses Are Unaffected in Young Adult PINK1-Deficient Rats|10.3389/fnins.2021.655901
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects|10.1080/03007995.2021.1965975
Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project|10.1186/s13195-021-00872-x
Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease|10.1097/fpc.0000000000000445
Restriction of Access to Deep Brain Stimulation for Refractory OCD: Failure to Apply the Federal Parity Act|10.3389/fpsyt.2021.706181
Humanized Biomimetic Nanovesicles for Neuron Targeting|10.1002/advs.202101437
The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model|10.1038/s41467-021-25060-1
Dying-back of ascending noradrenergic projections in Parkinson’s disease|10.1093/brain/awab286
Miro1 Impairment in a Parkinson’s At-Risk Cohort|10.3389/fnmol.2021.734273
Remote smartphone monitoring of Parkinson’s disease and individual response to therapy|10.1038/s41587-021-00974-9
Does the Anti‐Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes|10.1002/mdc3.13324
On‐Demand Therapy for OFF Episodes in Parkinson's Disease|10.1002/mds.28726
Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders|10.1002/mds.28738
Longitudinal tracking of neuronal mitochondria delineates PINK1/Parkin-dependent mechanisms of mitochondrial recycling and degradation|10.1126/sciadv.abf6580
Metabolic Profiling of Neocortical Tissue Discriminates Alzheimer’s Disease from Mild Cognitive Impairment, High Pathology Controls, and Normal Controls|10.1021/acs.jproteome.1c00290
Structural network topology and microstructural alterations of the anterior insula associate with cognitive and affective impairment in Parkinson’s disease|10.1038/s41598-021-95638-8
Whole brain and deep gray matter structure segmentation: Quantitative comparison between MPRAGE and MP2RAGE sequences|10.1371/journal.pone.0254597
C9orf72-G4C2 Intermediate Repeats and Parkinson’s Disease; A Data-Driven Hypothesis|10.3390/genes12081210
Fast 3D Clear: A Fast, Aqueous, Reversible Three-Day Tissue Clearing Method for Adult and Embryonic Mouse Brain and Whole Body|10.17632/jfcxnntcp5.2
Predicting correlated outcomes from molecular data|10.1093/bioinformatics/btab576
Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study|10.1186/s40478-021-01233-3
RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson’s disease|10.1038/s43587-021-00088-6
Generative image transformer (GIT): unsupervised continuous image generative and transformable model for [123I]FP-CIT SPECT images|10.1007/s12149-021-01661-0
Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow|10.1021/acs.analchem.1c01128
Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice|10.7554/elife.67604
Sex differences in brain atrophy and cognitive impairment in Parkinson’s disease patients with and without probable rapid eye movement sleep behavior disorder|10.1007/s00415-021-10728-x
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders|10.1136/jnnp-2021-326904
Assessing the Quality and Reliability of COVID-19 Information on Patient Organization Websites|10.3389/fcomm.2021.716683
Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy|10.1021/acsptsci.0c00162;
Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy|10.1021/acsptsci.0c00162
Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson’s disease|10.1007/s00415-021-10730-3
Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure|10.1002/advs.202101462
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update|10.3233/jpd-219006
Quality Improvement in Neurology|10.1212/wnl.0000000000012198
A conversation with Judith Campisi: Leader in the field of aging research|10.1016/j.arr.2021.101366
A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease|10.1016/j.parkreldis.2021.06.023
A pipeline for RNA-seq based eQTL analysis with automated quality control procedures|10.1186/s12859-021-04307-0
Antiglutamic Acid Decarboxylase 65 Antibody–Associated Hemiataxia|10.1212/cpj.0000000000000939
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder|10.1016/s1474-4422(21)00176-9
Clinical Diagnostic Accuracy of Early/Advanced Parkinson Disease|10.1212/cpj.0000000000001016
Commentary: A Boy with Spells of Unusual Movements after Failure in Exam|10.1002/mdc3.13291
Commentary: Atypical, Early‐Onset Dystonia‐Parkinsonism with Oculogyric Crises and Anterior Horn Cell Disorder due to a Novel DJ ‐1 Mutation|10.1002/mdc3.13296;
Commentary: Atypical, Early‐Onset Dystonia‐Parkinsonism with Oculogyric Crises and Anterior Horn Cell Disorder due to a Novel DJ ‐1 Mutation|10.1002/mdc3.13296
Commentary: Monochorea of the Upper Limb in a Patient with Spinocerebellar Ataxia Type 12|10.1002/mdc3.13290
Commentary: Paraneoplastic Syndrome Associated with Kelch‐Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor|10.1002/mdc3.13300
Commentary: Uremic Striatopallidal Syndrome Manifesting as Acute Onset Chorea|10.1002/mdc3.13299
Forward and backward walking share the same motor modules and locomotor adaptation strategies|10.1016/j.heliyon.2021.e07864
Loss of Lysosomal Proteins Progranulin and Prosaposin Associated with Increased Neurofibrillary Tangle Development in Alzheimer Disease|10.1093/jnen/nlab056
Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment|10.1002/exp.20210008
Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons|10.1016/j.nbd.2021.105409
Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein|10.1016/j.parkreldis.2021.06.010
Reply to: “Increased alpha‐Synuclein Level in CD45+ Blood Cells in Asymptomatic Carriers of GBA Mutations”|10.1002/mds.28678
Reply to: “Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?”|10.1002/mds.28697
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial|10.1038/s41591-021-01455-x
Uremic Striatopallidal Syndrome Manifesting as Acute Onset Chorea|10.1002/mdc3.13285
Use of Figurative Language by People With Parkinson Disease to Describe “Off” Periods|10.1212/cpj.0000000000001059
Deep brain stimulation programming strategies: segmented leads, independent current sources, and future technology|10.1080/17434440.2021.1962286
Auditory and olfactory findings in patients with USH2A‐related retinal degeneration—Findings at baseline from the rate of progression in USH2A‐related retinal degeneration natural history study (RUSH2A)|10.1002/ajmg.a.62437
Dream Content Predicts Motor and Cognitive Decline in Parkinson's Disease|10.1002/mdc3.13318
Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases|10.3390/ijms22158196
From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease|10.1042/bcj20210383
Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change|10.1002/mds.28730
The mechanisms of smell loss after SARS-CoV-2 infection|10.1016/s1474-4422(21)00202-7
A phenolic-rich extract from Ugni molinae berries reduces abnormal protein aggregation in a cellular model of Huntington’s disease|10.1371/journal.pone.0254834
Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning|10.1016/s2589-7500(21)00101-1
The effects of mood and cognition on daily functioning and quality of life in older people living with HIV and people with Parkinson’s disease.|10.1037/neu0000760
A Multi‐center Genome‐wide Association Study of Cervical Dystonia|10.1002/mds.28732
Men with FMR1 premutation alleles of less than 71 CGG repeats have low risk of being affected with fragile X-associated tremor/ataxia syndrome (FXTAS)|10.1136/jmedgenet-2021-107758
PARIS farnesylation prevents neurodegeneration in models of Parkinson’s disease|10.1126/scitranslmed.aax8891
TikTok Tics: A Pandemic Within a Pandemic|10.1002/mdc3.13316
A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine|10.2196/29511
A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson’s disease|10.1080/17425247.2021.1960820
Advanced Machine Learning Tools to Monitor Biomarkers of Dysphagia: A Wearable Sensor Proof-of-Concept Study|10.1159/000517144
Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice|10.1038/s41467-021-24567-x
Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration|10.1126/scisignal.abg3555
Insomnia symptom subtypes and manifestations of prodromal neurodegeneration: a population-based study in the Canadian Longitudinal Study on Aging|10.5664/jcsm.9562
Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease|10.1016/j.parkreldis.2021.07.024
Plasma membrane calcium ATPase downregulation in dopaminergic neurons alters cellular physiology and motor behaviour in Drosophila melanogaster|10.1111/ejn.15401
A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies|10.1007/s00401-021-02349-5
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease|10.1038/s41531-021-00203-9
Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs|10.31478/202107e
Distinct progression patterns across Parkinson disease clinical subtypes|10.1002/acn3.51436
Genetic risk, adherence to a healthy lifestyle, and cognitive decline in African Americans and European Americans|10.1002/alz.12435
LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease|10.3390/biom11081101
A high dose tango intervention for people with Parkinson's disease (PwPD)|10.1016/j.aimed.2021.07.005
A Role of Aging in the Progression of Cortical Excitability in Benign Adult Familial Myoclonus Epilepsy type 1 Patients|10.1002/mds.28718
Beyond tics: movement disorders in patients with Tourette syndrome|10.1007/s00702-021-02386-0
Fast and robust supervised machine learning approach for classification and prediction of Parkinson’s disease onset|10.1080/21681163.2021.1941262
Rationale and design to evaluate the PRIME Parkinson care model: a prospective observational evaluation of proactive, integrated and patient-centred Parkinson care in The Netherlands (PRIME-NL)|10.1186/s12883-021-02308-3
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease|10.1212/nxi.0000000000001036
No effect of Parkinson’s disease-polygenic load on striatal density of dopaminergic neuron in healthy subjects|10.1007/s12149-021-01657-w
Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow‐up|10.1002/brb3.2257
Rosmarinic Acid Potently Detoxifies Amylin Amyloid and Ameliorates Diabetic Pathology in a Transgenic Rat Model of Type 2 Diabetes|10.1021/acsptsci.1c00028
BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease|10.1111/ner.13504
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease|10.1002/mds.28706
Meaning and purpose in Huntington’s disease: a longitudinal study of its impact on quality of life|10.1002/acn3.51424
Temporal trajectory of biofluid markers in Parkinson’s disease|10.1038/s41598-021-94345-8
Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models|10.1002/mdc3.13311
The Experience of OFF Periods in Parkinson’s Disease: Descriptions, Triggers, and Alleviating Factors|10.17294/2330-0698.1836
A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson’s Disease|10.3233/jpd-202381
Altered network stability in progressive supranuclear palsy|10.1016/j.neurobiolaging.2021.07.007
Antiepileptogenesis and disease modification: Clinical and regulatory issues|10.1002/epi4.12526
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective|10.3233/jpd-202428
Domotics, Smart Homes, and Parkinson’s Disease|10.3233/jpd-202398
Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson’s Disease Cohorts|10.3233/jpd-212657
Striatal Acetylcholine–Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET–Informed Correlational Tractography|10.2967/jnumed.121.261939
Unhealthy Behaviours and Risk of Parkinson’s Disease: A Mendelian Randomisation Study|10.3233/jpd-202487
Video-Based Analyses of Parkinson’s Disease Severity: A Brief Review|10.3233/jpd-202402
An implantable human stem cell-derived tissue-engineered rostral migratory stream for directed neuronal replacement|10.1038/s42003-021-02392-8
The new platforms of health care|10.1038/s41746-021-00478-5
Transitioning to telegenetics in the COVID‐19 era: Patient satisfaction with remote genetic counseling in adult neurology|10.1002/jgc4.1470
A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study|10.1016/j.parkreldis.2021.07.013
Animal Models of Autosomal Recessive Parkinsonism|10.3390/biomedicines9070812
Modulation of Neuroinflammation by the Gut Microbiota in Prion and Prion-Like Diseases|10.3390/pathogens10070887
Development and Validation of a Prognostic Model for Cognitive Impairment in Parkinson’s Disease With REM Sleep Behavior Disorder|10.3389/fnagi.2021.703158
Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson’s disease|10.1007/s10286-021-00815-4
Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study|10.1002/mdc3.13307
Age-dependent alterations in key components of the nigrostriatal dopaminergic system and distinct motor phenotypes|10.1038/s41401-021-00713-5
Excess membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably associated with inclusion formation and toxicity|10.1093/hmg/ddab188
Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease|10.1002/mds.28712
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target|10.1111/bcp.14964
A Survey of People With Parkinson’s and Their Carers: The Management of Pain in Parkinson’s|10.1177/08919887211023592
APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer’s disease and age-matched non-demented brains|10.1186/s13041-021-00803-9
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting|10.1186/s13195-021-00868-7
Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression|10.1002/mds.28715
Telemedicine and Deep brain stimulation - Current practices and recommendations|10.1016/j.parkreldis.2021.07.001
Asymmetry at Disease Onset Is Not a Predictor of Parkinson’s Disease Progression|10.3233/jpd-202525
Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology|10.3390/ijms22147292
Parkinson’s Disease Motor Symptom Progression Slowed with Multisensory Dance Learning over 3-Years: A Preliminary Longitudinal Investigation|10.3390/brainsci11070895
Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling|10.3233/jpd-212636
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks|10.1212/wnl.0000000000012452
Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis|10.1002/prp2.816
TOMM40 ‘523’ poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson’s disease|10.1038/s41531-021-00200-y
Understanding the effect of smoking and drinking behavior on Parkinson's disease risk: a Mendelian randomization study|10.1038/s41598-021-93105-y
Copy Number Variation in Parkinson's Disease: An Update from Sub‐Saharan Africa|10.1002/mds.28710
Plant immune system activation is necessary for efficient interaction with auxin secreting beneficial bacteria|10.17632/8zyrz7ccbh.1
Diagnostic accuracy of narrow‐band imaging endoscopy with targeted biopsies compared with standard endoscopy with random biopsies in patients with Barrett's esophagus: A systematic review and meta‐analysis|10.1111/jgh.15577
MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression|10.1002/mds.28700
They Look but Do Not See—Gaze‐Evoked Eyelid Spasm|10.1002/mdc3.13279
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist|10.1016/j.neuropharm.2021.108693
Arousal characteristics in patients with Parkinson’s disease and isolated rapid eye movement sleep behavior disorder|10.1093/sleep/zsab167
Elevated Mood States in Patients With Parkinson’s Disease Treated With Deep Brain Stimulation: Diagnosis and Management Strategies|10.1176/appi.neuropsych.20080205
Lifestyle Factors and Parkinson’s Disease Risk in a Rural New England Case-Control Study|10.1155/2021/5541760
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease|10.1186/s13024-021-00468-x
Advances in protein-protein interaction network analysis for Parkinson's disease|10.1016/j.nbd.2021.105395
Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson’s disease|10.1016/j.celrep.2021.109333
Beyond Just Connectivity — Neuronal Activity Drives α‐Synuclein Pathology|10.1002/mds.28618
Coexistence of deep brain stimulators and cardiac implantable electronic devices: A systematic review of safety|10.1016/j.parkreldis.2021.04.018
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies|10.1007/s40263-021-00826-9
Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease|10.1016/j.nbd.2021.105368
Letter to the Editor: Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia—The SPASTOX Trial|10.1002/mds.28659
LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease|10.1016/j.neurobiolaging.2021.02.018
Managing Advanced Parkinson Disease|10.1177/08919887211018277
Parkinson disease-associated cognitive impairment|10.1038/s41572-021-00280-3
Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants|10.1136/bmjopen-2020-046329
Progress towards therapies for disease modification in Parkinson's disease|10.1016/s1474-4422(21)00061-2
Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view|10.1016/j.parkreldis.2021.05.013
Comparison between four published definitions of hyposmia in Parkinson's disease|10.1002/brb3.2258
Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials|10.2196/31371
Genetics of Parkinson’s disease in the Polish population|10.5603/pjnns.a2021.0013
Moving towards Integrated and Personalized Care in Parkinson’s Disease: A Framework Proposal for Training Parkinson Nurses|10.3390/jpm11070623
On demand therapy for Parkinson’s disease patients: Opportunities and choices|10.1080/00325481.2021.1936087
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial|10.1002/mds.28702
Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes|10.3389/fnagi.2021.676744
CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB|10.1002/mds.28704
Directed Brain Connectivity Identifies Widespread Functional Network Abnormalities in Parkinson’s Disease|10.1093/cercor/bhab237
High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis|10.1016/j.eclinm.2021.100988
Home Health Management of Parkinson Disease Deep Brain Stimulation|10.1001/jamaneurol.2021.1910
Too much for your own good: Excessive dopamine damages neurons and contributes to Parkinson's disease|10.1111/jnc.15442
White Matter Hyperintensities Are Associated With Severity of Essential Tremor in the Elderly|10.3389/fneur.2021.694286
Disrupted rich-club organization of brain structural networks in Parkinson’s disease|10.1007/s00429-021-02319-3
Parkinson's disease-related pattern (PDRP) identified using resting-state functional MRI: Validation study|10.1016/j.ynirp.2021.100026
Preoperative Evaluation of Parkinson’s Disease|10.7759/cureus.15933
An image-based flow cytometric approach to the assessment of the nucleus-to-cytoplasm ratio|10.1371/journal.pone.0253439
Coincident parkinsonism and myasthenia gravis: A case series|10.1016/j.parkreldis.2021.06.016
Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia?|10.1186/s12883-021-02265-x
Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study|10.1177/10783903211023565
Correction: VPS13D bridges the ER to mitochondria and peroxisomes via Miro|10.1083/jcb.20201000405052021c
Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease|10.3389/fneur.2021.636139
Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson’s Disease and Idiopathic Anosmia|10.3233/jpd-212683
The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play|10.1111/bph.15575
Impact of Chorea on Self-care Activity, Employment, and Health-care Resource Use in Patients with Huntington’s Disease|10.36469/001c.24620
Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD Samples|10.3389/fnagi.2021.704041
Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10|10.1038/s41598-021-91943-4
Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database|10.3389/fneur.2021.571800
Evaluation of Individualized Multi‐Disciplinary Inpatient Treatment for Functional Movement Disorders|10.1002/mdc3.13268
Impact of Chorea on Self-care Activity, Employment, and Health-care Resource Use in Patients with Huntington’s Disease|10.36469/jheor.2021.24620
Ondine's Curse in Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 Caused by MAPT Variants|10.1002/mdc3.13265
Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and Ballismus|10.1017/cjn.2021.136
Correction to A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of CaV1.3 L-Type Calcium Channels|10.1021/acschembio.1c00368
Freezing of gait and levodopa|10.1016/s1474-4422(21)00175-7
Frühzeichen der Parkinson-Erkrankung|10.1007/s42451-021-00352-4
Prehospital scales in acute ischaemic stroke management – Authors' reply|10.1016/s1474-4422(21)00169-1
Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation|10.1016/j.nbd.2021.105426
Rare CASP6N73T variant associated with hippocampal volume exhibits decreased proteolytic activity, synaptic transmission defect, and neurodegeneration|10.1038/s41598-021-91367-0
Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy|10.1016/j.apsb.2021.06.007
The Gastrointestinal Dysfunction Scale for Parkinson's Disease|10.1002/mds.28675
Validity and reliability of the suggested immobilization test for measurement of restless legs syndrome severity in adults with multiple sclerosis|10.1016/j.sleep.2021.06.005
Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients|10.3233/jpd-212694
In Silico Studies Comparing the Adjuvant Therapies Approved for Parkinson’s disease|10.22270/jddt.v11i3-s.4813
Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease|10.1002/acn3.51402
Novel Genes May Drive Progression in Parkinson's Disease|10.1097/01.nt.0000756456.16968.c1
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis|10.3233/jpd-212733
Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease|10.1002/mds.28682
BOOK REVIEW OF Cole, Allan Hugh, Jr. (2021). Counseling Persons with Parkinson’s Disease. New York: Oxford University Press|10.1080/01634372.2021.1932004
Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer’s disease|10.1038/s43587-021-00071-1
R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils|10.1007/s00401-021-02325-z
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation|10.1002/cpt.2277
Expression Quantitative Trait Loci (eQTLs) Associated with Retrotransposons Demonstrate their Modulatory Effect on the Transcriptome|10.3390/ijms22126319
Mild Neurological Signs in FMR1 Premutation Women in an Unselected Community‐Based Cohort|10.1002/mds.28683
Multimodal Longitudinal Neurophysiological Investigations in Dopa‐Responsive Dystonia|10.1002/mds.28679
NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson’s disease|10.1093/brain/awab214
Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset|10.1177/08919887211023586
Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease|10.1016/j.parkreldis.2021.06.004
Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease|10.1002/mds.28684
Gait Analysis in Progressive Supranuclear Palsy Phenotypes|10.3389/fneur.2021.674495
Hyperactive LRRK2 kinase impairs the trafficking of axonal autophagosomes|10.1080/15548627.2021.1936933
A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis|10.3390/cancers13122895
Characterizing white matter alterations subject to clinical laterality in drug‐naïve de novo Parkinson's disease|10.1002/hbm.25558
Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor|10.1126/sciadv.abg6677
Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model|10.1371/journal.pone.0252325
Correlates of deep brain stimulation consensus conference decision to treat primary dystonia|10.1016/j.clineuro.2021.106747
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease|10.1038/s41531-021-00174-x
A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways|10.3390/cancers13112840
ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy|10.1073/pnas.2025053118
Analysis of EEG Data Using Complex Geometric Structurization|10.1162/neco_a_01398
Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders|10.1212/wnl.0000000000012342
Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease|10.1523/eneuro.0559-20.2021
GPR120 Signaling Controls Amyloid-β Degrading Activity of Matrix Metalloproteinases|10.1523/jneurosci.2595-20.2021
Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2|10.1073/pnas.2100844118
Impaired awareness: Why people with multiple sclerosis continue using cannabis despite evidence to the contrary|10.1002/brb3.2220
Mathematical model for early stage identification of Parkinson’s disease using neurotransmitter: GABA|10.1007/s41870-021-00705-y
Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease|10.3389/fneur.2021.679927
An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of α-synuclein|10.1016/j.celrep.2021.109189
Cognitive function in men with non-motor features of Parkinson’s disease|10.1136/bmjno-2020-000112
Dietary Patterns and Individual Parkinsonian Signs Among Biracial Population of Older Adults|10.1093/cdn/nzab033_001
Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design|10.1016/j.conctc.2021.100785
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients|10.1016/j.parkreldis.2021.04.012
Expanding sexual and gender minority research in movement disorders: More than awareness and acceptance|10.1016/j.parkreldis.2021.05.019
Focused Workshops|10.1111/ene.14970
Folded concave penalized learning of high-dimensional MRI data in Parkinson’s disease|10.1016/j.jneumeth.2021.109157
Parkinson's disease|10.1016/s0140-6736(21)00218-x
Proceedings of Reanimation 2021, the French Intensive Care Society International Congress|10.1186/s13613-021-00862-0
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study|10.3233/jpd-212594
The emerging landscape of single-molecule protein sequencing technologies|10.1038/s41592-021-01143-1
The Records of the Human Sciences Research Council|10.1017/hia.2021.15
Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney|10.1002/alz.12380
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis|10.18553/jmcp.2021.27.6.785
Development and evaluation of [18F]Flotaza for Aβ plaque imaging in postmortem human Alzheimer’s disease brain|10.1016/j.bmcl.2021.128164
Thyroarytenoid Muscle Gene Expression in a Rat Model of Early‐Onset Parkinson's Disease|10.1002/lary.29661
Acetyl-dl-leucine improves restless legs syndrome: a case report|10.1007/s00415-021-10625-3
Cortical proteins may provide motor resilience in older adults|10.1038/s41598-021-90859-3
Deep learning‐based scheme to diagnose Parkinson's disease|10.1111/exsy.12739
Dystonia Responsive to Dopamine: POLG Mutations Should Be Considered If Sensory Neuropathy Is Present|10.14802/jmd.20159
Environmental Risk Factors for Progressive Supranuclear Palsy|10.14802/jmd.20173
Organizations join forces to support early diagnosis of Lewy body dementia|10.1002/alz.12386
Parkinsonism as a Sequela of SARS‐CoV‐2 Infection: Pure Hypoxic Injury or Additional COVID‐19‐Related Response?|10.1002/mds.28656
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease|10.1002/alz.12372
A Genetic Study of Cerebral Atherosclerosis Reveals Novel Associations with NTNG1 and CNOT3|10.3390/genes12060815
Randomized Sham-Controlled Pilot Study of Neurocardiac Function in Patients With Acute Ischaemic Stroke Undergoing Heart Rate Variability Biofeedback|10.3389/fneur.2021.669843
Swarm Learning for decentralized and confidential clinical machine learning|10.1038/s41586-021-03583-3
α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait–Balance Disorders|10.1002/ana.26102
An update on the neurological short tandem repeat expansion disorders and the emergence of long-read sequencing diagnostics|10.1186/s40478-021-01201-x
Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer’s Disease and Mild Cognitive Impairment|10.3233/jad-201457
Reference SVA insertion polymorphisms are associated with Parkinson’s Disease progression and differential gene expression|10.1038/s41531-021-00189-4
Predicting optimal deep brain stimulation parameters for Parkinson’s disease using functional MRI and machine learning|10.1038/s41467-021-23311-9
A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene|10.1016/j.neurobiolaging.2021.05.010
Disruptions of neurological services, its causes and mitigation strategies during COVID-19: a global review|10.1007/s00415-021-10588-5
Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia|10.1007/s40120-021-00256-1
Music to move persons with Parkinson’s disease: a personalized approach|10.1007/s00415-021-10615-5
Der Zusammenhang zwischen COVID-19 und Schlaganfall: Pathophysiologie und klinische Bedeutung|10.1055/a-1484-0224
Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimer’s disease|10.1186/s40478-021-01199-2
Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice?|10.1002/mds.28673
Machine Learning for Predicting Rare Clinical Outcomes—Finding Needles in a Haystack|10.1001/jamanetworkopen.2021.10738
PINK1/Parkin-Mediated Mitophagy Plays a Protective Role in the Bone Impairment Caused by Aluminum Exposure|10.1021/acs.jafc.1c01921
The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers|10.3233/jpd-212611
Faster disease progression in Parkinson’s disease with type 2 diabetes is not associated with increased α‐synuclein, tau, amyloid‐β or vascular pathology|10.1111/nan.12728
Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease|10.1002/mds.28616
powerEQTL: an R package and shiny application for sample size and power calculation of bulk tissue and single-cell eQTL analysis|10.1093/bioinformatics/btab385
Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup|10.1002/mds.28620
Long-term Employment Outcomes After Epilepsy Surgery in Childhood|10.1212/wnl.0000000000011418
Quality Improvement in Neurology|10.1212/wnl.0000000000011419
Quality of life after hospitalization predicts one-year readmission risk in a large Swiss cohort of medical in-patients|10.1007/s11136-021-02867-5
α‐Synuclein in Plasma‐Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease|10.1002/mds.28639
Bad Air and Parkinson Disease—The Fog May Be Lifting|10.1001/jamaneurol.2021.0863
Catalytic Synthesis of PEGylated EGCG Conjugates that Disaggregate Alzheimer’s Tau|10.1055/a-1509-5904
Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy|10.3389/fnagi.2021.658605
Short hydrogen bonds enhance nonaromatic protein-related fluorescence|10.1073/pnas.2020389118
Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells|10.1016/j.neuint.2021.105070
Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study|10.1007/s40120-021-00251-6
Restless Legs Syndrome Shows Increased Silent Postmortem Cerebral Microvascular Disease With Gliosis|10.1161/jaha.120.019627
Trajectories of pain over 6 years in early Parkinson’s disease: ICICLE-PD|10.1007/s00415-021-10586-7
α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy|10.1007/s00401-021-02324-0
Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach|10.1016/j.parkreldis.2021.05.011
DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease|10.1002/mdc3.13239
The Impact of Cloud Management Platforms on Nonprofit Business Models|10.1080/15228835.2021.1920556
An Open‐Label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel in Cervical Dystonia|10.1002/mdc3.13229
Cognition-Related Functional Topographies in Parkinson’s Disease: Localized Loss of the Ventral Default Mode Network|10.1093/cercor/bhab148
Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors|10.3390/bs11050074
Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics|10.1007/s12035-021-02418-6
Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease|10.1002/mds.28641
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease|10.1002/alz.12353
Posterior Cortical Cognitive Deficits Are Associated With Structural Brain Alterations in Mild Cognitive Impairment in Parkinson’s Disease|10.3389/fnagi.2021.668559
Subcortical microstructural diffusion changes correlate with gait impairment in Parkinson's disease|10.1016/j.parkreldis.2021.05.005
Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort|10.1002/mds.28611
Differential cardiopulmonary monitoring system for artifact-canceled physiological tracking of athletes, workers, and COVID-19 patients|10.1126/sciadv.abg3092
Identification of retinoblastoma binding protein 7 (Rbbp7) as a mediator against tau acetylation and subsequent neuronal loss in Alzheimer’s disease and related tauopathies|10.1007/s00401-021-02323-1
Imaging mass cytometry reveals generalised deficiency in OXPHOS complexes in Parkinson’s disease|10.1038/s41531-021-00182-x
Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential|10.1007/s00401-021-02316-0
Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease|10.1002/mds.28640
Microelectrode Arrays for Simultaneous Electrophysiology and Advanced Optical Microscopy|10.1002/advs.202004434
Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers|10.3233/jpd-212624
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease|10.1093/brain/awab191
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset|10.1007/s00210-021-02090-6
Neurons and Glia Interplay in α-Synucleinopathies|10.3390/ijms22094994
Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease|10.1002/mds.28628
Review of multi-omics data resources and integrative analysis for human brain disorders|10.1093/bfgp/elab024
TP53INP1 exerts neuroprotection under ageing and Parkinson’s disease-related stress condition|10.1038/s41419-021-03742-4
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource|10.1002/mds.28549
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement|10.1515/cclm-2020-1521
NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4|10.1126/sciadv.abf7114
Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning|10.1002/mds.28631
Dopamine Receptors in Parkinson's Disease: A Meta‐Analysis of Imaging Studies|10.1002/mds.28632
Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease|10.1038/s41588-021-00847-6
Impulse control disorders and related behaviors in Parkinson's disease: risk factors, clinical and genetic aspects, and management|10.1097/wco.0000000000000955
On the Road from Phenotypic Plasticity to Stem Cell Therapy|10.1523/jneurosci.0340-21.2021
Parkinson’s Disease Recognition Using SPECT Image and Interpretable AI: A Tutorial|10.1109/jsen.2021.3077949
The Parkinson's Detective, Caroline M. Tanner, MD, PhD, FAAN, on Environmental Factors and Prevention|10.1097/01.nt.0000752844.66769.73
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X Mouse|10.3390/biomedicines9050514
Scoring Algorithm‐Based Genomic Testing in Dystonia: A Prospective Validation Study|10.1002/mds.28614
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau|10.15252/emmm.202114022
Effect of gender in the onset and progression of Parkinson's disease|10.1109/ner49283.2021.9441293
Expectations of Benefit in a Trial of a Candidate Disease‐Modifying Treatment for Parkinson Disease|10.1002/mds.28630
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research|10.1186/s13063-021-05273-x
Investigating Cognitive Global Coordination in normal and autistic children using virtual reality environments – An EEG Study|10.1109/ner49283.2021.9441259
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease|10.1002/mds.28608
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease|10.1002/ana.26094
Ischemic Events After Intracerebral Hemorrhage|10.1001/jamaneurol.2021.0772
A New Approach to the Development of Disease‐Modifying Therapies for PD|10.1002/mds.28589
Alzheimer's Disease Alters Oligodendrocytic Glycolytic and Ketolytic Gene Expression|10.1096/fasebj.2021.35.s1.02461
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations|10.2147/ndt.s310605
Biomedical Research Must Change — But a Shift Toward Human-specific Research Methods Is Only Part of What Is Needed|10.1177/02611929211030417
Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo|10.1016/j.ymthe.2021.04.035
Challenges in the diagnosis of Parkinson's disease|10.1016/s1474-4422(21)00030-2
Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammation|10.1038/s41385-020-00354-7
Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment|10.1016/j.parkreldis.2021.03.027
Excitotoxicity Revisited: Mitochondria on the Verge of a Nervous Breakdown|10.1016/j.tins.2021.01.001
Identification of proteins and cellular pathways targeted by 2-nitroimidazole hypoxic cytotoxins|10.1016/j.redox.2021.101905
Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis|10.1016/j.parkreldis.2021.03.009
Improved motor outcome prediction in Parkinson's disease applying deep learning to DaTscan SPECT images|10.1016/j.compbiomed.2021.104312
Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes|10.1016/j.cub.2021.02.061
Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias|10.1016/j.isci.2021.102484
Predicting Neuropsychiatric Symptoms of Parkinson’s Disease with Measures of Striatal Dopaminergic Deficiency|10.2174/1567205018666210827122133
Prediction of Acute Respiratory Failure Requiring Advanced Respiratory Support in Advance of Interventions and Treatment: A Multivariable Prediction Model From Electronic Medical Record Data|10.1097/cce.0000000000000402
Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development|10.1016/j.jns.2021.117417
Reply to: “A New Approach to the Development of Disease‐Modifying Therapies for PD”|10.1002/mds.28588
Ultrasound delta-radiomics during radiotherapy to predict recurrence in patients with head and neck squamous cell carcinoma|10.1016/j.ctro.2021.03.002
A Multimodal Imaging Approach Demonstrates Reduced Midbrain Functional Network Connectivity Is Associated With Freezing of Gait in Parkinson's Disease|10.3389/fneur.2021.583593
Comparing the Two Prodromal Parkinson's Disease Research Criteria—Lessons for Future Studies|10.1002/mds.28637
Non-Motor Features of Parkinson’s Disease in Women|10.3233/jpd-202409
Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson’s Disease|10.3233/jpd-212535
Computational medication regimen for Parkinson’s disease using reinforcement learning|10.1038/s41598-021-88619-4
Feature selection and machine learning methods for optimal identification and prediction of subtypes in Parkinson's disease|10.1016/j.cmpb.2021.106131
Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages|10.1038/s41598-021-88877-2
Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson’s disease|10.1186/s13287-021-02326-5
Cell-Type Specific Changes in DNA Methylation of SNCA Intron 1 in Synucleinopathy Brains|10.3389/fnins.2021.652226
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study|10.1002/mds.28596
Measuring Patient Preferences at the FDA Center for Devices and Radiological Health: Reflections and Projections|10.1016/j.jval.2021.01.009
Preferences for Communication About End‐of‐Life Care in Atypical Parkinsonism|10.1002/mds.28633
The impact of COVID-19 on palliative care for people with Parkinson’s and response to future pandemics|10.1080/14737175.2021.1923480
Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity|10.3233/jpd-202508
Memory enhancement by multidomain group cognitive training in patients with Parkinson’s disease and mild cognitive impairment: long-term effects of a multicenter randomized controlled trial|10.1007/s00415-021-10568-9
Plasma NfL, clinical subtypes and motor progression in Parkinson's disease|10.1016/j.parkreldis.2021.04.016
Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema|10.1007/s11060-021-03762-2
DNA Methylation and Expression Profiles of Whole Blood in Parkinson’s Disease|10.3389/fgene.2021.640266
In silico comparative analysis of LRRK2 interactomes from brain, kidney and lung|10.1016/j.brainres.2021.147503
Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease|10.1002/ana.26090
Lymphoblastoid Cell Lines as Models to Study Mitochondrial Function in Neurological Disorders|10.3390/ijms22094536
Safety and Tolerability of Burst-Cycling Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease|10.3389/fnhum.2021.651168
Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses|10.1016/j.neurobiolaging.2021.04.011
Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients|10.1073/pnas.2026610118
Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus|10.1212/wnl.0000000000012064
Contribution of Basal Ganglia to the Sense of Upright: A Double-Blind Within-Person Randomized Trial of Subthalamic Stimulation in Parkinson’s Disease with Pisa Syndrome|10.3233/jpd-202388
Extracellular Vesicles as Biomarkers and Therapeutic Tools: From Pre-Clinical to Clinical Applications|10.3390/biology10050359
Further Characterization of Glycoform-Selective Prions of Variably Protease-Sensitive Prionopathy|10.3390/pathogens10050513
Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation|10.1093/brain/awab170
Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy|10.1126/sciadv.abg4922
The Role of Focused Ultrasound in the Management of Movement Disorders: Insights after 5 Years of Experience|10.1002/mdc3.13223
VPS13D bridges the ER to mitochondria and peroxisomes via Miro|10.1083/jcb.202010004
Alpha‐Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure|10.1002/ana.26089
Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease|10.1021/acsnano.1c00453
Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome|10.1016/j.cell.2021.03.048
Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells|10.3390/cells10050981
Prevalence and Risk Factors for Double Vision in Parkinson Disease|10.1002/mdc3.13220
Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression|10.1001/jamanetworkopen.2021.5845
Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline|10.3389/fnagi.2021.626974
The association between multiple risk factors, clinical correlations and molecular insights in Parkinson’s disease patients from Tamil Nadu population, India|10.1016/j.neulet.2021.135903
The International Parkinson Disease Genomics Consortium Africa|10.1016/s1474-4422(21)00100-9
High-throughput generation of midbrain dopaminergic neuron organoids from reporter human pluripotent stem cells|10.1016/j.xpro.2021.100463
Nurr1 repression mediates cardinal features of Parkinson’s disease in α-synuclein transgenic mice|10.1093/hmg/ddab118
The triple aim of clinical research|10.1177/17407745211001522
A 2-Pyridone Amide Inhibitor of Transcriptional Activity in Chlamydia trachomatis|10.1128/aac.01826-20
Consistent skin α-synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up study|10.1016/j.parkreldis.2021.04.007
Neurosurgeons perspective on the shift towards earlier use of deep brain stimulation for Parkinson disease|10.1016/j.inat.2021.101224
Principal Component Analysis of Striatal and Extrastriatal D2 Dopamine Receptor Positron Emission Tomography in Manganese-Exposed Workers|10.1093/toxsci/kfab045
Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer’s disease|10.1038/s41467-021-22399-3
Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia|10.1007/s40120-021-00246-3
Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods|10.1186/s13195-021-00812-9
miRMaster 2.0: multi-species non-coding RNA sequencing analyses at scale|10.1093/nar/gkab268
Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease|10.1002/ana.26085
Role of Neuroinflammation in the Establishment of the Neurogenic Microenvironment in Brain Diseases|10.1007/s43152-021-00028-x
Tourette Syndrome and Driving|10.1002/mdc3.13225
In situ architecture of neuronal α-Synuclein inclusions|10.1038/s41467-021-22108-0
A tutorial in photoacoustic microscopy and tomography signal processing methods|10.1063/5.0040783
Exploratory analysis of the genetics of impulse control disorders in Parkinson's disease using genetic risk scores|10.1016/j.parkreldis.2021.04.003
Genome-Wide Polygenic Risk Score Identifies Individuals at Elevated Parkinson’s Disease Risk (4286)|10.1212/wnl.96.15_supplement.4286
Olfactory Testing in Parkinson Disease and REM Behavior Disorder|10.1212/wnl.0000000000011743
Parkinson’s Disease and the COVID-19 Pandemic|10.3233/jpd-202320
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations|10.3233/jpd-202472
Brain proteome-wide association study implicates novel proteins in depression pathogenesis|10.1038/s41593-021-00832-6
Effects of the COVID-19 Pandemic on Parkinson’s Disease: a Single-Centered Qualitative Study|10.1017/cjn.2021.70
Multiomics integrative analysis identifies APOE allele-specific blood biomarkers associated to Alzheimer’s disease etiopathogenesis|10.18632/aging.202950
Position‐Related Paroxysmal Facial Twitching|10.1002/mdc3.13219
Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles|10.1016/j.jcyt.2021.01.001
Gait Parameters Measured from Wearable Sensors Reliably Detect Freezing of Gait in a Stepping in Place Task|10.3390/s21082661
Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism|10.1007/s00259-021-05302-6
A computational method for direct imputation of cell type-specific expression profiles and cellular compositions from bulk-tissue RNA-Seq in brain disorders|10.1093/nargab/lqab056
Bayesian estimation of cell type–specific gene expression with prior derived from single-cell data|10.1101/gr.268722.120
Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a C. elegans model of Parkinson’s disease|10.1007/s00044-021-02720-x
Gene-Environment Interactions in Progressive Supranuclear Palsy|10.3389/fneur.2021.664796
Worldwide barriers to genetic testing for movement disorders|10.1111/ene.14826
Accumulation of Brain Hypointense Foci on Susceptibility-Weighted Imaging in Childhood Ataxia Telangiectasia|10.3174/ajnr.a7107
Challenges and Limitations of Targeting the Keap1-Nrf2 Pathway for Neurotherapeutics: Bach1 De-Repression to the Rescue|10.3389/fnagi.2021.673205
Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression|10.1002/mds.28602
Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome|10.1002/mdc3.13207
Subcortical short‐term plasticity elicited by deep brain stimulation|10.1002/acn3.51275
A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care|10.3233/jpd-212593
Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts|10.3233/jpd-212570
Editorial: Celebrating the Diversity of Genetic Research to Dissect the Pathogenesis of Parkinson's Disease|10.3389/fneur.2021.648417
Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials|10.3389/fneur.2021.648532
Hispanic Perspectives on Parkinson’s Disease Care and Research Participation|10.3233/jad-210231
Prodromal Parkinson disease — time is brain|10.1038/s41582-021-00489-6
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection|10.1212/wnl.0000000000011704
Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias|10.1212/wnl.0000000000011699
Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia|10.1002/acn3.51358
Frequency of mutations in PRKN, PINK1, and DJ1 in Patients With Early-Onset Parkinson Disease from neighboring countries in Central Europe|10.1016/j.parkreldis.2021.03.026
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis|10.1002/mds.28599
ATP1A3-Related Disorders: An Ever-Expanding Clinical Spectrum|10.3389/fneur.2021.637890
Cerebello‐Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease|10.1002/mds.28603
Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single‐particle analysis platforms|10.1002/jev2.12079
Deep mining of oxysterols and cholestenoic acids in human plasma and cerebrospinal fluid: Quantification using isotope dilution mass spectrometry|10.1016/j.aca.2021.338259
Disruption of the Atrophy-based Functional Network in Multiple Sclerosis Is Associated with Clinical Disability: Validation of a Meta-Analytic Model in Resting-State Functional MRI|10.1148/radiol.2021203414
Distinct neural circuits are associated with subclinical neuropsychiatric symptoms in Parkinson's disease|10.1016/j.jns.2021.117365
Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments|10.1016/j.arcmed.2020.10.021
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis|10.1002/cncr.33516
Evidence forGRNconnecting multiple neurodegenerative diseases|10.1093/braincomms/fcab095
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial|10.1002/mds.28569
Genetic updates on paroxysmal dyskinesias|10.1007/s00702-021-02335-x
Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes|10.1212/nxg.0000000000000557
Intersection of immunometabolism and immunosenescence during aging|10.1016/j.coph.2021.01.003
Mindfulness based stress reduction in people with Parkinson's disease and their care partners|10.1016/j.ctcp.2021.101377
Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin|10.1016/j.neo.2021.02.003
Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease|10.1093/braincomms/fcab109
Variable number tandem repeats – Their emerging role in sickness and health|10.1177/15353702211003511
Will Artificial Intelligence Outperform the Clinical Neurologist in the Near Future? No|10.1002/mdc3.13200
Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson’s Disease|10.1007/s12035-021-02371-4
Pervasive cis effects of variation in copy number of large tandem repeats on local DNA methylation and gene expression|10.1016/j.ajhg.2021.03.016
Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease|10.1212/wnl.0000000000011649
Characterizing resting‐state networks in Parkinson’s disease: A multi‐aspect functional connectivity study|10.1002/brb3.2101
Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum|10.1097/rlu.0000000000003609
Lipidomics Prediction of Parkinson’s Disease Severity: A Machine-Learning Analysis|10.3233/jpd-202476
Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer|10.1002/mds.28556
Tablet-based patient educational interventions in care and management of complex movement disorders|10.1080/17483107.2021.1900934
Tau induces formation of α-synuclein filaments with distinct molecular conformations|10.1016/j.bbrc.2021.03.091
Public Engagement and Neurology: An Update|10.3390/brainsci11040429
Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database|10.1016/j.parkreldis.2021.03.007
Magnetic resonance imaging quality control, quality assurance and quality improvement|10.1007/s00247-021-05043-6
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease|10.3389/fneur.2021.645706
ATG4 family proteins drive phagophore growth independently of the LC3/GABARAP lipidation system|10.1016/j.molcel.2021.03.001
Lifetime neuropsychiatric symptoms in Huntington's disease: Implications for psychiatric nursing|10.1016/j.apnu.2021.03.006
Obtaining Objective Clinical Measures During Telehealth Evaluations of Dysarthria|10.1044/2020_ajslp-20-00243
Assessment of ANG variants in Parkinson's disease|10.1016/j.neurobiolaging.2021.03.006
Microdroplet-based one-step RT-PCR for ultrahigh throughput single-cell multiplex gene expression analysis and rare cell detection|10.1038/s41598-021-86087-4
Replication of a Novel Parkinson's Locus in a European Ancestry Population|10.1002/mds.28546
Evaluation, Acceptance, and Qualification of Digital Measures: From Proof of Concept to Endpoint|10.1159/000514730
Integrated miRNA-Seq and mRNA-Seq Study to Identify miRNAs Associated With Alzheimer’s Disease Using Post-mortem Brain Tissue Samples|10.3389/fnins.2021.620899
Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy|10.1002/mds.28568
Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9|10.1038/s41434-021-00244-y
PARKIN, PINK1, and DJ1 analysis in early-onset Parkinson’s disease in Ireland|10.1007/s11845-021-02563-w
Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population‐Based CLSA|10.1002/mds.28571
The cell biology of Parkinson’s disease|10.1083/jcb.202012095
Transcriptome-wide Association Study in Frontotemporal Dementia Identifies New Disease Loci by In Silico Analysis|10.1016/j.biopsych.2021.02.010
VPS35 D620N knockin mice recapitulate cardinal features of Parkinson’s disease|10.1111/acel.13347
Crowdsourcing digital health measures to predict Parkinson’s disease severity: the Parkinson’s Disease Digital Biomarker DREAM Challenge|10.1038/s41746-021-00414-7
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience|10.3389/fnins.2021.653377
Dynamic 18F-FPCIT PET: Quantification of Parkinson Disease Metabolic Networks and Nigrostriatal Dopaminergic Dysfunction in a Single Imaging Session|10.2967/jnumed.120.257345
Evidence for Early and Regular Physical Therapy and Exercise in Parkinson's Disease|10.1055/s-0041-1725133
Fast decoding cell type–specific transcription factor binding landscape at single-nucleotide resolution|10.1101/gr.269613.120
Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review|10.1002/mds.28517
Il-10 signaling reduces survival in mouse models of synucleinopathy|10.1038/s41531-021-00169-8
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase|10.1038/s41531-021-00172-z
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo|10.1186/s13024-021-00441-8
Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia|10.1016/j.cortex.2021.03.006
The experience of care partners of patients with Parkinson’s disease psychosis|10.1371/journal.pone.0248968
The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability|10.1007/s40266-021-00853-7
The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44|10.1016/j.ymgme.2021.03.012
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection|10.1016/j.cell.2021.03.026
HFE H63D Limits Nigral Vulnerability to Paraquat in Agricultural Workers|10.1093/toxsci/kfab020
Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats|10.1038/s41598-021-85293-4
White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease|10.1016/j.parkreldis.2021.02.031
Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population‐Based 10‐Year Study|10.1002/mds.28570
Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS|10.3389/fnins.2021.642324
Telemedicine in an Academic Movement Disorders Center during COVID-19|10.14802/jmd.20099
Expression of an alternatively spliced variant of SORL1 in neuronal dendrites is decreased in patients with Alzheimer’s disease|10.1186/s40478-021-01140-7
LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ciliogenesis blockade|10.26508/lsa.202101050
Retinal Ganglion Cells Functional Changes in a Mouse Model of Alzheimer’s Disease Are Linked with Neurotransmitter Alterations|10.3233/jad-201195
Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson’s disease progression|10.1038/s43587-021-00042-6
Dysregulated miRNAs mark Parkinson’s disease progression|10.1038/s43587-021-00046-2
Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinson’s disease|10.1093/sleep/zsab067
Transcript Variants of Genes Involved in Neurodegeneration Are Differentially Regulated by the APOE and MAPT Haplotypes|10.3390/genes12030423
Morphological analysis of subcortical structures for assessment of cognitive dysfunction in Parkinson’s disease using multi-atlas based segmentation|10.1007/s11571-021-09671-4
Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)|10.3233/jpd-202464
Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment|10.1002/mds.28548
LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons|10.3233/jpd-212562
Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation|10.14802/jmd.20090
PDKit: A data science toolkit for the digital assessment of Parkinson’s Disease|10.1371/journal.pcbi.1008833
Factors Associated with Health‐Related Quality of Life in Late‐Stage Parkinson's Disease|10.1002/mdc3.13186
Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease|10.1038/s41467-021-21669-4
Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats|10.1038/s41434-021-00249-7
Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites|10.1007/s00401-021-02285-4
CSPα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice|10.1093/brain/awab076
Laboratory‐Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group|10.1002/mdc3.13158
S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD|10.1073/pnas.2021368118
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases|10.3390/ijms22062805
A New Rise of Non-Human Primate Models of Synucleinopathies|10.3390/biomedicines9030272
Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer’s Disease or Dementia with Lewy Bodies|10.3233/jad-200323
Immediate effects of treadmill walking in individuals with Lewy body dementia and Huntington’s disease|10.1016/j.gaitpost.2021.03.016
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?|10.1038/s41531-021-00170-1
Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension|10.1007/s11910-021-01104-3
Novel Associations of BST1 and LAMP3 With REM Sleep Behavior Disorder|10.1212/wnl.0000000000011464
CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease|10.1093/brain/awab103
How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review|10.1038/s41531-021-00160-3
Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study|10.1111/ene.14803
Screen Fast, Screen Faster: A Pilot Study to Screen for Depressive Symptoms Using the Beck Depression Inventory Fast Screen in Parkinson's Disease With Mild Cognitive Impairment|10.3389/fneur.2021.640137
The Role of Genetic Testing for Parkinson’s Disease|10.1007/s11910-021-01100-7
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression|10.1002/mds.28551
ATP13A2 Regulates Cellular α-Synuclein Multimerization, Membrane Association, and Externalization|10.3390/ijms22052689
Data imputation and compression for Parkinson's disease clinical questionnaires|10.1016/j.artmed.2021.102051
GDNF signaling in subjects with minimal motor deficits and Parkinson's disease|10.1016/j.nbd.2021.105298
Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures|10.1016/j.parkreldis.2021.02.026
Common X‐Chromosome Variants Are Associated with Parkinson Disease Risk|10.1002/ana.26051
Distinct Roles of the Human Subthalamic Nucleus and Dorsal Pallidum in Parkinson’s Disease Impulsivity|10.1016/j.biopsych.2021.03.002
Serum Uric Acid in LRRK2 Related Parkinson’s Disease: Longitudinal Data from the PPMI Study|10.3233/jpd-202337
Reeling in the Zebrafish Cancer Models|10.1146/annurev-cancerbio-051320-014135
Density of Patient-Sharing Networks: Impact on the Value of Parkinson Care|10.34172/ijhpm.2021.15
Digital Technology in Movement Disorders: Updates, Applications, and Challenges|10.1007/s11910-021-01101-6
Incorporating Patient Preferences via Bayesian Decision Analysis|10.2215/cjn.12110720
Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder|10.1073/pnas.2020858118
Parkinson's Kinesia Paradoxa Is Not a Paradox|10.1002/mds.28550
A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene|10.3389/fneur.2021.635396
Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression|10.1002/alz.12310
Isotopic Evidence for Long-Distance Connections of the AD Thirteenth-Century Promontory Caves Occupants|10.1017/aaq.2020.116
Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease|10.3389/fncel.2021.626128
Pathogenic LRRK2 regulates ciliation probability upstream of tau tubulin kinase 2 via Rab10 and RILPL1 proteins|10.1073/pnas.2005894118
Probable REM sleep behavior disorder is associated with longitudinal cortical thinning in Parkinson’s disease|10.1038/s41531-021-00164-z
Thalamic morphology predicts the onset of freezing of gait in Parkinson’s disease|10.1038/s41531-021-00163-0
Adapting the proteostasis capacity to sustain brain healthspan|10.1016/j.cell.2021.02.007
Closed-Loop Deep Brain Stimulation to Treat Medication-Refractory Freezing of Gait in Parkinson’s Disease|10.3389/fnhum.2021.633655
Intracellular Thermometry to Study Protein Aggregation Related to Neurodegenerative Diseases|10.1016/j.tibs.2020.12.003
Investigating the relationship between the SNCA gene and cognitive abilities in idiopathic Parkinson’s disease using machine learning|10.1038/s41598-021-84316-4
Management of Secondary Poor Response to Botulinum Toxin in Cervical Dystonia: A Multicenter Audit|10.1002/mdc3.13181
Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease|10.1002/brb3.2086
Physical activity as a mediator of anxiety and cognitive functioning in Parkinson's disease|10.1016/j.mhpa.2021.100382
Reply to: “Cell Therapy for Huntington's Disease: Learning from Failure”|10.1002/mds.28500
Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders|10.1007/s40263-021-00796-y
The role of immune-mediated alterations and disorders in ALS disease|10.1016/j.humimm.2021.01.017
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism|10.1038/s41531-021-00162-1
TNF-α and α-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration|10.1016/j.celrep.2021.108895
Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease|10.1016/j.parkreldis.2021.01.005
Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts?|10.1097/01.jmq.0000735440.58551.5b
Challenges and Controversies in the Genetic Diagnosis of Hereditary Spastic Paraplegia|10.1007/s11910-021-01099-x
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation|10.1093/brain/awab073
No Evidence for a Causal Relationship Between Cancers and Parkinson’s Disease|10.3233/jpd-202474
Contribution of neuropsychiatric symptoms in Parkinson’s disease to different domains of caregiver burden|10.1007/s00415-021-10443-7
Frequency of Parkinsonism and Parkinson Disease in African Americans in the Chicago Community|10.1093/gerona/glab042
Impaired Structural Connectivity in Parkinson's Disease Patients with Mild Cognitive Impairment: A Study Based on Probabilistic Tractography|10.1089/brain.2020.0939
Open science takes on Parkinson’s disease|10.7554/elife.66546
Peripheral Klotho and Parkinson's Disease|10.1002/mds.28530
TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease|10.3389/fnagi.2021.638922
Bidirectional Correlations Between Dopaminergic Function and Motivation in Parkinson’s Disease|10.1177/0891988721996802
Differentially expressed genes in Alzheimer’s disease highlighting the roles of microglia genes including OLR1 and astrocyte gene CDK2AP1|10.1016/j.bbih.2021.100227
Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease|10.1101/gr.272484.120
Reckless Generosity, Parkinson's Disease and Dopamine: A Case Series and Literature Review|10.1002/mdc3.13156
A Long-Term, Real-Life Parkinson Monitoring Database Combining Unscripted Objective and Subjective Recordings|10.3390/data6020022
A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts|10.3390/cells10020480
Motor Thalamic Deep Brain Stimulation Alters Cortical Activity and Shows Therapeutic Utility for Treatment of Parkinson’s Disease Symptoms in a Rat Model|10.1016/j.neuroscience.2021.02.019
The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease|10.1016/j.nbd.2021.105312
A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease|10.1002/mds.28534
Am I My Cousin's Keeper? A Proposal to Protect Relatives of Genetic Database Subjects|10.18060/25052
Changes in Body Composition Before and After Parkinson's Disease Diagnosis|10.1002/mds.28536
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial|10.1002/mds.28533
Role of Peripheral Immune Cells for Development and Recovery of Chronic Pain|10.3389/fimmu.2021.641588
Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease|10.1093/jnen/nlaa160
β‐Blocker–Induced Tremor|10.1002/mdc3.13176
Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson disease and scans without evidence of dopaminergic deficit|10.1097/md.0000000000024837
LRRK2 Ablation Attenuates Alpha-Synuclein–Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo|10.1007/s13311-021-01007-8
Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia|10.2174/1567205018666210219105949
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study|10.1016/s1474-4422(20)30449-x
Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson’s disease cohort|10.1093/hmg/ddab058
Pharmacological validation of TDO as a target for Parkinson’s disease|10.1111/febs.15721
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial|10.1016/s1474-4422(20)30489-0
PathoFact: a pipeline for the prediction of virulence factors and antimicrobial resistance genes in metagenomic data|10.1186/s40168-020-00993-9
The status of neurology fellowships in the United States: clinical needs, educational barriers, and future outlooks|10.1186/s12909-021-02536-8
An efficient and scalable synthesis of thiazolo ring fused 2-pyridones using flow chemistry|10.24820/ark.5550190.p011.445
Bending curvatures of subducting plates: old versus young slabs|10.1093/gji/ggab070
Investigating ELOVL7 coding variants in multiple system atrophy|10.1016/j.neulet.2021.135723
Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain|10.1016/j.brainres.2021.147372
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture|10.1038/s41588-021-00785-3
Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease|10.1002/mdc3.13168
Non‐Motor Fluctuations in Parkinson's Disease: Validation of the Non‐Motor Fluctuation Assessment Questionnaire|10.1002/mds.28507
Objective screening for olfactory and gustatory dysfunction during the COVID‐19 pandemic: A prospective study in healthcare workers using self‐administered testing|10.1016/j.wjorl.2021.02.001
Quantitative intravital imaging in zebrafish reveals in vivo dynamics of physiological-stress-induced mitophagy|10.1242/jcs.256255
Doppler weather radar data assimilation at convective-allowing grid spacing for predicting an extreme weather event in Southern India|10.1080/01431161.2021.1880660
Modelling item scores of Unified Parkinson's Disease Rating Scale Part III for greater trial efficiency|10.1111/bcp.14777
Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery|10.2174/2589977513666210211163711
Single-Cell Imaging for Studies of Renal Uranium Transport and Intracellular Behavior|10.3390/min11020191
Validating Differential Volatilome Profiles in Parkinson’s Disease|10.1021/acscentsci.0c01028
Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease|10.1002/mds.28525
Generation of human midbrain organoids from induced pluripotent stem cells|10.12688/mniopenres.12816.2
Might it Be Possible to Assess Rigidity in PD Patients Remotely?|10.1002/mdc3.13167
The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status|10.1186/s13195-021-00778-8
Attitudes toward use and timing of deep brain stimulation: a patient’s with DBS perspective|10.1016/j.clineuro.2021.106553
Cognitive subtypes in individuals with essential tremor seeking deep brain stimulation|10.1080/13854046.2021.1882578
Genetic control of the human brain proteome|10.1016/j.ajhg.2021.01.012
Optimal Treatment of Depression and Anxiety in Parkinson's Disease|10.1016/j.jagp.2021.02.037
Quantitative Cellular Changes in the Thalamus of Patients with Multiple System Atrophy|10.1016/j.neuroscience.2021.02.003
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity|10.1016/j.parkreldis.2021.02.006
Receptor-type protein tyrosine phosphatase alpha (PTPα) mediates MMP14 localization and facilitates triple-negative breast cancer cell invasion|10.1091/mbc.e20-01-0060
Empfehlungen zur neuropsychologischen Diagnostik beim Morbus Parkinson|10.1055/a-1099-9332
Quality of life in isolated dystonia: non-motor manifestations matter|10.1136/jnnp-2020-325193
Sex differences for phenotype in pathologically defined dementia with Lewy bodies|10.1136/jnnp-2020-325668
Periphery and brain, innate and adaptive immunity in Parkinson’s disease|10.1007/s00401-021-02268-5
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease|10.1186/s13024-021-00427-6
State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease|10.1080/14656566.2021.1876666
Altered sphingolipid function in Alzheimer's disease; a gene regulatory network approach|10.1016/j.neurobiolaging.2021.02.001
Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement|10.1007/s10286-021-00782-w
Compound heterozygous variants in Wiskott-Aldrich syndrome like (WASL) gene segregating in a family with early onset Parkinson's disease|10.1016/j.parkreldis.2021.02.001
Moving From Wired to Wireless Brain Stimulation to Treat Movement Disorders: Are We Breaking Ground?|10.1002/mds.28499
Multiple reaction monitoring profiling (MRM profiling): Small molecule exploratory analysis guided by chemical functionality|10.1016/j.chemphyslip.2021.105048
The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD GBA|10.1002/mds.28472
Accelerometer data collected with a minimum set of wearable sensors from subjects with Parkinson’s disease|10.1038/s41597-021-00830-0
APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease|10.3389/fneur.2021.631145
Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology|10.1007/s12311-021-01239-6
Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson’s Disease|10.1007/s00415-021-10419-7
Limb and trunk accelerometer data collected with wearable sensors from subjects with Parkinson’s disease|10.1038/s41597-021-00831-z
Motor cortical excitability and paired-associative stimulation-induced plasticity in amnestic mild cognitive impairment and Alzheimer’s disease|10.1016/j.clinph.2021.01.011
Effects of Excess Brain-Derived Human α-Synuclein on Synaptic Vesicle Trafficking|10.3389/fnins.2021.639414
Protein disulfide isomerase ERp57 protects early muscle denervation in experimental ALS|10.1186/s40478-020-01116-z
Triggers and alleviating factors for fatigue in Parkinson’s disease|10.1371/journal.pone.0245285
Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study|10.1016/j.parkreldis.2021.01.024
Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson’s Disease|10.3233/jpd-202506
28th Annual Meeting of the Dysphagia Research Society|10.1007/s00455-020-10221-z
Bullous Pemphigoid Associated with Multiple System Atrophy: Case Series|10.1002/mdc3.13160
Infection and Risk of Parkinson’s Disease|10.3233/jpd-202279
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations|10.1007/s40263-020-00782-w
Burden of Neurological Disorders Across the US From 1990-2017|10.1001/jamaneurol.2020.4152
Chromatin Mechanics Dictates Subdiffusion and Coarsening Dynamics of Embedded Condensates|10.1016/j.bpj.2020.11.2012
Essential tremor and cognitive decline|10.1016/j.parkreldis.2020.12.012
Fidelity of the PINK1 knockout rat to oxidative stress and other characteristics of Parkinson disease|10.1016/j.freeradbiomed.2020.12.004
Genetic Testing for Parkinson Disease|10.1212/cpj.0000000000000831
Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets|10.1001/jamaneurol.2020.5257
Knowledge, Responsibilities, and Peer Advice From Care Partners of Patients With Parkinson Disease Psychosis|10.3389/fneur.2021.633645
Parkinson's Disease and COVID‐19: Do We Need to Be More Patient?|10.1002/mds.28469
Reply to: ‘Letter to the Editor on “Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities”’|10.1002/mds.28456
Supplement (online only): Proceedings of the 14th Göttingen Meeting of the German Neuroscience Society 2021|10.1515/nf-2021-2003
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study|10.1371/journal.pone.0245827
The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis|10.1016/j.smrv.2020.101384
The philosophy of Constantine the Philosopher of Nicaea|10.1515/bz-2021-9006
The Urgency of Justice in Research: Beyond COVID-19|10.1016/j.molmed.2020.11.004
Attentional dysfunction and the punding spectrum in Parkinson's disease|10.1016/j.parkreldis.2021.01.019
Real-world assessment of the impact of “OFF” episodes on health-related quality of life among patients with Parkinson’s disease in the United States|10.1186/s12883-021-02074-2
GP2: The Global Parkinson's Genetics Program|10.1002/mds.28494
Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk|10.1002/mds.28475
Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients|10.1002/ange.202014898
Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients|10.1002/anie.202014898
Skin conditions in early Parkinson's disease|10.1016/j.parkreldis.2021.01.018
Walking Speed Reliably Measures Clinically Significant Changes in Gait by Directional Deep Brain Stimulation|10.3389/fnhum.2020.618366
Acceptability and Feasibility of a Mindfulness Intervention Delivered via Videoconferencing for People With Parkinson’s|10.1177/0891988720988901
Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort|10.3389/fnins.2021.634666
Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis|10.1038/s41588-020-00773-z
Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer’s disease|10.1186/s40478-020-01117-y
The potential of biomaterials for central nervous system cellular repair|10.1016/j.neuint.2021.104971
A growth-factor-activated lysosomal K+ channel regulates Parkinson’s pathology|10.1038/s41586-021-03185-z
An AI Model for Neurodegenerative Diseases|10.1109/iccci50826.2021.9402493
Blood–brain barrier permeability in Parkinson’s disease patients with and without dyskinesia|10.1007/s00415-021-10411-1
Frequency of spinocerebellar ataxia mutations in patients with multiple system atrophy|10.1007/s10286-020-00759-1
Genotype–Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review|10.1002/mds.28485
A protease protection assay for the detection of internalized alpha-synuclein pre-formed fibrils|10.1371/journal.pone.0241161
Biphasic (Subtherapeutic) Levodopa-Induced Respiratory Dysfunction in Parkinson Disease|10.1212/cpj.0000000000001043
How Time Rules: Diurnal Motor Patterns in de novo Parkinson’s Disease|10.3233/jpd-202352
Next-Generation Diamond Electrodes for Neurochemical Sensing: Challenges and Opportunities|10.3390/mi12020128
Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism|10.1124/jpet.120.000229
Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies|10.1021/acschemneuro.0c00801
The Parkinson's Disease DNA Variant Browser|10.1002/mds.28488
Analysis of voice as an assisting tool for detection of Parkinson's disease and its subsequent clinical interpretation|10.1016/j.bspc.2021.102415
Characterizing Advanced Parkinson’s Disease: Romanian Subanalysis from the OBSERVE-PD Study|10.1155/2021/6635618
Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers|10.3389/fnagi.2020.627199
The Membrane Interactions of Synuclein: Physiology and Pathology|10.1146/annurev-pathol-031920-092547
N-terminal acetylation does not alter α-synuclein's interfacial properties|10.1016/j.ijbiomac.2021.01.147
Author Correction: The effect of LRRK2 loss-of-function variants in humans|10.1038/s41591-020-01185-6
Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease|10.1016/j.neuropharm.2021.108465
Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein|10.1002/jnr.24782
Urinary proteome profiling for stratifying patients with familial Parkinson’s disease|10.15252/emmm.202013257
Deubiquitinating enzyme amino acid profiling reveals a class of ubiquitin esterases|10.1073/pnas.2006947118
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism|10.3390/ijms22031045
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease|10.1002/alz.12254
An exploration of the coverage of aphasia in the Irish print media|10.1080/02687038.2021.1875733
Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease|10.1002/mds.28473
Huntington’s Disease Community Perspectives on Desired Characteristics of Disease Modifying Therapies|10.5334/tohm.584
LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8|10.3390/cells10020203
Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS|10.1523/jneurosci.1952-20.2020
A priori prediction of response in multicentre locally advanced breast cancer (LABC) patients using quantitative ultrasound and derivative texture methods|10.18632/oncotarget.27867
Salivary Aβ Secretion and Altered Oral Microbiome in Mouse Models of AD|10.2174/1567205018666210119151952
Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study|10.1016/j.parkreldis.2020.12.020
The 3-Item “Apathy” Subscale Within the GDS-15 Is Not Supported in De Novo Parkinson’s Disease Patients: Analysis of the PPMI Cohort|10.1177/0891988720988908
The Importance of Cross-Disciplinary Research: A Commentary on “Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease”|10.1016/j.jagp.2021.01.010
Acoustic Analysis of Intonation in Persons With Parkinson's Disease Receiving Transcranial Magnetic Stimulation and Intensive Voice Treatment|10.1016/j.jvoice.2020.12.019
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease|10.3791/62002
Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms|10.1042/bcj20200937
Pallidal stimulation as treatment for camptocormia in Parkinson’s disease|10.1038/s41531-020-00151-w
Stress and mindfulness in Parkinson’s disease – a survey in 5000 patients|10.1038/s41531-020-00152-9
Synaptic processes and immune-related pathways implicated in Tourette syndrome|10.1038/s41398-020-01082-z
Unmet Needs of People With Parkinson's Disease and Their Caregivers During COVID-19-Related Confinement: An Explorative Secondary Data Analysis|10.3389/fneur.2020.615172
Interplay between tau and α‐synuclein liquid–liquid phase separation|10.1002/pro.4025
The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease|10.1111/ene.14733
Fracture Risk Assessment in Atypical Parkinsonian Syndromes|10.1002/mdc3.13146
Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer’s disease|10.1126/science.aaw0843
Retrospective motion artifact correction of structural MRI images using deep learning improves the quality of cortical surface reconstructions|10.1016/j.neuroimage.2021.117756
Author response to comment on “The association between pain and impulse control behaviours in Parkinson's disease”|10.1016/j.parkreldis.2021.01.011
Early-Onset Parkinson Disease Screening in Patients From Nigeria|10.3389/fneur.2020.594927
Editorial introductions|10.1097/wco.0000000000000898
Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease|10.1016/j.parkreldis.2020.12.016
Impact of the apolipoprotein E ε4 allele on early Parkinson's disease progression|10.1016/j.parkreldis.2021.01.004
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study|10.1016/j.parkreldis.2020.12.024
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery|10.1186/s13195-020-00760-w
Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ|10.1016/j.parkreldis.2021.01.002
Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease|10.1002/mds.28467
Intracellular Thermometry at the Micro‐/Nanoscale and its Potential Application to Study Protein Aggregation Related to Neurodegenerative Diseases|10.1002/cbic.202000765
Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis|10.1136/jnnp-2020-324391
Posterior Cortical Atrophy phenotype in a GBA N370S mutation carrier: a case report|10.1186/s12883-020-02023-5
Chromatin mechanics dictates subdiffusion and coarsening dynamics of embedded condensates|10.1038/s41567-020-01125-8
The TCR repertoire of α-synuclein-specific T cells in Parkinson’s disease is surprisingly diverse|10.1038/s41598-020-79726-9
Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A|10.1007/s00259-020-05149-3
Drug Repurposing for Parkinson’s Disease by Integrating Knowledge Graph Completion Model and Knowledge Fusion of Medical Literature|10.3390/fi13010014
Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome|10.3389/fneur.2020.630391
Sex- and age‐dependent alterations of splenic immune cell profile and NK cell phenotypes and function in C57BL/6J mice|10.1186/s12979-021-00214-3
Transcript Variants of Genes Involved in Neurodegeneration Are Differentially Regulated by the Apoe and Mapt Haplotypes|10.20944/preprints202101.0149.v1
True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation|10.1007/s00259-020-05151-9
Olfactory impairment in Wilson’s disease|10.1002/brb3.2022
Tardive neurotoxicity of anticholinergic drugs: A review|10.1111/jnc.15244
Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities|10.1038/s41418-020-00706-7
The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease|10.1002/mds.28483
Multimodal phenotypic axes of Parkinson’s disease|10.1038/s41531-020-00144-9
Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities|10.3389/fcell.2020.615461
DeepSleep convolutional neural network allows accurate and fast detection of sleep arousal|10.1038/s42003-020-01542-8
Differential transcript usage unravels gene expression alterations in Alzheimer’s disease human brains|10.1038/s41514-020-00052-5
Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson’s Disease|10.3390/metabo11010029
Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice|10.1155/2021/2603641
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients|10.1038/s41531-020-00147-6
Sequence of clinical and neurodegeneration events in Parkinson’s disease progression|10.1093/brain/awaa461
Response to: The need of reliable warning signs for dysphagia in Parkinson’s disease: an often-overlooked issue|10.1080/17474124.2021.1842195
Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies|10.1093/jmcb/mjaa075
Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration|10.1080/00325481.2020.1857992
A bidirectional relationship between anxiety, depression and gastrointestinal symptoms in Parkinson’s disease|10.1016/j.prdoa.2021.100104
A case series and systematic review of rapid eye movement sleep behavior disorder outcome after deep brain stimulation in Parkinson's disease|10.1016/j.sleep.2020.11.025
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions|10.1016/j.prdoa.2021.100115
Amyloid Precursor Protein Variant, E665D, Associated With Unique Clinical and Biomarker Phenotype|10.1177/1533317520981225
Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease|10.1016/j.neurobiolaging.2020.07.002
Analysis of factors associated with early stage Parkinson’s disease based on daily activities and sleeping behaviour disorder|10.1088/1742-6596/1722/1/012045
Artificial Intelligence in Medicine|10.1007/978-3-030-77211-6
Assessing the relationship between monoallelic PRKN mutations and Parkinson’s risk|10.1093/hmg/ddaa273
Cell-attached and Whole-cell Patch-clamp Recordings of Dopamine Neurons in the Substantia Nigra Pars Compacta of Mouse Brain Slices|10.21769/bioprotoc.4109
Classification of PPMI MRI scans with voxel-based morphometry and machine learning to assist in the diagnosis of Parkinson’s disease|10.1016/j.cmpb.2020.105793
Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments|10.1002/dad2.12223
Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy|10.1016/j.cell.2020.11.018
Connectivity correlates to predict essential tremor deep brain stimulation outcome: Evidence for a common treatment pathway|10.1016/j.nicl.2021.102846
Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group|10.1002/dad2.12235
Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease|10.17925/usn.2021.17.1.36
Diagnostic Sparse Connectivity Networks with Regularization Template|10.1109/tkde.2021.3075668
Differential blood DNA methylation across Lewy body dementias|10.1002/dad2.12156
Disclosure of individual research results at federally funded Alzheimer's Disease Research Centers|10.1002/trc2.12213
Disease-Oriented Image Embedding With Pseudo-Scanner Standardization for Content-Based Image Retrieval on 3D Brain MRI|10.1109/access.2021.3129105
Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease|10.1016/j.prdoa.2021.100113
Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset|10.1007/s00702-020-02287-8
Effects of digitalized university curriculum-associated teaching on the equilibrium of autonomic neurophysiology and disposition of learners in medical school (EDUCATE-AND-LEARN): protocol for a randomized crossover study|10.1080/07853890.2021.1996626
Electroencephalography in Orthostatic Tremor: A Prospective Study of 30 Patients|10.5334/tohm.596
Exploring the contribution of the mitochondrial disulfide relay system to Parkinson’s disease: the PINK1/CHCHD4 interplay|10.4103/1673-5374.310679
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease|10.14336/ad.2021.0527
Functional movement disorder comorbidity in Parkinson's disease: Unraveling the web|10.1016/j.parkreldis.2020.10.022
How Will Aducanumab Approval Impact AD Research?|10.14283/jpad.2021.46
Identification of risk factors for impulse-control disorder symptoms in patients with Parkinson’s disease|10.1088/1742-6596/1722/1/012099
In Support of Electronic Versions of Movement Disorder Society Rating Scales|10.1002/mds.28368
Invited Speakers’ Session|10.5692/clinicalneurol.61_supplement_s1
K2S2O8-mediated coupling of 6-amino-7-aminomethyl-thiazolino-pyridones with aldehydes to construct amyloid affecting pyrimidine-fused thiazolino-2-pyridones|10.1039/d1ob01580j
Long-term success of low-frequency subthalamic nucleus stimulation for Parkinson’s disease depends on tremor severity and symptom duration|10.1093/braincomms/fcab165
Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay|10.21769/bioprotoc.4140
Mechanisms of VPS35-mediated neurodegeneration in Parkinson's disease|10.1016/bs.irmvd.2021.08.005
Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation study|10.1080/20016689.2021.1922163
MRI biomarkers of small vessel disease and cognition: A cross‐sectional study of a cognitively normal Mexican American cohort|10.1002/dad2.12236
Multi-Target Regression Rules With Random Output Selections|10.1109/access.2021.3051185
Myxedema Psychosis: Systematic Review and Pooled Analysis.|10.2147/ndt.s318651
Neuroimaging in Functional Neurological Disorder: State of the Field and Research Agenda|10.1016/j.nicl.2021.102623
Normative vs. patient-specific brain connectivity in deep brain stimulation|10.1016/j.neuroimage.2020.117307
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel|10.1001/jamaneurol.2020.3536
Opicapone: A third generation COMT inhibitor|10.1016/j.prdoa.2020.100083
Orofacial pain in 1916 patients with early or moderate Parkinson disease|10.1097/pr9.0000000000000923
Palmaris Brevis Syndrome: A Treatable Pseudodystonia|10.5334/tohm.659
Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease|10.1002/mds.28422
Parkinson's disease and skin|10.1016/j.parkreldis.2020.11.017
Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study|10.1177/2381468320978407
Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson’s Disease|10.1177/23814683211021380
Phenotypic Features of Isolated Essential Tremor, Essential Tremor Plus, and Essential Tremor-Parkinson’s Disease in a Movement Disorders Clinic|10.5334/tohm.581
POSTERS 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021, Boston, USA|10.14283/jpad.2021.58
Programming Directional Deep Brain Stimulation in Parkinson’s Disease: A Randomized Prospective Trial Comparing Early versus Delayed Stimulation Steering|10.1159/000517054
Promising drug targets and associated therapeutic interventions in Parkinson’s disease|10.4103/1673-5374.306066
R869C mutation in molecular motor KIF17 gene is involved in dementia with Lewy bodies|10.1002/dad2.12143
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia|10.1002/trc2.12106
Real-world assessment of “OFF” episode–related healthcare resource utilization among patients with Parkinson’s disease in the United States|10.1080/13696998.2021.1913009
Remote delivery of cognitive behavioral therapy to patients with functional neurological disorders: Promise and challenges|10.1016/j.ebr.2021.100469
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition|10.1158/1535-7163.mct-20-0259
Response to Telemedicine Visits From Patients With Parkinsonism During the COVID-19 Pandemic on Postvisit Surveys|10.1177/2374373521997224
Restoration of Noradrenergic Function in Parkinson’s Disease Model Mice|10.1177/17590914211009730
Retracted: An easy-to-use deep-learning model for highly accurate diagnosis of Parkinson's disease using SPECT images|10.1016/j.compmedimag.2020.101810
Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness|10.26502/fccm.92920221
Similarity of the non-amyloid-β component and C-terminal tail of monomeric and tetrameric alpha-synuclein with 14-3-3 sigma|10.1016/j.csbj.2021.09.011
Specific immune modulation of experimental colitis drives enteric alpha-synuclein accumulation and triggers age-related Parkinson-like brain pathology.|10.17879/freeneuropathology-2021-3326
Stimulation Sweet Spot in Subthalamic Deep Brain Stimulation – Myth or Reality? A Critical Review of Literature|10.1159/000516098
Subcortical grey matter changes associated with motor symptoms evaluated by the Unified Parkinson’s disease Rating Scale (part III): A longitudinal study in Parkinson’s disease|10.1016/j.nicl.2021.102745
Targeting mitophagy in Parkinson's disease|10.1074/jbc.rev120.014294
Targeting transglutaminase 2 as a potential disease modifying therapeutic strategy for synucleinopathies|10.4103/1673-5374.303027
Telephone visit efficacy for Parkinson’s disease during the COVID-19 pandemic|10.1016/j.prdoa.2021.100107
The Clinical Value of Patient Home Videos in Movement Disorders|10.5334/tohm.651
The global Alzheimer's Association round robin study on plasma amyloid β methods|10.1002/dad2.12242
The Isolation and Deep Sequencing of Mitochondrial DNA|10.1007/978-1-0716-1270-5_27
The Role of the Cerebellum in Tremor – Evidence from Neuroimaging|10.5334/tohm.660
The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre|10.1093/braincomms/fcab135
Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation|10.5334/tohm.661
Transfer learning‐trained convolutional neural networks identify novel MRI biomarkers of Alzheimer's disease progression|10.1002/dad2.12140
Twelve Drummers Drumming… With Dystonia|10.5334/tohm.577
Video-based Parkinson’s disease assessments in a nationwide cohort of Fox Insight participants|10.1016/j.prdoa.2021.100094
Characterization of gait variability in multiple system atrophy and Parkinson’s disease|10.1007/s00415-020-10355-y
Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease|10.1002/mds.28453
Comparison of methods for texture analysis of QUS parametric images in the characterization of breast lesions|10.1371/journal.pone.0244965
Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats|10.1016/j.nbd.2020.105246
A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy|10.1002/acn3.51280
Functional Correlates of Action Observation of Gait in Patients with Parkinson’s Disease|10.1155/2020/8869201
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat|10.1097/fbp.0000000000000601
Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease|10.3233/jpd-202390
[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates|10.1007/s00259-020-05133-x
Mural cell dysfunction leads to altered cerebrovascular tau uptake following repetitive head trauma|10.1016/j.nbd.2020.105237
A systematic review of group intervention for acquired dysarthria in adults|10.1080/09638288.2020.1859629
fISHing with immunohistochemistry for housekeeping gene changes in Alzheimer’s disease using an automated quantitative analysis workflow|10.1111/jnc.15283
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study|10.1016/j.jns.2020.117293
Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites|10.1042/bcj20200930
Diabetes Mellitus Is Associated With an Earlier Age of Onset of Huntington's Disease|10.1002/mds.28460
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy|10.1093/jnen/nlaa153
Prevalence and Relationship of Rest Tremor and Action Tremor in Parkinson’s Disease|10.5334/tohm.552
The Impact of COVID-19 on Neurology Education: A Medical Student Perspective|10.3389/feduc.2020.567421
Activation of the Akt1-CREB pathway promotes RNF146 expression to inhibit PARP1-mediated neuronal death|10.1126/scisignal.aax7119
Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)|10.1002/acn3.51236
Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease|10.1002/mdc3.13143
Netrin‐1 and its receptor DCC modulate survival and death of dopamine neurons and Parkinson’s disease features|10.15252/embj.2020105537
The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia|10.3390/ijms22010020
Topological Abnormalities of Functional Brain Network in Early-Stage Parkinson’s Disease Patients With Mild Cognitive Impairment|10.3389/fnins.2020.616872
Alpha‐Synuclein oligomerization and aggregation: All models are useful but only if we know what they model|10.1111/jnc.15275
Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study|10.1016/s1474-4422(20)30394-x
Are hedge funds' charitable donations strategic?|10.1016/j.jcorpfin.2020.101842
Molecular forms of neurogranin in cerebrospinal fluid|10.1111/jnc.15252
Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease|10.1002/mds.28424
Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta‐Analysis|10.1002/mds.28390
Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers|10.1016/j.neurobiolaging.2020.12.011
Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease|10.1038/s41418-020-00698-4
Using INFERNO to Infer the Molecular Mechanisms Underlying Noncoding Genetic Associations|10.1007/978-1-0716-1158-6_6
Association of RASSF1A, DCR2, and CASP8 Methylation with Survival in Neuroblastoma: A Pooled Analysis Using Reconstructed Individual Patient Data|10.1155/2020/7390473
Building a System to Engage and Sustain Research Careers for Physicians|10.1097/acm.0000000000003886
Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder|10.1002/acn3.51269
Outcomes of genetic test disclosure and genetic counseling in a large Parkinson's disease research study|10.1002/jgc4.1366
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease|10.1001/jamaneurol.2020.4725
Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation|10.1002/mds.28411
Classification of Parkinson's disease based on multi-modal features and stacking ensemble learning|10.1016/j.jneumeth.2020.109019
The Danish ‘ghetto initiatives’ and the changing nature of social citizenship, 2004–2018|10.1177/0261018320978504
Data Sharing Goals for Nonprofit Funders of Clinical Trials|10.2196/23011
Study of functional connectivity of central motor system in Parkinson’s disease using copula theory|10.1016/j.bspc.2020.102320
Assessment of LIN28A variants in Parkinson's disease in large European cohorts|10.1016/j.neurobiolaging.2020.12.002
ATP13A3 is a major component of the enigmatic mammalian polyamine transport system|10.1074/jbc.ra120.013908
Cognitive Outcomes for Essential Tremor Patients Selected for Thalamic Deep Brain Stimulation Surgery Through Interdisciplinary Evaluations|10.3389/fnhum.2020.578348
Functionalization of amyloid fibrils via the Bri2 BRICHOS domain|10.1038/s41598-020-78732-1
MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus|10.1182/blood.2020006374
Toward e‐Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales|10.1002/mdc3.13135
Neuromechanical Assessment of Activated vs. Resting Leg Rigidity Using the Pendulum Test Is Associated With a Fall History in People With Parkinson’s Disease|10.3389/fnhum.2020.602595
Potential Sex-Specific Effects of Apolipoprotein E ɛ4 on Cognitive Decline in Early Parkinson’s Disease|10.3233/jpd-202288
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)|10.1016/j.parkreldis.2020.12.002
Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20|10.1038/s41531-020-00139-6
Cortical volume abnormalities in posttraumatic stress disorder: an ENIGMA-psychiatric genomics consortium PTSD workgroup mega-analysis|10.1038/s41380-020-00967-1
Harnessing the paradoxical phenotypes of APOE ɛ2 and APOE ɛ4 to identify genetic modifiers in Alzheimer's disease|10.1002/alz.12240
The Future of GDNF in Parkinson's Disease|10.3389/fnagi.2020.593572
A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ episodes|10.1080/14737175.2020.1855145
Developing new treatments in partnership for primary mitochondrial disease: What does industry need from academics, and what do academics need from industry?|10.1002/jimd.12326
The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)|10.1002/cmdc.202000872
Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications|10.1002/mdc3.13117
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders|10.1212/nxi.0000000000000924
Pedunculopontine Nucleus Deep Brain Stimulation for Parkinsonian Disorders: A Case Series|10.1159/000511978
Review of computational approaches to Parkinson’s disease gene prediction|10.1109/iciss49785.2020.9315926
Chronic embedded cortico-thalamic closed-loop deep brain stimulation for the treatment of essential tremor|10.1126/scitranslmed.aay7680
Mitochondrial isolation: when size matters|10.12688/wellcomeopenres.16300.2
Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review|10.1002/mds.28404
An application of generalized matrix learning vector quantization in neuroimaging|10.1016/j.cmpb.2020.105708
Association of mitochondrial genomic background with risk of Multiple System Atrophy|10.1016/j.parkreldis.2020.10.040
Clinical characteristics and diagnostic clues to Neurometabolic causes of dystonia|10.1016/j.jns.2020.117167
Creating a patient‐centered guide to navigating cognitive change in Parkinson’s disease|10.1002/alz.041115
Data Donations for Mapping Risk in Google Search of Health Queries: A case study of unproven stem cell treatments in SEM|10.1109/ssci47803.2020.9308420
Differential transcript usage unravels transcriptional alterations in Alzheimer's disease human brains|10.1002/alz.038695
Epigenomic features related to microglia are associated with attenuated effect of APOE ε4 on Alzheimer’s disease risk in humans|10.1002/alz.043533
Evaluation of Prescription Practices of Domperidone in Parkinson’s Disease: A Cross Sectional Study Among French Neurologists|10.1007/s40263-020-00774-w
Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease|10.1016/j.nbd.2020.105088
Germline Saturation Mutagenesis Induces Skeletal Phenotypes in Mice|10.1002/jbmr.4323
MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features|10.1186/s40478-020-01097-z
Photoacoustic imaging biomarkers for monitoring biophysical changes during nanobubble-mediated radiation treatment|10.1016/j.pacs.2020.100201
Screening peripheral biopsies for alpha‐synuclein pathology using deep machine learning|10.1002/alz.047358
TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson’s Disease|10.1016/j.celrep.2020.108418
A Distinct EEG Marker of Celiac Disease‐Related Cortical Myoclonus|10.1002/mds.28407
Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment|10.1001/jamaneurol.2020.3962
Enhancement of Executive Functions but Not Memory by Multidomain Group Cognitive Training in Patients with Parkinson’s Disease and Mild Cognitive Impairment: A Multicenter Randomized Controlled Trial|10.1155/2020/4068706
Is Levodopa Response a Valid Indicator of Parkinson's Disease?|10.1002/mds.28406
Brain volumetric deficits in MAPT mutation carriers: a multisite study|10.1002/acn3.51249
Protein quality control by the proteasome and autophagy: A regulatory role of ubiquitin and liquid-liquid phase separation|10.1016/j.matbio.2020.11.003
Urinary Dysfunction Is Associated with Nigrostriatal Dopaminergic Degeneration in Early and Untreated Patients with Parkinson’s Disease|10.1155/2020/4981647
First Case of Parkinsonian‐Pyramidal Syndrome Associated with a TBK1 Mutation|10.1002/mds.28405
MR-guided focused ultrasound pallidotomy for Parkinson’s disease: safety and feasibility|10.3171/2020.6.jns192773
Reply: Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson’s disease and BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson’s disease|10.1093/brain/awaa369
A metabolomic study of cervical dystonia|10.1016/j.parkreldis.2020.11.020
CoolMPS: evaluation of antibody labeling based massively parallel non-coding RNA sequencing|10.1093/nar/gkaa1122
Impact of oral textures on aspiration and changes in swallow dynamics in patients with PD with DBS|10.1136/jnnp-2020-324579
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science|10.1159/000512500
Robust identification of Parkinson's disease subtypes using radiomics and hybrid machine learning|10.1016/j.compbiomed.2020.104142
Purification of Recombinant α-synuclein: A Comparison of Commonly Used Protocols|10.1021/acs.biochem.0c00725
Basal Ganglia Pathways Associated With Therapeutic Pallidal Deep Brain Stimulation for Tourette Syndrome|10.1016/j.bpsc.2020.11.005
Common diseases alter the physiological age-related blood microRNA profile|10.1038/s41467-020-19665-1
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism|10.1002/mds.28399
Spectral guided sparse inverse covariance estimation of metabolic networks in Parkinson's disease|10.1016/j.neuroimage.2020.117568
ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress|10.1073/pnas.1922342117
Constant Current versus Constant Voltage: Clinical Evidence Supporting a Fundamental Difference in the Modalities|10.1159/000510803
Endurance of Short Pulse Width Thalamic Stimulation Efficacy in Intention Tremor|10.1159/000511716
Machine Learning Methods to Predict Acute Respiratory Failure and Acute Respiratory Distress Syndrome|10.3389/fdata.2020.579774
Prevalence of Non‐Motor Symptoms and Non‐Motor Fluctuations in Parkinson's Disease Using the MDS‐NMS|10.1002/mdc3.13122
Structural and Textual Information Fusion for Symptom and Disease Representation Learning|10.1109/tkde.2020.3039469
The microgravity enhanced polymer-mediated siRNA gene silence by improving cellular uptake|10.1007/s41048-020-00121-y
MRI-visible perivascular spaces are associated with cerebrospinal fluid biomarkers in Parkinson’s disease|10.18632/aging.104200
A blinded, controlled trial of objective measurement in Parkinson’s disease|10.1038/s41531-020-00136-9
Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice|10.1017/s109285292000200x
Organotypic hippocampal slices, an emerging tool to model synucleinopathies|10.4103/1673-5374.297065
Transient Receptor Potential Channels as an Emerging Target for the Treatment of Parkinson’s Disease: An Insight Into Role of Pharmacological Interventions|10.3389/fcell.2020.584513
Corneal confocal microscopy detects small fibre neurodegeneration in Parkinson's disease using automated analysis|10.1038/s41598-020-76768-x
Resting‐State Functional Connectivity Predicts STN DBS Clinical Response|10.1002/mds.28376
Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic|10.1002/anie.202000451
Apathy in Parkinson disease|10.1212/wnl.0000000000010961
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms|10.3389/fcell.2020.598446
Psychosis‐Like Behavior and Hyperdopaminergic Dysregulation in Human α‐Synuclein BAC Transgenic Rats|10.1002/mds.28383
Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease|10.3389/fnagi.2020.603849
Teaching Video NeuroImages: Cluster Breathing in Brainstem-Sparing Bihemispheric Cerebral and Cerebellar Lesions|10.1212/wnl.0000000000011215
Transitional Care for Young People with Neurological Disorders: A Scoping Review with A Focus on Patients with Movement Disorders|10.1002/mds.28381
Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase–Associated Neurodegeneration|10.1002/mds.28392
From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease|10.1002/mds.28387
Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures|10.1002/mds.28377
Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies|10.1016/j.parkreldis.2020.11.008
Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease|10.1038/s41531-020-00134-x
Exosome markers of LRRK2 kinase inhibition|10.1038/s41531-020-00138-7
Human Dopaminergic Neurons Lacking PINK1 Exhibit Disrupted Dopamine Metabolism Related to Vitamin B6 Co-Factors|10.1016/j.isci.2020.101797
Molecular estimation of neurodegeneration pseudotime in older brains|10.1038/s41467-020-19622-y
Validation of human microRNA target pathways enables evaluation of target prediction tools|10.1093/nar/gkaa1161
Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy|10.3389/fneur.2020.603161
Brain Endothelial P-Glycoprotein Level Is Reduced in Parkinson’s Disease via a Vitamin D Receptor-Dependent Pathway|10.3390/ijms21228538
Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort|10.3389/fneur.2020.578924
Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease|10.1016/j.parkreldis.2020.11.010
Probabilistic Modelling of Gait for Robust Passive Monitoring in Daily Life|10.1109/jbhi.2020.3037857
Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion|10.1126/scitranslmed.aax0091
Cortical connectivity of the nucleus basalis of Meynert in Parkinson’s disease and Lewy body dementias|10.1093/brain/awaa411
Overlooked cryptic diversity inMuschampia(Lepidoptera: Hesperiidae) adds two species to the European butterfly fauna|10.1093/zoolinnean/zlaa171
The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein|10.1016/j.jmb.2020.11.005
A machine learning-based classification approach on Parkinson’s disease diffusion tensor imaging datasets|10.1186/s42466-020-00092-y
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease|10.1186/s13024-020-00412-5
Characterization of Small-Molecule-Induced Changes in Parkinson's-Related Trafficking via the Nedd4 Ubiquitin Signaling Cascade|10.1016/j.chembiol.2020.10.008
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity|10.1038/s41419-020-03172-8
Recent advances in understanding and treatment of Parkinson’s disease|10.12703/b/9-6
Suicide and Lewy body dementia: Report of a Lewy body dementia association working group|10.1002/gps.5462
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction|10.3389/fnhum.2020.583441
Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease|10.1002/mds.28382
Reforming the Process for Deep Brain Stimulation and Neurologic Device Approval in Rare Diseases|10.1001/jamaneurol.2020.4232
The economic benefit of timely, adequate, and adherence to Parkinson's disease treatment: the Value of Treatment Project 2|10.1111/ene.14584
Tremor-Dominant Cervical Dystonia: a Cerebellar Syndrome|10.1007/s12311-020-01211-w
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study|10.3233/jpd-202285
A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study|10.1002/mds.28364
Clustering of Alzheimer’s and Parkinson’s disease based on genetic burden of shared molecular mechanisms|10.1038/s41598-020-76200-4
Genetic parkinsonisms and cancer: a systematic review and meta-analysis|10.1515/revneuro-2020-0083
Genome‐Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients|10.1002/mds.28353
Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia|10.1002/mds.28361
Stereological investigation of 5-HT3 receptors in the substantia nigra and dorsal raphe nucleus in the rat|10.1016/j.jchemneu.2020.101881
Constipation and sleep behaviour disorder associate with processing speed and attention in males with Parkinson’s disease over five years follow-up|10.1038/s41598-020-75800-4
Population Prevalence of Deleterious SGCE Variants|10.5334/tohm.567
From trials to clinical practice: Temporal trends in the coverage of specialized allied health services for Parkinson's disease|10.1111/ene.14627
Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting|10.1002/mds.28348
Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease|10.1002/mds.28360
Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?|10.1186/s42466-020-00076-y
Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity|10.1042/bcj20200458
Globus Pallidus Internus (GPi) Deep Brain Stimulation for Parkinson’s Disease: Expert Review and Commentary|10.1007/s40120-020-00220-5
Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans|10.1016/j.neurobiolaging.2020.10.030
Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset|10.1016/j.neuropharm.2020.108386
The Emerging Role of the Lysosome in Parkinson’s Disease|10.3390/cells9112399
18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases|10.1093/brain/awaa276
A validation of a self-administered screening test for Parkinson's disease|10.1016/j.jns.2020.117116
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias|10.1016/s1474-4422(20)30314-8
Cell Replacement Therapy in Parkinson’s Disease—History of Development and Prospects for Use in Clinical Practice|10.1134/s0026893320060060
Development and Application of High-Throughput Single Cell Lipid Profiling: A Study of SNCA-A53T Human Dopamine Neurons|10.1016/j.isci.2020.101703
Estimation of Orofacial Kinematics in Parkinson’s Disease: Comparison of 2D and 3D Markerless Systems for Motion Tracking|10.1109/fg47880.2020.00112
Hitting the Bullseye: Are extracellular vesicles on target?|10.1002/jev2.12032
Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations|10.1016/j.parkreldis.2020.09.019
Longitudinal evolution of non-motor symptoms according to age at onset in early Parkinson's disease|10.1016/j.jns.2020.117157
Multimodal assessment of nigrosomal degeneration in Parkinson's disease|10.1016/j.parkreldis.2020.09.021
Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders|10.1016/j.tips.2020.09.003
Preferential microglial activation associated with pathological alpha synuclein transmission|10.1016/j.jocn.2020.09.027
Resting state activity and connectivity of the nucleus basalis of Meynert and globus pallidus in Lewy body dementia and Parkinson's disease dementia|10.1016/j.neuroimage.2020.117184
<p>Sensory Hypersensitivity Severity and Association with Obsessive-Compulsive Symptoms in Adults with Tic Disorder</p>|10.2147/ndt.s274165
Spatio-Temporal Attention and Magnification for Classification of Parkinson’s Disease from Videos Collected via the Internet|10.1109/fg47880.2020.00008
The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant|10.1016/j.parkreldis.2020.10.027
Time for a New Image of Parkinson Disease|10.1001/jamaneurol.2020.2412
Unmet needs in Parkinson disease: Motor and non-motor|10.1016/j.parkreldis.2020.09.024
Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+ T cells, and M1 macrophages|10.1136/jitc-2020-001617
Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease|10.1016/j.neurobiolaging.2020.10.019
Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT|10.1007/s00259-020-05085-2
Human Autopsy-Derived Scalp Fibroblast Biobanking for Age-Related Neurodegenerative Disease Research|10.3390/cells9112383
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials|10.1186/s13195-020-00703-5
Comparison of Machine learning models for Parkinson’s Disease prediction|10.1109/uemcon51285.2020.9298033
Genome‐Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease|10.1002/mds.28342
Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples|10.1080/15548627.2020.1834712
Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations|10.1093/brain/awaa401
Altered Brain Functional Network in Parkinson Disease With Rapid Eye Movement Sleep Behavior Disorder|10.3389/fneur.2020.563624
Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data|10.1002/mds.28339
Measuring Functional Status in Huntington's Disease|10.1002/mds.28363
Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease|10.1002/mds.28338
The Effects of Respiratory Training in Parkinson’s Disease: A Systematic Review|10.3233/jpd-202223
Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders|10.1001/jamaneurol.2020.3753
Intramolecular Povarov Reactions for the Synthesis of Chromenopyridine Fused 2-Pyridone Polyheterocycles Binding to α-Synuclein and Amyloid-β Fibrils|10.1021/acs.joc.0c01699
Effects of subthalamic nucleus deep brain stimulation on neuronal spiking activity in the substantia nigra pars compacta in a rat model of Parkinson’s disease|10.1016/j.neulet.2020.135443
Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease|10.1002/ana.25944
Extracellular microRNA 3’ end modification across diverse body fluids|10.1080/15592294.2020.1834922
Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism|10.1038/s41598-020-74495-x
STN Versus GPi Deep Brain Stimulation for Action and Rest Tremor in Parkinson’s Disease|10.3389/fnhum.2020.578615
Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms|10.1002/mds.28345
Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues|10.3390/cells9112344
EphA4 regulates Aβ production via BACE1 expression in neurons|10.1096/fj.202001510r
Extrastriatal SPECT-DAT uptake correlates with clinical and biological features of de novo Parkinson's disease|10.1016/j.neurobiolaging.2020.10.016
Investigation of Somatic Mutations in Human Brains Targeting Genes Associated With Parkinson's Disease|10.3389/fneur.2020.570424
The gut microbiota–brain axis in behaviour and brain disorders|10.1038/s41579-020-00460-0
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease|10.1126/sciadv.aaz9360
Modulation of beta bursts in subthalamic sensorimotor circuits predicts improvement in bradykinesia|10.1093/brain/awaa394
Patient-centred management of Parkinson's disease|10.1016/s1474-4422(20)30355-0
Patient-centred management of Parkinson's disease|10.1016/s1474-4422(20)30359-8
Patient-centred management of Parkinson's disease – Authors' reply|10.1016/s1474-4422(20)30360-4
Provisional case definitions for COVID-19-associated neurological disease|10.1016/s1474-4422(20)30373-2
The age-related trajectory of visual attention neural function is altered in adults living with HIV: A cross-sectional MEG study|10.1016/j.ebiom.2020.103065
Allosteric inhibition of LRRK2, where are we now|10.1042/bst20200424
Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's disease|10.1016/j.parkreldis.2020.10.033
Detect and correct bias in multi-site neuroimaging datasets|10.1016/j.media.2020.101879
Microgravity: A Tool for Protein Drug Development|10.47583/ijpsrr.2020.v64i02.014
Palliative Care for Persons Living With Parkinson Disease|10.1001/jama.2020.18333
Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany|10.3233/jad-200794
What's happening in Neurology ® Clinical Practice|10.1212/wnl.0000000000010792
Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiology|10.1002/alz.12211
The Human Coronavirus Receptor ANPEP (CD13) Is Overexpressed in Parkinson's Disease|10.1002/mds.28354
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease|10.1016/j.parkreldis.2020.10.029
Epigenome-wide association study of Alzheimer’s disease replicates 22 differentially methylated positions and 30 differentially methylated regions|10.1186/s13148-020-00944-z
Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinson’s Disease|10.1155/2020/1694547
Altered Functional Network Associated With Cognitive Performance in Early Parkinson Disease Measured by Eigenvector Centrality Mapping|10.3389/fnagi.2020.554660
Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links|10.1136/gutjnl-2020-322429
Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal|10.1186/s40035-020-00218-x
Gait Progression Over 6 Years in Parkinson’s Disease: Effects of Age, Medication, and Pathology|10.3389/fnagi.2020.577435
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes|10.3389/fneur.2020.572976
Robust Bayesian Analysis of Early-Stage Parkinson’s Disease Progression Using DaTscan Images|10.1109/tmi.2020.3031478
Effect of sex on aging-related decline of dopamine transporter in healthy subjects|10.1007/s12149-020-01538-8
Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease|10.1038/s41598-020-74195-6
Pilot Evaluation of a Pragmatic Network for Integrated Care and Self‐Management in Parkinson's Disease|10.1002/mds.28332
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability|10.1016/j.parkreldis.2020.10.020
Bundle analytics, a computational framework for investigating the shapes and profiles of brain pathways across populations|10.1038/s41598-020-74054-4
History of and Insights Into Spinal Cord Stimulation in Parkinson Disease|10.1177/1545968320956984
A detailed life history of a pleistocene steppe bison (Bison priscus) skeleton unearthed in Arctic Alaska|10.1016/j.quascirev.2020.106578
Extracellular clusterin limits the uptake of α‐synuclein fibrils by murine and human astrocytes|10.1002/glia.23920
Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions|10.1038/s41597-020-00642-8
Restless Leg Syndrome and Objectively‐Measured Atherosclerosis in the Canadian Longitudinal Study on Aging|10.1002/mds.28326
Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease|10.1016/j.nbd.2020.105134
Application of deep learning in detecting neurological disorders from magnetic resonance images: a survey on the detection of Alzheimer’s disease, Parkinson’s disease and schizophrenia|10.1186/s40708-020-00112-2
Characterization of a Cul9–Parkin double knockout mouse model for Parkinson’s disease|10.1038/s41598-020-73854-y
New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders|10.1007/s40473-020-00221-6
Rationale and Design of the PAIRED Trial: Partnered Dance Aerobic Exercise as a Neuroprotective, Motor, and Cognitive Intervention in Parkinson's Disease|10.3389/fneur.2020.00943
An Explainable Machine Learning Model for Early Detection of Parkinson's Disease using LIME on DaTSCAN Imagery|10.1016/j.compbiomed.2020.104041
Changes in Self- and Informant-Reported Frontal Behaviors in Parkinson’s Disease: A Longitudinal Study|10.1177/0891988720964257
Cognitive and motor deficits in older adults with HIV infection: Comparison with normal ageing and Parkinson’s disease|10.1111/jnp.12227
Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease|10.1111/ene.14576
Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology|10.1002/alz.12198
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)|10.3389/fnagi.2020.553635
A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic|10.1002/mds.28310
Quantitative Digitography Measures Fine Motor Disturbances in Chronically Treated HIV Similar to Parkinson’s Disease|10.3389/fnagi.2020.539598
Segmental dystonia after radical neck dissection and radiotherapy: a case report|10.1007/s10072-020-04792-w
Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations|10.1002/mds.28313
Frequency and burden of gastrointestinal symptoms in familial dysautonomia|10.1007/s10286-020-00735-9
Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study|10.1002/mds.28320
Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery|10.3389/fnmol.2020.538219
Parkinson's: A Disease of Aberrant Vesicle Trafficking|10.1146/annurev-cellbio-100818-125512
Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression|10.1038/s41467-020-18569-4
How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?|10.1016/j.parkreldis.2020.10.003
The Pseudodystonia of Paroxysmal Sympathetic Hyperactivity: A Reversible Post‐Anoxic Complication|10.1002/mdc3.13095
Inflammation in Experimental Models of α‐Synucleinopathies|10.1002/mds.28264
Biomarkers of environmental manganese exposure and associations with childhood neurodevelopment: a systematic review and meta-analysis|10.1186/s12940-020-00659-x
COVID-19's impact on neurology and national solutions through education|10.12968/bjnn.2020.16.5.209
Deep Brain Stimulation of the Subthalamic, Accumbens, or Caudate Nuclei for Patients With Severe Obsessive-Compulsive Disorder: A Randomized Crossover Controlled Study|10.1016/j.biopsych.2020.07.013
Microglia modulate neurodegeneration in Alzheimer’s and Parkinson’s diseases|10.1126/science.abb8587
Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations|10.7554/elife.58997
Analysis of heterozygous PRKN variants and copy number variations in Parkinson's disease|10.1016/j.parkreldis.2020.06.123
Approach to Cognitive Impairment in Parkinson’s Disease|10.1007/s13311-020-00963-x
Approaches to Disease Modification for Parkinson’s Disease: Clinical Trials and Lessons Learned|10.1007/s13311-020-00964-w
Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers|10.1212/wnl.0000000000010863
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease|10.1007/s13311-020-00965-9
Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study|10.1016/j.parkreldis.2020.06.312
Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease|10.1002/mds.28319
Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis|10.1007/s13311-020-00900-y
Comprehensive Analysis of Familial Parkinsonism Genes in Rapid‐Eye‐Movement Sleep Behavior Disorder|10.1002/mds.28318
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments|10.1007/s13311-020-00914-6
Detecting bradykinesia in early morning “OFF” episodes: a large database study using the Personal KinetiGraph® (PKG®)|10.1016/j.parkreldis.2020.06.322
Differences in the Presentation and Progression of Parkinson's Disease by Sex|10.1002/mds.28312
Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism|10.1007/s13311-020-00920-8
Evaluation of motor response inhibition in Parkinson's Disease and Alzheimer's Disease|10.1016/j.parkreldis.2020.06.314
Exploring the clinical burden of OFF periods in Parkinson disease|10.37765/ajmc.2020.88517
Exposure-response efficacy model of apomorphine sublingual film for the on-demand treatment of “OFF” episodes in patients with Parkinson's disease|10.1016/j.parkreldis.2020.06.311
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?|10.1007/s13311-020-00940-4
If LRRK2 Set the Fire, Can Nonsteroidal Anti‐inflammatory Drugs Wet the Flames?|10.1002/mds.28240
Impact of Levodopa/Carbidopa Intestinal Gel Delivery on CarePartner Burden and Quality of Life: Survey by Parkinson & Movement disorder alliance|10.1016/j.parkreldis.2020.06.325
Impact of OFF periods on aspects of employment for people with Parkinson's disease|10.1016/j.parkreldis.2020.06.323
Long-term clinical outcomes of bilateral GPi deep brain stimulation in advanced Parkinson’s disease: 5 years and beyond|10.3171/2020.6.jns20617
Management of Tardive Syndrome: Medications and Surgical Treatments|10.1007/s13311-020-00898-3
Mechanisms behind Neurological Conditions Revealed, Adjusted|10.1089/gen.40.10.15
Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci|10.1371/journal.pone.0239824
Mitochondrial isolation: when size matters|10.12688/wellcomeopenres.16300.1;
Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention|10.1007/s13311-020-00960-0
Pallidal Connectivity Profiling of Stimulation‐Induced Dyskinesia in Parkinson's Disease|10.1002/mds.28324
Parkinson’s Disease Detection Using Ensemble Architecture from MR Images|10.1109/bibe50027.2020.00167
Pathogenic LRRK2 requires secondary factors to induce cellular toxicity|10.1042/bsr20202225
PINK1 p.Leu347Pro mutations in Malays: Prevalence and illustrative cases|10.1016/j.parkreldis.2020.08.015
Somatic mutations in neurodegeneration: An update|10.1016/j.nbd.2020.105021
The economic impact of OFF periods in Parkinson disease|10.37765/ajmc.2020.88518
The financial burden of Parkinson's disease is greater for caregivers of people experiencing OFF periods|10.1016/j.parkreldis.2020.06.313
The HoloLens Augmented Reality System Provides Valid Measures of Gait Performance in Healthy Adults|10.1109/thms.2020.3016082
The impact of motor and non-motor wearing-off on the quality of life of patients with Parkinson's disease|10.1016/j.parkreldis.2020.06.324
Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs|10.1176/appi.neuropsych.19070165
A Stearoyl–Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α‐Synuclein Mice|10.1002/ana.25920
Biomarker Use for Dementia With Lewy Body Diagnosis|10.1097/wad.0000000000000414
Involvement of dopaminergic signaling in the cross talk between the renin-angiotensin system and inflammation|10.1007/s00281-020-00819-8
Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in vivo|10.1002/sctm.20-0014
Conversational analysis of consciousness during seizures|10.1016/j.yebeh.2020.107486
Deep brain stimulation of the ventralis oralis anterior thalamic nucleus is effective for dystonic tremor|10.1016/j.parkreldis.2020.09.040
Dopamine imaging in prodromal Parkinson disease trials|10.1212/wnl.0000000000010957
Multi-layer Trajectory Clustering: a Network Algorithm for Disease Subtyping|10.1088/2057-1976/abad8f
The exploration of Parkinson’s disease: a multi-modal data analysis of resting functional magnetic resonance imaging and gene data|10.1007/s11682-020-00392-6
The UF Deep Brain Stimulation Cognitive Rating Scale (DBS-CRS): Clinical Decision Making, Validity, and Outcomes|10.3389/fnhum.2020.578216
Differential Associations of Apolipoprotein E ε4 Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome|10.1001/jamanetworkopen.2020.18221
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease|10.1001/jamaneurol.2020.3311
The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders|10.1002/mds.28232
Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension|10.1007/s00415-020-10240-8
Novel Programming Features Help Alleviate Subthalamic Nucleus Stimulation‐Induced Side Effects|10.1002/mds.28252
Statistical Agnostic Mapping: A framework in neuroimaging based on concentration inequalities|10.1016/j.inffus.2020.09.008
Time will tell: Decision making in premanifest and manifest Huntington’s disease|10.1002/brb3.1843
145th Annual Meeting American Neurological Association|10.1002/ana.25865
Alternative Splicing Regulation of an Alzheimer’s Risk Variant in CLU|10.3390/ijms21197079
Brain Alchemy: Transforming Astrocytes into Neurons for Neurodegenerative Disease|10.1002/mdc3.13090
Deficiency of the serine peptidase Kallikrein 6 does not affect the levels and the pathological accumulation of a‐synuclein in mouse brain|10.1111/jnc.15199
Diffusion Tensor Imaging in Parkinson's Disease and Parkinsonian Syndrome: A Systematic Review|10.3389/fneur.2020.531993
Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies|10.3389/fneur.2020.576117
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds|10.3389/fcell.2020.562522
Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease|10.1002/mds.28299
Longitudinal association between dopamine agonists and weight in Parkinson's disease|10.1016/j.parkreldis.2020.09.037
Quality improvement in neurology|10.1212/wnl.0000000000010634
Non‐coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women|10.1002/alz.12181
Blinded RT‐QuIC Analysis of α‐Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients|10.1002/mds.28242
Fast Purification of Recombinant Monomeric Amyloid-β from E. coli and Amyloid-β-mCherry Aggregates from Mammalian Cells|10.1021/acschemneuro.0c00300
Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus|10.1002/mds.28251
How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology|10.1016/j.nbd.2020.105086
Tactile Temporal Discrimination Is Impaired in Myoclonus‐Dystonia|10.1002/mds.28253
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson’s Disease: A Feasibility Study|10.3233/jpd-202188
Brain 5‐HT1A Receptor Binding in Multiple System Atrophy: An [18F]‐MPPF PET Study|10.1002/mds.28295
Enabling precision rehabilitation interventions using wearable sensors and machine learning to track motor recovery|10.1038/s41746-020-00328-w
Identifying Risk Genes and Interpreting Pathogenesis for Parkinson’s Disease by a Multiomics Analysis|10.3390/genes11091100
REM sleep behavior disorder in early Parkinson’s disease predicts the rapid dopaminergic denervation|10.1016/j.parkreldis.2020.09.032
Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R|10.1016/j.nbd.2020.105079
The multi‐faceted role of mitochondria in the pathology of Parkinson’s disease|10.1111/jnc.15154
Anxiety in Parkinson's disease is associated with changes in the brain fear circuit|10.1016/j.parkreldis.2020.09.020
Expanding Data Collection for the MDSGene Database: X‐linked Dystonia‐Parkinsonism as Use Case Example|10.1002/mds.28289
Program and Abstracts of the 31st International Symposium on the Autonomic Nervous System|10.1007/s10286-020-00728-8
DYT-TUBB4A (DYT4 Dystonia)|10.1212/wnl.0000000000010882
How firms undertake organizational changes to shift to more-exploratory strategies: A process perspective|10.1016/j.respol.2020.104118
Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein|10.1016/j.brainres.2020.147131
Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease|10.1212/wnl.0000000000010749
Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures|10.1186/s40478-020-01035-z
Gene expression within the periaqueductal gray is linked to vocal behavior and early-onset parkinsonism in Pink1 knockout rats|10.1186/s12864-020-07037-4
Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease|10.1038/s41598-020-72190-5
Reply to: “A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders”|10.1002/mds.28315
Automated Analysis of Diffusion‐Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease|10.1002/mds.28281
Connecting Viral Pandemics to Ecological Population Growth Models|10.25334/kkgc-w370
Developing therapies for Parkinson's disease|10.1016/s1474-4422(20)30320-3
Orthostatic hypotension preceding dementia with Lewy bodies by over 15 years: a clinicopathologic case report|10.1007/s10286-020-00730-0
Reply to: Nonfatal Drowning in People with Parkinson's Disease|10.1002/mdc3.13080
A Survey of Rare Epigenetic Variation in 23,116 Human Genomes Identifies Disease-Relevant Epivariations and CGG Expansions|10.1016/j.ajhg.2020.08.019
Assessment of Wearing Off in Parkinson’s disease using objective measurement|10.1007/s00415-020-10222-w
Dysarthria and Speech Intelligibility Following Parkinson’s Disease Globus Pallidus Internus Deep Brain Stimulation|10.3233/jpd-202246
The Emerging Role of RHOT1/Miro1 in the Pathogenesis of Parkinson's Disease|10.3389/fneur.2020.00587
A Comparative Photophysical Study of Structural Modifications of Thioflavin T-Inspired Fluorophores|10.1021/acs.jpclett.0c01549
Protein synthesis is suppressed in sporadic and familial Parkinson’s disease by LRRK2|10.1096/fj.202001046r
Dystonic Golfer's cramp: Pilot study of propranolol and looking at the hole|10.1016/j.parkreldis.2020.09.018
Association of PICALM with Cognitive Impairment in Parkinson's Disease|10.1002/mds.28283
At the dawn of the transcriptomic medicine|10.1177/1535370220954788
Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance|10.1002/mds.28263
Hemispheric Network Expression in Parkinson’s Disease: Relationship to Dopaminergic Asymmetries|10.3233/jpd-202117
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease|10.3233/jpd-202249
Four‐Year Follow‐up of [18F]Fluorodeoxyglucose Positron Emission Tomography–Based Parkinson's Disease–Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression|10.1002/mds.28260
Genome Sequences of Novel Torque Teno Viruses Identified in Human Brain Tissue|10.1128/mra.00924-20
New 2013 incidence peak in childhood narcolepsy: more than vaccination?|10.1093/sleep/zsaa172
A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson’s disease|10.1126/scitranslmed.aau3960
Dopaminergic therapy and prefrontal activation during walking in individuals with Parkinson’s disease: does the levodopa overdose hypothesis extend to gait?|10.1007/s00415-020-10089-x
Mining genetic and transcriptomic data using machine learning approaches in Parkinson’s disease|10.1038/s41531-020-00127-w
An Increased Burden of Highly Active Retrotransposition Competent L1s Is Associated with Parkinson’s Disease Risk and Progression in the PPMI Cohort|10.3390/ijms21186562
Calcium, Bioenergetics, and Parkinson’s Disease|10.3390/cells9092045
Coexistent Osteoarthritis and Parkinson’s Disease: Data from the Parkinson’s Foundation Outcomes Project|10.3233/jpd-202170
Perceptions of Compensation Strategies for Gait Impairments in Parkinson’s Disease: A Survey Among 320 Healthcare Professionals|10.3233/jpd-202176
The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease|10.3233/jpd-202251
Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein|10.1186/s13024-020-00380-w
Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial|10.1002/mds.28248
When antibodies mislead: the quest for validation|10.1038/d41586-020-02549-1
Non-Coding RNAs in the Brain-Heart Axis: The Case of Parkinson’s Disease|10.3390/ijms21186513
Characterization of Anchorless Human PrP With Q227X Stop Mutation Linked to Gerstmann-Sträussler-Scheinker Syndrome In Vivo and In Vitro|10.1007/s12035-020-02098-8
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients|10.1002/acn3.51164
Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration|10.1212/cpj.0000000000000959
Progressive Ataxia with Hemiplegic Migraines: a Phenotype of CACNA1A Missense Mutations, Not CAG Repeat Expansions|10.1007/s12311-020-01185-9
Use of photoacoustic imaging for monitoring vascular disrupting cancer treatments|10.1002/jbio.202000209
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons|10.3389/fcell.2020.559791
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy|10.1002/mds.28218
A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of CaV1.3 L-Type Calcium Channels|10.1021/acschembio.0c00577
Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group|10.1002/mdc3.13052
Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease|10.1002/ana.25897
Serum BDNF levels correlate with regional cortical thickness in minor depression: a pilot study|10.1038/s41598-020-71317-y
Telemedicine in Movement Disorders: Leçons du COVID‐19|10.1002/mds.28297
Validation of the Waterless Empirical Taste Test (WETT®)|10.3758/s13428-020-01463-8
Application of the ‘5-2-1’ Screening Criteria in Advanced Parkinson’s Disease: Interim Analysis of DUOGLOBE|10.2217/nmt-2020-0021
Clinical spectrum of the pentanucleotide repeat expansion in the RFC1 gene in ataxia syndromes|10.1212/wnl.0000000000010744
Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life|10.1002/mdc3.13085
A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders|10.1002/mds.28296
Abstracts|10.1111/jsr.13181
Chemosensory Dysfunction in COVID‐19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample|10.1177/0194599820954825
Chorea in IgLON5‐Mediated Autoimmune Encephalitis|10.1002/mdc3.13061
Fluence-matching technique using photoacoustic radiofrequency spectra for improving estimates of oxygen saturation|10.1016/j.pacs.2020.100182
Glycopeptide drugs: A pharmacological dimension between “Small Molecules” and “Biologics”|10.1016/j.peptides.2020.170369
High‐Frequency Palatal Tremor and Stimulus‐Sensitive Leg Myoclonus with Degeneration of Inferior Olivary Nuclei in Celiac Disease|10.1002/mdc3.13079
Meaning and Dignity Therapies for Psychoneurology in Neuropalliative Care: A Vision for the Future|10.1089/jpm.2020.0129
Moving towards home-based community-centred integrated care in Parkinson's disease|10.1016/j.parkreldis.2020.07.001
Neural activity in functional movement disorders after inpatient rehabilitation|10.1016/j.pscychresns.2020.111125
Neutrophil activation in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid|10.1016/j.arr.2020.101130
Personalized Care Management for Persons with Parkinson’s Disease|10.3233/jpd-202126
Race, Kidney Transplants, Immunosuppression Research, and White Supremacy under Apartheid, 1960–80|10.3138/cbmh.376-072019
Robust and facile purification of full-length, untagged human Nedd4 as a recombinant protein from Escherichia coli|10.1016/j.pep.2020.105649
The association between pain and impulse control behaviours in Parkinson's disease|10.1016/j.parkreldis.2020.07.005
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?|10.3233/jpd-202104
The New Normal in Clinical Trials: Decentralized Studies|10.1002/ana.25892
The role of natural killer cells in Parkinson’s disease|10.1038/s12276-020-00505-7
Towards defining reference materials for measuring extracellular vesicle refractive index, epitope abundance, size and concentration|10.1080/20013078.2020.1816641
Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy|10.1016/j.parkreldis.2020.06.030
What People with Parkinson’s Disease Want|10.3233/jpd-202107
Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age|10.1016/j.pneurobio.2020.101904
Estimation of bias-corrected intraclass correlation coefficient for unbalanced clustered studies with continuous outcomes|10.1080/03610918.2020.1811332
Perspective: Evolution of Control Variables and Policies for Closed-Loop Deep Brain Stimulation for Parkinson’s Disease Using Bidirectional Deep-Brain-Computer Interfaces|10.3389/fnhum.2020.00353
Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease|10.1001/jamanetworkopen.2020.15072
The Alzheimer's disease‐associated C99 fragment of APP regulates cellular cholesterol trafficking|10.15252/embj.2019103791
The Parkinson's Disease Genome‐Wide Association Study Locus Browser|10.1002/mds.28197
Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease|10.1523/jneurosci.1468-19.2020
Dopamine-mediated improvements in dynamic balance control in Parkinson’s disease|10.1016/j.gaitpost.2020.08.132
Impact of Off Periods on Persons With Parkinson Disease and Care Partners|10.1212/cpj.0000000000000921
Striatal dopaminergic denervation and hypomimia in Parkinson's disease|10.1111/ene.14483
The Impact of COVID‐19 on Access to Parkinson's Disease Medication|10.1002/mds.28293
The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results|10.1007/s00702-020-02247-2
Validation of differentially expressed brain‐enriched microRNAs in the plasma of PD patients|10.1002/acn3.51146
Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of 11C-DTBZ PET Combined with Correlational Tractography|10.2967/jnumed.120.248500
First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A|10.2967/jnumed.120.249144
Long‐Term Follow‐Up and Evolution of ADCY5 — From a Ballistic to Dystonic Phenotype|10.1002/mdc3.13069
Loss‐of‐Function Variants in HOPS Complex Genes VPS16 and VPS41 Cause Early Onset Dystonia Associated with Lysosomal Abnormalities|10.1002/ana.25879
A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2|10.3389/fnmol.2020.00153
Clinical and Demographic Characteristics of Upper Limb Dystonia|10.1002/mds.28223
Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and “OFF” episodes|10.1016/j.parkreldis.2020.08.028
A New Dataset for Facial Motion Analysis in Individuals With Neurological Disorders|10.1109/jbhi.2020.3019242
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders|10.1001/jama.2020.12134
Multivariate prediction of dementia in Parkinson’s disease|10.1038/s41531-020-00121-2
Akinetic rigid symptoms are associated with decline in a cortical motor network in Parkinson’s disease|10.1038/s41531-020-00120-3
Depressive symptoms are associated with worse cognitive prognosis in patients with newly diagnosed idiopathic Parkinson disease|10.1111/psyg.12601
KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation|10.1093/brain/awaa304
Reply To: Cerebral Vasomotor Reactivity in Parkinson's Disease: A Missing Link between Dysautonomia, White Matter Lesions, and Cognitive Decline?|10.1002/mdc3.13073
Stigma Consciousness and Work Outcomes of Senior Woman Administrators: The Role of Workplace Incivility|10.1123/jsm.2019-0422
The “zig-zag” sign in Progressive Supranuclear Palsy|10.1016/j.parkreldis.2020.08.014
Diphenyl triazine hybrids inhibit α-synuclein fibrillogenesis: Design, synthesis and in vitro efficacy studies|10.1016/j.ejmech.2020.112705
Interpretation of health-related quality of life outcomes in Parkinson’s disease from the EARLYSTIM Study|10.1371/journal.pone.0237498
Real-Life Gait Performance as a Digital Biomarker for Motor Fluctuations: The Parkinson@Home Validation Study|10.2196/19068
Diet pattern and prodromal features of Parkinson disease|10.1212/wnl.0000000000010523
Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells|10.3389/fnins.2020.00820
Recent Advances on Graph Analytics and Its Applications in Healthcare|10.1145/3394486.3406469
Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction|10.1038/s41586-020-2673-2
The Access Technology Program of the Indiana Clinical Translational Sciences Institute (CTSI): A model to facilitate access to cutting-edge technologies across a state|10.1017/cts.2020.525
A novel homozygous KY variant causing a complex neurological disorder|10.1016/j.ejmg.2020.104031
Huntingtin Aggregates in the Olfactory Bulb in Huntington’s Disease|10.3389/fnagi.2020.00261
Lowering the risk of Parkinson’s disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes|10.1093/brain/awaa287
Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy|10.1016/j.parkreldis.2020.08.013
The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson’s disease|10.1007/s00415-020-10156-3
Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes|10.1007/s00415-020-10163-4
Building genomic infrastructure: Sequencing platinum‐standard reference‐quality genomes of all cetacean species|10.1111/mms.12721
Iron-responsive-like elements and neurodegenerative ferroptosis|10.1101/lm.052282.120
Parkinson disease with mild cognitive impairment: Domain‐specific cognitive complaints predict dementia|10.1111/ane.13326
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status|10.1002/alz.12161
Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys|10.1016/j.ebiom.2020.102944
Association of specific biotypes in patients with Parkinson disease and disease progression|10.1212/wnl.0000000000010498
Body-first versus brain-first biological subtyping of Parkinson’s disease|10.1093/brain/awaa293
Cerebrospinal Fluid Levels of Kininogen‐1 Indicate Early Cognitive Impairment in Parkinson's Disease|10.1002/mds.28192
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression|10.1002/mds.28206
Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor|10.5334/tohm.59
The Global Brain Health Survey: Development of a Multi-Language Survey of Public Views on Brain Health|10.3389/fpubh.2020.00387
Deletion of DJ-1 in rats affects protein abundance and mitochondrial function at the synapse|10.1038/s41598-020-70486-0
Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer’s disease|10.1093/hmg/ddaa182
Emotions Modulate Subthalamic Nucleus Activity: New Evidence in Obsessive-Compulsive Disorder and Parkinson’s Disease Patients|10.1016/j.bpsc.2020.08.002
Progressive multifokale Leukenzephalopathie – ein Update|10.1007/s42451-020-00220-7
Risk factors for possible REM sleep behavior disorders|10.1212/wnl.0000000000010610
The In Situ Structure of Parkinson’s Disease-Linked LRRK2|10.1016/j.cell.2020.08.004
The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease|10.3390/cells9081878
Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients|10.1002/mds.28261
Microglial burden, activation and dystrophy patterns in frontotemporal lobar degeneration|10.1186/s12974-020-01907-0
The Role of Alpha-Synuclein and Other Parkinson’s Genes in Neurodevelopmental and Neurodegenerative Disorders|10.3390/ijms21165724
Using Wearable Sensors and Machine Learning to Automatically Detect Freezing of Gait during a FOG-Provoking Test|10.3390/s20164474
Can kinematic parameters of 3D reach-to-target movements be used as a proxy for clinical outcome measures in chronic stroke rehabilitation? An exploratory study|10.1186/s12984-020-00730-1
Association of MAPT subhaplotypes with clinical and demographic features in Parkinson’s disease|10.1002/acn3.51139
Development and validation of a sensitive HPLC-HESI-MS/MS method for quantitative determination of bitopertin in rat and marmoset plasma|10.12688/mniopenres.12850.1
Neuro‐oxysterols and neuro‐sterols as ligands to nuclear receptors, GPCRs, ligand‐gated ion channels and other protein receptors|10.1111/bph.15191
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults|10.1212/wnl.0000000000010596
Developing a family engagement plan for Native Hawaiian and Pacific IslanderSTEMstudents in higher education: A review and critique of the literature|10.1111/apv.12288
Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVID‐19 patients|10.1002/alr.22680
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era|10.1002/med.21718
Therapeutic innovation in Parkinson’s disease: a 2020 update on disease-modifying approaches|10.1080/14737175.2020.1800454
Upregulating β-hexosaminidase activity in rodents prevents α-synuclein lipid associations and protects dopaminergic neurons from α-synuclein-mediated neurotoxicity|10.1186/s40478-020-01004-6
Validation of a Reversed Phase UPLC-MS/MS Method to Determine Dopamine Metabolites and Oxidation Intermediates in Neuronal Differentiated SH-SY5Y Cells and Brain Tissue|10.1021/acschemneuro.0c00336
Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?|10.1002/mds.28220
The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson’s disease|10.1186/s12883-020-01874-2
5Qs: An Activity to Support Students Develop Skills to Interpret Research Observations|10.25334/ygq4-5977
A Letter to a Young Scientist: Prompting Students To Reflect On And Recognize Their Own Growth As Scientists|10.25334/cbp1-t733
ADNC-RS, a clinical-genetic risk score, predicts Alzheimer’s pathology in autopsy-confirmed Parkinson’s disease and Dementia with Lewy bodies|10.1007/s00401-020-02199-7
Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation|10.1016/j.canlet.2020.07.015
Does Serum Urate Change as Parkinson’s Disease Progresses?|10.3233/jpd-202064
Elevator Pitch: An Activity to Help Students Communicate Their Research|10.25334/t9x4-sq93
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease|10.1212/wnl.0000000000010404
A Failed Future|10.1002/mds.28130
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer|10.1016/j.lungcan.2020.05.018
Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia|10.1055/s-0040-1715134
Chronicling the philanthropic arm of neurological surgery: a review of the growth and development of the Neurosurgery Research & Education Foundation|10.3171/2020.5.jns201474
"""Eine Impfung wäre viel praktischer als die Infusion von Antikörpern"""|10.1007/s15005-020-1426-y
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool|10.1016/j.parkreldis.2020.06.023
Genome-Wide Association Study Meta-Analysis of Stroke in 22 000 Individuals of African Descent Identifies Novel Associations With Stroke|10.1161/strokeaha.120.029123
Huntington's disease in Bangladesh|10.1016/s1474-4422(20)30216-7
Incidence and risk factors for seizures associated with deep brain stimulation surgery|10.3171/2020.5.jns20125
Infusion Therapies for Parkinson’s Disease|10.1007/s11910-020-01062-2
Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers|10.1016/j.parkreldis.2020.05.033
Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review|10.1016/j.jns.2020.116886
Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease|10.1016/j.parkreldis.2020.07.022
The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders|10.1001/jamaneurol.2020.1452
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease|10.1016/j.parkreldis.2019.02.027
The UPRosome – decoding novel biological outputs of IRE1α function|10.1242/jcs.218107
Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study|10.1136/bmjopen-2020-038911
Cortical disinhibition in Parkinson’s disease|10.1093/brain/awaa274
Has Deep Brain Stimulation Changed the Very Long‐Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study|10.1002/mdc3.13039
Multimodal Balance Training Supported by Rhythmic Auditory Stimuli in Parkinson Disease: Effects in Freezers and Nonfreezers|10.1093/ptj/pzaa146
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance|10.1038/s41575-020-0339-z
Parkinson’s Disease: We Care!|10.3233/jpd-209003
Phenomenology and Outcomes of In‐Patients With Parkinson's Disease During the Coronavirus Disease 2019 Pandemic|10.1002/mds.28205
APP‐Related Corticobasal Syndrome: Expanding the List of Corticobasal Degeneration Look Alikes|10.1002/mdc3.13037
Artificial Intelligence in Neuroradiology: Current Status and Future Directions.|10.3174/ajnr.a6681
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease|10.1136/jnnp-2020-322904
Quality of life outcomes after globus pallidus internus deep brain stimulation in idiopathic or inherited isolated dystonia: a meta-analysis|10.1136/jnnp-2019-322575
Sex and freezing of gait in Parkinson’s disease: a systematic review and meta-analysis|10.1007/s00415-020-10117-w
Development and evaluation of [125I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain|10.1002/syn.22183
The cerebral tremor circuit in a patient with Holmes tremor|10.1002/acn3.51143
Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C’s that Will Shape the Future of Telemedicine|10.3233/jpd-202109
Deep Phenotyping of Parkinson’s Disease|10.3233/jpd-202006
Editorial: Protein Degradation Pathways in Parkinson's Disease and Neurodegeneration|10.3389/fnins.2020.00741
Eosinophils and White Fat: Protection from Worms and Inflammaging|10.1089/rej.2020.2375
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop|10.3233/jpd-202004
Parkinson disease|10.1212/wnl.0000000000009952
Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson’s Disease Parkinson’s Progression Markers Initiative Participants|10.3233/jpd-201973
Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease|10.1038/s41582-020-0394-7
Early postnatal injections of whole vaccines compared to placebo controls: Differential behavioural outcomes in mice|10.1016/j.jinorgbio.2020.111200
Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches|10.1016/j.jns.2020.117059
Quantitative ultrasound radiomics for therapy response monitoring in patients with locally advanced breast cancer: Multi-institutional study results|10.1371/journal.pone.0236182
A Parkinson's disease Circ RNA s Resource reveals a link between circ SLC 8A1 and oxidative stress|10.15252/emmm.201911942
Precision Neurology for Parkinson’s Disease: Coupling Miro1‐Based Diagnosis With Drug Discovery|10.1002/mds.28194
Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease|10.1002/mds.28202
Killer Cell Immunoglobulin-like Receptor Variants Are Associated with Protection from Symptoms Associated with More Severe Course in Parkinson Disease|10.4049/jimmunol.2000144
Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series|10.1016/j.nbd.2020.105027
Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review|10.3390/toxins12080470
GLP-1 receptor agonists for Parkinson's disease|10.1002/14651858.cd012990.pub2
Moving towards genomic therapy for amyotrophic lateral sclerosis|10.1038/s41582-020-0393-8
Remote Digital Monitoring for Medical Product Development|10.1111/cts.12851
Understanding the relationship between freezing of gait and other progressive supranuclear palsy features|10.1016/j.parkreldis.2020.07.009
Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis|10.3233/jpd-202047
Exome Sequencing Reveals Signal Transduction Genes Involved in Impulse Control Disorders in Parkinson's Disease|10.3389/fneur.2020.00641
Genetic risk scores and hallucinations in patients with Parkinson disease|10.1212/nxg.0000000000000492
HHMI SEA-PHAGES and GENES: Course-based UREs Designed for All|10.25334/bdwg-nw48
Genetically modified organisms and food security in Southern Africa: conundrum and discourse|10.1080/21645698.2020.1794489
Initiating pharmacotherapy in early Parkinson's disease|10.1016/s1474-4422(20)30225-8
MicroRNA Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways|10.1002/mds.28143
Spinocerebellar ataxia type 6 family with phenotypic overlap with Multiple System Atrophy|10.5603/pjnns.a2020.0053
µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease|10.1523/jneurosci.0610-20.2020
Cargo and cell‐specific differences in extracellular vesicle populations identified by multiplexed immunofluorescent analysis|10.1080/20013078.2020.1789326
Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations|10.3390/cells9071719
Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond|10.3233/jpd-202121
The intrinsically restructured fovea is correlated with contrast sensitivity loss in Parkinson’s disease|10.1007/s00702-020-02224-9
A case of spastic paraplegia type 11 with a variation in the SPG11 gene|10.1186/s43042-020-00072-6
Prediction of age at onset in Parkinson’s disease using objective specific neuroimaging genetics based on a sparse canonical correlation analysis|10.1038/s41598-020-68301-x
Progress in LRRK2-Associated Parkinson’s Disease Animal Models|10.3389/fnins.2020.00674
Validation of Inertial Sensing-Based Wearable Device for Tremor and Bradykinesia Quantification|10.1109/jbhi.2020.3009319
Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson’s Disease|10.3390/ijms21144966
miR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer's disease|10.1007/s00401-020-02185-z
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance|10.1002/mds.28189
The role of RHOT1 and RHOT2 genetic variation on Parkinson disease risk and onset|10.1016/j.neurobiolaging.2020.07.003
The unfolded protein response is activated in the olfactory system in Alzheimer’s disease|10.1186/s40478-020-00986-7
Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up|10.1002/mds.28139
GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort|10.1002/mds.28195
Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12‐Week Controlled Trial|10.1002/mds.28196
Therapeutic antisense oligonucleotides for movement disorders|10.1002/med.21706
Fast 3D Clear: A Fast, Aqueous-Based, Reversible Three-Day Tissue Clearing Method for Adult and Embryonic Mouse Brain and Whole Body|10.17632/65cr9wnkm2.1
Reply to Comment on: The Most Bothersome Aspects of off Periods Reported by Individuals with Parkinson's Disease|10.1002/mdc3.13021
Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease|10.1212/wnl.0000000000010316
Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine‐Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme‐Linked Immunosorbent Assay–Based Method|10.1002/mds.28175
Genome-wide epigenetic analyses in Japanese immigrant plantation workers with Parkinson’s disease and exposure to organochlorines reveal possible involvement of glial genes and pathways involved in neurotoxicity|10.1186/s12868-020-00582-4
Current and projected future economic burden of Parkinson’s disease in the U.S.|10.1038/s41531-020-0117-1
Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series|10.1007/s00415-020-09871-8
Electrocardiographic changes predate Parkinson’s disease onset|10.1038/s41598-020-68241-6
RFC1 expansions can mimic hereditary sensory neuropathy with cough and Sjögren syndrome|10.1093/brain/awaa244
LRRK2 and Protein Aggregation in Parkinson’s Disease: Insights From Animal Models|10.3389/fnins.2020.00719
Measuring Medication Adherence in Parkinson's Disease: A Systematic Review of Contributing Components in Rating Scales|10.1002/mdc3.13006
A Gain‐of‐Function Mutation in KCNMA1 Causes Dystonia Spells Controlled With Stimulant Therapy|10.1002/mds.28138
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study|10.1016/s2352-3018(20)30073-4
Clinical and pathologic features of cognitive-predominant corticobasal degeneration|10.1212/wnl.0000000000009734
USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation|10.26508/lsa.202000768
Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity|10.1073/pnas.1922184117
Long-term Parkinson’s disease quality of life after staged DBS: STN vs GPi and first vs second lead|10.1038/s41531-020-0115-3
A Novel Phenotype Associated with CaSR‐Related Familial Brain Calcifications|10.1002/mdc3.13009
Atypical clinical presentation of pathologically proven Parkinson's disease: The role of Parkinson's disease related metabolic pattern|10.1016/j.parkreldis.2020.06.035
Neural closed-loop deep brain stimulation for freezing of gait|10.1016/j.brs.2020.06.018
Neuroharmony: A new tool for harmonizing volumetric MRI data from unseen scanners|10.1016/j.neuroimage.2020.117127
Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson’s Disease|10.1007/s10571-020-00914-2
Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimer’s disease|10.1016/j.neurobiolaging.2020.06.018
Cell death and survival pathways in Alzheimer's disease: an integrative hypothesis testing approach utilizing -omic data sets|10.1016/j.neurobiolaging.2020.06.022
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset|10.1007/s00210-020-01933-y
Realistic simulation of virtual multi-scale, multi-modal patient trajectories using Bayesian networks and sparse auto-encoders|10.1038/s41598-020-67398-4
Sex effects on brain structure in de novo Parkinson’s disease: a multimodal neuroimaging study|10.1093/brain/awaa234
A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands|10.1002/mds.28112
Modeling of Electric Fields in Individual Imaging Atlas for Capsular Threshold Prediction of Deep Brain Stimulation in Parkinson's Disease: A Pilot Study|10.3389/fneur.2020.00532
Performance of longitudinal item response theory models in shortened or partial assessments|10.1007/s10928-020-09697-x
StoCast: Stochastic Disease Forecasting With Progression Uncertainty|10.1109/jbhi.2020.3006719
The footprint of orthostatic hypotension in parkinsonian syndromes|10.1016/j.parkreldis.2020.06.029
A revolution in biochemistry and molecular biology education informed by basic research to meet the demands of 21st century career paths|10.1074/jbc.aw120.011104
ASENT2020 Annual Meeting Abstracts|10.1007/s13311-020-00896-5
Childbirth and Delayed Parkinson's Onset: A Reproducible Nonbiological Artifact of Societal Change|10.1002/mds.28135
Clinical implications of gastric complications on levodopa treatment in Parkinson's disease|10.1016/j.parkreldis.2020.05.001
Effect of data length on time delay and embedding dimension for calculating the Lyapunov exponent in walking|10.1098/rsif.2020.0311
Effects of exercise on sleep in neurodegenerative disease|10.1016/j.nbd.2020.104859
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models|10.1016/j.lungcan.2020.03.022
Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease|10.1109/esgco49734.2020.9158194
Human brain connectivity: Clinical applications for clinical neurophysiology|10.1016/j.clinph.2020.03.031
Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis|10.1016/j.jceh.2020.04.012
Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease|10.1002/acn3.51109
Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care|10.1016/s1474-4422(20)30064-8
ISEV2020 Abstract Book|10.1080/20013078.2020.1784511
Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models|10.1016/j.celrep.2020.107908
Motor outcomes and adverse effects of deep brain stimulation for dystonic tremor: A systematic review|10.1016/j.parkreldis.2020.06.008
New hopes for disease modification in Parkinson's Disease|10.1016/j.neuropharm.2020.108085
Not only loud but also intelligible|10.1016/j.eclinm.2020.100456
Parkinson's disease motor subtype changes during 20 years of follow-up|10.1016/j.parkreldis.2019.05.024
Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat|10.1139/cjpp-2019-0551
Proteomic analysis of transitional cell carcinoma–like variant of tubo-ovarian high-grade serous carcinoma|10.1016/j.humpath.2020.02.006
Snca-GFP Knock-In Mice Reflect Patterns of Endogenous Expression and Pathological Seeding|10.1523/eneuro.0007-20.2020
The Evolution-Driven Signature of Parkinson’s Disease|10.1016/j.tins.2020.05.001
Transcranial static magnetic stimulation —From bench to bedside and beyond—|10.1016/j.neures.2019.12.005
Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action|10.1016/j.euroneuro.2020.05.006
Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review|10.1136/bmjopen-2020-038704
Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland|10.3389/fneur.2020.00527
Deep brain stimulation in early-stage Parkinson disease|10.1212/wnl.0000000000009946
Does increased forefoot load contribute to freezing of gait in Parkinson's disease? A clinical observation|10.1016/j.parkreldis.2020.06.021
Influence of species and processing parameters on recovery and content of brain tissue‐derived extracellular vesicles|10.1080/20013078.2020.1785746
Vesicle trafficking and lipid metabolism in synucleinopathy|10.1007/s00401-020-02177-z
Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease|10.1074/mcp.ra120.002055
Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease|10.1007/s00401-020-02181-3
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset|10.1007/s00210-020-01927-w
Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi‐institutional study|10.1002/cam4.3255
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis|10.1016/j.parkreldis.2020.06.026
Single-vesicle imaging quantifies calcium’s regulation of nanoscale vesicle clustering mediated by α-synuclein|10.1038/s41378-020-0147-1
Deep Brain Stimulation Impact on Social and Occupational Functioning in Parkinson's Disease with Early Motor Complications|10.1002/mdc3.13015
GBA variants in REM sleep behavior disorder|10.1212/wnl.0000000000010042
Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice|10.1016/j.omtn.2020.06.027
Genetic Analysis of RAB39B in an Early-Onset Parkinson's Disease Cohort|10.3389/fneur.2020.00523
Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD)|10.3233/jpd-202090
Deep brain stimulation lead removal in Tourette syndrome|10.1016/j.parkreldis.2020.06.025
Dynamical system based compact deep hybrid network for classification of Parkinson disease related EEG signals|10.1016/j.neunet.2020.06.018
Implementation and Patient Experience of Outpatient Teleneurology|10.1089/tmj.2020.0032
Secondary Worsening Following DYT1 Dystonia Deep Brain Stimulation: A Multi-country Cohort|10.3389/fnhum.2020.00242
DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study|10.1016/j.parkreldis.2020.06.019
Evaluation of an Interdisciplinary Screening Program for People With Parkinson Disease and Movement Disorders|10.1016/j.arrct.2020.100067
Parkinson’s disease: etiopathogenesis and treatment|10.1136/jnnp-2019-322338
Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities|10.1002/mds.28171
The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates|10.1007/s12035-020-01988-1
GBA variation and susceptibility to multiple system atrophy|10.1016/j.parkreldis.2020.06.007
Partial Correlation Coefficient for a Study With Repeated Measurements|10.1080/19466315.2020.1784780
Clinical and imaging features of newly recognized Kelch-like protein 11 paraneoplastic syndrome|10.1212/wnl.0000000000009895
A computational model‐based analysis of basal ganglia pathway changes in Parkinson’s disease inferred from resting‐state fMRI|10.1111/ejn.14868
A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson’s Disease: Study Protocol and Design|10.3233/jpd-202019
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia|10.3233/jpd-202010
Effects of self-administered cannabidiol in a patient with multiple system atrophy|10.1007/s10286-020-00704-2
GuiltyTargets: Prioritization of Novel Therapeutic Targets With Network Representation Learning|10.1109/tcbb.2020.3003830
Happiness: A Novel Outcome in Parkinson Studies?|10.3233/jpd-201999
Parkinson's Disease Research on the African Continent: Obstacles and Opportunities|10.3389/fneur.2020.00512
Timing Is Everything: The T‐Cell Response to α‐Synuclein Is Maximal in Early Parkinson's|10.1002/mds.28122
Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries|10.3233/jpd-202040
Understanding the Lexicon of Fatigue in Parkinson’s Disease|10.3233/jpd-202029
A novel method for calculating beta band burst durations in Parkinson’s disease using a physiological baseline|10.1016/j.jneumeth.2020.108811
Alpha‐Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies|10.1002/ana.25824
Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset|10.1002/mds.28144
Genetic Architecture of Parkinson's Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research|10.3389/fneur.2020.00524
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach|10.1186/s13024-020-00388-2
Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum|10.1016/j.neurobiolaging.2020.06.007
Enhancing convolution-based sentiment extractor via dubbed N-gram embedding-related drug vocabulary|10.1007/s13721-020-00248-5
Getting ahead in the race for a cure: How nonprofits are financing biomedical R&D|10.1016/j.respol.2020.104032
Identifying and predicting Parkinson’s disease subtypes through trajectory clustering via bipartite networks|10.1371/journal.pone.0233296
LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?|10.3389/fnins.2020.00577
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial|10.1016/s1474-4422(20)30136-8
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease|10.1002/ana.25811
Genetic variants and functional pathways associated with resilience to Alzheimer’s disease|10.1093/brain/awaa209
LRRK2 Phosphorylation, More Than an Epiphenomenon|10.3389/fnins.2020.00527
The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease|10.3390/biom10060912
β-Glucocerebrosidase activity in GBA -linked Parkinson disease|10.1212/wnl.0000000000009989
ATP10B and the risk for Parkinson’s disease|10.1007/s00401-020-02172-4
Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning|10.1007/s00259-020-04897-6
White Matter Hyperintensities in the Synucleinopathies: Orthostatic Hypotension, Supine Hypertension, or Both?|10.1002/mdc3.13000
White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson's Disease|10.1002/mdc3.13003
Lack of evidence for genetic association of saposins A, B, C and D with Parkinson’s disease|10.1093/brain/awaa214
The Nrf2-mediated defense mechanism associated with HFE genotype limits vulnerability to oxidative stress-induced toxicity|10.1016/j.tox.2020.152525
Feasibility and behavioral effects of prolonged static and dynamic standing as compared to sitting in older adults with type 2 diabetes mellitus|10.1186/s12877-020-01600-0
Human plasma biomarker responses to inhalational general anaesthesia without surgery|10.1016/j.bja.2020.04.085
PINOT: an intuitive resource for integrating protein-protein interactions|10.1186/s12964-020-00554-5
Induction of the Endoplasmic-Reticulum-Stress Response: MicroRNA-34a Targeting of the IRE1α-Branch|10.3390/cells9061442
Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?|10.1002/mds.28115
Clinical Progression of Parkinson’s Disease: Insights from the NINDS Common Data Elements|10.3233/jpd-201932
Endogenous Rab29 does not impact basal or nigericin and monensin stimulated LRRK2 pathway activity|
“I Want to Do It, But I Want to Make Sure That I Do It Right.” Views of Patients with Parkinson’s Disease Regarding Early Stem Cell Clinical Trial Participation|10.1080/23294515.2020.1775721
Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease|10.1038/s41598-020-66319-9
Conopeptide-Functionalized Nanoparticles Selectively Antagonize Extrasynaptic N-Methyl-d-aspartate Receptors and Protect Hippocampal Neurons from Excitotoxicity In Vitro|10.1021/acsnano.0c00866;
Conopeptide-Functionalized Nanoparticles Selectively Antagonize Extrasynaptic N-Methyl-d-aspartate Receptors and Protect Hippocampal Neurons from Excitotoxicity In Vitro|10.1021/acsnano.0c00866
Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations|10.1016/j.parkreldis.2020.04.002
Sex Disparities in Autonomic Symptom Treatment in Parkinson's Disease|10.1002/mdc3.12997
Levodopa-carbidopa intestinal gel is an option in Parkinson’s disease with hyponatremia induced by dopamine agonists|10.1007/s10072-020-04501-7
Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson’s Disease|10.3389/fnagi.2020.00161
Identifying Treatments for Taste and Smell Disorders: Gaps and Opportunities|10.1093/chemse/bjaa038
Quantifying Spatiotemporal Gait Parameters with HoloLens in Healthy Adults and People with Parkinson’s Disease: Test-Retest Reliability, Concurrent Validity, and Face Validity|10.3390/s20113216
Association Between Cerebrospinal Fluid Biomarkers and Age-related Brain Changes in Patients with Normal Pressure Hydrocephalus|10.1038/s41598-020-66154-y
Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity|10.1038/s41467-020-16564-3
First occurrence of the pest Drosophila suzukii (Diptera: Drosophilidae) in the Comoros Archipelago (Western Indian Ocean)|10.4001/003.028.0078
LRRK2-Related Parkinson’s Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis|10.3389/fnins.2020.00556
Neurophysiological Correlates of Gait in the Human Basal Ganglia and the PPN Region in Parkinson’s Disease|10.3389/fnhum.2020.00194
Reply to: Psychophysical olfactory testing in COVID‐19: is smell function really impaired in nearly all patients?|10.1002/alr.22638
Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report|10.1186/s12883-020-01757-6
β-Adrenoceptor Drugs and Parkinson’s Disease: A Nationwide Nested Case–Control Study|10.1007/s40263-020-00736-2
Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population‐Based Cohort|10.1002/mds.28127
Deubiquitinating Enzymes in Parkinson’s Disease|10.3389/fphys.2020.00535
No Correlation Between White Matter Changes and Mild Parkinsonian Signs in Individuals Aged Older Than 75 Years|10.1002/mds.28120
Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease|10.1186/s40478-020-00950-5
Transcriptomic stratification of late-onset Alzheimer's cases reveals novel genetic modifiers of disease pathology|10.1371/journal.pgen.1008775
A comprehensive review of the diagnosis and treatment of Parkinson’s disease dysphagia and aspiration|10.1080/17474124.2020.1769475
Ansätze zur Etablierung von Präzisionsmedizin bei der Parkinson-Krankheit mit dem Schwerpunkt Genetik|10.1055/a-1149-2204
Artificial intelligence within the interplay between natural and artificial computation: Advances in data science, trends and applications|10.1016/j.neucom.2020.05.078
Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications|10.1007/s00415-020-09954-6
Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event‐based model of disease progression|10.1002/alz.12083
Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice|10.1016/j.neuroscience.2020.05.047
4169 The influence of serious mental illness on medical care of patients with lower back pain in the emergency department|10.1017/cts.2020.360
4203 Re-engineering the Approach to Extremely Preterm Breech Deliveries with Student Led Team Science|10.1017/cts.2020.358
4265 Effect of individual characteristics, healthcare access, and built environment on care coordination outcomes related to cardiovascular disease risk factors|10.1017/cts.2020.356
4319 Team Science in Parkinson’s Research: Connecting Clinicians and Computational Teams|10.1017/cts.2020.359
4556 Gender homophily in translational collaborations; a network analysis study of investigators at one academic medical center|10.1017/cts.2020.357
Alzheimer’s Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation|10.1016/j.celrep.2020.107843
Anticipatory feelings: Neural correlates and linguistic markers|10.1016/j.neubiorev.2020.02.015
Diagnostic Delay in Cervical Dystonia: Dystonia with Antecedent Essential Tremor?|10.1002/mds.28103
Engineered microtissue as an anatomically inspired model of Parkinson's disease|10.1016/j.cobme.2020.07.004
Exercise and Sleep in Parkinson's Disease|10.1002/mds.28032
Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease|10.1212/nxg.0000000000000430
Huntington’s Disease and Hypertension: Sorting Out Mixed Messages|10.1002/mds.28076
Identification of Conserved Proteomic Networks in Neurodegenerative Dementia|10.1016/j.celrep.2020.107807
Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans|10.1001/jamaneurol.2020.0428
Implementation of a Novel Bluetooth Technology for Remote Deep Brain Stimulation Programming: The Pre– and Post–COVID‐19 Beijing Experience|10.1002/mds.28098
Private variants in PRKN are associated with late-onset Parkinson's disease|10.1016/j.parkreldis.2020.05.003
Remote telemedicine evaluation of deep brain stimulation candidacy|10.1212/cpj.0000000000000723
Reply to: Diagnostic Delay in Cervical Dystonia‐Dystonia With Antecedent ET ?|10.1002/mds.28102
The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension|10.1016/j.parkreldis.2020.04.011
The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question—are polyphenols a viable therapeutic option against proteinopathies?|10.21037/atm.2020.01.117
TransMatch: A Transfer-Learning Scheme for Semi-Supervised Few-Shot Learning|10.1109/cvpr42600.2020.01287
Variations in Cardiovascular Structure, Function, and Geometry in Midlife Associated With a History of Hypertensive Pregnancy|10.1161/hypertensionaha.119.14530
Fluctuation Imaging of LRRK2 Reveals that the G2019S Mutation Alters Spatial and Membrane Dynamics|10.3390/molecules25112561
How have advances in genetic technology modified movement disorder nosology?|10.1111/ene.14294
Randomized controlled three-arm study of NADA acupuncture for alcohol addiction|10.1016/j.addbeh.2020.106488
Usability of the Experience Sampling Method in Parkinson's Disease on a Group and Individual Level|10.1002/mds.28028
Capgras Delusion in Posterior Cortical Atrophy–A Quantitative Multimodal Imaging Single Case Study|10.3389/fnagi.2020.00133
Decision Support for Medication Change of Parkinson's Disease Patients|10.1016/j.cmpb.2020.105552
Item Response Theory Analysis of the MDS ‐ UPDRS Motor Examination: Tremor vs. Nontremor Items|10.1002/mds.28110
Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson’s Disease|10.1007/s40263-020-00727-3
[11C]dihydrotetrabenazine Positron Emission Tomography in Manganese-Exposed Workers|10.1097/jom.0000000000001915
Deep Learning Identifies Digital Biomarkers for Self-Reported Parkinson's Disease|10.1016/j.patter.2020.100042
Structural connectivity predicts clinical outcomes of deep brain stimulation for Tourette syndrome|10.1093/brain/awaa188
Variational Autoencoder Modular Bayesian Networks for Simulation of Heterogeneous Clinical Study Data|10.3389/fdata.2020.00016
A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms|10.3389/fneur.2020.00454
Changes in Regional Cerebral Perfusion Over Time in Idiopathic REM Sleep Behavior Disorder|10.1002/mds.28092
The effect of LRRK2 loss-of-function variants in humans|10.1038/s41591-020-0893-5
Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET‐Based Assay of Synapsin III Binding|10.1002/cmdc.202000128
Intrepidly studying deep brain stimulation in patients with Parkinson's disease|10.1016/s1474-4422(20)30138-1
Long before Huntington's disease: what matters most?|10.1016/s1474-4422(20)30156-3
Mechanisms, regulation and functions of the unfolded protein response|10.1038/s41580-020-0250-z
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study|10.1016/s1474-4422(20)30108-3
Tremor: so common, so difficult|10.1136/jnnp-2020-323189
“LRRK2: Autophagy and Lysosomal Activity”|10.3389/fnins.2020.00498
Quantitative Measurements of LRRK2 in Human Cerebrospinal Fluid Demonstrates Increased Levels in G2019S Patients|10.3389/fnins.2020.00526
CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories|10.1002/mds.28056
Dietary antioxidants associated with slower progression of parkinsonian signs in older adults|10.1080/1028415x.2020.1769411
Pareidolias and cognition in isolated REM sleep behavior disorder|10.1016/j.parkreldis.2020.05.017
Retracted: Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease|10.1002/ana.25788
Sex‐specific association of urate and levodopa‐induced dyskinesia in Parkinson’s disease|10.1111/ene.14337
LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson’s|10.3389/fnins.2020.00443
Why People With Parkinson's Disease Experience Near‐Drowning—and How to Prevent It|10.1002/mdc3.12989
A Method of Assessment of Human Natural Killer Cell Phenotype and Function in Whole Blood|10.3389/fimmu.2020.00963
Guilt-by-Association – Functional Insights Gained From Studying the LRRK2 Interactome|10.3389/fnins.2020.00485
Impact of the size of the normal database on the performance of the specific binding ratio in dopamine transporter SPECT|10.1186/s40658-020-00304-z
Transgenic Overexpression of GPNMB Protects Against MPTP-Induced Neurodegeneration|10.1007/s12035-020-01921-6
When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis|10.1007/s00415-020-09892-3
Dopamine is associated with prioritization of reward-associated memories in Parkinson’s disease|10.1093/brain/awaa182
Effects of Moderate Static Magnetic Field on Neural Systems Is a Non-invasive Mechanical Stimulation of the Brain Possible Theoretically?|10.3389/fnins.2020.00419
Mitochondrial tRNA methylation in Alzheimer’s disease and progressive supranuclear palsy|10.1186/s12920-020-0727-9
Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson’s Disease|10.3233/jpd-202078
Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis|10.3389/fncel.2020.00129
Absence of Sac2/INPP5F enhances the phenotype of a Parkinson’s disease mutation of synaptojanin 1|10.1073/pnas.2004335117
Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease|10.1016/j.jagp.2020.05.014
Inconsistent Movement Disorders Society–Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative|10.1002/mds.28108
Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain|10.1038/s41593-020-0635-5
Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort|10.1186/s12883-020-01777-2
Managing Device‐Aided Treatments in Parkinson's Disease in Times of COVID‐19|10.1002/mdc3.12985
Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study|10.1002/mds.28085
Genetic characterization of Parkinson's disease patients in Ecuador and Colombia|10.1016/j.parkreldis.2020.05.005
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates|10.1126/sciadv.aaz9165
LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human iPSC-Derived Neurons|10.3389/fnins.2020.00442
Minimalist approaches to cancer tissue-of-origin classification by DNA methylation|10.1038/s41379-020-0547-7
Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function|10.1016/j.omtn.2020.05.009
Questioning the Meaning of a Change on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Noncomparable Scores and Item-Specific Effects Over Time|10.1177/1073191120915273
Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression|10.1002/mds.28073
Clinical trials in REM sleep behavioural disorder: challenges and opportunities|10.1136/jnnp-2020-322875
MAPT haplotype–stratified GWAS reveals differential association for AD risk variants|10.1002/alz.12099
Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease|10.1002/mds.28051
The Head Retraction Reflex in Niemann‐Pick Type C: A Novel Diagnostic Clue|10.1002/mdc3.12976
Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson’s Disease During the COVID-19 Pandemic: New Expectations for the Future|10.3233/jpd-202108
Morphological Characterization of Functional Brain Imaging by Isosurface Analysis in Parkinson’s Disease|10.1142/s0129065720500446
Detection of Aspiration, Penetration, and Pharyngeal Residue During Flexible Endoscopic Evaluation of Swallowing (FEES): Comparing the Effects of Color, Coating, and Opacity|10.1007/s00455-020-10131-0
Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?|10.1016/j.expneurol.2020.113357
Non-motor Clinical and Biomarker Predictors Enable High Cross-Validated Accuracy Detection of Early PD but Lesser Cross-Validated Accuracy Detection of Scans Without Evidence of Dopaminergic Deficit|10.3389/fneur.2020.00364
Parkinson's disease motor subtypes and bilateral GPi deep brain stimulation: One-year outcomes|10.1016/j.parkreldis.2020.05.004
Reduced complement of dopaminergic neurons in the substantia nigra pars compacta of mice with a constitutive “low footprint” genetic knockout of alpha-synuclein|10.1186/s13041-020-00613-5
SERIAL‐ORDER recall in working memory across the cognitive spectrum of Parkinson’s disease and neuroimaging correlates|10.1111/jnp.12208
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0|10.1007/s00259-020-04817-8
The Accumulation of Tau in Postsynaptic Structures: A Common Feature in Multiple Neurodegenerative Diseases?|10.1177/1073858420916696
Clinical and Imaging Markers of Prodromal Parkinson's Disease|10.3389/fneur.2020.00395
Intramitochondrial proteostasis is directly coupled to α-synuclein and amyloid β1-42 pathologies|10.1074/jbc.ra119.011650
Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease|10.3389/fneur.2020.00324
Unified deep learning approach for prediction of Parkinson's disease|10.1049/iet-ipr.2019.1526
Advantages of timing the duration of a freezing of gait-provoking test in individuals with Parkinson’s disease|10.1007/s00415-020-09856-7
Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson’s disease|10.1136/jnnp-2019-321759
Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose|10.1371/journal.pone.0230815
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease|10.1007/s40265-020-01310-2
CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers|10.1186/s40035-020-00192-4
Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease|10.3389/fneur.2020.00370
Revised Self-Monitoring Scale|10.1212/wnl.0000000000009451
Health-Related Quality of Life Outcomes from Botulinum Toxin Treatment in Spasticity|10.3390/toxins12050292
The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade?|10.1080/14728222.2020.1758668
Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice|10.1080/14737175.2020.1752669
Serum triglycerides in Alzheimer disease|10.1212/wnl.0000000000009436
A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation|10.1002/mds.28083
All that’s fit to preprint|10.1038/s41587-020-0536-x
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate|10.1016/j.nbd.2020.104789
An Overview of the Current State and the Future of Ataxia Treatments|10.1016/j.ncl.2020.01.008
Corneal confocal microscopy: ready for prime time|10.1111/cxo.12887
Cortical Thickness, Neurocognition and Social Cognition in Euthymic Individuals With Bipolar Disorder and Their Healthy Siblings|10.1016/j.biopsych.2020.02.967
Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression|10.1007/s00702-020-02194-y
Cross-Platform Comparison of Immunoassay Technologies to Assess Cytokine Markers in Patients With Post-Traumatic Stress Disorder and Parkinson’s Disease|10.1016/j.biopsych.2020.02.968
Deciphering DDX3X Syndrome to Capture Determinants of Intellectual Disability|10.1016/j.biopsych.2020.02.969
ePresentation Sessions|10.1111/ene.14307
Expert comment: “A case of missing pathology in a patient with LRRK2 Parkinson's disease”|10.1016/j.parkreldis.2019.11.005
How Do I Examine Patients With Functional Tremor?|10.1002/mdc3.12966
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how|10.1016/s1474-4422(20)30036-3
Kinesthetic Cells within the Subthalamic Nucleus and Deep Brain Stimulation for Parkinson Disease|10.1016/j.wneu.2020.04.160
Long-term unsupervised mobility assessment in movement disorders|10.1016/s1474-4422(19)30397-7
Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism|10.1002/mds.28060
Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID‐19 Experience|10.1002/mdc3.12965
Medical cannabis as an alternative therapeutics for Parkinsons’ disease: Systematic review|10.1016/j.ctcp.2020.101154
miRSwitch: detecting microRNA arm shift and switch events|10.1093/nar/gkaa323
Neuroimaging the consciousness of self: Review, and conceptual-methodological framework|10.1016/j.neubiorev.2020.01.023
Oral Sessions|10.1111/ene.14306
PINK1 and Parkin: team players in stress-induced mitophagy|10.1515/hsz-2020-0135
Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease|10.1016/j.parkreldis.2020.04.009
Surgical Treatment of Parkinson Disease|10.1016/j.ncl.2020.01.001
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease|10.1002/mds.28075
Treatment of Nonmotor Symptoms Associated with Parkinson Disease|10.1016/j.ncl.2019.12.003
Treatment of Tardive Dyskinesia|10.1016/j.ncl.2020.01.004
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease|10.1002/mds.28066
Objective measurement in Parkinson’s disease: a descriptive analysis of Parkinson’s symptom scores from a large population of patients across the world using the Personal KinetiGraph®|10.1186/s40734-020-00087-6
Physical activity and cognition in young‐onset Parkinson’s disease|10.1111/ane.13256
Serial Dopamine Transporter Imaging of Nigrostriatal Function in Parkinson’s Disease With Probable REM Sleep Behavior Disorder|10.3389/fnins.2020.00349
Spectrum of impulse control behaviours in Parkinson’s disease: pathophysiology and management|10.1136/jnnp-2019-322453
The GTPase Rab27b regulates the release, autophagic clearance, and toxicity of α-synuclein|10.1074/jbc.ra120.013337
Fractures in the prodromal period of Parkinson disease|10.1212/wnl.0000000000009452
Intracellular delivery of Parkin rescues neurons from accumulation of damaged mitochondria and pathological α-synuclein|10.1126/sciadv.aba1193
Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease|10.1002/mds.28064
The turning and barrier course reveals gait parameters for detecting freezing of gait and measuring the efficacy of deep brain stimulation|10.1371/journal.pone.0231984
Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson’s disease|10.1016/j.cytox.2020.100027
Multiple-Hit Hypothesis in Parkinson’s Disease: LRRK2 and Inflammation|10.3389/fnins.2020.00376
Research criteria for the diagnosis of prodromal dementia with Lewy bodies|10.1212/wnl.0000000000009323
Differential diagnosis of parkinsonian syndromes: a comparison of clinical and automated - metabolic brain patterns’ based approach|10.1007/s00259-020-04785-z
Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils|10.1016/j.neuroscience.2020.04.032
Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s disease|10.1038/s41588-020-0610-9
Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease|10.1002/mds.28026
Attracting neurology's next generation|10.1212/wnl.0000000000009461
Forecasts for the Attainment of Major Research Milestones in Parkinson’s Disease|10.3233/jpd-201933
Intra-striatal AAV2.retro administration leads to extensive retrograde transport in the rhesus macaque brain: implications for disease modeling and therapeutic development|10.1038/s41598-020-63559-7
SparkINFERNO: a scalable high-throughput pipeline for inferring molecular mechanisms of non-coding genetic variants|10.1093/bioinformatics/btaa246
The mGlu2/3 antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu2 activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset|10.1007/s00702-020-02196-w
A data-driven system to identify REM sleep behavior disorder and to predict its progression from the prodromal stage in Parkinson's disease|10.1016/j.sleep.2020.04.010
Active Learning in Psychiatry Education: Current Practices and Future Perspectives|10.3389/fpsyt.2020.00211
From a deep learning model back to the brain—Identifying regional predictors and their relation to aging|10.1002/hbm.25011
Letter: Evaluation and Surgical Treatment of Functional Neurosurgery Patients With Implanted Deep Brain Stimulation and Vagus Nerve Stimulation Pulse Generators During the COVID-19 Pandemic|10.1093/neuros/nyaa185
Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival|10.1002/mds.28070
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits|10.1126/scitranslmed.aav0820
miEAA 2.0: integrating multi-species microRNA enrichment analysis and workflow management systems|10.1093/nar/gkaa309
Movement Disorder Society–Unified Parkinson's Disease Rating Scale Use in the Covid‐19 Era|10.1002/mds.28094
Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia|10.1371/journal.pone.0231720
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease|10.3389/fnagi.2020.00097
Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive‐Compulsive Behavior? A Cross‐Sectional Study|10.1002/mds.28053
Nitric Oxide-Dependent Protein Post-Translational Modifications Impair Mitochondrial Function and Metabolism to Contribute to Neurodegenerative Diseases|10.1089/ars.2019.7916
Role of data measurement characteristics in the accurate detection of Parkinson’s disease symptoms using wearable sensors|10.1186/s12984-020-00684-4
Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1‐Year Prospective Trial|10.1002/mds.28065
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease|10.1038/s41467-020-15626-w
RE-KINECT|10.1097/jcp.0000000000001201
Glycocalyx‐Like Hydrogel Coatings for Small Diameter Vascular Grafts|10.1002/adfm.201908963
Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease|10.1136/jnnp-2020-322857
Smell dysfunction: a biomarker for COVID‐19|10.1002/alr.22587
SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder|10.1016/j.neurobiolaging.2020.04.005
Autophagy in neurodegeneration: New insights underpinning therapy for neurological diseases|10.1111/jnc.15002
Age at Onset of Parkinson’s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations|10.3233/jpd-191829
Alterations of Brain Signal Oscillations in Older Individuals with HIV Infection and Parkinson’s Disease|10.1007/s11481-020-09914-x
Carepartner Communication on Parkinson Disease Psychosis (4116)|10.1212/wnl.94.15_supplement.4116
Choosing a Parkinson Disease Treatment|10.1001/jama.2020.1224
Detecting the Cognitive Prodrome of Dementia in Parkinson’s Disease|10.3233/jpd-191857
Modeling PD Progression in the PPMI Cohort: Implications for Clinical Trial Design (4402)|10.1212/wnl.94.15_supplement.4402
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy|10.1002/mds.28034
Olfaction in LRRK2 Linked Parkinson’s Disease: Is It Different from Idiopathic Parkinson’s Disease?|10.3233/jpd-201972
Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advance Parkinson’s Disease (4418)|10.1212/wnl.94.15_supplement.4418
PPMI 2.O New Science/New Cohorts - Transforming PPMI (2490)|10.1212/wnl.94.15_supplement.2490
Validation of Fox Insight Cohort via Virtual Research Visits (4749)|
Validation of Fox Insight Cohort via Virtual Research Visits (4749)|10.1212/wnl.94.15_supplement.4749
White Matter Hyperintensities Related to Parkinson's Disease Executive Function|10.1002/mdc3.12956
A Comprehensive Review of Brain Connectomics and Imaging to Improve Deep Brain Stimulation Outcomes|10.1002/mds.28045
Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer’s disease|10.1111/bpa.12842
Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease|10.1002/mds.28037
Variants in the Niemann–Pick type C gene NPC1 are not associated with Parkinson's disease|10.1016/j.neurobiolaging.2020.03.021
Binding of the Human 14-3-3 Isoforms to Distinct Sites in the Leucine-Rich Repeat Kinase 2|10.3389/fnins.2020.00302
Corticobasal Degeneration Reveals Its Signature by Tau Strains|10.1002/mds.28054
Frequency of and risk factors for potentially inappropriate medication use in Parkinson’s disease|10.1093/ageing/afaa033
Benign SLC39A14 Course of Dystonia‐Parkinsonism Secondary to Inherited Manganese Accumulation|10.1002/mdc3.12947
Impact of the COVID‐19 Pandemic on Parkinson's Disease and Movement Disorders|10.1002/mds.28067
Impact of the COVID‐19 Pandemic on Parkinson's Disease and Movement Disorders|10.1002/mdc3.12953
Multiomics Analyses Identify Genes and Pathways Relevant to Essential Tremor|10.1002/mds.28031
Phenomenology and Management of Subthalamic Stimulation‐Induced Dyskinesia in Patients With Isolated Dystonia|10.1002/mdc3.12946
Reply to Gender Differences in Functional Movement Disorders: Sociocultural or Biological?|10.1002/mdc3.12950
Virus Bioresistor (VBR) for Detection of Bladder Cancer Marker DJ-1 in Urine at 10 pM in One Minute|10.1021/acs.analchem.0c00534
Missing heritability in Parkinson’s disease: the emerging role of non-coding genetic variation|10.1007/s00702-020-02184-0
Advantages and Recent Developments of Autologous Cell Therapy for Parkinson’s Disease Patients|10.3389/fncel.2020.00058
Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson’s Disease in the Harvard Biomarkers Study|10.3233/jpd-191882
Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion|10.1212/nxi.0000000000000711
Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset|10.1007/s00702-020-02185-z
Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson’s Disease?|10.3233/jpd-191877
Impact of depressive symptoms on self-perceived severity of autonomic dysfunction in multiple system atrophy: relevance for patient-reported outcomes in clinical trials|10.1007/s10286-020-00681-6
Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience|10.3233/jpd-191901
Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson’s Disease: A 7 Tesla Imaging Study|10.3233/jpd-191890
The Impact of Deep Brain Stimulation on Sleep in Parkinson’s Disease: An update|10.3233/jpd-191862
The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities|10.3233/jpd-202038
A call for better depression treatment in people with Parkinson disease|10.1212/wnl.0000000000009285
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update|10.1080/14728214.2020.1763954
Left Prefrontal Connectivity Links Subthalamic Stimulation with Depressive Symptoms|10.1002/ana.25734
Telephone-based cognitive behavioral therapy for depression in Parkinson disease|10.1212/wnl.0000000000009292
A Novel Parkinson’s Disease Model: PINK1/PARKIN Double‐Knockout Rats|10.1096/fasebj.2020.34.s1.03409
Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease|10.1016/j.ceb.2020.01.001
Advances in studying protein disorder with solid-state NMR|10.1016/j.ssnmr.2020.101643
Autophagy in Parkinson's Disease|10.1016/j.jmb.2020.01.037
Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics|10.1016/j.parkreldis.2019.11.015
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine|10.1016/j.nbd.2020.104782
Improved motion correction for functional MRI using an omnibus regression model|10.1109/isbi45749.2020.9098688
INVESTIGATING MOTOR LEARNING IN A LRRK2 MOUSE MODEL OF PARKINSON’S DISEASE|10.1096/fasebj.2020.34.s1.04831
Long-term, stable, targeted biodelivery and efficacy of GDNF from encapsulated cells in the rat and Goettingen miniature pig brain|10.1016/j.crphar.2020.04.001
Mechanism of Activation of the Ubiquitin E3 Ligase, Parkin|10.1096/fasebj.2020.34.s1.07607
MRI biomarkers of motor and non-motor symptoms in Parkinson's disease|10.1016/j.parkreldis.2019.10.002
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease|10.1002/acn3.51022
Prevalence of GBA p.K198E mutation in Colombian and Hispanic populations|10.1016/j.parkreldis.2020.03.008
Progressive supranuclear palsy: Advances in diagnosis and management|10.1016/j.parkreldis.2020.04.014
Quantitative Thermal Imaging Biomarkers to Detect Acute Skin Toxicity From Breast Radiation Therapy Using Supervised Machine Learning|10.1016/j.ijrobp.2019.12.032
Regulator of G protein signaling 6 (RGS6) is a critical modulator of reward behavior and dopamine signaling in the mesolimbic circuit|10.1096/fasebj.2020.34.s1.09944
Role of GSK3β and the A‐Type Potassium Channel in the Behavioral Phenotype of a Mouse Model of Parkinson’s Disease|10.1096/fasebj.2020.34.s1.08876
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease|10.1523/jneurosci.2936-19.2020
The Discovery of the Dardarin Gene 15 Years Later: A Globalized Local History|10.1002/mds.27969
The microbiome-gut-brain axis in acute and chronic brain diseases|10.1016/j.conb.2019.11.009
Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease|10.1111/bpa.12839
From correlational approaches to meta-analytical symptom reading in individual patients: Bilateral lesions in the inferior frontal junction specifically cause dysexecutive syndrome|10.1016/j.cortex.2020.03.010
Low Cholesterol Level Linked to Reduced Semantic Fluency Performance and Reduced Gray Matter Volume in the Medial Temporal Lobe|10.3389/fnagi.2020.00057
Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson’s Disease|10.3233/jpd-191896
A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease|10.1186/s13024-020-00370-y
Automatic Facial Landmark Localization in Clinical Populations - Improving Model Performance with a Small Dataset|10.21203/rs.3.rs-19405
Distribution of Parkinson’s disease associated RAB39B in mouse brain tissue|10.1186/s13041-020-00584-7
PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72|10.1042/bcj20190664
Factor Analysis and Clustering of the Movement Disorder Society–Non‐Motor Rating Scale|10.1002/mds.28002
Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology|10.3389/fnhum.2020.00054
Progressive Supranuclear Palsy and Statin Use|10.1002/mds.28038
Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly|10.1212/wnl.0000000000009315
Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications|10.1007/s00415-020-09806-3
Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series|10.1097/wnf.0000000000000384
Robot-Driven Locomotor Perturbations Reveal Synergy-Mediated, Context-Dependent Feedforward and Feedback Mechanisms of Adaptation|10.1038/s41598-020-61231-8
Defining research priorities in dystonia|10.1212/wnl.0000000000009140
MIDN locus structural variants and Parkinson's Disease risk|10.1002/acn3.51012
Do Patients With Parkinson’s Disease With Freezing of Gait Respond Differently Than Those Without to Treadmill Training Augmented by Virtual Reality?|10.1177/1545968320912756
Formation of α‐synuclein aggregates in aqueous ethylammonium nitrate solutions|10.1002/bip.23352
Protein transmission in neurodegenerative disease|10.1038/s41582-020-0333-7
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke–Supported Network for Excellence in Neuroscience Clinical Trials|10.1001/jamaneurol.2020.0367
The role of disease duration and severity on novel clinical subtypes of Parkinson disease|10.1016/j.parkreldis.2020.03.013
Defective Human Motion Perception in Cervical Dystonia Correlates With Coexisting Tremor|10.1002/mds.28017
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation|10.3791/58956
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation|10.3791/58956-v
Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways|10.1016/j.neuron.2020.02.034
The genetic architecture of the human cerebral cortex|10.1126/science.aay6690
CNS-Derived Blood Exosomes as a Promising Source of Biomarkers: Opportunities and Challenges|10.3389/fnmol.2020.00038
Potential sources of interference with the highly sensitive detection and quantification of alpha‐synuclein seeds by qRT‐QuIC|10.1002/2211-5463.12844
Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates|10.1093/brain/awaa096
Disease modification and biomarker development in Parkinson disease|10.1212/wnl.0000000000009107
Improving anxiety in Parkinson's disease: A cautionary tale about mobile health technologies|10.1016/j.parkreldis.2020.03.010
Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease|10.1111/ene.14221
Crohn’s and Parkinson’s Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo|10.1007/s11481-020-09909-8
Rebooting Late-Life Mental Health Innovation and Entrepreneurship With Convergence Science|10.1016/j.jagp.2020.03.003
Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease|10.1093/brain/awaa090
A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer’s disease|10.1186/s12974-020-01750-3
Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export|10.1007/s00401-020-02145-7
Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies|10.1042/bcj20190843
Autonomic dysfunction is associated with neuropsychological impairment in Lewy body disease|10.1007/s00415-020-09783-7
Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration|10.1038/s41467-020-15119-w
Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson’s Disease: Data from the PPMI Study|10.3233/jpd-191860
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model|10.1186/s13104-020-04994-7
Latency of subthalamic nucleus deep brain stimulation-evoked cortical activity as a potential biomarker for postoperative motor side effects|10.1016/j.clinph.2020.02.021
Seeing ophthalmologic problems in Parkinson disease|10.1212/wnl.0000000000009214
Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report|10.1186/s12883-020-01670-y
Comprehensive assessment of PINK1 variants in Parkinson's disease|10.1016/j.neurobiolaging.2020.03.003
Leucine Rich Repeat Kinase 2 and Innate Immunity|10.3389/fnins.2020.00193
Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade|10.1111/ene.14200
Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice|10.1016/j.neurobiolaging.2020.02.026
Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease|10.1002/mds.27993
Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease|10.1007/s00415-020-09743-1
Current Directions in Deep Brain Stimulation for Parkinson’s Disease—Directing Current to Maximize Clinical Benefit|10.1007/s40120-020-00181-9
Regulatory T Cells in Cancer|10.1146/annurev-cancerbio-030419-033428
Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy|10.1002/mds.28010
Clinical outcomes of globus pallidus deep brain stimulation for Parkinson disease: a comparison of intraoperative MRI– and MER-guided lead placement|10.3171/2019.12.jns192010
Estimating brain age based on a uniform healthy population with deep learning and structural magnetic resonance imaging|10.1016/j.neurobiolaging.2020.02.009
Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson’s Disease|10.3389/fnagi.2020.00055
Initiation and propagation of α-synuclein aggregation in the nervous system|10.1186/s13024-020-00368-6
Lack of Asymmetry of Nigrostriatal Dopaminergic Function in Healthy Subjects|10.1002/mds.28019
Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic|10.1002/ange.202000451
A new biology of cell penetrating peptides|10.1002/pep2.24154
Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients|10.1001/jamaoncol.2020.0001
Transcriptomic signatures of brain regional vulnerability to Parkinson’s disease|10.1038/s42003-020-0804-9
Cognitive load amplifies Parkinson’s tremor through excitatory network influences onto the thalamus|10.1093/brain/awaa083
Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson’s Disease|10.1016/j.neuroscience.2020.02.046
Contributions of individual and combined Glu-B1x and Glu-B1y high-molecular-weight glutenin subunits to semolina functionality and pasta quality|10.1016/j.jcs.2020.102943
Deep brain stimulation in essential tremor: targets, technology, and a comprehensive review of clinical outcomes|10.1080/14737175.2020.1737017
ESHRD: deconvolution of brain homogenate RNA expression data to identify cell-type-specific alterations in Alzheimer’s disease|10.18632/aging.102840
Constructing treatment episodes from concomitant medication logs: a prospective observational study|10.1136/bmjopen-2019-034305
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration|10.1038/s41591-020-0762-2
Essential tremor-plus: a controversial new concept|10.1016/s1474-4422(19)30398-9
Global Landscape and Dynamics of Parkin and USP30-Dependent Ubiquitylomes in iNeurons during Mitophagic Signaling|10.1016/j.molcel.2019.11.013
Impaired Motor Recycling during Action Selection in Parkinson’s Disease|10.1523/eneuro.0492-19.2020
Investigating lymphocyte populations in patients with Parkinson’s disease|10.21037/atm.2020.02.29
Mitochondria at the interface between neurodegeneration and neuroinflammation|10.1016/j.semcdb.2019.05.028
Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease|10.1016/j.ejphar.2020.172914
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia|10.1038/s41591-020-0755-1
Social Impact of Connected Landmark Lighting: A Social Sensing Approach|10.1109/iotm.0001.1900088
Three-Plane–assembled Deep Learning Segmentation of Gliomas|10.1148/ryai.2020190011
β-adrenoreceptors and the risk of Parkinson's disease|10.1016/s1474-4422(19)30400-4
An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases|10.3390/cells9030576
Outcome measurement in functional neurological disorder: a systematic review and recommendations|10.1136/jnnp-2019-322180
Personalized prediction of depression in patients with newly diagnosed Parkinson's disease: A prospective cohort study|10.1016/j.jad.2020.02.046
Selective Fluorogenic β-Glucocerebrosidase Substrates for Convenient Analysis of Enzyme Activity in Cell and Tissue Homogenates|10.1021/acschembio.9b01044
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide|10.1002/mdc3.12921
Contingent negative variation: a biomarker of abnormal attention in functional movement disorders|10.1111/ene.14189
Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease|10.1001/jamaneurol.2019.5154
Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease|10.1038/s41597-020-0401-2
Handheld Cough Testing: A Novel Tool for Cough Assessment and Dysphagia Screening|10.1007/s00455-020-10097-z
Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease|10.1002/mds.28009
Diphasic Worsening of Freezing of Gait in Parkinson's Disease|10.1002/mdc3.12918
Validation of a Parkinson Disease Predictive Model in a Population-Based Study|10.1155/2020/2857608
Well Water and Parkinson’s Disease in Medicare Beneficiaries: A Nationwide Case-Control Study|10.3233/jpd-191793
A lncRNA survey finds increases in neuroprotective LINC‐PINT in Parkinson’s disease substantia nigra|10.1111/acel.13115
Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis|10.1136/jnnp-2019-322169
Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study|10.1016/j.nbd.2020.104813
Longitudinal change in autonomic symptoms predicts activities of daily living and depression in Parkinson’s disease|10.1007/s10286-020-00672-7
Probing Reversible Guest Binding with Hyperpolarized 129Xe-NMR: Characteristics and Applications for Cucurbit[n]urils|10.3390/molecules25040957
Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease|10.1002/mds.28006
Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology|10.1016/j.nbd.2020.104810
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study|10.1002/mds.27989
Dopamine Metabolism May Have Unexpected Benefits for Mitochondrial Energy Production|10.1002/mds.28005
Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment|10.1186/s13024-020-00362-y
The Most Bothersome Aspects of Off Periods Reported by Individuals with Parkinson's Disease|10.1002/mdc3.12915
Brainstem atrophy in Gulf War Illness|10.1016/j.neuro.2020.02.006
Cross‐sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson’s disease|10.1111/ene.14177
From Passive Patient to Engaged Partner: My Journey With Parkinson Disease|10.2196/12566
The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease|10.1002/mds.27999
Co-occurring WARS2 and CHRNA6 mutations in a child with a severe form of infantile parkinsonism|10.1016/j.parkreldis.2020.02.003
Brain perfusion patterns are altered in chronic knee pain: a spatial covariance analysis of arterial spin labelling MRI|10.1097/j.pain.0000000000001829
LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis|10.7554/elife.51071
Pathology‐Proven Corticobasal Degeneration Presenting as Richardson's Syndrome|10.1002/mdc3.12900
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa|10.1155/2020/9716317
Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease|10.1038/s41598-020-59414-4
Impulse control and related behaviors in Parkinson’s disease with dementia|10.1111/ene.14169
Longitudinal follow-up with VIM thalamic deep brain stimulation for dystonic or essential tremor|10.1212/wnl.0000000000008875
Diagnosis and Treatment of Parkinson Disease|10.1001/jama.2019.22360
Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease|10.1016/j.parkreldis.2020.02.001
Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder|10.1212/wnl.0000000000008926
Wearable-based mobility monitoring: the long road ahead|10.1016/s1474-4422(20)30033-8
Child Neurology: Genetically determined dystonias with childhood onset|10.1212/wnl.0000000000009040
Lysosome and Inflammatory Defects in GBA1 ‐Mutant Astrocytes Are Normalized by LRRK2 Inhibition|10.1002/mds.27994
Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment|10.1002/mds.27991
Teaching NeuroImages: The dentate sign in subacute cerebellar ataxia|10.1212/wnl.0000000000009006
Do Parkinson disease subject and caregiver-reported Epworth sleepiness scale reponses correlate?|10.1016/j.clineuro.2020.105728
Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry|10.1007/s00216-020-02439-5
APOE genotype regulates pathology and disease progression in synucleinopathy|10.1126/scitranslmed.aay3069
Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy|10.1038/s41586-020-1984-7
The parkin-coregulated gene product PACRG promotes TNF signaling by stabilizing LUBAC|10.1126/scisignal.aav1256
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study|10.1038/s41467-019-14279-8
Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review|10.1002/mdc3.12899
RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson’s Disease|10.1124/mol.119.118836
Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2|10.1016/j.str.2020.01.005
Tensor decomposition of stimulated monocyte and macrophage gene expression profiles identifies neurodegenerative disease-specific trans-eQTLs|10.1371/journal.pgen.1008549
Abstracts|10.1002/mdc3.12905
Analysis of common and rare VPS13C variants in late-onset Parkinson disease|10.1212/nxg.0000000000000385
Cognition in multiple system atrophy: a single‐center cohort study|10.1002/acn3.50987
Diabetes, BMI, and Parkinson's|10.1002/mds.27941
Effects of a community-based Exercise Program On mobility, balance, cognition, sleep, Activities of Daily living, and Quality of Life in PD: A Pilot Study|10.2217/nmt-2019-0027
Grey matter abnormalities are associated only with severe cognitive decline in early stages of Parkinson's disease|10.1016/j.cortex.2019.09.015
Keep calm and beam on? Unmet needs in radiotherapy and deep brain stimulation|10.1016/j.parkreldis.2020.01.005
Management of Orthostatic Hypotension|10.1212/con.0000000000000816
Multidisciplinary Care to Optimize Functional Mobility in Parkinson Disease|10.1016/j.cger.2019.09.008
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders|10.1016/j.nbd.2019.104619
Orthostatic Hypotension in Parkinson Disease|10.1016/j.cger.2019.09.002
Renal Dysfunction Might Be a Marker of Cardiovascular Dysautonomia in Prodromal Α‐Synucleinopathies|10.1002/mds.27840
Stem-Cell Research of Parkinson Disease: Bibliometric Analysis of Research Productivity from 1999 to 2018|10.1016/j.wneu.2019.10.087
Tears – more to them than meets the eye: why tears are a good source of biomarkers in Parkinson's disease|10.2217/bmm-2019-0364
Molecular Signatures of Neuroinflammation Induced by αSynuclein Aggregates in Microglial Cells|10.3389/fimmu.2020.00033
Subcortical Intermittent Theta-Burst Stimulation (iTBS) Increases Theta-Power in Dorsolateral Prefrontal Cortex (DLPFC)|10.3389/fnins.2020.00041
Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?|10.1016/j.parkreldis.2020.01.017
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies|10.1186/s40478-020-0879-z
Relationship of Movement Disorders Society–Unified Parkinson's Disease Rating Scale Nonmotor Symptoms to Cognitive Functioning in Patients with Parkinson's Disease|10.1002/mdc3.12902
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease|10.1007/s00401-020-02126-w
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts|10.3233/jpd-191786
Exercise Reverses Dysregulation of T-Cell-Related Function in Blood Leukocytes of Patients With Parkinson's Disease|10.3389/fneur.2019.01389
Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset|10.1016/j.ejphar.2020.172957
Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease|10.1016/j.parkreldis.2020.01.009
Fine‐Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies|10.1002/ana.25687
Improvement of classification performance of Parkinson’s disease using shape features for machine learning on dopamine transporter single photon emission computed tomography|10.1371/journal.pone.0228289
LRRK2 in Parkinson disease: challenges of clinical trials|10.1038/s41582-019-0301-2
Brain Damage With Heart Failure|10.1161/circresaha.119.315813
Impaired Saccade Adaptation in Tremor-Dominant Cervical Dystonia—Evidence for Maladaptive Cerebellum|10.1007/s12311-020-01104-y
PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression|10.1002/mds.27963
Characterization of a Parkinson’s disease rat model using an upgraded paraquat exposure paradigm|10.1111/ejn.14683
Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease|10.3390/molecules25030453
Prognostic factors of Rapid symptoms progression in patients with newly diagnosed parkinson’s disease|10.1016/j.artmed.2020.101807
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson’s disease|10.1093/brain/awaa020
Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score|10.1002/mds.27974
Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau|10.1093/brain/awaa021
White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study|10.1016/j.pnpbp.2020.109871
Clinical and Neuropathological Features Associated With Loss of RAB39B|10.1002/mds.27951
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease|10.3233/jpd-191841
Gait characterization for patients with orthostatic tremor|10.1016/j.parkreldis.2020.01.007
mHealth and wearable technology should replace motor diaries to track motor fluctuations in Parkinson’s disease|10.1038/s41746-019-0214-x
Network Analysis for Complex Neurodegenerative Diseases|10.1007/s40142-020-00181-z
Utilization Behavior Associated with Communicating Hydrocephalus with Resolution Post–Ventriculoperitoneal Shunting|10.1002/mdc3.12898
Falls Risk in Relation to Activity Exposure in High-Risk Older Adults|10.1093/gerona/glaa007
Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person|10.3233/jpd-191808
Tactile and proprioceptive dysfunction differentiates cervical dystonia with and without tremor|10.1212/wnl.0000000000008916
A pooled meta-analysis of GPi and STN deep brain stimulation outcomes for cervical dystonia|10.1007/s00415-020-09703-9
The highly selective mGlu2 receptor positive allosteric modulator LY‐487,379 alleviates l‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease|10.1111/ejn.14679
CLU rs11136000 Promotes Early Cognitive Decline in Parkinson's Disease|10.1002/mds.27949
Endothelial Immune Activation by Medin: Potential Role in Cerebrovascular Disease and Reversal by Monosialoganglioside‐Containing Nanoliposomes|10.1161/jaha.119.014810
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults|10.1001/jamaneurol.2019.4565
A simple, versatile and robust centrifugation‐based filtration protocol for the isolation and quantification of α‐synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α‐synuclein research|10.1111/jnc.14955
Co-Existence of tau and α-synuclein pathology in fetal graft tissue at autopsy: A case report|10.1016/j.parkreldis.2019.12.013
Linear Ubiquitin Chains: Cellular Functions and Strategies for Detection and Quantification|10.3389/fchem.2019.00915
Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study|10.1007/s40266-019-00740-2
Impact of Overweight and Obesity on Functional and Clinical Outcomes of Early Parkinson's Disease|10.1016/j.jamda.2019.11.019
Striatum Shape Hypertrophy in Early Stage Parkinson’s Disease With Excessive Daytime Sleepiness|10.3389/fnins.2019.01353
A Wilted Flower: Lotus Position Dystonia|10.1002/mdc3.12886
Emerging regenerative medicine and tissue engineering strategies for Parkinson’s disease|10.1038/s41531-019-0105-5
Perspectives on Deep Brain Stimulation and Its Earlier Use for Parkinson’s Disease: A Qualitative Study of US Patients|10.3390/brainsci10010034
Reversible orolingual dyskinesia in a case of juvenile onset psychosis and cognitive decline: Expert commentary|10.1016/j.parkreldis.2019.12.015
Diagnostic experience reported by caregivers of patients with frontotemporal degeneration|10.1212/cpj.0000000000000738
Disease severity and quality of life in homebound people with advanced Parkinson disease|10.1212/cpj.0000000000000716
Neurodegeneration in Narcolepsy‐Associated Rapid Eye Movement Sleep Behavior Disorder|10.1002/mdc3.12895
Norovirus infection results in eIF2α independent host translation shut-off and remodels the G3BP1 interactome evading stress granule formation.|10.17863/cam.48874
Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease|10.1212/cpj.0000000000000702
Structure–Functional–Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands|10.1021/acsmedchemlett.9b00575
Symptom burden among individuals with Parkinson disease|10.1212/cpj.0000000000000746
The New Freezing of Gait Questionnaire: Unsuitable as an Outcome in Clinical Trials?|10.1002/mdc3.12893
Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants|10.1212/cpj.0000000000000680
Deregulated Automatic Generation Control using Novel Opposition-based Interactive Search Algorithm Cascade Controller Including Distributed Generation and Electric Vehicle|10.1007/s40998-019-00306-3
Developing Quantitative Skills Using HHMI BioInteractive Resources|10.25334/gw48-xb61
NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy|10.1073/pnas.1909110117
Parkinson’s disease: proteinopathy or lipidopathy?|10.1038/s41531-019-0103-7
Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA|10.1073/pnas.1905057117
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease|10.1186/s13195-019-0574-0
Structural brain correlates of irritability and aggression in early manifest Huntington’s disease|10.1007/s11682-019-00237-x
18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies|10.1093/braincomms/fcaa040
Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration|10.1002/alz.12001
ACValidator: A novel assembly-based approach for in silico verification of circular RNAs|10.1093/biomethods/bpaa010
Analysis of α-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies|10.1093/braincomms/fcaa010
Automatic Parkinson disease detection at early stages as a pre-diagnosis tool by using classifiers and a small set of vocal features|10.1016/j.bbe.2020.01.003
Autophagy in hepatic adaptation to stress|10.1016/j.jhep.2019.08.026
Brain Atrophy Following Deep Brain Stimulation: Management of a Moving Target|10.5334/tohm.546
Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease|10.1093/braincomms/fcaa004
Cerebrovascular medin is associated with Alzheimer's disease and vascular dementia|10.1002/dad2.12072
Clinical Phenotype of <b><i>LRRK2</i></b> R1441C in 2 Chinese Sisters|10.1159/000508131
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020|10.14283/jpad.2020.58
Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort|10.1002/alz.12046
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia|10.5334/tohm.585
Delayed Diagnoses of SGCE Myoclonus-Dystonia|10.5334/tohm.334
Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients|10.1016/j.prdoa.2020.100042
Differential effects of deep brain stimulation and levodopa on brain activity in Parkinson’s disease|10.1093/braincomms/fcaa005
Dissociative Tremor Response with Pallidal Deep Brain Stimulation in Parkinson’s Disease|10.5334/tohm.568
Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson’s disease|10.1016/j.nicl.2020.102362
Electro-Myo-Stimulation Induced Tic Exacerbation – Increased Tendencies for the Formation of Perception-Action Links in Tourette Syndrome|10.5334/tohm.547
Extending the Spectrum of Nonmotor Symptoms with Olfaction in Premotor Huntington’s Disease: A Pilot Study|10.1159/000518136
Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes|10.21769/bioprotoc.3572
Frontostriatal Structural Connectivity and Striatal Glutamatergic Levels in Treatment-Resistant Schizophrenia: An Integrative Analysis of DTI and 1H-MRS|10.1093/schizbullopen/sgaa057
Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases|10.1002/alz.12011
Herpesvirus Infections and Risk of Parkinson’s Disease|10.1159/000512874
Identification of a nanomolar affinity α-synuclein fibril imaging probe by ultra-high throughput in silico screening|10.1039/d0sc02159h
Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease|10.1016/j.nicl.2020.102391
Instrumental Analysis of Gait Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorder|10.1002/mds.27938
Las narrativas expandidas a través del product placement inverso: el caso de las zapatillas NikeMAG|10.6035/2174-0992.2020.19.11
Late Upper Palaeolithic hunter-gatherers in the Central Mediterranean: New archaeological and genetic data from the Late Epigravettian burial Oriente C (Favignana, Sicily)|10.1016/j.quaint.2020.01.025
Machine learning methods for optimal prediction of motor outcome in Parkinson’s disease|10.1016/j.ejmp.2019.12.022
Mapping typical and hypokinetic dysarthric speech production network using a connected speech paradigm in functional MRI|10.1016/j.nicl.2020.102285
Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development|10.1007/s43441-019-00034-0
Mnemonic Similarity Task to study episodic memory in Parkinson's disease|10.1016/j.prdoa.2020.100062
Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out|10.1093/braincomms/fcz052
O-GlcNAcylation inhibits the oligomerization of alpha-synuclein by declining intermolecular hydrogen bonds through a steric effect|10.1088/1478-3975/abb6dc
Origins of atrophy in Parkinson linked to early onset and local transcription patterns|10.1093/braincomms/fcaa065
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls|10.14336/ad.2019.0805
Pathogenic Pathways in Early-Onset Autosomal Recessive Parkinson's Disease Discovered Using Isogenic Human Dopaminergic Neurons|10.1016/j.stemcr.2019.12.005
PDmethDB: A curated Parkinson’s disease associated methylation information database|10.1016/j.csbj.2020.11.015
Personalized care management for persons with Parkinson's disease: A telenursing solution|10.1016/j.prdoa.2020.100070
Prevalence of REM sleep behavior disorder in Sun City, Arizona|10.1016/j.heliyon.2019.e03140
Pyk2 overexpression in postsynaptic neurons blocks amyloid β1–42-induced synaptotoxicity in microfluidic co-cultures|10.1093/braincomms/fcaa139
Quality of life outcomes after deep brain stimulation in dystonia: A systematic review|10.1016/j.parkreldis.2019.11.016
Remote cognitive and behavioral assessment: Report of the Alzheimer Society of Canada Task Force on dementia care best practices for COVID‐19|10.1002/dad2.12111
Reply to: “Predictors of Motor Complications in Early Parkinson's Disease”|10.1002/mds.27904
Status Dystonicus, Oculogyric Crisis and Paroxysmal Dyskinesia in a 25 Year-Old Woman with a Novel KCNMA1 Variant, K457E|10.5334/tohm.549
Striatal shape alteration as a staging biomarker for Parkinson’s Disease|10.1016/j.nicl.2020.102272
Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease: Valuable Programming Insights from Anecdotal Observations|10.1159/000505701
Synthesis and characterization of high affinity fluorogenic α-synuclein probes|10.1039/c9cc09849f
The dance of the nanobubbles: detecting acoustic backscatter from sub-micron bubbles using ultra-high frequency acoustic microscopy|10.1039/d0nr05390b
The Parkinson’s Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures|10.1093/braincomms/fcaa046
ThX – a next-generation probe for the early detection of amyloid aggregates|10.1039/c9sc04730a
Transdifferentiation of Mouse Embryonic Fibroblasts into Dopaminergic Neurons Reactivates LINE-1 Repetitive Elements|10.1016/j.stemcr.2019.12.002
Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease|10.1039/c9em00578a
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium|10.1002/alz.12033
Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale|10.1159/000507827
Клеточная заместительная терапия при болезни Паркинсона – история развития и перспективы использования в клинической практике|10.31857/s0026898420060063
Clinical Trial Highlights – Infusion Therapies|10.3233/jpd-199005
Participation and consultation engagement strategies have complementary roles: A case study of patient and public involvement in clinical practice guideline development|10.1111/hex.13018
Unique white matter structural connectivity in early-stage drug-naive Parkinson disease|10.1212/wnl.0000000000008867
Characterization of AN6001, a positive allosteric modulator of α6β2-containing nicotinic acetylcholine receptors|10.1016/j.bcp.2019.113788
The Effects of Music-Contingent Gait Training on Cognition and Mood in Parkinson Disease: A Feasibility Study|10.1177/1545968319893303
Treatment Stratification of Patients with Metastatic Castration-Resistant Prostate Cancer by Machine Learning|10.1016/j.isci.2019.100804
Deubiquitinase USP29 Governs MYBBP1A in the Brains of Parkinson’s Disease Patients|10.3390/jcm9010052
Dyskinesia Matters|10.1002/mds.27959
Metabolic Network Abnormalities in Drug‐Naïve Parkinson's Disease|10.1002/mds.27960
Multimodal Balance Training Supported by Rhythmical Auditory Stimuli in Parkinson’s Disease: A Randomized Clinical Trial|10.3233/jpd-191752
The “Long and Winding Road” of the Disease‐Modifying Effects of Levodopa Has Not Ended Yet|10.1002/mds.27961
A Longitudinal Wearable Sensor Study in Huntington’s Disease|10.3233/jhd-190375
Screening of the glucocerebrosidase (GBA) gene in South Africans of African ancestry with Parkinson's disease|10.1016/j.neurobiolaging.2019.12.011
Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis|10.1016/j.parkreldis.2019.11.023
Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease|10.1212/wnl.0000000000008677
Brain MRI Reveals Ascending Atrophy in Parkinson's Disease Across Severity|10.3389/fneur.2019.01329
Integrated Therapy for Functional Movement Disorders: Time for a Change|10.1002/mdc3.12888
Predict cognitive decline with clinical markers in Parkinson’s disease (PRECODE-1)|10.1007/s00702-019-02125-6
The misallocation of climate research funding|10.1016/j.erss.2019.101349
Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models|10.1172/jci130819
Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease|10.1007/s10286-019-00652-6
Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study|10.1136/jnnp-2019-321794
Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain|10.1038/s41593-019-0556-3
Effects of menopause on sleep quality and sleep disorders: Canadian Longitudinal Study on Aging|10.1097/gme.0000000000001462
Excessive daytime sleepiness is associated to the development of swallowing impairment in a cohort of early stage drug naïve Parkinson's disease patients|10.1016/j.jns.2019.116626
Freezing of Gait and Its Levodopa Paradox|10.1001/jamaneurol.2019.4006
Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study|10.1038/s41386-019-0589-z
The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease|10.1001/jamaneurol.2019.3983
Movement disorders in 2019: from antibodies to lifestyle interventions|10.1016/s1474-4422(19)30438-7
Multiple sclerosis in 2019: predicting progression|10.1016/s1474-4422(19)30441-7
A cornerstone initiative for progress in Parkinson's disease|10.1016/s1474-4422(19)30432-6
Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review|10.1002/mdc3.12874
Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study|10.1016/j.parkreldis.2019.12.008
Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease|10.1038/s41586-019-1828-5
PINK1 phosphorylates ubiquitin predominantly in astrocytes|10.1038/s41531-019-0101-9
Sex Differences in Cognitive Changes in De Novo Parkinson’s Disease|10.1017/s1355617719001085
The Role of the Cerebellum in Degenerative Ataxias and Essential Tremor: Insights From Noninvasive Modulation of Cerebellar Activity|10.1002/mds.27919
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study|10.1016/s1474-4422(19)30396-5
Experience and Impact of OFF Periods in Parkinson’s Disease: A Survey of Physicians, Patients, and Carepartners|10.3233/jpd-191785
Ten Years of the International Parkinson Disease Genomics Consortium: Progress and Next Steps|10.3233/jpd-191854
LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients|10.1038/s41467-019-13413-w
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease|10.3389/fnmol.2019.00299
Cerebellar Deep Brain Stimulation for Acquired Hemidystonia|10.1002/mdc3.12876
Circulating Brain‐Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease|10.1002/mds.27928
Effectiveness of Physiotherapy on Freezing of Gait in Parkinson's Disease: A Systematic Review and Meta‐Analyses|10.1002/mds.27936
Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration|10.1096/fj.201900567rr
Suicidal risk and demoralization in Parkinson disease|10.1007/s00415-019-09632-2
Differences in topological progression profile among neurodegenerative diseases from imaging data|10.7554/elife.49298
Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease|10.1212/wnl.0000000000008699
Short latency cortical evoked potentials elicited by subthalamic nucleus deep brain stimulation: Commentary and results from paired pulse studies|10.1016/j.clinph.2019.11.015
Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study|10.1016/j.nicl.2019.102112
DNA methylome study of human cerebellar tissues identified genes and pathways possibly involved in essential tremor|10.1093/pcmedi/pbz028
Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation|10.1186/s12974-019-1652-8
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies|10.1016/s1474-4422(19)30320-5
Immunotherapy in Parkinson’s disease: Current status and future directions|10.1016/j.nbd.2019.104587
Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice|10.1186/s12974-019-1636-8
Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing|10.1186/s40478-019-0873-5
Nonlinear Z‐score modeling for improved detection of cognitive abnormality|10.1016/j.dadm.2019.08.003
Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates|10.1186/s40478-019-0865-5
Parkinson's disease‐associated dyskinesia in countries with low access to levodopa‐sparing regimens|10.1002/mds.27891
Characterization of age-related microstructural changes in locus coeruleus and substantia nigra pars compacta|10.1016/j.neurobiolaging.2019.11.016
Enhancement of glycolysis: A Potential Disease‐Modifying Strategy for Parkinson's Disease|10.1002/mds.27934
Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease|10.1136/jmedgenet-2019-106283
Predicting severity and prognosis in Parkinson's disease from brain microstructure and connectivity|10.1016/j.nicl.2019.102111
Cervical Dystonia Incidence and Diagnostic Delay in a Multiethnic Population|10.1002/mds.27927
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration|10.1016/j.jalz.2019.08.196
Increased Dynamics of α-Synuclein Fibrils by β-Synuclein Leads to Reduced Seeding and Cytotoxicity|10.1038/s41598-019-54063-8
Adherence and Efficacy of Olfactory Training as a Treatment for Persistent Olfactory Loss|10.1177/1945892419887895
Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease|10.1016/j.parkreldis.2019.11.020
Parkinson’s disease prognostic scores for progression of cognitive decline|10.1038/s41598-019-54029-w
Leucine‐rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease|10.1111/jnc.14908
Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells|10.1155/2019/4246350
Texture Features of Magnetic Resonance Images: A Marker of Slight Cognitive Deficits in Parkinson's Disease|10.1002/mds.27931
Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications|10.1002/mds.27892
Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation|10.1371/journal.pbio.3000495
Exosome/microvesicle content is altered in leucine‐rich repeat kinase 2 mutant induced pluripotent stem cell‐derived neural cells|10.1002/cne.24819
α‐Synuclein in blood cells differentiates Parkinson’s disease from healthy controls|10.1002/acn3.50944
Patient and caregiver characteristics associated with caregiver burden in Parkinson’s disease: a palliative care approach|10.21037/apm.2019.10.01
Apathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive decline|10.1212/wnl.0000000000008683
Safety and efficacy of superior turbinate biopsies as a source of olfactory epithelium appropriate for morphological analysis|10.1007/s00405-019-05728-7
Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease|10.1002/mdc3.12870
Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder|10.1111/ene.14127
No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease|10.1016/j.neurobiolaging.2019.11.006
Differentiation of multiple system atrophy from Parkinson’s disease by structural connectivity derived from probabilistic tractography|10.1038/s41598-019-52829-8
Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine|10.1002/mdc3.12851
Motor Complications in Parkinson's Disease: 13‐Year Follow‐up of the CamPaIGN Cohort|10.1002/mds.27882
Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies|10.1016/j.parkreldis.2019.11.009
A functionalized hydroxydopamine quinone links thiol modification to neuronal cell death|10.1016/j.redox.2019.101377
Interactive effects of age and recent substance use on striatal shape morphology at substance use disorder treatment entry|10.1016/j.drugalcdep.2019.107728
Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease|10.1016/j.parkreldis.2019.11.006
Parkinson’s Disease–Mild Cognitive Impairment (PD-MCI): A Useful Summary of Update Knowledge|10.3389/fnagi.2019.00303
The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study|10.1007/s00259-019-04550-x
Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer|10.1158/1078-0432.ccr-19-1376
The good and bad of therapeutic strategies that directly target α‐synuclein|10.1002/iub.2194
Aggressiveness after centromedian nucleus stimulation engages prefrontal thalamocortical circuitry|10.1016/j.brs.2019.10.023
Epidural Spinal Cord Stimulation Improves Motor Function in Rats With Chemically Induced Parkinsonism|10.1177/1545968319876891
Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists|10.1038/s41436-019-0684-x
Hsp110 mitigates α-synuclein pathology in vivo|10.1073/pnas.1903268116
Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload|10.1038/s41418-019-0442-2
Perception of whole-body motion during balance perturbations is impaired in Parkinson's disease and is associated with balance impairment|10.1016/j.gaitpost.2019.10.029
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study|10.1016/s1474-4422(19)30319-9
Increased striatal dopamine in carriers of GBA mutations: compensation or epiphenomenon?|10.1016/s1474-4422(19)30355-2
A Systems-Based Map of Human Brain Cell-Type Enriched Genes and Malignancy-Associated Endothelial Changes|10.1016/j.celrep.2019.09.088
Deep learning for clustering of multivariate clinical patient trajectories with missing values|10.1093/gigascience/giz134
Integrated proteogenetic analysis reveals the landscape of a mitochondrial-autophagosome synapse during PARK2-dependent mitophagy|10.1126/sciadv.aay4624
Static magnetic field stimulation of the supplementary motor area modulates resting-state activity and motor behavior|10.1038/s42003-019-0643-8
Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson’s Disease|10.3389/fphar.2019.01294
Knowledge and attitudes of Parkinson’s disease risk in the Gaucher population|10.1002/jgc4.1185
Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles|10.1002/mds.27884
PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins|10.7554/elife.50416
Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases|10.1002/mds.27867
The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population‐Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight|10.1002/mds.27864
Distinct tau PET patterns in atrophy‐defined subtypes of Alzheimer's disease|10.1016/j.jalz.2019.08.201
Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies|10.1002/ana.25629
Gender Differences in Functional Movement Disorders|10.1002/mdc3.12864
Autophagic- and Lysosomal-Related Biomarkers for Parkinson’s Disease: Lights and Shadows|10.3390/cells8111317
Driving genotype treatment options down the right path(way)|10.1002/mds.27893
Freezing of gait: understanding the complexity of an enigmatic phenomenon|10.1093/brain/awz314
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures|10.1016/j.jalz.2019.06.4956
Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia|10.1093/brain/awz350
A turn for the worse: Turning performance in Parkinson's disease and Essential tremor|10.1016/j.clinbiomech.2019.09.008
Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease|10.1016/j.parkreldis.2019.10.022
Technology-Enabled Clinical Trials|10.1161/circulationaha.119.040798
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis|10.1007/s00259-019-04533-y
Genetic architecture of subcortical brain structures in 38,851 individuals|10.1038/s41588-019-0511-y
A novel approach to study markers of dopamine signaling in peripheral immune cells|10.1016/j.jim.2019.112686
Status dystonicus induced by deep brain stimulation surgery|10.1007/s10072-019-04083-z
Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases|10.1083/jcb.201902184
Neuropsychological Test Performances and Depression in Early-Stage De Novo Parkinson’s Disease|10.1093/arclin/acz067
A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease|10.1126/scitranslmed.aau6870
Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation|10.1016/j.nbd.2019.104623
Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence|10.1016/j.jns.2019.116523
Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?|10.1016/j.parkreldis.2019.10.012
Is Pallido‐Pyramidal Syndrome Still a Useful Concept? No|10.1002/mdc3.12843
LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease|10.1016/j.nbd.2019.104626
Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?|10.1016/j.ymgme.2019.10.001
Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRI|10.3171/2019.6.jns19548
Therapeutic approaches to cholinergic deficiency in Lewy body diseases|10.1080/14737175.2020.1676152
Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy|10.1371/journal.pone.0223621
Stabilization of α-synuclein oligomers using formaldehyde|10.1371/journal.pone.0216764
ToolBox: Live Imaging of intracellular organelle transport in induced pluripotent stem cell‐derived neurons|10.1111/tra.12701
ARSA variants in α-synucleinopathies|10.1093/brain/awz340
A combined miRNA–piRNA signature to detect Alzheimer’s disease|10.1038/s41398-019-0579-2
Feasibility of repeat and bilateral submandibular gland needle biopsies in Parkinson's disease|10.1016/j.parkreldis.2019.10.006
Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research|10.1159/000502951
The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease|10.1038/s41418-019-0408-4
Bundled Three-Dimensional Human Axon Tracts Derived from Brain Organoids|10.1016/j.isci.2019.10.004
Diagnosis of Parkinson’s Disease at an Early Stage Using Volume Rendering SPECT Image Slices|10.1007/s13369-019-04152-7
Hiding in Plain Sight: Functional Neurological Disorders in the News|10.1176/appi.neuropsych.19010025
Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose|10.1016/j.jpba.2019.07.014
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment|10.1016/j.parkreldis.2019.06.025
Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker|10.1016/j.parkreldis.2019.09.031
The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects|10.1016/j.neuint.2019.104495
β-catenin aggregation in models of ALS motor neurons: GSK3β inhibition effect and neuronal differentiation|10.1016/j.nbd.2019.104497
Short Versus Conventional Pulse‐Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison|10.1002/mds.27863
Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies|10.1002/mds.27872
Visual Sensory Processing is Altered in Myoclonus Dystonia|10.1002/mds.27857
Temporal discrimination threshold and blink reflex recovery cycle in cervical dystonia – two sides of the same coin?|10.1016/j.parkreldis.2019.09.028
Assessing cancer center researcher and provider perspectives on patient engagement|10.1093/tbm/ibz132
Introduction of Network-Based Healthcare at Kaiser Permanente|10.3233/jpd-191620
Miro1 Marks Parkinson’s Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson’s Models|10.1016/j.cmet.2019.08.023
Apoptosis signal regulating kinase 1 deletion mitigates α-synuclein pre-formed fibril propagation in mice|10.1016/j.neurobiolaging.2019.09.012
Feasibility and utility of a clinician dashboard from wearable and mobile application Parkinson’s disease data|10.1038/s41746-019-0169-y
Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial|10.1016/j.parkreldis.2019.09.026
Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs|10.1002/cpt.1634
Quadruple Decision Making for Parkinson’s Disease Patients: Combining Expert Opinion, Patient Preferences, Scientific Evidence, and Big Data Approaches to Reach Precision Medicine|10.3233/jpd-191712
How to evaluate effects of occupational therapy – lessons learned from an exploratory randomized controlled trial|10.1016/j.parkreldis.2019.09.013
Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment|10.1002/hbm.24782
mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells|10.1242/dmm.038596
Microscopic Viscosity of Neuronal Plasma Membranes Measured Using Fluorescent Molecular Rotors: Effects of Oxidative Stress and Neuroprotection|10.1021/acsami.9b10426
Proceedings of the Sixth Deep Brain Stimulation Think Tank Modulation of Brain Networks and Application of Advanced Neuroimaging, Neurophysiology, and Optogenetics|10.3389/fnins.2019.00936
Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts|10.1002/mds.27845
Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development|10.1002/mds.27818
Transportation innovation to aid Parkinson disease trial recruitment|10.1016/j.conctc.2019.100449
Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes|10.1093/brain/awz296
PDkit|10.1145/3341162.3346277
The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain|10.1016/j.expneurol.2019.113062
Contrast Acuity With Different Colors in Parkinson's Disease|10.1002/mdc3.12821
Deep brain stimulation and genetic variability in Parkinson’s disease: a review of the literature|10.1038/s41531-019-0091-7
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial|10.1212/wnl.0000000000008194
Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging|10.1093/jnen/nlz080
Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?|10.1002/mds.27823
Understanding the Links Between Cardiovascular Disease and Parkinson's Disease|10.1002/mds.27836
What’s the target: understanding two decades of in silico microRNA-target prediction|10.1093/bib/bbz111
Characterization of the Basic Membrane Properties of Neurons of the Rat Dorsal Motor Nucleus of the Vagus in Paraquat-Induced Models of Parkinsonism|10.1016/j.neuroscience.2019.08.048
Intracellular crowding by age-dependent neuromelanin accumulation disrupts neuronal proteostasis and triggers Parkinson disease pathology|10.1080/15548627.2019.1659621
Harnessing ionic mechanisms to achieve disease modification in neurodegenerative disorders|10.1016/j.phrs.2019.104343
Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability|10.1016/j.parkreldis.2019.07.010
Recent developments in drug-induced movement disorders: a mixed picture|10.1016/s1474-4422(19)30152-8
Small Molecules to Improve ER Proteostasis in Disease|10.1016/j.tips.2019.07.003
The Neuropsychiatry of Parkinson Disease: A Perfect Storm|10.1016/j.jagp.2019.03.002
Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium|10.1016/j.jalz.2019.05.013
Bilateral subthalamic nucleus deep brain stimulation increases fixational saccades during movement preparation: evidence for impaired preparatory set|10.1007/s00221-019-05636-6
Role of striatal ΔFosB in l -Dopa–induced dyskinesias of parkinsonian nonhuman primates|10.1073/pnas.1907810116
Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology|10.1016/j.ymthe.2019.08.010
The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion|10.1007/s00401-019-02066-0
Alterations in Blood Monocyte Functions in Parkinson's Disease|10.1002/mds.27815
Home‐Based Monitoring of Falls Using Wearable Sensors in Parkinson's Disease|10.1002/mds.27830
MR‐based age‐related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan|10.1002/hbm.24771
Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson’s disease|10.1007/s10286-019-00632-w
Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures|10.3233/jpd-181518
Effects of Verbal Cueing on Respiratory-Swallow Patterning, Lung Volume Initiation, and Swallow Apnea Duration in Parkinson’s Disease|10.1007/s00455-019-10050-9
Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay|10.3389/fnins.2019.00889
Communication About OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners|10.3389/fneur.2019.00892
Influence of Striatal Dopamine, Cerebral Small Vessel Disease, and Other Risk Factors on Age-Related Parkinsonian Motor Signs|10.1093/gerona/glz161
Do longitudinal cerebrospinal fluid profiles correspond to postmortem brain pathology in LRRK 2 Parkinson's disease?|10.1111/ene.14060
Factors in the disease severity of ATP1A3 mutations: Impairment, misfolding, and allele competition|10.1016/j.nbd.2019.104577
Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease|10.1186/s13024-019-0335-3
Synthesis of Densely Functionalized N-Alkenyl 2-Pyridones via Benzyne-Induced Ring Opening of Thiazolino-Fused 2-Pyridones|10.1021/acs.orglett.9b02549
Dystonia as complication of thalamic neurosurgery|10.1016/j.parkreldis.2019.08.008
The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson’s Disease|10.1080/13825585.2019.1653445
The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk|10.1126/scitranslmed.aau2291
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells|10.1038/s41598-019-47352-9
Microstructural White Matter Characteristics in Parkinson's Disease With Depression: A Diffusion Tensor Imaging Replication Study|10.3389/fneur.2019.00884
Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy|10.1016/j.jaip.2019.07.040
Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management|10.1021/acssensors.9b01127
Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy|10.1186/s40035-019-0164-x
Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease|10.1016/j.parkreldis.2019.08.003
Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: an in vivo11C-BU99008 PET study|10.1093/brain/awz260
Hypertension and progressive supranuclear palsy|10.1016/j.parkreldis.2019.07.036
CONTRIBUTORS|10.1212/01.con.0000578728.22103.71
Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson’s disease|10.1016/j.neubiorev.2019.05.016
Quantitative mobility metrics from a wearable sensor predict incident parkinsonism in older adults|10.1016/j.parkreldis.2019.06.012
Roles for the adaptive immune system in Parkinson’s and Alzheimer’s diseases|10.1016/j.coi.2019.07.004
Vesicular degradation pathways in neurons: at the crossroads of autophagy and endo-lysosomal degradation|10.1016/j.conb.2019.01.005
Young-onset Parkinson's disease: Its unique features and their impact on quality of life|10.1016/j.parkreldis.2019.06.001
Deep Learning With EEG Spectrograms in Rapid Eye Movement Behavior Disorder|10.3389/fneur.2019.00806
Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease|10.1002/mds.27806
Phosphorylation of Ser111 in Rab8a Modulates Rabin8-Dependent Activation by Perturbation of Side Chain Interaction Networks|10.1021/acs.biochem.9b00516
Sleep Disturbance as Potential Risk and Progression Factor for Parkinson’s Disease|10.3233/jpd-191627
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease|10.3233/jpd-191648
Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls|10.1002/mds.27807
Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism|10.1016/j.neuropharm.2019.107725
Depressive symptoms precede cognitive impairment in de novo Parkinson’s disease patients: Analysis of the PPMI cohort.|10.1037/neu0000583
Orthostatic hypotension as a risk factor for longitudinal deterioration of cognitive function in the elderly|10.1111/ene.14050
Parkinson’s progression prediction using machine learning and serum cytokines|10.1038/s41531-019-0086-4
Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis|10.1038/s41593-019-0457-5
Deep brain stimulation induced normalization of the human functional connectome in Parkinson’s disease|10.1093/brain/awz239
The Michael J. Fox Foundation for Parkinson’s Research Strategy to Advance Therapeutic Development of PINK1 and Parkin|10.3390/biom9080296
The value of cerebrospinal fluid α‐synuclein and the tau/α‐synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology|10.1111/ene.14032
Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm|10.1038/s41388-019-0895-2
Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer’s disease|10.1038/s41380-019-0458-5
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease|10.1186/s12974-019-1532-2
REM sleep behavior disorder predicts functional dependency in early Parkinson's disease|10.1016/j.parkreldis.2019.07.025
NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drug‐inducible neuroprotection from oxidative stress|10.1096/fj.201900830r
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease|10.1186/s12883-019-1394-3
miR-34a as hub of T cell regulation networks|10.1186/s40425-019-0670-5
Hallucinations, somatic‐functional disorders of PD‐DLB as expressions of thalamic dysfunction|10.1002/mds.27781
Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice|10.1172/jci.insight.126769
Genetic risk of Parkinson disease and progression:|10.1212/nxg.0000000000000348
Measuring Parkinson's disease over time: The real‐world within‐subject reliability of the MDS‐UPDRS|10.1002/mds.27790
The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain|10.1073/pnas.1900289116
Spreading of alpha‐synuclein – relevant or epiphenomenon?|10.1111/jnc.14779
Phosphorylation in two discrete tau domains regulates a stepwise process leading to postsynaptic dysfunction|10.1113/jp277459
Progressive brain atrophy in Parkinson's disease patients who convert to mild cognitive impairment|10.1111/cns.13188
Altered dynamics of visual contextual interactions in Parkinson’s disease|10.1038/s41531-019-0085-5
Regional transcriptional architecture of Parkinson’s disease pathogenesis and network spread|10.1093/brain/awz223
Common BACE2 Polymorphisms are Associated with Altered Risk for Alzheimer’s Disease and CSF Amyloid Biomarkers in APOE ε4 Non-Carriers|10.1038/s41598-019-45896-4
HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors|10.1097/pgp.0000000000000620
Parkinson's Disease Detection Using Isosurfaces-Based Features and Convolutional Neural Networks|10.3389/fninf.2019.00048
Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils|10.1016/j.nbd.2019.104525
An artificial neural network model for clinical score prediction in Alzheimer disease using structural neuroimaging measures|10.1503/jpn.180016
An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele|10.1016/j.nbd.2019.02.023
Gait impairments in Parkinson's disease|10.1016/s1474-4422(19)30044-4
Importance of the initial response to GPi deep brain stimulation in dystonia: A nine year quality of life study|10.1016/j.parkreldis.2019.04.024
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration|10.1016/j.jalz.2019.04.007
Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding|
Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease|10.1016/j.jns.2019.05.009
Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond|10.1007/s00018-019-03203-4
Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease|10.1002/mds.27776
Optimized machine learning methods for prediction of cognitive outcome in Parkinson's disease|10.1016/j.compbiomed.2019.103347
[11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers|10.1007/s00259-019-04369-6
MAPT p.V363I mutation|10.1212/nxg.0000000000000347
Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease|10.1371/journal.pone.0217566
SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease|10.1002/mds.27770
Motor phenotype classification in moderate to advanced PD in BioFIND study|10.1016/j.parkreldis.2019.06.017
Quantitative magnetization transfer imaging of the human locus coeruleus|10.1016/j.neuroimage.2019.06.049
Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson’s disease.|10.1037/neu0000577
High-accuracy Automated Diagnosis of Parkinson's Disease|10.2174/1573405615666190620113607
Identification of N-linked glycans as specific mediators of neuronal uptake of acetylated α-Synuclein|10.1371/journal.pbio.3000318
Remote Monitoring of Treatment Response in Parkinson's Disease: The Habit of Typing on a Computer|10.1002/mds.27772
Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders|10.1002/mds.27740
Correlation analysis of [18F]ROStrace using ex vivo autoradiography and dihydroethidium fluorescent imaging in lipopolysaccharide-treated animals|10.1016/j.bbrc.2019.06.062
Reply to letter to the editor “Adaptive DBS in Parkinson's disease: Headlines, perspectives and challenges”|10.1016/j.brs.2019.06.014
New transgenic models of Parkinson's disease using genome editing technology|10.1016/j.nrleng.2017.08.006
New aspects of USP30 biology in the regulation of pexophagy|10.1080/15548627.2019.1615304
Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers|10.1016/j.parkreldis.2019.05.038
Consensus Paper: Experimental Neurostimulation of the Cerebellum|10.1007/s12311-019-01041-5
Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson’s disease patient fibroblasts|10.1093/hmg/ddz126
Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study|10.1016/j.parkreldis.2019.05.040
Harnessing digital technology to predict, diagnose, monitor, and develop treatments for brain disorders|10.1038/s41746-019-0123-z
Polymerization of Oxidized DJ-1 via Noncovalent and Covalent Binding: Significance of Disulfide Bond Formation|10.1021/acsomega.9b00324
Using global team science to identify genetic parkinson's disease worldwide|10.1002/ana.25514
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo|10.3791/59758-v
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo|10.3791/59758
A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia|10.1016/j.parkreldis.2019.02.035
Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression|10.1016/j.ebiom.2019.05.064
Illuminating G-Protein-Coupling Selectivity of GPCRs|10.1016/j.cell.2019.04.044
Management of Dysphagia in Acquired and Progressive Neurologic Conditions|10.1055/s-0039-1688981
Defining α-synuclein species responsible for Parkinson’s disease phenotypes in mice|10.1074/jbc.ra119.007743
End-of-life experiences in dementia with Lewy bodies: Qualitative interviews with former caregivers|10.1371/journal.pone.0217039
Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases|10.1002/mds.27728
The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration|10.1002/mds.27718
Deep brain stimulation has state-dependent effects on motor connectivity in Parkinson’s disease|10.1093/brain/awz164
Ultra‐low‐dose PET reconstruction using generative adversarial network with feature matching and task‐specific perceptual loss|10.1002/mp.13626
Joint-Connectivity-Based Sparse Canonical Correlation Analysis of Imaging Genetics for Detecting Biomarkers of Parkinson’s Disease|10.1109/tmi.2019.2918839
One Step Into the Future: New iPSC Tools to Advance Research in Parkinson’s Disease and Neurological Disorders|10.3233/jpd-181515
Gait and postural disorders in parkinsonism: a clinical approach|10.1007/s00415-019-09382-1
Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset|10.1038/s41531-019-0080-x
The neuro-toxin MPTP does not prevent reproduction in marmosets|10.12688/mniopenres.12818.2
Non-canonical function of IRE1α determines mitochondria-associated endoplasmic reticulum composition to control calcium transfer and bioenergetics|10.1038/s41556-019-0329-y
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease|10.1007/s00702-019-02015-x
GenePy - a score for estimating gene pathogenicity in individuals using next-generation sequencing data|10.1186/s12859-019-2877-3
Association between insomnia disorder and cognitive function in middle-aged and older adults: a cross-sectional analysis of the Canadian Longitudinal Study on Aging|10.1093/sleep/zsz114
Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils|10.1016/j.nbd.2019.05.012
L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression|10.1016/j.parkreldis.2019.05.022
Clinical phenotype in carriers of intermediate alleles in the huntingtin gene|10.1016/j.jns.2019.05.010
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH‐EXAMINER as a potential clinical trial endpoint|10.1016/j.jalz.2019.01.012
Clinical implications of early caudate dysfunction in Parkinson’s disease|10.1136/jnnp-2018-320157
Early‐onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation|10.1002/mds.27710
Identifying and ranking potential driver genes of Alzheimer’s disease using multiview evidence aggregation|10.1093/bioinformatics/btz365
Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding|10.1016/j.annepidem.2019.04.010
Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease|10.1016/j.parkreldis.2019.05.014
Spring is in the air: seasonal profiles indicate vernal change of miRNA activity|10.1080/15476286.2019.1612217
Cysteine oxidation and redox signaling in dopaminergic neurons physiology and in Parkinson’s disease|10.1016/j.cophys.2019.04.025
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort|10.1007/s00415-019-09348-3
The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss|10.1016/j.expneurol.2019.05.002
TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers|10.1186/s13024-019-0319-3
Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting|10.1186/s13550-019-0506-9
Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression|10.1038/s41531-019-0079-3
Clinical and methodological challenges for assessing freezing of gait: Future perspectives|10.1002/mds.27709
Increased Cortical Thickness in Attentional Networks in Parkinson’s Disease with Minor Hallucinations|10.1155/2019/5351749
Dopamine Receptor D3 Expression Is Altered in CD4+ T-Cells From Parkinson's Disease Patients and Its Pharmacologic Inhibition Attenuates the Motor Impairment in a Mouse Model|10.3389/fimmu.2019.00981
Endocytic iron trafficking and mitochondria in Parkinson’s disease|10.1016/j.biocel.2019.02.009
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)|10.1016/j.parkreldis.2018.12.025
Low Vitamin B12 and Parkinson Disease|10.1016/j.mayocp.2019.01.039
Resting-state fMRI in Parkinson's disease patients with cognitive impairment: A meta-analysis|10.1016/j.parkreldis.2018.12.016
Jumping to overcome freezing of gait while turning in Parkinson's disease|10.1016/j.parkreldis.2019.04.021
Head tremor at disease onset: an ataxic phenotype of cervical dystonia|10.1007/s00415-019-09341-w
The neuro-toxin MPTP does not prevent reproduction in marmosets|10.12688/mniopenres.12818.1
Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum|10.1016/j.neuroscience.2019.04.033
Phosphoregulation on mitochondria: Integration of cell and organelle responses|10.1111/cns.13141
Somatosensory-motor cortex interactions measured using dual-site transcranial magnetic stimulation|10.1016/j.brs.2019.04.009
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer|10.1177/0271678x19843776
Selective vulnerability in α-synucleinopathies|10.1007/s00401-019-02010-2
Barriers and facilitators of communication about off periods in Parkinson’s disease: Qualitative analysis of patient, carepartner, and physician Interviews|10.1371/journal.pone.0215384
Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson’s Disease Patients|10.1038/s41598-019-42535-w
eBrain: a Three Dimensional Simulation Tool to Study Drug Delivery in the Brain|10.1038/s41598-019-42261-3
White Matter Tract Alterations in Drug-Naïve Parkinson's Disease Patients With Excessive Daytime Sleepiness|10.3389/fneur.2019.00378
Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard|10.1021/acs.jproteome.8b00920
Improving patient‐centred care for persons with Parkinson's: Qualitative interviews with care partners about their engagement in discussions of “off” periods|10.1111/hex.12884
Linking vitamin B12 and a trembling disorder|10.1038/s41422-019-0166-3
Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): Initiation of a Long-Term Observational Study (P2.8-011)|
Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): Initiation of a Long-Term Observational Study (P2.8-011)|10.1212/wnl.92.15_supplement.p2.8-011
Automatic Scoring of Parkinson’s Disease Motor Symptoms Using a Smartwatch (P2.8-001)|
Automatic Scoring of Parkinson’s Disease Motor Symptoms Using a Smartwatch (P2.8-001)|10.1212/wnl.92.15_supplement.p2.8-001
Critical Path for Parkinson’s: Catalyzing Innovation for Parkinson’s Clinical Trials through Data Sharing and Regulatory Science (P2.8-010)|10.1212/wnl.92.15_supplement.p2.8-010
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma|10.1038/s41467-019-09633-9
Exploring the Experience of Wearing Off in Parkinson’s Disease: A Qualitative Research Approach (P5.8-050)|10.1212/wnl.92.15_supplement.p5.8-050
Intraoperative localization of spatially and spectrally distinct resting-state networks in Parkinson’s disease|10.3171/2018.11.jns181684
NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s Disease: Study Design and Status Update (P3.8-035)|10.1212/wnl.92.15_supplement.p3.8-035
Patient-Centered Clinical Trial Design: A Case Study in Parkinson’s Disease (P2.8-008)|10.1212/wnl.92.15_supplement.p2.8-008
Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants (P3.8-006)|10.1212/wnl.92.15_supplement.p3.8-006
Cognitive Performance in Parkinson’s Disease in the Brain Health Registry|10.3233/jad-181009
Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age|10.1038/s41467-019-09613-z
Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms|10.1002/mds.27659
Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study|10.1016/j.parkreldis.2019.03.025
Heritability and genetic variance of dementia with Lewy bodies|10.1016/j.nbd.2019.04.004
Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson’s Disease|10.1021/acs.jproteome.8b00982
Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers|10.3233/jad-190069
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System|10.1016/j.dadm.2019.01.011
The sncRNA Zoo: a repository for circulating small noncoding RNAs in animals|10.1093/nar/gkz227
Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease|10.1016/j.neuroimage.2018.01.021
Distinct Missense Mutations of the Parkinson's Disease‐Related Ubiquitin Kinase PINK1 Alter Auto‐ or Substrate‐Phosphorylation|10.1096/fasebj.2019.33.1_supplement.lb329
Episodic recognition memory and the hippocampus in Parkinson's disease: A review|10.1016/j.cortex.2018.11.021
Influence of analytic techniques on comparing DTI-derived measurements in early stage Parkinson's disease|10.1016/j.heliyon.2019.e01481
Multimodal MRI evaluation of parkinsonian limbic pathologies|10.1016/j.neurobiolaging.2019.01.004
Nucleic Acid–Based Therapeutics for Parkinson’s Disease|10.1007/s13311-019-00714-7
Quantitative Proteomics of Presynaptic Mitochondria Reveal an Overexpression and Biological Relevance of Neuronal MitoNEET in Postnatal Brain Development|10.1002/dneu.22684
The virtual reality of Parkinson's disease freezing of gait: A systematic review|10.1016/j.parkreldis.2018.11.013
Unknown fates of (brain) oxidation or UFO: Close encounters with neuronal senescence|10.1016/j.freeradbiomed.2019.01.012
Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy|10.3233/jpd-191590
Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disease|10.1016/j.jalz.2019.01.011
A multi-ancestry genome-wide study incorporating gene–smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure|10.1093/hmg/ddz070
Early Detection of Parkinson’s Disease by Using SPECT Imaging and Biomarkers|10.1515/jisys-2018-0261
The Parkinson’s phenome—traits associated with Parkinson’s disease in a broadly phenotyped cohort|10.1038/s41531-019-0077-5
Comparative study of PROMISⓇ self-efficacy for managing chronic conditions across chronic neurologic disorders|10.1007/s11136-019-02164-2
Early Dyskinesias in Parkinson’s Disease Patients With Parkin Mutation: A Primary Corticostriatal Synaptopathy?|10.3389/fnins.2019.00273
A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson’s disease|10.1073/pnas.1821778116
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease|10.1111/boc.201800068
Anemia in men and increased Parkinson's disease risk: A population-based large scale cohort study|10.1016/j.parkreldis.2019.03.010
Causes and outcomes of hospitalization in Lewy body dementia: A retrospective cohort study|10.1016/j.parkreldis.2019.03.014
A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies|10.1002/mds.27671
The Parkinson's disease e‐diary: Developing a clinical and research tool for the digital age|10.1002/mds.27673
Discovery of Volatile Biomarkers of Parkinson’s Disease from Sebum|10.1021/acscentsci.8b00879
Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity|10.1007/s00401-019-01993-2
Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies|10.1016/j.parkreldis.2019.03.005
The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson’s Disease|10.3389/fnagi.2019.00057
DNA methylation changes associated with Parkinson’s disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood|10.1080/15592294.2019.1588682
The Parkinson’s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4|10.1038/s41598-019-40808-y
Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings|10.1186/s13195-019-0476-1
Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes|10.1136/jnnp-2018-320151
Pyridine-Fused 2-Pyridones via Povarov and A3 Reactions: Rapid Generation of Highly Functionalized Tricyclic Heterocycles Capable of Amyloid Fibril Binding|10.1021/acs.joc.8b03015
Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein|10.1126/scisignal.aau4543
Vitamin B12 modulates Parkinson’s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection|10.1038/s41422-019-0153-8
Artificial Neural Network–Based Prediction of Outcome in Parkinson’s Disease Patients Using DaTscan SPECT Imaging Features|10.1007/s11307-019-01334-5
Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis|10.1038/s41467-019-08858-y
M1 Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder|10.1016/j.biopsych.2019.02.020
Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease|10.1002/mds.27646
Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration|10.1073/pnas.1814909116
Predictive model of spread of Parkinson's pathology using network diffusion|10.1016/j.neuroimage.2019.03.001
Reduced habit-driven errors in Parkinson’s Disease|10.1038/s41598-019-39294-z
A comprehensive screening of copy number variability in dementia with Lewy bodies|10.1016/j.neurobiolaging.2018.10.019
Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders Through Genome-Wide Association Studies|10.1176/appi.ajp.2018.18070857
Prioritizing Parkinson’s disease genes using population-scale transcriptomic data|10.1038/s41467-019-08912-9
Real-World Experience With VMAT2 Inhibitors|10.1097/wnf.0000000000000326
Tau immunoreactivity in peripheral tissues of human aging and select tauopathies|10.1016/j.neulet.2018.12.031
Memory impairment in Parkinson’s disease: The retrieval versus associative deficit hypothesis revisited and reconciled.|10.1037/neu0000503
Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways|10.1186/s40478-019-0675-9
Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)|10.1007/s00415-019-09250-y
Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease|10.3233/jpd-191576
LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice|10.1186/s40478-019-0679-5
Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease|10.1002/ana.25450
Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells|10.3389/fimmu.2019.00303
Dual threshold neural closed loop deep brain stimulation in Parkinson disease patients|10.1016/j.brs.2019.02.020
Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity|10.3390/ijms20040994
Dopamine neuronal protection in the mouse Substantia nigra by GHSR is independent of electric activity|10.1016/j.molmet.2019.02.005
Correction to Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase|10.1021/acs.jmedchem.9b00284
Network abnormalities among non‐manifesting Parkinson disease related LRRK2 mutation carriers|10.1002/hbm.24543
SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease|10.1002/mds.27642
Expert comment to: Novel Xp21.1 deletion associated with unusual features in large McLeod syndrome kindred|10.1016/j.parkreldis.2019.02.024
High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra|10.1148/radiol.2019181042
Awake Testing during Deep Brain Stimulation Surgery Predicts Postoperative Stimulation Side Effect Thresholds|10.3390/brainsci9020044
T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease|10.3389/fimmu.2019.00239
Higher urate in LRRK2 mutation carriers resistant to Parkinson disease|10.1002/ana.25436
Progressive brain atrophy in chronically infected and treated HIV+ individuals|10.1007/s13365-019-00723-4
OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial|10.1016/j.parkreldis.2019.02.009
Transplant and risk of Parkinson disease|10.1016/j.parkreldis.2019.02.013
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases|10.1212/wnl.0000000000006926
Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson’s disease|10.1371/journal.pone.0211699
Altered functional network topology correlates with clinical measures in very early-stage, drug-naïve Parkinson's disease|10.1016/j.parkreldis.2019.02.001
Neural correlates of distinct cognitive phenotypes in early Parkinson's disease|10.1016/j.jns.2019.02.013
Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD|10.1007/s00401-019-01962-9
An estimate of the total number of true human miRNAs|10.1093/nar/gkz097
A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson’s Disease|10.3233/jpd-181448
Cholinergic system changes of falls and freezing of gait in Parkinson's disease|10.1002/ana.25430
l ‐3,4‐dihydroxyphenylalanine ( l ‐DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha‐synuclein mouse models of Parkinson's disease|10.1111/jnc.14676
Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph|10.1186/s13195-019-0469-0
The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A|10.1074/jbc.ra118.005008
A review of basal ganglia circuits and physiology: Application to deep brain stimulation|10.1016/j.parkreldis.2019.01.009
Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid|10.1016/j.parkreldis.2018.11.016
Identification of β-synuclein on secretory granules in chromaffin cells and the effects of α- and β-synuclein on post-fusion BDNF discharge and fusion pore expansion|10.1016/j.neulet.2019.01.056
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease|10.1111/cts.12619
No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease|10.1016/j.neurobiolaging.2018.09.022
18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes|10.1186/s13195-019-0470-7
Physical activity mediates the association between striatal dopamine transporter availability and cognition in Parkinson's disease|10.1016/j.parkreldis.2019.01.027
Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders|10.1007/s11481-019-09835-4
Associations between daily-living physical activity and laboratory-based assessments of motor severity in patients with falls and Parkinson's disease|10.1016/j.parkreldis.2019.01.022
End of life planning in parkinsonian diseases|10.1016/j.parkreldis.2019.01.026
Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder|10.1038/s41531-018-0073-1
Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson's disease|10.1016/j.cortex.2019.01.016
Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions|10.1093/aje/kwz005
Data-Driven Subtyping of Parkinson’s Disease Using Longitudinal Clinical Records: A Cohort Study|10.1038/s41598-018-37545-z
Earlier Dopaminergic Treatment in Parkinson's Disease Is Not Associated With Improved Outcomes|10.1002/mdc3.12724
Clinical and anatomical predictors for freezing of gait and falls after subthalamic deep brain stimulation in Parkinson's disease patients|10.1016/j.parkreldis.2019.01.021
Active information storage in Parkinson’s disease: a resting state fMRI study over the sensorimotor cortex|10.1007/s11682-019-00037-3
The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease|10.1002/mds.27614
Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?|10.1111/ejn.14314
Abstract #81: Improving Neurostimulation Clinical Trial Design with Patient Experience Data|10.1016/j.brs.2018.12.088
Targeting the Dopaminergic System in Autoimmunity|10.1007/s11481-019-09834-5
miR-34a: a new player in the regulation of T cell function by modulation of NF-κB signaling|10.1038/s41419-018-1295-1
Bidirectional dopamine modulation of excitatory and inhibitory synaptic inputs to subthalamic neuron subsets containing α4β2 or α7 nAChRs|10.1016/j.neuropharm.2019.01.015
Risk of Parkinson's disease dementia related to level I MDS PD‐MCI|10.1002/mds.27617
Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase|10.1021/acs.jmedchem.8b01294
Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION|10.1002/mgg3.564
Identifying the neural correlates of doorway freezing in Parkinson's disease|10.1002/hbm.24506
Crystal structure of the WD40 domain dimer of LRRK2|10.1073/pnas.1817889116
Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease|10.3389/fnins.2018.00967
Multimodal dopaminergic and free-water imaging in Parkinson's disease|10.1016/j.parkreldis.2019.01.007
Reduced gray matter volume in cognitively preserved COMT 158Val/Val Parkinson’s disease patients and its association with cognitive decline|10.1007/s11682-018-0022-y
Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development|10.1177/2168479018817517;
Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology|10.3390/ijms20010141
Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas|10.1172/jci120848
Smell status in functional movement disorders: New clues for diagnosis and underlying mechanisms|10.1016/j.clineuro.2018.12.017
Abstract|10.1177/2398212819855490
Alzheimer's Disease and Its Potential Alternative Therapeutics.|10.4172/2161-0460.1000477
Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE‐ε4/TOMM40 long poly‐T repeat allele variants|10.1016/j.trci.2019.08.005
Anodal tDCS modulates cortical activity and synchronization in Parkinson's disease depending on motor processing|10.1016/j.nicl.2019.101689
Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease|10.1016/j.nicl.2019.101986
Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy – A double-validation whole-brain meta-analysis|10.1016/j.nicl.2019.101722
Bayesian Longitudinal Modeling of Early Stage Parkinson’s Disease Using DaTscan Images|10.1007/978-3-030-20351-1_31
BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED|10.14283/jpad.2019.6
Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level|10.1016/j.nicl.2019.101720
Cognitive processes that indirectly affect olfactory dysfunction in Parkinson's disease|10.1016/j.prdoa.2019.07.003
Complementary motivational roles of nigroaccumbens and nigrostriatal dopaminergic pathways|10.1002/mds.27504
Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease|10.3988/jcn.2019.15.1.102
FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis|10.1016/j.nicl.2018.11.004
Free-water imaging of the hippocampus is a sensitive marker of Alzheimer's disease|10.1016/j.nicl.2019.101985
Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells|10.1039/c9nr01277j
Hippocampal CA1 subfield predicts episodic memory impairment in Parkinson's disease|10.1016/j.nicl.2019.101824
Huntington disease: A quarter century of progress since the gene discovery|10.1016/j.jns.2018.09.022
Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations|10.1016/j.nicl.2019.101856
Neurophysics Assessment of the Muscle Bioenergy Generated by Transcranial Magnetic Stimulation|10.34133/2019/7109535
Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial|10.1016/j.prdoa.2019.07.006
Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures|10.1016/j.prdoa.2019.08.006
Quantification of blood–brain barrier transport and neuronal toxicity of unlabelled multiwalled carbon nanotubes as a function of surface charge|10.1039/c9nr02866h
Targeting the proteostasis network in Huntington’s disease|10.1016/j.arr.2018.11.006
The experience of off periods: Qualitative analysis of interviews with persons with Parkinson's and carepartners|10.1016/j.prdoa.2019.07.008
To be or not to be pink(1): contradictory findings in an animal model for Parkinson’s disease|10.1093/braincomms/fcz016
LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients|10.1002/mds.27601
Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts|10.1002/mds.27608
Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization|10.1007/s12035-018-1449-2
Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation|10.1016/j.stemcr.2018.11.021
Ultra–Low-Dose18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs|10.1148/radiol.2018180940
Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies|10.1038/s41598-018-35729-1
Large-scale validation of miRNAs by disease association, evolutionary conservation and pathway activity|10.1080/15476286.2018.1559689
Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease|10.1007/s00401-018-1947-3
Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease|10.3389/fnmol.2018.00454
Non-Dopaminergic Therapies|10.3233/jpd-181472
Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies|10.3233/jpd-181488
The Emerging Evidence of the Parkinson Pandemic|10.3233/jpd-181474
Updating Our Definitions of Parkinson’s Disease for a Molecular Age|10.3233/jpd-181487
A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology|10.1038/s41593-018-0298-7
Entorhinal Cortex Atrophy in Early, Drug-naive Parkinson’s Disease with Mild Cognitive Impairment|10.14336/ad.2018.1116
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease|10.1007/s00401-018-1948-2
Deep brain stimulation of the substantia nigra for freezing of gait in Parkinson's disease: is it about stimulation frequency?|10.1016/j.parkreldis.2018.12.010
Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale‐2 in Parkinson's disease|10.1002/mds.27575
Immune system responses in Parkinson's disease: Early and dynamic|10.1111/ejn.14290
Regional gray matter changes and age predict individual treatment response in Parkinson's disease|10.1016/j.nicl.2018.101636
Self-reported physical activity levels and clinical progression in early Parkinson's disease|10.1016/j.parkreldis.2018.11.006
Non-motor predictors of freezing of gait in Parkinson’s disease|10.1016/j.gaitpost.2018.12.009
Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB|10.1073/pnas.1813365115
Characterizing patient compliance over six months in remote digital trials of Parkinson’s and Huntington disease|10.1186/s12911-018-0714-7
Destabilizing Domains Enable Long-Term and Inert Regulation of GDNF Expression in the Brain|10.1016/j.omtm.2018.08.008
The atypical RhoGTPase RhoE/Rnd3 is a key molecule to acquire a neuroprotective phenotype in microglia|10.1186/s12974-018-1386-z
CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies|10.1021/acschemneuro.8b00620
Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons|10.1016/j.ajhg.2018.10.018
A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease|10.1002/mds.27555
Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein|10.1038/s41598-018-35464-7
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia|10.1038/s41591-018-0223-3
Normal and pathological neuronal distribution of the human mesencephalic locomotor region|10.1002/mds.27578
Understanding the role of genetic variability in LRRK2 in Indian population|10.1002/mds.27558
Intracellular metalloprotease activity controls intraneuronal Aβ aggregation and limits secretion of Aβviaexosomes|10.1096/fj.201801319r
Renewed assessment of the risk of emergent advanced cell therapies to transmit neuroproteinopathies|10.1007/s00401-018-1941-9
Information processing deficit in older adults with HIV infection: A comparison with Parkinson’s disease.|10.1037/neu0000500
Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)|10.1002/mds.27492
Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain|10.1016/j.nano.2018.11.006
Benefits of pallidal stimulation in dystonia are linked to cerebellar volume and cortical inhibition|10.1038/s41598-018-34880-z
Wearable sensors for Parkinson’s disease: which data are worth collecting for training symptom detection models|10.1038/s41746-018-0071-z
Genetic analysis of neurodegenerative diseases in a pathology cohort|10.1016/j.neurobiolaging.2018.11.007
Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington’s disease|10.1186/s12874-018-0592-9
Recruitment of patients with de novo Parkinson disease: successful strategies in a randomized exercise clinical trial|10.1186/s13063-018-2958-z
RAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes Centrosomal Deficits via RAB8A|10.3389/fnmol.2018.00417
Dietary Patterns, Physical Activity, Sleep, and Risk for Dementia and Cognitive Decline|10.1007/s13668-018-0247-9
Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson’s disease|10.1136/jnnp-2018-319364
Magnetic resonance T1w/T2w ratio: A parsimonious marker for Parkinson disease|10.1002/ana.25376
Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression|10.1038/s41598-018-35130-y
A pathway for Parkinson’s Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain|10.7554/elife.40202
Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates|10.1021/acschemneuro.8b00526
Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board|10.1002/mds.27540
Portrait of blood-derived extracellular vesicles in patients with Parkinson’s disease|10.1016/j.nbd.2018.11.002
RAB7A phosphorylation by TBK1 promotes mitophagy via the PINK-PARKIN pathway|10.1126/sciadv.aav0443
Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure|10.3389/fendo.2018.00608
Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease|10.1016/j.ebiom.2018.10.039
Phosphorylation of Parkin at serine 65 is essential for its activationin vivo|10.1098/rsob.180108
Predicting early cognitive decline in newly-diagnosed Parkinson's patients: A practical model|10.1016/j.parkreldis.2018.06.031
The E3 Ubiquitin Ligases TRIM17 and TRIM41 Modulate α-Synuclein Expression by Regulating ZSCAN21|10.1016/j.celrep.2018.11.002
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice|10.1126/scitranslmed.aah4066
Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease|10.3390/metabo8040071
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort|10.1002/acn3.644
The vermiform appendix impacts the risk of developing Parkinson’s disease|10.1126/scitranslmed.aar5280
δ-Secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer’s disease|10.1038/s41380-018-0286-z
A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein|10.3233/jpd-181471
Parkin targets NOD2 to regulate astrocyte endoplasmic reticulum stress and inflammation|10.1002/glia.23482
The Luxembourg Parkinson’s Study: A Comprehensive Approach for Stratification and Early Diagnosis|10.3389/fnagi.2018.00326
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4|10.1186/s12974-018-1337-8
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease|10.1038/s41598-018-34490-9
PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology|10.1002/mds.27523
The transition between turning and sitting in patients with Parkinson's disease: A wearable device detects an unexpected sequence of events|10.1016/j.gaitpost.2018.10.018
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers|10.1016/j.jalz.2018.08.012
Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies|10.1093/hmg/ddy365
Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress|10.1016/j.neuropharm.2018.10.013
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease|10.1038/s41598-018-33921-x
Phenotypic Reprogramming of Striatal Neurons into Dopaminergic Neuron-like Cells in the Adult Mouse Brain|10.1016/j.stemcr.2018.09.004
Validation of a performance‐based assessment of cognitive functional ability in Parkinson's disease|10.1002/mds.27487
Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference|10.1038/s41467-018-05892-0
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease|10.1007/s12311-018-0981-y
Progressive Decline in Gray and White Matter Integrity in de novo Parkinson’s Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data|10.3389/fnagi.2018.00318
Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2|10.1007/s11064-018-2650-4
123I‐FP‐CIT SPECT [(123) I‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐N‐(3‐fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α‐synuclein Parkinson's disease cohort versus Parkinson's disease|10.1002/mds.27451
Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease|10.1186/s13024-018-0282-4
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial|10.1016/j.parkreldis.2018.10.005
Abstracts from the 50th European Society of Human Genetics Conference: Posters|10.1038/s41431-018-0247-7
Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson’s disease patients OFF and ON medications|10.1016/j.neuropsychologia.2018.07.024
Importance of low diagnostic Accuracy for early Parkinson's disease|10.1002/mds.27485
Meta-analysis of amantadine efficacy for improving preclinical research reliability|10.1002/mds.27486
Modeling Parkinson’s disease and treatment complications in rodents: Potentials and pitfalls of the current options|10.1016/j.bbr.2017.12.014
Sleep disorders and Parkinson disease; lessons from genetics|10.1016/j.smrv.2018.01.006
The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress|10.1016/j.redox.2018.07.021
The Linked Clinical Trials initiative (LCT) for Parkinson's disease|10.1111/ejn.14175
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches|10.1021/acs.bioconjchem.8b00548
Modulation of intracellular calcium signaling by microRNA-34a-5p|10.1038/s41419-018-1050-7
Regional vesicular acetylcholine transporter distribution in human brain: A [18F]fluoroethoxybenzovesamicol positron emission tomography study|10.1002/cne.24541
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction|10.1016/j.nbd.2018.09.018
Animal models of neurodegenerative diseases|10.1038/s41593-018-0236-8
CSF Aβ1–42 level is associated with cognitive decline in early Parkinson’s disease with rapid eye movement sleep behavior disorder|10.1186/s40035-018-0129-5
USP 14 inhibition corrects an in vivo model of impaired mitophagy|10.15252/emmm.201809014
Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)|10.3233/jpd-181434
Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat|10.1038/s41531-018-0066-0
Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study|10.1111/ane.13028
Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease|10.1002/pmic.201800108
Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients|10.1038/s41598-018-31988-0
Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders|10.1001/jama.2018.12917
β2‐adrenoreceptor medications and risk of Parkinson disease|10.1002/ana.25341
Insights into the Influence of Specific Splicing Events on the Structural Organization of LRRK2|10.3390/ijms19092784
Common and rare GCH1 variants are associated with Parkinson's disease|10.1016/j.neurobiolaging.2018.09.008
An mGlu4‐Positive Allosteric Modulator Alleviates Parkinsonism in Primates|10.1002/mds.27462
Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests|10.1002/mds.110
Modeling and prediction of clinical symptom trajectories in Alzheimer’s disease using longitudinal data|10.1371/journal.pcbi.1006376
Autonomic dysfunction and white matter microstructural changes in drug-naïve patients with Parkinson’s disease|10.7717/peerj.5539
Multi-objective particle swarm optimization for postoperative deep brain stimulation targeting of subthalamic nucleus pathways|10.1088/1741-2552/aae12f
Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease|10.1038/s41593-018-0223-0
Amyloid oligomer interactions and polymorphisms: disease-relevant distinct assembly of α-synuclein and tau|10.1038/s41386-018-0204-8
Depressive symptoms may increase the risk of the future development of freezing of gait in patients with Parkinson's disease: Findings from a 5-year prospective study|10.1016/j.parkreldis.2018.09.013
Repeated Spiral Drawings in Essential Tremor: a Possible Limb-Based Measure of Motor Learning|10.1007/s12311-018-0974-x
Antidepressant potential of metabotropic glutamate receptor mGlu2 and mGlu3 negative allosteric modulators|10.1038/s41386-018-0192-8
Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease|10.1186/s40478-018-0596-z
Early detection of Parkinson’s disease through patient questionnaire and predictive modelling|10.1016/j.ijmedinf.2018.09.008
Impaired hepatic amyloid-beta degradation in Alzheimer’s disease|10.1371/journal.pone.0203659
Inflammasomes: An Emerging Mechanism Translating Environmental Toxicant Exposure Into Neuroinflammation in Parkinson’s Disease|10.1093/toxsci/kfy219
Nicotinamide-N-methyltransferase controls behavior, neurodegeneration and lifespan by regulating neuronal autophagy|10.1371/journal.pgen.1007561
Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms|10.1016/j.parkreldis.2018.09.004
Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease|10.1016/j.nbd.2018.09.004
Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials|10.1016/j.parkreldis.2018.09.005
Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice|10.1016/j.nbd.2018.09.003
Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques|10.1371/journal.pone.0202201
L-DOPA functionalized, multi-branched gold nanoparticles as brain-targeted nano-vehicles|10.1016/j.nano.2018.08.011
Nucleus Basalis of Meynert Stimulation for Dementia: Theoretical and Technical Considerations|10.3389/fnins.2018.00614
A Cortical Pathogenic Theory of Parkinson’s Disease|10.1016/j.neuron.2018.07.028
Heritability estimates of cortical anatomy: The influence and reliability of different estimation strategies|10.1016/j.neuroimage.2018.05.014
Lead-DBS v2: Towards a comprehensive pipeline for deep brain stimulation imaging|10.1016/j.neuroimage.2018.08.068
Peripheral neuropathy is associated with more frequent falls in Parkinson's disease|10.1016/j.parkreldis.2018.04.006
Post-stroke Movement Disorders: The Clinical, Neuroanatomic, and Demographic Portrait of 284 Published Cases|10.1016/j.jstrokecerebrovasdis.2018.04.028
Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease|10.1111/ene.13797
Algorithmic Complexity of EEG for Prognosis of Neurodegeneration in Idiopathic Rapid Eye Movement Behavior Disorder (RBD)|10.1007/s10439-018-02112-0
Antibody biomarker for de novo Parkinson disease: attempted validation|10.1038/s41531-018-0064-2
Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations|10.1080/15548627.2018.1509818
Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson’s disease|10.1186/s12974-018-1286-2
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease|10.1084/jem.20180484
Proteomic and functional data sets on synaptic mitochondria from rats with genetic ablation of Parkin|10.1016/j.dib.2018.08.053
Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder|10.1007/s11682-018-9939-4
Subthalamic nucleus deep brain stimulation reduces freezing of gait subtypes and patterns in Parkinson's disease|10.1016/j.brs.2018.08.016
Active site alanine mutations convert deubiquitinases into high‐affinity ubiquitin‐binding proteins|10.15252/embr.201745680
Increased substantia nigra echogenicity in LRRK2 family members without mutations|10.1002/mds.27443
Validation of the MDS clinical diagnostic criteria for Parkinson's disease|10.1002/mds.27362
Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study|10.1111/jnc.14569
Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy|10.1007/s12035-018-1313-4
Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer’s and Parkinson’s disease models of neurodegeneration|10.1093/hmg/ddy308
Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy|10.1007/s00401-018-1900-5
Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease|10.1016/j.parkreldis.2018.08.010
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model|10.1038/s41531-018-0062-4
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease|10.1371/journal.pone.0201964
Tau protein aggregation is associated with cellular senescence in the brain|10.1111/acel.12840
Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators|10.1038/s41380-018-0206-2
Microlesion effects, suboptimal lead placement and disease progression are critical determinants for DBS tolerance in essential tremor|10.1016/j.clinph.2018.07.024
Finding useful biomarkers for Parkinson's disease|
Finding useful biomarkers for Parkinson’s disease|10.1126/scitranslmed.aam6003
Abnormal Spontaneous Brain Activity in Early Parkinson’s Disease With Mild Cognitive Impairment: A Resting-State fMRI Study|10.3389/fphys.2018.01093
Robust Ensemble Classification Methodology for I123-Ioflupane SPECT Images and Multiple Heterogeneous Biomarkers in the Diagnosis of Parkinson's Disease|10.3389/fninf.2018.00053
Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)|10.1093/jnen/nly056
Clinical deep brain stimulation strategies for orientation-selective pathway activation|10.1088/1741-2552/aad978
Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk|
VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites|10.1083/jcb.201807019
Disease-related patterns of in vivo pathology in Corticobasal syndrome|10.1007/s00259-018-4104-2
Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy|10.1016/j.parkreldis.2018.08.004
Distribution of oxidized DJ-1 in Parkinson’s disease-related sites in the brain and in the peripheral tissues: effects of aging and a neurotoxin|10.1038/s41598-018-30561-z
Post hoc analysis of the Exenatide‐PD trial—Factors that predict response|10.1111/ejn.14096
Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV|10.1038/s41380-018-0130-5
Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery|10.1016/j.jconrel.2018.08.006
Unraveling the Pathways to Neuronal Homeostasis and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors|10.3390/ijms19082280
Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration|10.1111/jnc.14471
Age-Related Deficits in Taste and Smell|10.1016/j.otc.2018.03.014
Higher serum cholesterol and decreased Parkinson's disease risk: A statin‐free cohort study|10.1002/mds.27413
Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains|10.1016/j.expneurol.2018.07.016
Mendel and urate: Acid test or random noise?|10.1016/j.parkreldis.2018.08.005
PP1 Phosphatase Complexes: Undruggable No Longer|10.1016/j.cell.2018.08.007
Monitoring PARKIN RBR Ubiquitin Ligase Activation States with UbFluor|10.1002/cpch.45
Леводопа/карбідопа пролонгованого вивільнення в лікуванні хвороби Паркінсона|10.22141/2224-0713.3.97.2018.133682
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease|10.1038/s41419-018-0848-7
Altered resting‐state functional connectivity of the putamen and internal globus pallidus is related to speech impairment in Parkinson's disease|10.1002/brb3.1073
Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson’s disease brains with Lewy body pathology|10.1016/j.brainres.2018.07.023
LRRK2 activation in idiopathic Parkinson’s disease|10.1126/scitranslmed.aar5429
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease|10.1007/s00401-018-1892-1
The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target|10.1093/brain/awy215
Functional Connectivity-Based Modelling Simulates Subject-Specific Network Spreading Effects of Focal Brain Stimulation|10.1007/s12264-018-0256-0
The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition|10.1016/j.expneurol.2018.07.012
Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis|10.1073/pnas.1801109115
Hybrid deep brain stimulation system to manage stimulation-induced side effects in essential tremor patients|10.1016/j.parkreldis.2018.07.013
Combined accelerometer and genetic analysis to differentiate essential tremor from Parkinson’s disease|10.7717/peerj.5308
The Therapeutic Potential of Metformin in Neurodegenerative Diseases|10.3389/fendo.2018.00400
A new model to study cell-to-cell transfer of αSynuclein in vivo|10.1016/j.bbrc.2018.07.053
NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease|10.1038/s41531-018-0061-5
The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies|10.1111/cge.13405
Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis|10.1093/hmg/ddy260
Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease|10.1016/j.cmet.2018.06.014
Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review|10.1097/wnf.0000000000000296
The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6|10.1016/j.expneurol.2018.07.005
Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease|10.3389/fneur.2018.00560
MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson’s Disease Patients|10.1007/s12035-018-1219-1
Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning|10.1038/s41598-018-28840-w
Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation|10.1007/s11682-018-9920-2
TMEM106B haplotypes have distinct gene expression patterns in aged brain|10.1186/s13024-018-0268-2
Automated Deep Brain Stimulation Programming for Tremor|10.1109/tnsre.2018.2852222
Sequencing of the GBA coactivator, Saposin C, in Parkinson disease|10.1016/j.neurobiolaging.2018.06.034
Sex-specific genetic predictors of Alzheimer’s disease biomarkers|10.1007/s00401-018-1881-4
A comprehensive analysis of SNCA‐related genetic risk in sporadic parkinson disease|10.1002/ana.25274
A similarity-based approach to leverage multi-cohort medical data on the diagnosis and prognosis of Alzheimer's disease|10.1093/gigascience/giy085
Freezing of gait: Promising avenues for future treatment|10.1016/j.parkreldis.2018.03.009
Hoehn and Yahr stage 3 and postural stability item in the movement disorder society–unified Parkinson's disease rating scale|10.1002/mds.27453
Mapping movement, mood, motivation and mentation in the subthalamic nucleus|10.1098/rsos.171177
O2‐09‐04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH|10.1016/j.jalz.2018.06.2691
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease|10.1016/j.neuropharm.2017.09.023
Reply To: Detection of Alpha-Synuclein in Saliva: The Importance of Preanalytical Assessment|10.1002/mds.27424
Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease|10.1080/15548627.2018.1461294
Diaphanous 1 (DIAPH1) is Highly Expressed in the Aged Human Medial Temporal Cortex and Upregulated in Myeloid Cells During Alzheimer’s Disease|10.3233/jad-180088
Microstructural Changes in Patients With Parkinson's Disease Comorbid With REM Sleep Behaviour Disorder and Depressive Symptoms|10.3389/fneur.2018.00441
Prevalence of Parkinson’s disease across North America|10.1038/s41531-018-0058-0
Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson’s Disease and Cross-Cultural Comparison|10.1177/1073191118778896
Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor|10.1016/j.parkreldis.2018.06.029
Longitudinal analysis of impulse control disorders in Parkinson disease|10.1212/wnl.0000000000005816
Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus|10.1016/j.neuron.2018.05.023
Cognitive Profiles and Hub Vulnerability in Parkinson's Disease|10.3389/fneur.2018.00482
Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability|10.1016/j.bmcl.2018.06.034
Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries|10.1371/journal.pone.0198166
Increased Brain Exposure of an Alpha-Synuclein Fibrillization Modulator by Utilization of an Activated Ester Prodrug Strategy|10.1021/acschemneuro.8b00236
Stratification of candidate genes for Parkinson’s disease using weighted protein-protein interaction network analysis|10.1186/s12864-018-4804-9
Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation|10.3233/jad-180121
Dual role of USP 30 in controlling basal pexophagy and mitophagy|10.15252/embr.201745595
Tau-targeting therapies for Alzheimer disease|10.1038/s41582-018-0013-z
Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models|10.1007/s00401-018-1873-4
Consensus for the measurement of the camptocormia angle in the standing patient|10.1016/j.parkreldis.2018.06.013
Genetic variants associated with Alzheimer’s disease confer different cerebral cortex cell-type population structure|10.1186/s13073-018-0551-4
A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease|10.1016/j.parkreldis.2018.06.001
Movement disorders in non-encephalopathic Hashimoto's thyroiditis|10.1016/j.parkreldis.2018.06.008
Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein|10.1016/j.nbd.2018.05.018
Gene Therapy Strategies to Restore ER Proteostasis in Disease|10.1016/j.ymthe.2018.04.004
Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?|10.1016/j.toxicon.2017.09.004
Mechanism of parkin activation by PINK1|10.1038/s41586-018-0224-x
mGlu4 allosteric modulation for treating Parkinson's disease|10.1016/j.neuropharm.2018.03.027
The spectrum of “off” in Parkinson's disease: What have we learned over 40 years?|10.1016/j.parkreldis.2018.02.001
Immunosuppressants and risk of Parkinson disease|10.1002/acn3.580
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons|10.1186/s40478-018-0550-0
Partial ablation of the orexin field induces a sub-narcoleptic phenotype in a conditional mouse model of orexin neurodegeneration|10.1093/sleep/zsy116
Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson’s Disease and Their First-Degree Unaffected Relatives|10.1007/s10548-018-0653-8
Dopamine Transporter/α-Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinson’s Disease: An In Situ Proximity Ligation Assay Study|10.3390/ijms19061611
Early Gray Matter Volume Loss in MAPT H1H1 de Novo PD Patients: A Possible Association With Cognitive Decline|10.3389/fneur.2018.00394
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease|10.1016/j.ejmg.2018.05.005
A novel extended form of alpha-synuclein 3′UTR in the human brain|10.1186/s13041-018-0371-x
RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease|10.1074/jbc.ra118.001747
High-resolution local field potentials measured with deep brain stimulation arrays|10.1088/1741-2552/aabdf5
Patterns and Predictors of Tic Suppressibility in Youth With Tic Disorders|10.3389/fpsyt.2018.00188
Separation of Subcutaneous Fat From Muscle in Surface Electrical Impedance Myography Measurements Using Model Component Analysis|10.1109/tbme.2018.2839977
Determination of Imaging Biomarkers to Decipher Disease Trajectories and Differential Diagnosis of Neurodegenerative Diseases (DIsease TreND)|10.1016/j.jneumeth.2018.05.009
Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity|10.1007/s00204-018-2222-z
LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages|10.15252/embj.201798694
Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease|10.1186/s13024-018-0255-7
Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson’s Disease|10.1007/s12035-018-1109-6
Cognitive training for freezing of gait in Parkinson’s disease: a randomized controlled trial|10.1038/s41531-018-0052-6
Human cerebral collateral arteriole function in subjects with normal cognition, mild cognitive impairment, and dementia|10.1152/ajpheart.00206.2018
Somatic copy number gains of α-synuclein (SNCA) in Parkinson’s disease and multiple system atrophy brains|10.1093/brain/awy157
Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene|10.1016/j.parkreldis.2018.05.009
Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis|10.1016/j.parkreldis.2018.05.020
Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease|10.1002/term.2698
α‐Synuclein stimulation of monoamine oxidase‐B and legumain protease mediates the pathology of Parkinson's disease|10.15252/embj.201798878
Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson’s Disease Reveals Distinct Metabolic Profiles|10.1021/acs.jproteome.8b00224
Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder|10.1002/mds.27385
Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism|10.1002/mds.27404
Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson’s disease|10.1073/pnas.1718946115
Varying the rate of intravenous cocaine infusion influences the temporal dynamics of both drug and dopamine concentrations in the striatum|10.1111/ejn.13941
Alpha Synuclein Fibrils Contain Multiple Binding Sites for Small Molecules|10.1021/acschemneuro.8b00177
Alterations of Brain Structural Network in Parkinson’s Disease With and Without Rapid Eye Movement Sleep Behavior Disorder|10.3389/fneur.2018.00334
Generation of three-dimensional human neuronal cultures: application to modeling CNS viral infections|10.1186/s13287-018-0881-6
The deterministic role of 5-mers in microRNA-gene targeting|10.1080/15476286.2018.1462652
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease|10.1016/j.parkreldis.2018.05.003
The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human|10.1042/bcj20180248
Brain and gut: Partners in crime|10.1002/mds.27407
Circular RNA expression and regulatory network prediction in posterior cingulate astrocytes in elderly subjects|10.1186/s12864-018-4670-5
Computer-aided diagnosis for (123I)FP-CIT imaging: impact on clinical reporting|10.1186/s13550-018-0393-5
Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson’s Disease|10.1038/s41598-018-24783-4
Phosphorylated α‐synuclein in the retina is a biomarker of Parkinson's disease pathology severity|10.1002/mds.27392
Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine|10.1038/s41386-018-0088-7
Genetic variants related to urate and risk of Parkinson's disease|10.1016/j.parkreldis.2018.04.031
Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease|10.1016/j.parkreldis.2018.02.007
α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons|10.1186/s40478-018-0537-x
Pink1 −/− Rats Show Early-Onset Swallowing Deficits and Correlative Brainstem Pathology|10.1007/s00455-018-9896-5
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study|10.1016/s1474-4422(18)30126-1
ELISA method to detect α-synuclein oligomers in cell and animal models|10.1371/journal.pone.0196056
Impulsivity in Parkinson’s Disease Is Associated With Alterations in Affective and Sensorimotor Striatal Networks|10.3389/fneur.2018.00279
Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro|10.1021/acsomega.7b01897
Development of an optogenetic toolkit for neural circuit dissection in squirrel monkeys|10.1038/s41598-018-24362-7
Minimal Clinically Important Difference for UPDRS‐III in Daily Practice|10.1002/mdc3.12632
Neuroanatomical phenotypes in mental illness: identifying convergent and divergent cortical phenotypes across autism, ADHD and schizophrenia|10.1503/jpn.170094
Sex, Age, and Emotional Valence: Revealing Possible Biases in the ‘Reading the Mind in the Eyes’ Task|10.3389/fpsyg.2018.00570
Fishing for Drug Targets: A Focus on Diazirine Photoaffinity Probe Synthesis|10.1021/acs.jmedchem.7b01561
Detection of alpha‐synuclein conformational variants from gastro‐intestinal biopsy tissue as a potential biomarker for Parkinson's disease|10.1111/nan.12486
Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop|10.1002/glia.23337
Association Between Peripheral Inflammation and DATSCAN Data of the Striatal Nuclei in Different Motor Subtypes of Parkinson Disease|10.3389/fneur.2018.00234
Automated Quality Control for Sensor Based Symptom Measurement Performed Outside the Lab|10.3390/s18041215
Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity|10.1038/s41531-018-0049-1
Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD|10.1136/jnnp-2018-318060
Testing a longitudinal compensation model in premanifest Huntington’s disease|10.1093/brain/awy122
A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)|10.1212/wnl.90.15_supplement.p5.068
Clinician-Input Study (CIS-PD): how the Fox Wearable Companion Application can influence treatment and care in Parkinson’s disease (P3.048)|
Clinician-Input Study (CIS-PD): how the Fox Wearable Companion Application can influence treatment and care in Parkinson’s disease (P3.048)|10.1212/wnl.90.15_supplement.p3.048
Cognitive behavioural therapy for anxiety disorders in Parkinson's disease: Design of a randomised controlled trial to assess clinical effectiveness and changes in cerebral connectivity|10.1016/j.jpsychores.2018.04.002
Foundations for a Patient-Reported Natural History of Parkinson Disease: Cross sectional Analysis of the MJFF Fox Insight (FI) Platform (P2.056)|10.1212/wnl.90.15_supplement.p2.056
Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease|10.3389/fnins.2018.00230
Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation|10.1016/j.jns.2018.04.002
Deep Brain Stimulation associated gliosis: A post-mortem study|10.1016/j.parkreldis.2018.04.009
Small intestinal bacterial overgrowth in Parkinson's disease: Tribulations of a trial|10.1016/j.parkreldis.2018.04.003
PKA-RII subunit phosphorylation precedes activation by cAMP and regulates activity termination|10.1083/jcb.201708053
The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism|10.1016/j.parkreldis.2018.04.005
An updated diagnostic approach to subtype definition of vascular parkinsonism – Recommendations from an expert working group|10.1016/j.parkreldis.2017.12.030
Correlations between CSF proteins and spontaneous neuronal activity in Parkinson’s disease|10.1016/j.neulet.2018.02.062
Cytoprotective mechanisms of DJ-1 against oxidative stress through modulating ERK1/2 and ASK1 signal transduction|10.1016/j.redox.2017.09.008
Dynamics of PARKIN-Dependent Mitochondrial Ubiquitylation in Induced Neurons and Model Systems Revealed by Digital Snapshot Proteomics|10.1016/j.molcel.2018.03.012
Hypercholinergic activity in LRRK2 Parkinson's disease|10.1016/s1474-4422(18)30073-5
In Silico Labeling: Predicting Fluorescent Labels in Unlabeled Images|10.1016/j.cell.2018.03.040
Mild cognitive impairment disrupts attention network connectivity in Parkinson's disease: A combined multimodal MRI and meta-analytical study|10.1016/j.neuropsychologia.2018.03.011
Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases|10.1016/j.clim.2016.09.014
Toward defining deep brain stimulation targets in MNI space: A subcortical atlas based on multimodal MRI, histology and structural connectivity|10.1016/j.neuroimage.2017.05.015
Application of the Movement Disorder Society prodromal criteria in healthy G2019S‐LRRK2 carriers|10.1002/mds.27342
Alpha‐synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation|10.15252/embr.201744617
Impact of motor fluctuations on real-life gait in Parkinson’s patients|10.1016/j.gaitpost.2018.03.045
mGlu1 and mGlu5 modulate distinct excitatory inputs to the nucleus accumbens shell|10.1038/s41386-018-0049-1
Detecting Motor Impairment in Early Parkinson’s Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting|10.2196/jmir.9462
GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice|10.1038/s41598-018-23795-4
NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate|10.1002/jnr.24230
Amyloid-β Increases Tau by Mediating Sirtuin 3 in Alzheimer’s Disease|10.1007/s12035-018-0977-0
Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment|10.1002/mds.27345
Age‐ and sex‐related heterogeneity in prodromal Parkinson's disease|10.1002/mds.27349
Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats|10.1007/s11064-018-2514-y
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort|10.1002/mds.27361
Optical Structural Analysis of Individual α‐Synuclein Oligomers|10.1002/ange.201710779
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease|10.1002/mds.27326
Disease progression models for dominantly-inherited Alzheimer’s disease|10.1093/brain/awy089
LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder|10.1016/j.parkreldis.2018.03.019
White Matter Tract Alterations in Drug-Naïve Parkinson’s Disease Patients With Impulse Control Disorders|10.3389/fneur.2018.00163
A comparison of publicly available linear MRI stereotaxic registration techniques|10.1016/j.neuroimage.2018.03.025
Progression of regional grey matter atrophy in multiple sclerosis|10.1093/brain/awy088
Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study|10.3389/fnagi.2018.00045
Glucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies Treatment|10.1002/mdc3.12611
Initial cognitive changes in Parkinson's disease|10.1002/mds.27330
Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy|10.1186/s13024-018-0245-9
The Effect of Obesity on the Availabilities of Dopamine and Serotonin Transporters|10.1038/s41598-018-22814-8
M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition|10.1038/s41386-018-0033-9
Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia|10.1007/s13311-018-0620-9
Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease|10.1038/sdata.2018.36
Unraveling the role of motoneuron autophagy in ALS|10.1080/15548627.2018.1432327
Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease|10.1016/j.expneurol.2018.03.008
Subtype definition of vascular parkinsonism|10.1016/j.parkreldis.2018.03.005
Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale|10.1016/j.parkreldis.2018.03.002
PET Imaging of Microglial Activation—Beyond Targeting TSPO|10.3390/molecules23030607
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor|10.1186/s12974-018-1100-1
Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins|10.1002/pmic.201700444
Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease|10.1371/journal.pone.0192497
Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease|10.1002/mds.27301
Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease|10.1002/mdc3.12583
Impact of antibiotics on smell dysfunction|10.1016/j.wjorl.2018.03.002
Measurement of chemosensory function|10.1016/j.wjorl.2018.03.001
Pharmacological interventions for psychosis in Parkinson’s disease patients|10.1080/14656566.2018.1445721
Sex disparities in health and health care utilization after Parkinson diagnosis: Rethinking PD associated disability|10.1016/j.parkreldis.2017.12.012
The genetics of Parkinson disease|10.1016/j.arr.2017.12.007
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies|10.1002/mds.27344
Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease|10.1002/mds.27337
Cerebral blood flow predicts differential neurotransmitter activity|10.1038/s41598-018-22444-0
Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort|10.1016/j.parkreldis.2018.02.047
Review: Somatic mutations in neurodegeneration|10.1111/nan.12465
The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1|10.3389/fnmol.2018.00064
Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease|10.1016/j.parkreldis.2018.02.044
CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts|10.1016/j.jalz.2018.01.010
Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson’s disease|10.1073/pnas.1713849115
The concept of alpha-synuclein as a prion-like protein: ten years after|10.1007/s00441-018-2814-1
Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease|10.1093/brain/awy072
PINK 1 autophosphorylation is required for ubiquitin recognition|10.15252/embr.201744981
Resonance assignments of an α-synuclein fibril prepared in Tris buffer at moderate ionic strength|10.1007/s12104-018-9808-5
Synapsin III is a key component of α‐synuclein fibrils in Lewy bodies of PD brains|10.1111/bpa.12587
Generation of RAB39B knockout isogenic human embryonic stem cell lines to model RAB39B-mediated Parkinson's disease|10.1016/j.scr.2018.02.015
Risk variants of the α-synuclein locus and REM sleep behavior disorder in Parkinson’s disease: a genetic association study|10.1186/s12883-018-1023-6
Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer’s disease|10.1186/s13195-018-0349-z
Physical Activity in Early Parkinson Disease|10.3233/jpd-171218
Design, synthesis, and in vitro evaluation of quinolinyl analogues for α-synuclein aggregation|10.1016/j.bmcl.2018.02.031
PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions|10.1016/j.molcel.2018.01.026
Who will remain tremor dominant? The possible role of cognitive reserve in the time course of two common Parkinson’s disease motor subtypes|10.1007/s00702-018-1859-3
Multiple system atrophy and apolipoprotein E|10.1002/mds.27297
Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease|10.1002/mds.27335
Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series|10.1002/mds.27347
Cortical structural involvement and cognitive dysfunction in early Parkinson's disease|10.1002/nbm.3900
Exploring variability in basal ganglia connectivity with functional MRI in healthy aging|10.1007/s11682-018-9824-1
Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease|10.1002/mds.27300
Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease|10.1002/mds.27284
Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity|10.3389/fnmol.2018.00036
CLIPPERS: A Treatable Cause of Spastic Ataxia|10.1002/mdc3.12602
Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease|10.1016/j.parkreldis.2018.02.022
The role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’ system?|10.1007/s00401-018-1812-4
Bilateral deep brain stimulation of the subthalamic nucleus increases pointing error during memory-guided sequential reaching|10.1007/s00221-018-5197-3
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease|10.1016/j.expneurol.2018.01.015
Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries|10.1016/j.parkreldis.2018.02.008
At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease|10.1002/mds.27310
Cortical atrophy patterns in early Parkinson's disease patients using hierarchical cluster analysis|10.1016/j.parkreldis.2018.02.006
Data-driven models of dominantly-inherited Alzheimer’s disease progression|10.1093/brain/awy050
New Developments in Genetic rat models of Parkinson's Disease|10.1002/mds.27296
Holmes Tremor‐Like Phenotype in DYT1 Dystonia|10.1002/mdc3.12585
Long-lasting effects of transcranial static magnetic field stimulation on motor cortex excitability|10.1016/j.brs.2018.02.005
High complement levels in astrocyte‐derived exosomes of Alzheimer disease|10.1002/ana.25172
The nosology of tardive syndromes|10.1016/j.jns.2018.02.008
Increasing the use of mobile technology–derived endpoints in clinical trials|10.1177/1740774518755393
TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson’s Disease with Opposite Effects|10.1007/s12031-018-1031-4
Alpha galactosidase A activity in Parkinson's disease|10.1016/j.nbd.2018.01.012
The Promise and Pitfalls of Facebook Advertising: a Genetic Counselor's Perspective|10.1007/s10897-017-0207-3
A Culturally Tailored Community Health Worker Intervention Leads to Improvement in Patient-Centered Outcomes for Immigrant Patients With Type 2 Diabetes|10.2337/cd17-0068
Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration|10.1016/j.bbadis.2017.11.004
Myosin VI-Dependent Actin Cages Encapsulate Parkin-Positive Damaged Mitochondria|10.1016/j.devcel.2018.01.007
PAKs in the brain: Function and dysfunction|10.1016/j.bbadis.2017.11.005
Time to get personal: A framework for personalized targeting of oxidative stress in neurotoxicity and neurodegenerative disease|10.1016/j.cotox.2018.02.003
Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists|10.1111/bph.14123
Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice|10.1016/j.ebiom.2018.01.035
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease|10.1016/j.nbd.2018.01.004
Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review|10.1159/000486347
A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests|10.3389/fnagi.2018.00011
Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents|10.3233/jpd-171248
Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease|10.1002/mds.27280
Evidence for encephalopsin immunoreactivity in interneurones and striosomes of the monkey striatum|10.1007/s00221-018-5191-9
Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts|10.1038/s41598-018-19865-2
Incorporating spatial constraint in co-activation pattern analysis to explore the dynamics of resting-state networks: An application to Parkinson's disease|10.1016/j.neuroimage.2018.01.019
Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think Tank|10.3389/fnins.2017.00734
Slower saccadic reading in Parkinson’s disease|10.1371/journal.pone.0191005
Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation|10.1186/s13024-018-0235-y
Changes in neuronal activity of cortico‐basal ganglia–thalamic networks induced by acute dopaminergic manipulations in rats|10.1111/ejn.13805
Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors|10.1021/acschemneuro.7b00435
Optical Structural Analysis of Individual α‐Synuclein Oligomers|10.1002/anie.201710779
The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease|10.1002/mdc3.12591
Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?|10.1002/mdc3.12589
α-Synuclein Oligomers Induce a Unique Toxic Tau Strain|10.1016/j.biopsych.2017.12.018
Deep gray matter volume loss drives disability worsening in multiple sclerosis|10.1002/ana.25145
Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia|10.1007/s13670-018-0234-4
Basal Mitophagy Occurs Independently of PINK1 in Mouse Tissues of High Metabolic Demand|10.1016/j.cmet.2017.12.008
Physiological effects of subthalamic nucleus deep brain stimulation surgery in cervical dystonia|10.1136/jnnp-2017-317098
Relationships between lewy and tau pathologies in 375 consecutive non‐Alzheimer's olfactory bulbs|10.1002/mds.27250
Glial scars are permeable to the neurotoxic environment of chronic stroke infarcts|10.1016/j.nbd.2018.01.007
Three-dimensional Tissue Engineered Aligned Astrocyte Networks to Recapitulate Developmental Mechanisms and Facilitate Nervous System Regeneration|10.3791/55848
The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease|10.1002/mds.27270
Transethnic Evaluation Identifies Low-Frequency Loci Associated With 25-Hydroxyvitamin D Concentrations|10.1210/jc.2017-01802
7T MRI subthalamic nucleus atlas for use with 3T MRI|10.1117/1.jmi.5.1.015002
Loss of kallikrein‐related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice|10.15252/emmm.201708184
The LRRK2 signalling system|10.1007/s00441-017-2759-9
Association study of essential tremor genetic loci in Parkinson's disease|10.1016/j.neurobiolaging.2018.01.001
TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD|10.1038/s41593-017-0047-3
Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson's disease|10.1016/j.trci.2018.04.009
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease|10.1016/j.nbd.2017.04.004
Amnestic mild cognitive impairment individuals with dissimilar pathologic origins show common regional vulnerability in the default mode network|10.1016/j.dadm.2018.08.004
Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition|10.1016/j.bbadis.2017.07.005
Bayesian latent time joint mixed‐effects model of progression in the Alzheimer's Disease Neuroimaging Initiative|10.1016/j.dadm.2018.07.008
Biomarkers for cognitive dysfunction in Parkinson's disease|10.1016/j.parkreldis.2017.07.023
Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease|10.1016/j.nicl.2018.05.006
Brain tissue pulsatility is related to clinical features of Parkinson's disease|10.1016/j.nicl.2018.07.017
Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson’s Disease|10.1016/j.celrep.2017.12.092
Effect of rs3910105 in the Synuclein Gene on Dopamine Transporter Availability in Healthy Subjects|10.3349/ymj.2018.59.6.787
Effects of Exercise on Non-motor Symptoms in Parkinson’s Disease|10.1016/j.clinthera.2017.11.004
Estimating the Evolution of Disease in the Parkinson’s Progression Markers Initiative|10.1159/000488780
Interactome Screening Identifies the ER Luminal Chaperone Hsp47 as a Regulator of the Unfolded Protein Response Transducer IRE1α|10.1016/j.molcel.2017.12.028
Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET|10.1016/j.nicl.2018.05.022
Magnetic Resonance-Guided Focused Ultrasound in Neurosurgery: Taking Lessons from the Past to Inform the Future|10.3346/jkms.2018.33.e279
Molecular rotors report on changes in live cell plasma membrane microviscosity upon interaction with beta-amyloid aggregates|10.1039/c8sm01633j
Patterns of grey matter loss associated with motor subscores in early Parkinson's disease|10.1016/j.nicl.2017.11.009
Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease|10.1016/j.nicl.2018.01.009
Testing the Protein Propagation Hypothesis of Parkinson Disease|10.1177/1179069518786715
The Binding of BF-227-Like Benzoxazoles to Human α-Synuclein and Amyloid β Peptide Fibrils|10.1177/1536012118796297
The Role of TMEM230 Gene in Parkinson's Disease.|10.3233/jpd-181421
The Unfolded Protein Response and Cell Fate Control|10.1016/j.molcel.2017.06.017
Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease|10.1016/j.parkreldis.2017.07.021
Using Molecular Tweezers to Remodel Abnormal Protein Self-Assembly and Inhibit the Toxicity of Amyloidogenic Proteins|10.1007/978-1-4939-7811-3_24
Venous Thromboembolism during Interventional MRI-Guided Stereotactic Surgery|10.1159/000486642
White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients|10.1016/j.nicl.2018.09.025
No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson’s disease|10.1093/brain/awx378
Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide|10.1016/j.neuron.2017.12.012
Mitotic defects lead to neuronal aneuploidy and apoptosis in frontotemporal lobar degeneration caused by MAPT mutations|10.1091/mbc.e17-01-0031
Network connectivity determines cortical thinning in early Parkinson’s disease progression|10.1038/s41467-017-02416-0
Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study|10.1093/brain/awx376
A randomized, double‐blind, placebo‐controlled trial of camicinal in Parkinson's disease|10.1002/mds.27259
Can we accurately classify schizophrenia patients from healthy controls using magnetic resonance imaging and machine learning? A multi-method and multi-dataset study|10.1016/j.schres.2017.11.038
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease|10.1093/jnen/nlx110
The role of microbial amyloid in neurodegeneration|10.1371/journal.ppat.1006654
A high-resolution map of the human small non-coding transcriptome|10.1093/bioinformatics/btx814
Combining clinical and biofluid markers for early Parkinson's disease detection|10.1002/acn3.509
Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease|10.1371/journal.pone.0189161
Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease|10.1016/j.neurobiolaging.2017.12.012
A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging|10.1016/j.neuroimage.2017.12.050
Photophysics of diphenyl-pyrazole compounds in solutions and α-synuclein aggregates|10.1016/j.bbagen.2017.12.007
The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson's disease|10.1016/j.neuroimage.2017.12.012
A Marked Point Process Framework for Extracellular Electrical Potentials|10.3389/fnsys.2017.00095
Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study|10.1016/s1474-4422(17)30400-3
Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease|10.1111/febs.14332
Neurodegeneration: Keeping ATF4 on a Tight Leash|10.3389/fncel.2017.00410
Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness|10.1016/j.sleep.2017.11.1137
Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease|10.3389/fcell.2017.00110
Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons|10.1016/j.nbd.2017.12.005
iPS cells in the study of PD molecular pathogenesis|10.1007/s00441-017-2749-y
Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease|10.1001/jamaneurol.2017.3713
The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1|10.1002/cbic.201700500
Reverters from PD-MCI to cognitively intact are at risk for future cognitive impairment: Analysis of the PPMI cohort|10.1016/j.parkreldis.2017.12.006
Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase|10.15252/embj.201798099
Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term|10.1007/s00401-017-1792-9
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features|10.1002/mds.27232
Failure of Sequential Pallidal and Motor Thalamus DBS for Rapid‐Onset Dystonia‐Parkinsonism (DYT12)|10.1002/mdc3.12559
The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein|10.1016/j.nbd.2017.11.006
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease|10.1016/j.expneurol.2017.07.019
Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease|10.1016/j.expneurol.2017.08.001
Exercise response in Parkinson’s disease: insights from a cross-sectional comparison with sedentary controls and a per-protocol analysis of a randomised controlled trial|10.1136/bmjopen-2017-017194
Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia|10.1007/s10286-017-0487-6
Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease|10.1016/j.expneurol.2017.10.001
Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: the N3iPD study (nigrosomalironimagingin Parkinson’s disease)|10.1136/bmjopen-2017-016904
Targeting urate to reduce oxidative stress in Parkinson disease|10.1016/j.expneurol.2017.06.017
Therapeutic approaches to target alpha-synuclein pathology|10.1016/j.expneurol.2017.10.003
A proteomic network approach across the ALS ‐ FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain|10.15252/emmm.201708202
Altered Differentiation Potential of Gaucher’s Disease iPSC Neuronal Progenitors due to Wnt/β-Catenin Downregulation|10.1016/j.stemcr.2017.10.029
Applying a community-based participatory research framework to patient and family engagement in the development of patient-centered outcomes research and practice|10.1093/tbm/ibx026
Comparison of machine learning and semi-quantification algorithms for (I123)FP-CIT classification: the beginning of the end for semi-quantification?|10.1186/s40658-017-0196-1
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.|10.1016/j.neuropharm.2017.11.046
Exploring the reproducibility of functional connectivity alterations in Parkinson’s disease|10.1371/journal.pone.0188196
Orthostatic hypotension in Parkinson disease: Impact on health care utilization|10.1016/j.parkreldis.2017.11.344
Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers|10.1093/brain/awx344
Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience|10.1186/s13073-017-0486-1
Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers|10.1186/s40478-017-0492-y
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias|10.1016/j.parkreldis.2017.11.338
Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice|10.1038/s41598-017-15813-8
α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration|10.1186/s40478-017-0494-9
Phosphorylation of LAMP2A by p38 MAPK couples ER stress to chaperone-mediated autophagy|10.1038/s41467-017-01609-x
Coordinated reset vibrotactile stimulation shows prolonged improvement in Parkinson's disease|10.1002/mds.27223
Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson’s disease|10.1093/brain/awx333
Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels|10.1186/s12883-017-0978-z
Functional Brain Imaging Synthesis Based on Image Decomposition and Kernel Modeling: Application to Neurodegenerative Diseases|10.3389/fninf.2017.00065
An invisible ubiquitin conformation is required for efficient phosphorylation by PINK 1|10.15252/embj.201797876
Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase|10.1042/bcj20170802
Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils|10.1042/bcj20170803
Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis|10.7554/elife.31012
About miRNAs, miRNA seeds, target genes and target pathways|10.18632/oncotarget.22363
Cocaine and desipramine elicit distinct striatal noradrenergic and behavioral responses in selectively bred obesity-resistant and obesity-prone rats|10.1016/j.bbr.2017.11.009
Neuropathological and transcriptomic characteristics of the aged brain|10.7554/elife.31126
SAMTOR is an S -adenosylmethionine sensor for the mTORC1 pathway|10.1126/science.aao3265
Parkinson's disease prevalence in Fabry disease: A survey study|10.1016/j.ymgmr.2017.10.013
White Matter Changes Correlates of Peripheral Neuroinflammation in Patients with Parkinson’s Disease|10.1016/j.neuroscience.2017.10.050
Data-Driven Sequence of Changes to Anatomical Brain Connectivity in Sporadic Alzheimer’s Disease|10.3389/fneur.2017.00580
Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease|10.1097/rlu.0000000000001885
Characterization of oromotor and limb motor dysfunction in the DJ1 -/- model of Parkinson disease|10.1016/j.bbr.2017.10.036
Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation|10.1021/acschemneuro.7b00385
Increased odds of bladder and bowel symptoms in early Parkinson's disease|10.1002/nau.23443
Positron emission tomography in Parkinson’s disease: insights into impulsivity|10.1080/09540261.2017.1398139
APP/Aβ structural diversity and Alzheimer's disease pathogenesis|10.1016/j.neuint.2017.08.007
Increasing Efficiency of Recruitment in Early Parkinson’s Disease Trials: A Case Study Examination of the STEADY-PD III Trial|10.3233/jpd-171199
Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?|10.3233/jpd-171240
Mitostasis in Neurons: Maintaining Mitochondria in an Extended Cellular Architecture|10.1016/j.neuron.2017.09.055
MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP|10.1016/j.parkreldis.2017.10.020
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature|10.1002/mds.27193
S-Nitrosylation of PINK1 Attenuates PINK1/Parkin-Dependent Mitophagy in hiPSC-Based Parkinson’s Disease Models|10.1016/j.celrep.2017.10.068
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry|10.1080/15622975.2017.1375556
Genetic influences on cognition in progressive supranuclear palsy|10.1002/mds.27196
Structure of PINK1 in complex with its substrate ubiquitin|10.1038/nature24645
Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases|10.1016/j.jalz.2017.09.012
Cognition and the course of prodromal Parkinson's disease|10.1002/mds.27189
Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson’s disease|10.1371/journal.pone.0186508
Square biphasic pulse deep brain stimulation for essential tremor: The BiP tremor study|10.1016/j.parkreldis.2017.10.015
Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study|10.1016/j.nicl.2017.10.020
Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease|10.1002/acn3.489
A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons|10.1021/acschemneuro.7b00329
Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case|10.1186/s40478-017-0482-0
MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy|10.3389/fnmol.2017.00329
Symptom Dimensions of Depression and Apathy and Their Relationship With Cognition in Parkinson’s Disease|10.1017/s1355617717001011
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls|10.1212/wnl.0000000000004609
Association of red cell distribution width with all-cause and cardiovascular-specific mortality in African American and white adults: a prospective cohort study|10.1186/s12967-017-1313-6
Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease|10.1096/fj.201700731r
A homologue of the Parkinson’s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover|10.1038/s41467-017-01103-4
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease|10.1093/brain/awx285
Correlation of Plasma EGF with Striatal Dopamine Transporter Availability in Healthy Subjects|10.1038/s41598-017-13771-9
The End Is the Beginning: Parkinson’s Disease in the Light of Brain Imaging|10.3389/fnagi.2017.00330
Traumatic brain injury in the prodromal period of Parkinson's disease: A large epidemiological study using medicare data|10.1002/ana.25074
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort|10.1136/jnnp-2017-316213
Network Structure and Function in Parkinson’s Disease|10.1093/cercor/bhx267
Pedestrian safety in patients with Parkinson's disease: A case‐control study|10.1002/mds.27124
Genetic variants affecting equivalent protein family positions reflect human diversity|10.1038/s41598-017-12971-7
Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?|10.1002/mdc3.12545
18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study|10.1002/ana.25060
The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders|10.1016/j.pneurobio.2016.01.006
Hexokinases link DJ-1 to the PINK1/parkin pathway|10.1186/s13024-017-0212-x
Patients’ Opinions on Genetic Counseling on the Increased Risk of Parkinson Disease among Gaucher Disease Carriers|10.1007/s10897-017-0161-0
The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology|10.3389/fnmol.2017.00311
Microstructural network alterations of olfactory dysfunction in newly diagnosed Parkinson’s disease|10.1038/s41598-017-12947-7
Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease|10.1002/mds.27184
Essential Tremor and Depression|10.1002/mdc3.12530
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation|10.1016/s1474-4422(17)30328-9
Mechanism and regulation of the Lys6-selective deubiquitinase USP30|10.1038/nsmb.3475
Par3 and aPKC regulate BACE1 endosome-to-TGN trafficking through PACS1|10.1016/j.neurobiolaging.2017.08.024
Progression of MDS‐UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort|10.1002/mdc3.12553
Structural connectome alterations in prodromal and de novo Parkinson's disease patients|10.1016/j.parkreldis.2017.09.019
Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling|10.1016/j.molcel.2017.08.020
Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice|10.7554/elife.28377
TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease|10.1073/pnas.1713969114
A Nigro−Vagal Pathway Controls Gastric Motility and Is Affected in a Rat Model of Parkinsonism|10.1053/j.gastro.2017.08.069
More than constipation – bowel symptoms in Parkinson's disease and their connection to gut microbiota|10.1111/ene.13398
Parkinson's disease susceptibility variants and severity of Lewy body pathology|10.1016/j.parkreldis.2017.09.009
The ice test to differentiate essential tremor from Parkinson’s disease tremor|10.1016/j.clinph.2017.08.015
Color discrimination errors associate with axial motor impairments in Parkinson's Disease|10.1002/mdc3.12527
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease|10.1126/science.aam9080
Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype|10.1002/acn3.447
MitoNEET (CISD1) Knockout Mice Show Signs of Striatal Mitochondrial Dysfunction and a Parkinson’s Disease Phenotype|10.1021/acschemneuro.7b00287
Preparation of biogenic gas vesicle nanostructures for use as contrast agents for ultrasound and MRI|10.1038/nprot.2017.081
Subthalamic neural entropy is a feature of freezing of gait in freely moving people with Parkinson's disease|10.1016/j.nbd.2017.09.002
Alcohol improves cerebellar learning deficit in myoclonus–dystonia: A clinical and electrophysiological investigation|10.1002/ana.25035
Engineered Axonal Tracts as “Living Electrodes” for Synaptic‐Based Modulation of Neural Circuitry|10.1002/adfm.201701183
Serum lipid alterations in GBA-associated Parkinson's disease|10.1016/j.parkreldis.2017.08.026
Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient|10.1097/wnf.0000000000000230
Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis|10.1016/j.ebiom.2017.09.009
Detection, risk factors, and functional consequences of cerebral microinfarcts|10.1016/s1474-4422(17)30196-5
Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson’s disease|10.1371/journal.pone.0184117
Effects of α-synuclein on axonal transport|10.1016/j.nbd.2016.12.008
Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in vitro and in Fxn-deficient KIKO mice in vivo|10.1016/j.neuropharm.2017.05.011
α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration|10.1016/j.nbd.2017.05.014
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease|10.1126/science.aaf3934
Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients|10.1002/mds.27136
Clinicopathologic discrepancies in a population‐based incidence study of parkinsonism in olmsted county: 1991‐2010|10.1002/mds.27125
Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease|10.1002/mds.27132
The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder|10.1002/mds.27105
Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells|10.1038/s41598-017-10501-z
The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease|10.1007/s12035-017-0748-3
The LRR-Roc-COR module of theChlorobium tepidumRoco protein: crystallization and X-ray crystallographic analysis|10.1107/s2053230x17011955
Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide|10.1016/j.nbd.2017.08.009
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease|10.1186/s12974-017-0935-1
LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection|10.1084/jem.20170014
GBA mutations in Parkinson disease: earlier death but similar neuropathological features|10.1111/ene.13395
The facial morphology in Down syndrome: A 3D comparison of patients with and without obstructive sleep apnea|10.1002/ajmg.a.38399
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias|10.1007/s11910-017-0789-z
Recombinant &#945;- &#946;- and &#947;-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays|10.3791/55361
Alpha-synuclein oligomers: a new hope|10.1007/s00401-017-1755-1
Cholinergic activity and levodopa‐induced dyskinesia: a multitracer molecular imaging study|10.1002/acn3.438
LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease|10.1093/hmg/ddx320
Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles|10.1371/journal.pone.0181844
Measures of impulsivity in Parkinson's disease decrease after DBS in the setting of stable dopamine therapy|10.1016/j.parkreldis.2017.08.006
Beliefs About Use of Complementary Health Approaches for Parkinson's Disease|10.1097/hnp.0000000000000229
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial|10.1016/s0140-6736(17)31585-4
Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease|10.1038/s41598-017-07181-0
BRAPH: A graph theory software for the analysis of brain connectivity|10.1371/journal.pone.0178798
Establishing the role of rare coding variants in known Parkinson's disease risk loci|10.1016/j.neurobiolaging.2017.07.009
Microglial phenotypes in Parkinson’s disease and animal models of the disease|10.1016/j.pneurobio.2016.04.006
mzStudio: A Dynamic Digital Canvas for User-Driven Interrogation of Mass Spectrometry Data|10.3390/proteomes5030020
The role of neurotransmitters in the development of Parkinson's disease‐related psychosis|10.1111/ene.13376
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia|10.1186/s13195-017-0276-4
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis|10.1111/cts.12492
Parkinson disease–associatedLRRK2 G2019Stransgene disrupts marrow myelopoiesis and peripheral Th17 response|10.1189/jlb.1a0417-147rr
No evidence for toxicity after long-term photobiomodulation in normal non-human primates|10.1007/s00221-017-5048-7
Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study|10.1111/1475-6773.12744
A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations|10.1002/mds.27090
Motor subtype changes in early Parkinson's disease|10.1016/j.parkreldis.2017.07.018
Vagally mediated effects of brain stem dopamine on gastric tone and phasic contractions of the rat|10.1152/ajpgi.00180.2017
Evaluating community health workers' attributes, roles, and pathways of action in immigrant communities|10.1016/j.ypmed.2017.07.020
Minimal clinically important difference of the Modified Fatigue Impact Scale in Parkinson's disease|10.1016/j.parkreldis.2017.07.016
Striatal cholinergic interneurons and Parkinson's disease|10.1111/ejn.13638
Tissue-specific network-based genome wide study of amygdala imaging phenotypes to identify functional interaction modules|10.1093/bioinformatics/btx344
Comparison of Cortical and Subcortical Measurements in Normal Older Adults across Databases and Software Packages|10.3233/adr-170008
Mentally stimulating activities associate with better cognitive performance in Parkinson disease|10.1007/s00702-017-1761-4
O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson’s disease|10.1186/s13041-017-0311-1
Temporal Order of Alzheimer’s Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies|10.3233/jad-170448
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease|10.1038/ng.3916
Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort|10.1007/s00415-017-8562-4
UbMES and UbFluor: Novel probes for ring-between-ring (RBR) E3 ubiquitin ligase PARKIN|10.1074/jbc.m116.773200
Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form|10.1016/j.nbd.2017.07.007
Progress toward an integrated understanding of Parkinson’s disease|10.12688/f1000research.11820.1
Integrating Next-Generation Genomic Sequencing and Mass Spectrometry To Estimate Allele-Specific Protein Abundance in Human Brain|10.1021/acs.jproteome.7b00324
Ligand Dependent Switch from RXR Homo- to RXR-NURR1 Heterodimerization|10.1021/acschemneuro.7b00216
The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions|10.1038/s41598-017-05760-9
multiplierzv2.0: A Python-based ecosystem for shared access and analysis of native mass spectrometry data|10.1002/pmic.201700091
DNA isolation protocol effects on nuclear DNA analysis by microarrays, droplet digital PCR, and whole genome sequencing, and on mitochondrial DNA copy number estimation|10.1371/journal.pone.0180467
Predictors of anxiety in early-stage Parkinson's disease – Results from the first two years of a prospective cohort study|10.1016/j.parkreldis.2017.06.024
Fine-Tuning ER Stress Signal Transducers to Treat Amyotrophic Lateral Sclerosis|10.3389/fnmol.2017.00216
Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease|10.1038/nsmb.3433
D-512, a novel dopamine D2/3receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats|10.1111/bph.13937
Deregulation of α-synuclein in Parkinson’s disease: Insight from epigenetic structure and transcriptional regulation of SNCA|10.1016/j.pneurobio.2017.04.004
Improved Neuroimaging Atlas of the Dentate Nucleus|10.1007/s12311-017-0872-7
Parkin and PINK1 functions in oxidative stress and neurodegeneration|10.1016/j.brainresbull.2016.12.004
Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease|10.1016/j.taap.2017.04.004
Suspected non-Alzheimer's pathology – Is it non-Alzheimer's or non-amyloid?|10.1016/j.arr.2017.02.003
Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings|10.1007/s10897-017-0123-6
Multiple reaction monitoring (MRM)‐profiling for biomarker discovery applied to human polycystic ovarian syndrome|10.1002/rcm.7927
Quantitative proteomics identifies altered O‐GlcNAcylation of structural, synaptic and memory‐associated proteins in Alzheimer's disease|10.1002/path.4929
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease|10.1186/s40478-017-0456-2
Estimation of genetic risk function with covariates in the presence of missing genotypes|10.1002/sim.7376
Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson’s Disease|10.3390/brainsci7070074
Latent Cognitive Phenotypes in De Novo Parkinson’s Disease: A Person-Centered Approach|10.1017/s1355617717000406
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double‐blind, placebo‐controlled multicenter study|10.1002/mds.27092
Dopamine-dependent changes of cortical excitability induced by transcranial static magnetic field stimulation in Parkinson’s disease|10.1038/s41598-017-04254-y
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry|10.1002/mds.27059
An Observational Study of the Effect of Levodopa–Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients|10.1007/s12325-017-0571-2
Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia|10.1111/jnc.14104
Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts|10.1016/s1474-4422(17)30122-9
BCL-2 family: integrating stress responses at the ER to control cell demise|10.1038/cdd.2017.82
Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity|10.1038/s41531-017-0021-5
Neuropathologic features of TOMM40 '523 variant on late‐life cognitive decline|10.1016/j.jalz.2017.05.002
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates|10.1186/s40478-017-0451-7
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons|10.1001/jama.2017.6669
Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study|10.1371/journal.pmed.1002314
A Bayesian mathematical model of motor and cognitive outcomes in Parkinson’s disease|10.1371/journal.pone.0178982
Mild cognitive impairment as a risk factor for Parkinson's disease dementia|10.1002/mds.27002
Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology|10.1002/acn3.421
Connectivity Predicts deep brain stimulation outcome in Parkinson disease|10.1002/ana.24974
A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein|10.1007/s13311-017-0544-9
Role of LRRK2 in the regulation of dopamine receptor trafficking|10.1371/journal.pone.0179082
The missing, the short, and the long: Levodopa responses and dopamine actions|10.1002/ana.24961
Cutaneous Alpha-Synuclein From Paraffin Embedded Autopsy Specimens in Parkinson’s Disease|10.3233/jpd-171088
Dorsal Raphe Dopamine Neurons Modulate Arousal and Promote Wakefulness by Salient Stimuli|10.1016/j.neuron.2017.05.020
Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome|10.1016/j.neuron.2017.06.010
Anatomically Inspired Three-dimensional Micro-tissue Engineered Neural Networks for Nervous System Reconstruction, Modulation, and Modeling|10.3791/55609
Heritability of hippocampal subfield volumes using a twin and non-twin siblings design|10.1002/hbm.23654
4R-Cembranoid Improves Outcomes after 6-Hydroxydopamine Challenge in Both In vitro and In vivo Models of Parkinson's Disease|10.3389/fnins.2017.00272
Longitudinal assessment of excessive daytime sleepiness in early Parkinson’s disease|10.1136/jnnp-2016-315023
Progression marker of Parkinson’s disease: a 4-year multi-site imaging study|10.1093/brain/awx146
Tau/α‐synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study|10.1002/mds.27001
Factor structure of the Montreal Cognitive Assessment items in a sample with early Parkinson's disease|10.1016/j.parkreldis.2017.05.023
The Retina in Multiple System Atrophy: Systematic Review and Meta-Analysis|10.3389/fneur.2017.00206
Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson’s Symptoms|10.3389/fnagi.2017.00151
Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa Cohort|10.1002/mdc3.12511
Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins|10.1007/s00401-017-1722-x
Effect of low versus high frequency stimulation on freezing of gait and other axial symptoms in Parkinson patients with bilateral STN DBS: a mini-review|10.1186/s40035-017-0083-7
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease|10.1371/journal.pone.0175674
Return of D4 Dopamine Receptor Antagonists in Drug Discovery|10.1021/acs.jmedchem.7b00151
Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts|10.1002/mds.27035
Current Practice and the Future of Deep Brain Stimulation Therapy in Parkinson's Disease|10.1055/s-0037-1601893
Domain‐specific cognitive impairment in non‐demented Parkinson's disease psychosis|10.1002/gps.4736
Motor Complications of Dopaminergic Medications in Parkinson's Disease|10.1055/s-0037-1602423
Neuropsychological Subgroups in Non-Demented Parkinson’s Disease: A Latent Class Analysis|10.3233/jpd-171081
Recognizing Atypical Parkinsonisms: “Red Flags” and Therapeutic Approaches|10.1055/s-0037-1602422
The Phenomenology of Parkinson's Disease|10.1055/s-0037-1601869
VPS35, the Retromer Complex and Parkinson’s Disease|10.3233/jpd-161020
Normative morphometric data for cerebral cortical areas over the lifetime of the adult human brain|10.1016/j.neuroimage.2017.05.019
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?|10.1002/mds.27038
Which ante mortem clinical features predict progressive supranuclear palsy pathology?|10.1002/mds.27034
Parkin regulation of CHOP modulates susceptibility to cardiac endoplasmic reticulum stress|10.1038/s41598-017-02339-2
Altered cargo proteins of human plasma endothelial cell–derived exosomes in atherosclerotic cerebrovascular disease|10.1096/fj.201700149
Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice|10.1016/j.nlm.2017.05.001
Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update|10.1021/acschemneuro.6b00440
Freesurfer cortical normative data for adults using Desikan-Killiany-Tourville and ex vivo protocols|10.1016/j.neuroimage.2017.04.035
Cystinosin, the small GTPase Rab11, and the Rab7 effector RILP regulate intracellular trafficking of the chaperone-mediated autophagy receptor LAMP2A|10.1074/jbc.m116.764076
Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease|10.1016/j.parkreldis.2017.05.001
Limbic grey matter changes in early Parkinson's disease|10.1002/hbm.23610
Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease|10.1016/j.parkreldis.2017.02.008
Lewy Body Disorders|10.1016/j.ncl.2017.01.004
RIC3 variants are not associated with Parkinson's disease in French-Canadians and French|10.1016/j.neurobiolaging.2017.01.005
Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation|10.1038/s41598-017-01587-6
GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2|10.1093/hmg/ddx161
The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity|10.1186/s13024-017-0174-z
Endoplasmic reticulum proteostasis impairment in aging|10.1111/acel.12599
Imaging genetics approach to Parkinson’s disease and its correlation with clinical score|10.1038/srep46700
Lack of interleukin-13 receptor α1 delays the loss of dopaminergic neurons during chronic stress|10.1186/s12974-017-0862-1
Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression|10.1016/j.jagp.2017.04.011
Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) (P1.013)|10.1212/wnl.88.16_supplement.p1.013
Fox Insight: a Large-Scale Web-Enabled Parkinson’s Disease Study (P4.007)|
Fox Insight: a Large-Scale Web-Enabled Parkinson’s Disease Study (P4.007)|10.1212/wnl.88.16_supplement.p4.007
Genetic analysis of α‐synuclein 3′ untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies|10.1016/j.jalz.2017.03.001
Neuropathic Gaucher’s Mutations: Shifting Parkinson’s Into High Gear (S1.002)|10.1212/wnl.88.16_supplement.s1.002
Targeted deletion of GD3 synthase protects against MPTP‐induced neurodegeneration|10.1111/gbb.12377
Association between autonomic dysfunction and fatigue in Parkinson disease|10.1016/j.jns.2017.04.023
Nonsinusoidal Beta Oscillations Reflect Cortical Pathophysiology in Parkinson's Disease|10.1523/jneurosci.2208-16.2017
Chronic multisite brain recordings from a totally implantable bidirectional neural interface: experience in 5 patients with Parkinson's disease|10.3171/2016.11.jns161162
DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers|10.1371/journal.pone.0175424
Drug repurposing to target proteostasis and prevent neurodegeneration: accelerating translational efforts|10.1093/brain/awx107
Ubiquitin and Parkinson's disease through the looking glass of genetics|10.1042/bcj20160498
Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases|10.1016/j.parkreldis.2017.04.006
Unraveling the Biologic Basis for Domain-Specific Cognitive Decline|10.1016/j.jagp.2017.04.007
Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson’s disease on chromosome 7p15.3|10.1007/s10048-017-0514-8
Novel conformation‐selective alpha‐synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease|10.1111/nan.12402
Whole transcriptome profiling of the human hippocampus suggests an involvement of the KIBRA rs17070145 polymorphism in differential activation of the MAPK signaling pathway|10.1002/hipo.22731
A sensitive assay reveals structural requirements for α-synuclein fibril growth|10.1074/jbc.m116.767053
Falls in people with Parkinson’s disease: A prospective comparison of community and home-based falls|10.1016/j.gaitpost.2017.04.005
Integrated molecular landscape of Parkinson’s disease|10.1038/s41531-017-0015-3
Media hype: Patient and scientific perspectives on misleading medical news|10.1002/mds.26993
The Unfolded Protein Response: At the Intersection between Endoplasmic Reticulum Function and Mitochondrial Bioenergetics|10.3389/fonc.2017.00055
Methamphetamine‐induced mitochondrial oxidant stress mediated by monoamine oxidase metabolism of dopamine|10.1096/fasebj.31.1_supplement.987.3
Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss|10.1016/j.neuro.2017.03.008
Parkinson disease in Gaucher disease|10.1186/s40734-017-0054-2
Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial|10.1016/j.parkreldis.2017.03.017
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease|10.1002/mds.26976
The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease|10.2217/bmm-2016-0366
The prodromal phase of leucine‐rich repeat kinase 2–associated Parkinson disease: Clinical and imaging Studies|10.1002/mds.26964
Nurr1:RXRα heterodimer activation as monotherapy for Parkinson’s disease|10.1073/pnas.1616874114
Kinetin Riboside and Its ProTides Activate the Parkinson’s Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization|10.1021/acs.jmedchem.6b01897
Disentangling the neural correlates of corticobasal syndrome and corticobasal degeneration with systematic and quantitative ALE meta-analyses|10.1038/s41531-017-0012-6
LRRK2 levels in immune cells are increased in Parkinson’s disease|10.1038/s41531-017-0010-8
The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2|10.1042/bcj20160909
An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression|10.1002/prca.201700045
Cortical surface‐based threshold‐free cluster enhancement and cortexwise mediation|10.1002/hbm.23563
Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes|10.1016/j.cels.2017.02.009
Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology|10.1016/j.neurobiolaging.2017.03.007
Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease|10.1016/j.neurobiolaging.2017.03.012
TMEM230 in Parkinson's disease|10.1016/j.neurobiolaging.2017.03.014
Photobiomodulation-induced changes in a monkey model of Parkinson’s disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum|10.1007/s00221-017-4937-0
Your algorithm might think the hippocampus grows in Alzheimer's disease: Caveats of longitudinal automated hippocampal volumetry|10.1002/hbm.23559
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice|10.1186/s40478-017-0426-8
Protein misfolding in neurodegenerative diseases: implications and strategies|10.1186/s40035-017-0077-5
Structure-guided mutagenesis reveals a hierarchical mechanism of Parkin activation|10.1038/ncomms14697
A screening tool to detect clinical manganese neurotoxicity|10.1016/j.neuro.2017.02.009
Disease-Specific Regions Outperform Whole-Brain Approaches in Identifying Progressive Supranuclear Palsy: A Multicentric MRI Study|10.3389/fnins.2017.00100
Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients|10.3389/fnagi.2017.00038
Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff|10.3233/jpd-179001
Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road|10.1186/s40734-017-0052-4
Consensus classification of posterior cortical atrophy|10.1016/j.jalz.2017.01.014
Freezing of gait and fall detection in Parkinson’s disease using wearable sensors: a systematic review|10.1007/s00415-017-8424-0
Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons|10.1523/eneuro.0216-16.2017
Neuropsychiatric symptoms in untreated Parkinson&rsquo;s disease|10.2147/ndt.s130997
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l‐DOPA treatment and changes in levodopa‐induced dyskinesia|10.1111/jnc.13997
Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers|10.1007/s00401-017-1685-y
In vivo detection of lateral–ventral tier nigral degeneration in Parkinson's disease|10.1002/hbm.23547
Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials|10.1002/mds.26913
Multi-modal and targeted imaging improves automated mid-brain segmentation|10.1117/12.2254428
Multi-scale hippocampal parcellation improves atlas-based segmentation accuracy|10.1117/12.2254425
Red hair, MC1R variants, and risk for Parkinson's disease – a meta‐analysis|10.1002/acn3.381
Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease|10.2174/1567205014666170203093219
Engineering Iron Responses in Mammalian Cells by Signal-Induced Protein Proximity|10.1021/acssynbio.6b00255
Post translational modification of Parkin|10.1186/s13062-017-0176-3
Classification of brain disease in magnetic resonance images using two-stage local feature fusion|10.1371/journal.pone.0171749
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease|10.1186/s40734-017-0051-5
A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned|10.1016/j.parkreldis.2017.02.003
Defining the contribution of neuroinflammation to Parkinson’s disease in humanized immune system mice|10.1186/s13024-017-0158-z
Reliable Identification of Living Dopaminergic Neurons in Midbrain Cultures Using RNA Sequencing and TH-promoter-driven eGFP Expression|10.3791/54981
AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models|10.3390/genes8020063
The LRRK2–macroautophagy axis and its relevance to Parkinson's disease|10.1042/bst20160265
Hypomethylation of intron1 of α-synuclein gene does not correlate with Parkinson’s disease|10.1186/s13041-017-0285-z
Are Parkinson’s Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study|10.1017/s1355617717000017
Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson’s disease patients with defined cholinergic losses|10.1016/j.neuroimage.2017.02.006
An Anatomically Resolved Mouse Brain Proteome Reveals Parkinson Disease-relevant Pathways|10.1074/mcp.m116.061440
Probabilistic conversion of neurosurgical DBS electrode coordinates into MNI space|10.1016/j.neuroimage.2017.02.004
LRRK2(I2020T) functional genetic interactors that modify eye degeneration and dopaminergic cell loss in Drosophila|10.1093/hmg/ddx030
AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease|10.1186/s40478-017-0416-x
Association Between Pathology and Electroencephalographic Activity in Parkinson’s Disease|10.1177/1550059417696179
Elevated 5hmC levels characterize DNA of the cerebellum in Parkinson’s disease|10.1038/s41531-017-0007-3
Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity|10.1016/j.nbd.2016.11.004
Parkinson Sac Domain Mutation in Synaptojanin 1 Impairs Clathrin Uncoating at Synapses and Triggers Dystrophic Changes in Dopaminergic Axons|10.1016/j.neuron.2017.01.019
Regional volumetric change in Parkinson's disease with cognitive decline|10.1016/j.jns.2016.12.030
Serotonin transporter in Parkinson's disease: A meta‐analysis of positron emission tomography studies|10.1002/ana.24859
The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease|10.1016/j.parkreldis.2017.01.015
The Mitochondrial Rhomboid Protease PARL Is Regulated by PDK2 to Integrate Mitochondrial Quality Control and Metabolism|10.1016/j.celrep.2017.01.029
Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson’s disease|10.1073/pnas.1621218114
Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing|10.1186/s13059-017-1147-9
Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension|10.1002/mdc3.12478
The human subthalamic nucleus and globus pallidus internus differentially encode reward during action control|10.1002/hbm.23496
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease|10.1016/j.expneurol.2017.01.012
Chelerythrine promotes Ca2+-dependent calpain activation in neuronal cells in a PKC-independent manner|10.1016/j.bbagen.2017.01.021
Leucine-Rich Repeat Kinase 2 (Lrrk2)-Sensitive Na+/K+ ATPase Activity in Dendritic Cells|10.1038/srep41117
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease|10.1186/s13024-017-0154-3
An early and late peak in microglial activation in Alzheimer’s disease trajectory|10.1093/brain/aww349
Essential pitfalls in “essential” tremor|10.1002/mds.26919
Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease|10.3233/jpd-160985
The Identification of Alpha-Synuclein as the First Parkinson Disease Gene|10.3233/jpd-179003
Inflammatory profile discriminates clinical subtypes in LRRK2‐associated Parkinson's disease|10.1111/ene.13223
Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling|10.1186/s13024-017-0153-4
The Neurosteroidogenic Enzyme 5α-Reductase Mediates Psychotic-Like Complications of Sleep Deprivation|10.1038/npp.2017.13
Multicellular hypothesis for the pathogenesis of Alzheimer's disease|10.1096/fj.201601221r
Combating Parkinson’s disease-associated toxicity by modulating proteostasis|10.1073/pnas.1620082114
α-Synuclein binds and sequesters PIKE-L into Lewy bodies, triggering dopaminergic cell death via AMPK hyperactivation|10.1073/pnas.1618627114
Intra‐ and inter‐network functional alterations in Parkinson's disease with mild cognitive impairment|10.1002/hbm.23499
Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies|10.1016/j.cca.2017.01.010
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?|10.1038/s41531-016-0002-0
Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor|10.1111/cns.12670
Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders|10.3389/fnhum.2016.00693
Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease|10.1038/srep40263
A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor|10.1093/jnen/nlw105
Orientation selective deep brain stimulation|10.1088/1741-2552/aa5238
Particle swarm optimization for programming deep brain stimulation arrays|10.1088/1741-2552/aa52d1
The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease|10.1093/jnen/nlw103
A storm in Sāmoa: an environmental microhistory|10.1080/13642529.2016.1270565
A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity|10.1159/000477990
Alterations in striato-thalamo-pallidal intrinsic functional connectivity as a prodrome of Parkinson's disease|10.1016/j.nicl.2017.08.003
Association between Various Brain Pathologies and Gait Disturbance|10.1159/000456541
Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients|10.1016/j.toxrep.2017.03.005
Chaperone-Based Therapies for Disease Modification in Parkinson’s Disease|10.1155/2017/5015307
Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients|10.1016/j.nicl.2017.08.013
Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson’s Disease (CAPTURE PD): Protocol for a Multicenter Study|10.3389/fneur.2017.00212
Distinct alterations in Parkinson's medication-state and disease-state connectivity|10.1016/j.nicl.2017.09.004
Divalent metal ions control activity and inhibition of protein kinases|10.1039/c7mt00204a
Dual-Task Performance in GBA Parkinson’s Disease|10.1155/2017/8582740
Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action|10.1523/eneuro.0117-16.2017
Functional connectivity disruptions correlate with cognitive phenotypes in Parkinson's disease|10.1016/j.nicl.2017.03.002
Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images|10.1016/j.nicl.2017.08.021
Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's|10.2217/pme-2016-0087
Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging|10.1016/j.celrep.2016.12.011
PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival|10.1016/j.celrep.2016.12.090
Predicting primary progressive aphasias with support vector machine approaches in structural MRI data|10.1016/j.nicl.2017.02.003
Protective effects of fisetin and other berry flavonoids in Parkinson's disease|10.1039/c7fo00809k
Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging|10.1016/j.nicl.2017.09.010
Should Skin Biopsies Be Performed in Patients Suspected of Having Parkinson’s Disease?|10.1155/2017/6064974
Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Is Not Associated with Increased Body Mass Index|10.1155/2017/7163801
Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential|10.1016/j.nbd.2016.07.009
Urate as a Marker of Risk and Progression of Neurodegenerative Disease|10.1007/s13311-016-0497-4
The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer’s Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging|10.3233/jad-160925
Nrf2 mitigates LRRK2- and α-synuclein–induced neurodegeneration by modulating proteostasis|10.1073/pnas.1522872114
Cross-validation of optimized composites for preclinical Alzheimer's disease|10.1016/j.trci.2016.12.001
The melanoma‐linked “redhead” MC1R influences dopaminergic neuron survival|10.1002/ana.24852
Weighted Protein Interaction Network Analysis of Frontotemporal Dementia|10.1021/acs.jproteome.6b00934
Leucine‐rich repeat kinase 2 and Parkinson's disease|10.1002/pmic.201600092
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases|10.1016/j.nbd.2016.12.013
Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease|10.1093/hmg/ddw429
Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults|10.3390/geriatrics1040033
The clinical heterogeneity of drug-induced myoclonus: an illustrated review|10.1007/s00415-016-8357-z
A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease|10.1016/j.cels.2016.11.006
Heritability of the shape of subcortical brain structures in the general population|10.1038/ncomms13738
Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission|10.1111/cns.12660
Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene|10.1016/j.parkreldis.2016.12.002
Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease|10.1080/00207454.2016.1269088
Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites|10.1007/s40336-016-0217-4
Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation|10.1002/mds.26882
LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies|10.1002/mds.26892
Patient Perspectives on Deep Brain Stimulation Clinical Research in Early Stage Parkinson’s Disease|10.3233/jpd-161031
Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1|10.1016/j.parkreldis.2016.10.005
Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease|10.1016/j.neurobiolaging.2016.07.013
Imaging analysis of Parkinson’s disease patients using SPECT and tractography|10.1038/srep38070
Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences|10.1093/bib/bbw114
Proceedings of the Fourth Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies|10.3389/fnint.2016.00038
Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging|10.1111/jgs.14670
Structural cerebellar correlates of cognitive and motor dysfunctions in cerebellar degeneration|10.1093/brain/aww327
Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study|10.1016/s1474-4422(16)30328-3
Cognitive phenotypes in parkinson's disease differ in terms of brain‐network organization and connectivity|10.1002/hbm.23474
Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT score|10.1111/ejn.13476
Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson’s Disease|10.3389/fnagi.2016.00271
Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations|10.1371/journal.pone.0166053
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ|10.1371/journal.pone.0165964
Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety|10.1002/wnan.1444
Sixty‐hertz stimulation improves bradykinesia and amplifies subthalamic low‐frequency oscillations|10.1002/mds.26837
Assessing Visuospatial Skills in Parkinson's: Comparison of Neuropsychological Assessment Battery Visual Discrimination to the Judgment of Line Orientation|10.1093/arclin/acw102
Role of sulfiredoxin as a peroxiredoxin-2 denitrosylase in human iPSC-derived dopaminergic neurons|10.1073/pnas.1608784113
Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia|10.1097/wad.0000000000000161
Loss-of-function mutations in theATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78)|10.1093/brain/aww307
Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism|10.1093/brain/aww261
Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activity|10.1242/dmm.025684
RNF213 Is Associated with Intracranial Aneurysms in the French-Canadian Population|10.1016/j.ajhg.2016.09.001
Progression of Regional Microstructural Degeneration in Parkinson’s Disease: A Multicenter Diffusion Tensor Imaging Study|10.1371/journal.pone.0165540
Intake of antioxidant vitamins and risk of Parkinson's disease|10.1002/mds.26819
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease|10.3389/fnagi.2016.00254
TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau|10.7554/elife.19809
A harmonized segmentation protocol for hippocampal and parahippocampal subregions: Why do we need one and what are the key goals?|10.1002/hipo.22671
CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson’s Disease—A Preliminary Report|10.1371/journal.pone.0164762
T2-Imaging Changes in the Nigrosome-1 Relate to Clinical Measures of Parkinson’s Disease|10.3389/fneur.2016.00174
White matter microstructural characteristics in newly diagnosed Parkinson’s disease: An unbiased whole-brain study|10.1038/srep35601
Is Axonal Degeneration a Key Early Event in Parkinson’s Disease?|10.3233/jpd-160881
The Effects of Physical Activity in Parkinson’s Disease: A Review|10.3233/jpd-160790
Clinical and demographic characteristics related to onset site and spread of cervical dystonia|10.1002/mds.26817
Dexmedetomidine for refractory adrenergic crisis in familial dysautonomia|10.1007/s10286-016-0383-5
Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity|10.1016/j.neurobiolaging.2016.10.006
Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression|10.1002/pmic.201600057
Dual Tasking for the Differentiation between Depression and Mild Cognitive Impairment|10.3389/fnagi.2016.00235
Digitized Spiral Drawing: A Possible Biomarker for Early Parkinson’s Disease|10.1371/journal.pone.0162799
mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1|10.1038/srep35106
Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease|10.1126/scitranslmed.aad8858
Additional rare variant analysis in Parkinson’s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance|10.1093/hmg/ddw348
Machine Learning Interface for Medical Image Analysis|10.1007/s10278-016-9910-0
Neuropsychological impairment in prodromal Parkinson's disease|10.1016/j.jns.2016.10.007
Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases|10.1038/sdata.2016.89
Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease|10.1016/j.parkreldis.2016.10.006
N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase|10.1016/j.nbd.2016.10.001
Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans|10.1038/srep34477
Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration|10.1002/mds.26815
Computer keyboard interaction as an indicator of early Parkinson’s disease|10.1038/srep34468
AAV viral vector delivery to the brain by shape-conforming MR-guided infusions|10.1016/j.jconrel.2016.02.034
Adaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbations|10.1016/j.brainres.2016.02.033
Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum|10.1016/j.neurobiolaging.2016.06.003
Gene therapy to target ER stress in brain diseases|10.1016/j.brainres.2016.04.064
Injury to the nervous system: A look into the ER|10.1016/j.brainres.2016.04.053
LRRK2 inhibitors and their potential in the treatment of Parkinson&rsquo;s disease: current perspectives|10.2147/cpaa.s102191
Perspective: Data sharing for discovery|10.1038/538s4a
The best medicine? The influence of physical activity and inactivity on Parkinson's disease|10.1002/mds.26728
Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease|10.1016/j.neuropharm.2016.09.028
Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes|10.1016/j.parkreldis.2016.09.025
Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease|10.1038/srep34579
PREFACE: Divergent roles of ER stress in neurodegeneration and brain disorders|10.1016/j.brainres.2016.09.014
Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI|10.1007/s10334-016-0590-z
Ade novocompound targeting α-synuclein improves deficits in models of Parkinson’s disease|10.1093/brain/aww238
SWATH-MS proteome profiling data comparison of DJ-1, Parkin, and PINK1 knockout rat striatal mitochondria|10.1016/j.dib.2016.09.031
Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease|10.3390/brainsci6040041
Self-Reported Symptoms of Parkinson’s Disease by Sex and Disease Duration|10.1177/0193945916670904
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's|10.1002/ana.24781
Hippocampal shape alterations are associated with regional Aβ load in cognitively normal elderly individuals|10.1111/ejn.13408
Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism|10.1038/gt.2016.62
Ruminative brooding is associated with salience network coherence in early pubertal youth|10.1093/scan/nsw133
Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA|10.1007/s00216-016-9863-7
Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson’s Disease|10.1016/j.stem.2016.08.002
Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies|10.1016/j.neurobiolaging.2016.08.023
Identification of small molecules that bind to the mitochondrial protein mitoNEET|10.1016/j.bmcl.2016.09.009
Structural insights into Parkin substrate lysine targeting from minimal Miro substrates|10.1038/srep33019
Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies|10.1002/acn3.337
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF|10.1186/s13024-016-0130-3
Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease|10.1096/fj.201600816r
Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys|10.1021/acschemneuro.6b00186
Multiplex immunoassay characterization and species comparison of inflammation in acute and non-acute ischemic infarcts in human and mouse brain tissue|10.1186/s40478-016-0371-y
Neuropsychiatric characteristics of GBA-associated Parkinson disease|10.1016/j.jns.2016.08.059
Environmental Exposures and Parkinson’s Disease|10.3390/ijerph13090881
Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer’s Disease|10.3233/jad-160528
Integration of transcriptomic and genomic data suggests candidate mechanisms for APOE4-mediated pathogenic action in Alzheimer’s disease|10.1038/srep32583
Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson’s Disease and Control Subjects|10.3233/jpd-160888
Epidemiology of Major Neurodegenerative Diseases in Women: Contribution of the Nurses’ Health Study|10.2105/ajph.2016.303324
Impaired perception of biological motion in Parkinson’s disease.|10.1037/neu0000276
Magnetic resonance imaging as a potential biomarker for Parkinson's disease|10.1016/j.trsl.2015.12.006
Sensory aspects in myasthenia gravis: A translational approach|10.1016/j.jns.2016.07.014
The polarity protein Par3 regulates APP trafficking and processing through the endocytic adaptor protein Numb|10.1016/j.nbd.2016.03.022
Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases|10.1101/cshperspect.a023630
Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease|10.1001/jamaneurol.2016.2245
Loss of Pink1 modulates synaptic mitochondrial bioenergetics in the rat striatum prior to motor symptoms: concomitant complex I respiratory defects and increased complex II‐mediated respiration|10.1002/prca.201600005
Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies|10.1002/acn3.338
Large-Scale Wearable Sensor Deployment in Parkinson’s Patients: The Parkinson@Home Study Protocol|10.2196/resprot.5990
Structural connectivity profile of scans without evidence of dopaminergic deficit (SWEDD) patients compared to normal controls and Parkinson’s disease patients|10.1186/s40064-016-3110-8
Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery|10.1038/srep31732
Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors|10.7554/elife.17111
A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein|10.1186/s13024-016-0125-0
Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression|10.1002/mds.26754
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension|10.1186/s12883-016-0665-5
LRRK2 deficiency impacts ceramide metabolism in brain|10.1016/j.bbrc.2016.08.082
Cargo proteins of plasma astrocyte‐derived exosomes in Alzheimer's disease|10.1096/fj.201600756r
Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker|10.1038/srep31391
Parkinson's disease is ready for precision medicine|10.2217/pme-2016-0052
Moving Parkinson care to the home|10.1002/mds.26744
Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease|10.1084/jem.20160368
Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism‐like phenotype in mice|10.15252/embj.201593585
Predictive Big Data Analytics: A Study of Parkinson’s Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations|10.1371/journal.pone.0157077
Commentary: XBP-1 Is a Cell-Nonautonomous Regulator of Stress Resistance and Longevity|10.3389/fnagi.2016.00182
Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein|10.1073/pnas.1610099113
LRRK2 variation and dementia with Lewy bodies|10.1016/j.parkreldis.2016.07.015
Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors|10.1042/bcj20160557
Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor protein‐specific antibodies|10.1111/acel.12508
Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson’s disease patients|10.1038/srep30793
A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism|10.1007/s00259-016-3464-8
miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1)|10.1186/s13024-016-0121-4
Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats|10.1016/j.neuropharm.2016.07.025
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers|10.1021/acschemneuro.6b00036
Arm swing as a potential new prodromal marker of Parkinson's disease|10.1002/mds.26720
Loss of SYNJ1 dual phosphatase activity leads to early onset refractory seizures and progressive neurological decline|10.1093/brain/aww180
Manual-Protocol Inspired Technique for Improving Automated MR Image Segmentation during Label Fusion|10.3389/fnins.2016.00325
LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts|10.1038/srep29945
Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia|10.1016/j.cortex.2016.07.004
Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases|10.1080/14756366.2016.1193734
Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population‐based elderly cohort|10.1016/j.jalz.2016.06.001
Parkinsonian monkeys with prior levodopa‐induced dyskinesias followed by fetal dopamine precursor grafts do not display graft‐induced dyskinesias|10.1002/cne.24081
Nocardia asteroides‐Induced movement abnormalities in mice: Relevance for Parkinson's disease?|10.1002/mds.26711
Nilotinib – Differentiating the Hope from the Hype|10.3233/jpd-160904
A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers|10.1007/s00429-016-1271-4
Subcortical Volumes Differ in Parkinson’s Disease Motor Subtypes: New Insights into the Pathophysiology of Disparate Symptoms|10.3389/fnhum.2016.00356
Effects of a higher dose of near-infrared light on clinical signs and neuroprotection in a monkey model of Parkinson's disease|10.1016/j.brainres.2016.07.005
Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity|10.1021/acschemneuro.6b00154
Discovery and characterization of a novel series of N -phenylsulfonyl-1 H -pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu 4 )|10.1016/j.bmcl.2016.05.029
The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder|10.1016/j.neurobiolaging.2016.03.029
Using Qualitative Methods to Understand Physical Activity and Weight Management Among Bangladeshis in New York City, 2013|10.5888/pcd13.160077
Epigenetic regulation in Parkinson’s disease|10.1007/s00401-016-1590-9
Semisynthetic and in Vitro Phosphorylation of Alpha-Synuclein at Y39 Promotes Functional Partly Helical Membrane-Bound States Resembling Those Induced by PD Mutations|10.1021/acschembio.6b00539
Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts|10.1073/pnas.1523708113
Hepatitis B Virus-Induced Parkin-Dependent Recruitment of Linear Ubiquitin Assembly Complex (LUBAC) to Mitochondria and Attenuation of Innate Immunity|10.1371/journal.ppat.1005693
Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter case–control study|10.1016/j.yebeh.2016.05.032
Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism|10.1016/j.pjnns.2016.05.008
Juvenile onset Parkinsonism with “pure nigral” degeneration and POLG1 mutation|10.1016/j.parkreldis.2016.06.013
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension|10.1097/wnf.0000000000000168
MAPT haplotype diversity in multiple system atrophy|10.1016/j.parkreldis.2016.06.010
Post-traumatic Functional Mirror Movements in Klippel-Feil Syndrome|10.1002/mdc3.12405
Problematic Mobile Gaming in Parkinson's Disease: An Impulse Control Disorder for the Smartphone|10.1002/mdc3.12378
α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease|10.1002/acn3.321
Mitochondrial DNA Rearrangement Spectrum in Brain Tissue of Alzheimer’s Disease: Analysis of 13 Cases|10.1371/journal.pone.0154582
Ser(P)‐1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease|10.1002/mds.26686
Neuroimmunology of the Interleukins 13 and 4|10.3390/brainsci6020018
Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition|10.1093/jnen/nlw047
A grounded theory study on the influence of sleep on Parkinson’s symptoms|10.1186/s13104-016-2114-3
Deep brain stimulation for the treatment of uncommon tremor syndromes|10.1080/14737175.2016.1194756
Model-Based Comparison of Deep Brain Stimulation Array Functionality with Varying Number of Radial Electrodes and Machine Learning Feature Sets|10.3389/fncom.2016.00058
Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease|10.1136/jnnp-2015-312690
Scheduled, intermittent stimulation of the thalamus reduces tics in Tourette syndrome|10.1016/j.parkreldis.2016.05.033
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease|10.1186/s12883-016-0610-7
Physiological, pathological, and engineered cell identity reprogramming in the central nervous system|10.1002/wdev.234
Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: A harbinger of freezing of gait?|10.1002/mds.26665
The mitochondrial kinase PINK1: functions beyond mitophagy|10.1111/jnc.13655
Increased 5-hydroxymethylation levels in the sub ventricular zone of the Alzheimer's brain|10.1016/j.nepig.2016.04.002
Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson’s Disease|10.1007/s13311-016-0449-z
Neuroscience Training for the 21st Century|10.1016/j.neuron.2016.05.030
Structural Brain Alterations Associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease|10.1038/srep26782
Two-Pore Channels and Parkinson's Disease: Where's the Link?|10.1166/msr.2016.1051
Histone H3 acetylation in the postmortem Parkinson’s disease primary motor cortex|10.1016/j.neulet.2016.05.060
A review of disease progression models of Parkinson's disease and applications in clinical trials|10.1002/mds.26644
JUMPg: An Integrative Proteogenomics Pipeline Identifying Unannotated Proteins in Human Brain and Cancer Cells|10.1021/acs.jproteome.6b00344
Motor subtype in Parkinson's disease: Different disorders or different stages of disease?|10.1002/mds.26657
Cerebrospinal Fluid Amyloid β<sub>1-42</sub>, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease|10.14802/jmd.16017
Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo|10.1021/acschembio.6b00217
Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease|10.1089/ars.2015.6598
Vagal neurocircuitry and its influence on gastric motility|10.1038/nrgastro.2016.76
Inflammatory profile in LRRK2-associated prodromal and clinical PD|10.1186/s12974-016-0588-5
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease|10.1002/mds.26659
Cautionary optimism: caffeine and Parkinson’s disease risk|10.1186/s40734-016-0037-8
LRRK2 Regulates Voltage-Gated Calcium Channel Function|10.3389/fnmol.2016.00035
Objective characterization of daily living transitions in patients with Parkinson’s disease using a single body-fixed sensor|10.1007/s00415-016-8164-6
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease|10.1016/j.pnpbp.2016.05.004
Parkinson's disease-related network topographies characterized with resting state functional MRI|10.1002/hbm.23260
Central Hypoventilation in Progressive Supranuclear Palsy|10.1002/mdc3.12348
Pure Autonomic Failure Versus Prodromal Dysautonomia in Parkinson's Disease: Insights from the Bedside|10.1002/mdc3.12360
Dentate nucleus iron deposition is a potential biomarker for tremor‐dominant Parkinson's disease|10.1002/nbm.3554
Predictors of time to initiation of symptomatic therapy in early Parkinson's disease|10.1002/acn3.317
Neurogenesis in Cancun: where science meets the sea|10.1242/dev.138412
Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases|10.1080/14728222.2016.1182990
Analysis of Mitochondrial haemoglobin in Parkinson's disease brain|10.1016/j.mito.2016.05.001
Enabling breakthroughs in Parkinson’s disease with wearable technologies and big data analytics|10.21037/mhealth.2016.04.02
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias|10.1186/s13041-016-0234-2
Normative data for subcortical regional volumes over the lifetime of the adult human brain|10.1016/j.neuroimage.2016.05.016
Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease|10.1016/j.neurobiolaging.2016.04.023
How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?|10.1111/jnc.13627
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial|10.1176/appi.ajp.2015.15050648
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action|10.1016/j.drudis.2016.01.013
Transplantable living scaffolds comprised of micro-tissue engineered aligned astrocyte networks to facilitate central nervous system regeneration|10.1016/j.actbio.2016.04.021
Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy|10.1016/j.bmcl.2016.04.041
How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?|10.1016/j.parkreldis.2016.04.027
Morphological Alterations in the Thalamus, Striatum, and Pallidum in Autism Spectrum Disorder|10.1038/npp.2016.64
Technology in Parkinson's disease: Challenges and opportunities|10.1002/mds.26642
shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity|10.1371/journal.pgen.1005995
A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid|10.1371/journal.pone.0153564
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort|10.1002/mds.26613
Free‐water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO‐B inhibitor|10.1002/hbm.23213
Motor and nonmotor heterogeneity of LRRK2‐related and idiopathic Parkinson's disease|10.1002/mds.26614
Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson’s Disease|10.1186/s13024-016-0097-0
α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease|10.1002/ana.24664
A multivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging|10.1016/j.neuroimage.2016.04.001
Characterization of RNA isolated from eighteen different human tissues: results from a rapid human autopsy program|10.1007/s10561-016-9555-8
Executive functioning and risk-taking behavior in Parkinson’s disease patients with impulse control disorders|10.1007/s00702-016-1549-y
MRI biomarkers — a precision medicine tool in neurology?|10.1038/nrneurol.2016.51
Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease|10.1136/jnnp-2015-312848
Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)|10.1021/acschemneuro.6b00035
Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging|10.1002/acn3.309
Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease|10.1016/j.parkreldis.2016.04.007
Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease|10.1002/mds.26621
Gene Prioritization for Imaging Genetics Studies Using Gene Ontology and a Stratified False Discovery Rate Approach|10.3389/fninf.2016.00014
α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology|10.1186/s12974-016-0532-8
Personality and reported quality of life in Parkinson's disease|10.1002/gps.4475
Benzoyl chloride derivatization with liquid chromatography–mass spectrometry for targeted metabolomics of neurochemicals in biological samples|10.1016/j.chroma.2016.04.006
Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies|10.1186/s40478-016-0305-8
Cholinergic Mesopontine Signals Govern Locomotion and Reward through Dissociable Midbrain Pathways|10.1016/j.neuron.2016.03.028
Neuropathological basis of nonmotor manifestations of Parkinson's disease|10.1002/mds.26605
Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists|10.1016/j.bmcl.2016.03.102
Prevalence of Submandibular Gland Synucleinopathy in Parkinson’s Disease, Dementia with Lewy Bodies and other Lewy Body Disorders|10.3233/jpd-150680
Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson’s Disease|10.3233/jpd-150712
Untangling Cortico-Striatal Connectivity and Cross-Frequency Coupling in L-DOPA-Induced Dyskinesia|10.3389/fnsys.2016.00026
Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited|10.1002/hbm.23192
Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease|10.1002/mds.26597
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study|10.1007/s00401-016-1552-2
Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration|10.1371/journal.pgen.1005944
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data|10.1016/s1474-4422(16)00071-5
Improving cerebellar segmentation with statistical fusion|10.1117/12.2216966
On the fallacy of quantitative segmentation for T1-weighted MRI|10.1117/12.2216994
Novel method to ascertain chromatin accessibility at specific genomic loci from frozen brain homogenates and laser capture microdissected defined cells|10.1016/j.nepig.2016.03.001
Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations|10.1177/0271678x16637880
The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer’s Disease|10.3233/jad-150859
Clinimetric testing of the comprehensive cervical dystonia rating scale|10.1002/mds.26534
Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder|10.1016/j.parkreldis.2016.03.006
Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort|10.1001/jamaneurol.2015.4800
Lewy bodies are incidental in essential tremor|10.1016/j.parkreldis.2016.02.025
LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?|10.2174/1570159x13666151030102847
Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease|10.2174/1570159x13666151030103027
mGlu5positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome|10.1093/hmg/ddw074
A suggested minimum standard deep brain stimulation evaluation for essential tremor|10.1016/j.jns.2016.01.041
Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats|10.1016/j.neuroscience.2016.01.020
Preparation of S-glycoside surfactants and cysteine thioglycosides using minimally competent Lewis acid catalysis|10.1016/j.carres.2015.12.008
Vocal tics in Tourette's syndrome|10.1016/s1474-4422(16)00021-1
4-amino-7-chloroquinoline derivatives for treating Parkinson’s disease: implications for drug discovery|10.1517/17460441.2016.1154529
Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase|10.1021/acs.jmedchem.5b01780
Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers|10.1002/mds.26529
Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia—A Meta-Regression Analysis|10.3389/fncel.2016.00046
Activation of the unfolded protein response promotes axonal regeneration after peripheral nerve injury|10.1038/srep21709
Central nervous system uptake of intranasal glutathione in Parkinson’s disease|10.1038/npjparkd.2016.2
Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation|10.1007/s00702-016-1524-7
Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults|10.1111/ene.12974
Mystery solved: Trehalose kickstarts autophagy by blocking glucose transport|10.1126/scisignal.aaf1937
Fluorescent false neurotransmitter reveals functionally silent dopamine vesicle clusters in the striatum|10.1038/nn.4252
The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease|10.1016/j.parkreldis.2016.02.020
Olfactory impairment predicts cognitive decline in early Parkinson's disease|10.1016/j.parkreldis.2016.02.013
Assessing medication role on neuropathological findings in Parkinson's disease|10.1002/mds.26536
Parkinson's disease-related fatigue: A case definition and recommendations for clinical research|10.1002/mds.26511
Near-infrared light (670 nm) reduces MPTP-induced parkinsonism within a broad therapeutic time window|10.1007/s00221-016-4578-8
Age at onset and Parkinson disease phenotype|10.1212/wnl.0000000000002461
ALS‐linked protein disulfide isomerase variants cause motor dysfunction|10.15252/embj.201592224
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders|10.1111/jnc.13390
Sorting out release, uptake and processing of alpha‐synuclein during prion‐like spread of pathology|10.1111/jnc.13449
Of Pesticides and Men: a California Story of Genes and Environment in Parkinson’s Disease|10.1007/s40572-016-0083-2
Prospective study of plasma urate and risk of Parkinson disease in men and women|10.1212/wnl.0000000000002351
The effects of dopamine on digit span in Parkinson’s disease|10.1186/s40734-016-0033-z
Environmental and occupational risk factors for progressive supranuclear palsy: Case‐control study|10.1002/mds.26512
Teaching Video NeuroImages: Faciobrachial dystonic seizures|10.1212/wnl.0000000000002359
Pre‐existing differences and diet‐induced alterations in striatal dopamine systems of obesity‐prone rats|10.1002/oby.21411
Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP‐C|10.1002/mds.26499
The Relationship Between Mobility Dysfunction Staging and Global Cognitive Performance|10.1097/wad.0000000000000136
Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments|10.1016/j.nicl.2016.02.012
Design of a Multi-Pinhole Collimator for I-123 DaTscan Imaging on Dual-Headed SPECT Systems in Combination with a Fan-Beam Collimator|10.1109/tns.2016.2515519
New insights into cellular α-synuclein homeostasis in health and disease|10.1016/j.conb.2015.07.007
Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy|10.1097/jcp.0000000000000444
Regulation of Memory Formation by the Transcription Factor XBP1|10.1016/j.celrep.2016.01.028
Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion‐like behaviour of alpha‐synuclein|10.1111/nan.12299
Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes|10.1111/ene.12940
Prefrontal White Matter Structure Mediates the Influence of GAD1 on Working Memory|10.1038/npp.2016.14
Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor–Nuclear Receptor Related 1 Protein Dimer Activation|10.1021/acs.jmedchem.5b01702
Converging mediators from immune and trophic pathways to identify Parkinson disease dementia|10.1212/nxi.0000000000000193
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases|10.7554/elife.12813
Kinematic A daptive D eep B rain S timulation for R esting T remor in P arkinson's D isease|10.1002/mds.26482
Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease|10.1002/mds.26483
Randomized Controlled Trial of a Home-Based Action Observation Intervention to Improve Walking in Parkinson Disease|10.1016/j.apmr.2015.12.029
Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings|10.1002/mds.26476
Clinical signs in functional (psychogenic) gait disorders: a brief survey|10.1186/s40734-016-0031-1
Mood Differences Among Parkinson’s Disease Patients With Mild Cognitive Impairment|10.1176/appi.neuropsych.15090221
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease|10.1186/s13024-016-0072-9
Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants|10.1212/nxg.0000000000000044
Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases|10.3389/fnins.2015.00507
Different PD-MCI criteria and risk of dementia in Parkinson’s disease: 4-year longitudinal study|10.1038/npjparkd.2015.27
The IgLON Family Member Negr1 Promotes Neuronal Arborization Acting as Soluble Factor via FGFR2|10.3389/fnmol.2015.00089
Impairment of PARK14-dependent Ca2+ signalling is a novel determinant of Parkinson’s disease|10.1038/ncomms10332
Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson's disease: A resting state functional MRI study|10.1016/j.parkreldis.2016.01.012
Synthesis of a Bis-thio-acetone (BTA) Analogue of the Lysine Isopeptide Bond and its Application to Investigate the Effects of Ubiquitination and SUMOylation on α-Synuclein Aggregation and Toxicity|10.1021/acschembio.5b01042
Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats|10.1016/j.pbb.2016.01.004
Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease|10.3389/fnins.2015.00500
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia|10.1152/jn.00868.2015
Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases|10.1146/annurev-pharmtox-010715-103548
LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate|10.1186/s13024-015-0066-z
Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease|10.1021/acs.analchem.5b04227
Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson’s Disease|10.1155/2016/7351985
Autosomal dominant Parkinson's disease caused by SNCA duplications|10.1016/j.parkreldis.2015.09.007
Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson’s Disease|10.14336/ad.2016.0505
Biomarkers in Parkinson's disease: Advances and strategies|10.1016/j.parkreldis.2015.09.048
Combined Optogenetic and Chemogenetic Control of Neurons|10.1007/978-1-4939-3512-3_14
Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood‐based biomarkers|10.1016/j.dadm.2016.03.002
Genetic susceptibility variants in parkinsonism|10.1016/j.parkreldis.2015.09.011
Glutathione as a Biomarker in Parkinson’s Disease: Associations with Aging and Disease Severity|10.1155/2016/9409363
Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort|10.1159/000448243
Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson’s Disease|10.14336/ad.2015.1110
Molecular tweezers for lysine and arginine – powerful inhibitors of pathologic protein aggregation|10.1039/c6cc04640a
Motor Speech Apraxia in a 70-Year-Old Man with Left Dorsolateral Frontal Arachnoid Cyst: A [18F]FDG PET-CT Study|10.1155/2016/8941035
Non-radioactive in vitro PINK1 Kinase Assays Using Ubiquitin or Parkin as Substrate|10.21769/bioprotoc.1946
Nucleolar PARP-1 Expression Is Decreased in Alzheimer’s Disease: Consequences for Epigenetic Regulation of rDNA and Cognition|10.1155/2016/8987928
Optimizing diagnosis in Parkinson's disease: Radionuclide imaging|10.1016/j.parkreldis.2015.09.029
Protein S -Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases|10.1016/j.tips.2015.10.002
Rapid Eye Movement Sleep Homeostatic Response: A Potential Marker for Early Detection of Parkinson’s Disease|10.4172/2161-0460.1000255
Telemedicine Care for Nursing Home Residents with Parkinsonism|10.1111/jgs.13909
UbFluor: a mechanism-based probe for HECT E3 ligases|10.1039/c6sc01167e
Using Tractography to Distinguish SWEDD from Parkinson’s Disease Patients Based on Connectivity|10.1155/2016/8704910
White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration|10.1016/j.dadm.2016.03.001
Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization|10.1074/jbc.m115.705095
Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology|10.1007/s00401-015-1526-9
Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians|10.3233/jad-150651
Development of Passive Immunotherapies for Synucleinopathies|10.1002/mds.26481
Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders|10.1038/mt.2015.232
Compensatory neural mechanisms in cognitively unimpaired P arkinson disease|10.1002/ana.24585
A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier|10.1002/mds.26450
Intact working memory in non‐manifesting LRRK2 carriers – an fMRI study|10.1111/ejn.13120
Neonatal mitochondrial abnormalities due to PINK1 deficiency: Proteomics reveals early changes relevant to Parkinson׳s disease|10.1016/j.dib.2015.11.070
GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function|10.1371/journal.pgen.1005710
Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches|10.3389/fneur.2015.00256
How common are ALS plateaus and reversals?|10.1212/wnl.0000000000002251
Synthesis of Multiring Fused 2-Pyridones via a Nitrene Insertion Reaction: Fluorescent Modulators of α-Synuclein Amyloid Formation|10.1021/acs.orglett.5b03190
PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies|10.1159/000441421
Anosognosia increases caregiver burden in mild cognitive impairment|10.1002/gps.4394
Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease|10.2174/156720501301151207100616
Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis|10.1016/j.biopsych.2015.11.022
Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease|10.1002/acn3.268
Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson’s Disease|10.1371/journal.pone.0143351
Neuroimaging and clinical predictors of fatigue in Parkinson disease|10.1016/j.parkreldis.2015.11.029
Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases|10.1016/j.nbd.2015.03.017
Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson’s disease patients? A Systematic Review|10.1007/s11065-015-9307-8
Effect of augmenting cholinergic function on gait and balance|10.1186/s12883-015-0523-x
Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice|10.1016/j.neuron.2015.11.018
Intracellular Target-Specific Accretion of Cell Penetrating Peptides and Bioportides: Ultrastructural and Biological Correlates|10.1021/acs.bioconjchem.5b00529
Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells|10.1186/s12974-015-0449-7
Olfaction inParkinsingle and compound heterozygotes in a cohort of young onset Parkinson's disease patients|10.1111/ane.12538
Simple, Scalable Proteomic Imaging for High-Dimensional Profiling of Intact Systems|10.1016/j.cell.2015.11.025
Current disease modifying approaches to treat Parkinson’s disease|10.1007/s00018-015-2101-1
The Discovery of Central Nervous System Lymphatic Vessels: The Missing Link That Closes the Circle of Brain Immunosurveillance|10.1002/mdc3.12282
DYT6 Dystonia: A Neuropathological Study|10.1159/000440863
Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms|10.1016/j.parkreldis.2015.11.016
Familial Aggregation and Co-Aggregation of Essential Tremor and Parkinson's Disease|10.1159/000442021
High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease|10.1016/j.jneumeth.2015.11.009
Is PARKIN parkinsonism a cancer predisposition syndrome?|10.1212/nxg.0000000000000031
Lewy bodies in essential tremor are no different than in controls|10.1016/j.parkreldis.2015.11.025
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community|10.1001/jamaneurol.2015.3098
Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson’s Disease|10.3233/jpd-150682
CK2 acts as a potent negative regulator of receptor-mediated insulin release in vitro and in vivo|10.1073/pnas.1519430112
Whole-Exome Sequencing in Familial Parkinson Disease|10.1001/jamaneurol.2015.3266
Deep clinical and neuropathological phenotyping of Pick disease|10.1002/ana.24559
Reply to letter: Plasma fasting cholesterol profiles and age at onset in Parkinson's disease|10.1002/mds.26447
Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid|10.1007/s13311-015-0404-4
Resting‐state functional connectivity of the striatum in early‐stage Parkinson's disease: Cognitive decline and motor symptomatology|10.1002/hbm.23056
A novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression|10.1038/srep16615
Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson’s Disease Patients|10.1371/journal.pone.0142582
Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain|10.1016/j.bbi.2015.11.007
Teaching NeuroImages: Recurrent SSPE presenting as Anton syndrome with cortical ribboning|10.1212/wnl.0000000000002096
GBA‐associated parkinsonism and dementia: beyond α‐synucleinopathies?|10.1111/ene.12894
14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening|10.1093/hmg/ddv453
The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results|10.1186/s12967-015-0704-9
Ceruloplasmin functional changes in Parkinson’s disease-cerebrospinal fluid|10.1186/s13024-015-0055-2
Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases|10.1016/j.neurobiolaging.2015.10.028
Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases|10.1111/nan.12294
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease|10.1136/jnnp-2015-311827
Stochastic electrotransport selectively enhances the transport of highly electromobile molecules|10.1073/pnas.1510133112
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia|10.1016/j.neuron.2015.10.039
Differential spectral quantitative electroencephalography patterns between control and Parkinson's disease cohorts|10.1111/ene.12878
Increased CSF biomarkers of angiogenesis in Parkinson disease|10.1212/wnl.0000000000002151
A Novel Lead Design for Modulation and Sensing of Deep Brain Structures|10.1109/tbme.2015.2492921
Identification of candidate genes for familial early-onset essential tremor|10.1038/ejhg.2015.228
Tau positron emission tomographic imaging in aging and early Alzheimer disease|10.1002/ana.24546
NEDD4-mediated HSF1 degradation underlies α-synucleinopathy|10.1093/hmg/ddv445
Deep brain stimulation of the ventromedial prefrontal cortex causes reorganization of neuronal processes and vasculature|10.1016/j.neuroimage.2015.10.049
Visual Hallucinations in Eye Disease and Lewy Body Disease|10.1016/j.jagp.2015.10.007
A novel class of negative allosteric modulators of NMDA receptor function|10.1016/j.bmcl.2015.10.046
Bent out of shape: α‐Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease|10.1016/j.febslet.2015.10.023
Molecular heterogeneity of midbrain dopaminergic neurons – Moving toward single cell resolution|10.1016/j.febslet.2015.10.022
MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials|10.1016/j.neurobiolaging.2015.09.018
Which figure copy test is more sensitive for cognitive impairment in Parkinson's disease: Wire cube or interlocking pentagons?|10.1016/j.clineuro.2015.10.019
Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis|10.1002/mdc3.12243
Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions|10.1002/mds.26445
Leucine‐rich repeat kinase 2 interacts with p21‐activated kinase 6 to control neurite complexity in mammalian brain|10.1111/jnc.13369
Whole-body tissue stabilization and selective extractions via tissue-hydrogel hybrids for high-resolution intact circuit mapping and phenotyping|10.1038/nprot.2015.122
Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1|10.15252/embj.201591593
Parkinson disease and incidental Lewy body disease|10.1212/wnl.0000000000002102
O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease|10.1038/nchem.2361
Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease|10.1016/j.ebiom.2015.09.053
Isolating Visual and Proprioceptive Components of Motor Sequence Learning in ASD|10.1002/aur.1537
The NINDS Parkinson's disease biomarkers program|10.1002/mds.26438
Peripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects|10.3233/jpd-150666
Variants in GBA , SNCA , and MAPT influence Parkinson disease risk, age at onset, and progression|10.1016/j.neurobiolaging.2015.09.014
Mitochondrial dynamics and viral infections: A close nexus|10.1016/j.bbamcr.2014.12.040
Regeneration through Reprogramming Adult Cell Identity in Vivo|10.1016/j.ajpath.2015.02.025
Deep Brain Stimulation in a Case of Mitochondrial Disease|10.1002/mdc3.12241
Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition|10.1007/s12035-015-9435-4
Is the MC1R variant p.R160W associated with Parkinson's?|10.1002/ana.24527
Striatal and Cortical β‐Amyloidopathy and Cognition in Parkinson's Disease|10.1002/mds.26369
Activation of acid-sensing ion channels by localized proton transient reveals their role in proton signaling|10.1038/srep14125
A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro|10.1016/j.neulet.2015.09.015
Feasibility of Virtual Research Visits in Fox Trial Finder|10.3233/jpd-150549
Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation|10.3233/jpd-150630
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease 1|10.3233/jpd-150570
REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers|10.1002/mds.26413
Aberrant intracellular localization of H3k4me3 demonstrates an early epigenetic phenomenon in Alzheimer's disease|10.1016/j.neurobiolaging.2015.08.017
Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease|10.1002/acn3.246
Longitudinal study of normal cognition in Parkinson disease|10.1212/wnl.0000000000002001
Functional Role of the Disulfide Isomerase ERp57 in Axonal Regeneration|10.1371/journal.pone.0136620
Improvement of dyskinesias withl-dopa infusion in advanced Parkinson's disease|10.1111/ane.12483
Sustained attention training reduces spatial bias in Parkinson’s disease: a pilot case series|10.1080/13554794.2015.1088035
Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons|10.1111/ejn.13066
Large-scale assessment of polyglutamine repeat expansions in Parkinson disease|10.1212/wnl.0000000000002016
Longitudinal Study of Gray Matter Changes in Parkinson Disease|10.3174/ajnr.a4447
Network structure of brain atrophy in de novo Parkinson's disease|10.7554/elife.08440
A novel retinal biomarker for Parkinson's disease: Quantifying the foveal pit with optical coherence tomography|10.1002/mds.26411
Oligomeric α‐synuclein and β‐amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases|10.1111/ejn.13056
Bypassing the blood–brian barrier using established skull base reconstruction techniques|10.1016/j.wjorl.2015.09.001
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease|10.1007/s12031-015-0647-x
ER stress signaling and neurodegeneration: At the intersection between Alzheimer's disease and Prion-related disorders|10.1016/j.virusres.2014.12.018
Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases|10.1097/nen.0000000000000235
Interactions between misfolded protein oligomers and membranes: A central topic in neurodegenerative diseases?|10.1016/j.bbamem.2015.01.018
The D3 dopamine receptor: From structural interactions to function|10.1016/j.euroneuro.2014.11.021
tranSMART Foundation Datathon 1.0: The cross neurodegenerative diseases challenge|10.1016/j.atg.2015.08.004
Thalamic deep brain stimulation for drug-induced tremor|10.1016/j.parkreldis.2015.08.033
Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening|10.1371/journal.pone.0136930
Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration|10.1016/j.parkreldis.2015.08.027
Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson’s disease|10.1038/emm.2015.54
Conformational heterogeneity of the Roc domains in C. tepidum Roc–COR and implications for human LRRK2 Parkinson mutations|10.1042/bsr20150128
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation|10.1186/s13024-015-0038-3
Citalopram for the Treatment of Agitation in Alzheimer Dementia|10.1177/0891988715601735
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease|10.1002/mds.26359
The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies|10.1016/j.parkreldis.2015.08.018
Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains|10.1186/s13195-015-0139-9
Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment|10.1186/s12883-015-0403-4
Genome-wide variant by serum urate interaction in Parkinson's disease|10.1002/ana.24504
Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers|10.1016/j.nbd.2015.08.011
Reaction-Based “Off–On” Fluorescent Probe Enabling Detection of Endogenous Labile Fe2+ and Imaging of Zn2+-induced Fe2+ Flux in Living Cells and Elevated Fe2+ in Ischemic Stroke|10.1021/acs.bioconjchem.5b00259
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)|10.1002/mds.26374
Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers|10.1016/j.parkreldis.2015.08.007
Active immunization therapies for Parkinson's disease and multiple system atrophy|10.1002/mds.26377
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study|10.1016/s1474-4422(15)00178-7
Spherical statistics for characterizing the spatial distribution of deep brain stimulation effects on neuronal activity|10.1016/j.jneumeth.2015.08.001
Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy|10.1007/s00234-015-1563-z
Intensive Rehabilitation Enhances Lymphocyte BDNF-TrkB Signaling in Patients With Parkinson’s Disease|10.1177/1545968315600272
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release|10.1016/j.parkreldis.2015.07.025
Dysrhythmia of timed movements in Parkinson׳s disease and freezing of gait|10.1016/j.brainres.2015.07.041
ER proteostasis addiction in cancer biology: Novel concepts|10.1016/j.semcancer.2015.04.003
Fall risk is associated with amplified functional connectivity of the central executive network in patients with Parkinson’s disease|10.1007/s00415-015-7865-6
Inflammation is genetically implicated in Parkinson’s disease|10.1016/j.neuroscience.2014.10.028
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET|10.1002/mds.26302
S-Nitrosylation in neurogenesis and neuronal development|10.1016/j.bbagen.2014.12.013
The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease|10.1007/s00415-015-7868-3
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson’s disease|10.1016/j.neuroscience.2014.09.049
Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia|10.1111/bph.13215
Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a PINK1 gene knockout rat model of Parkinson's disease|10.1002/jnr.23625
GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder|10.1002/acn3.228
Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson’s disease|10.1093/brain/awv202
Disease-modifying strategies for Parkinson's disease|10.1002/mds.26354
Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients|10.1002/mds.26290
Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson’s Disease Brains Are Differentially Generated in Mammalian Cell Models|10.3390/biom5031634
Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study|10.1371/journal.pmed.1001854
Theoretical Optimization of Stimulation Strategies for a Directionally Segmented Deep Brain Stimulation Electrode Array|10.1109/tbme.2015.2457873
Unawareness of Hyposmia in Elderly People With and Without Parkinson's Disease|10.1002/mdc3.12220
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents l-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice|10.1016/j.neuroscience.2015.07.032
Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils|10.1021/acs.jmedchem.5b00571
Efficient estimation of nonparametric genetic risk function with censored data|10.1093/biomet/asv030
Microglial Hv1 proton channel promotes cuprizone‐induced demyelination through oxidative damage|10.1111/jnc.13242
Subject-specific computational modeling of DBS in the PPTg area|10.3389/fncom.2015.00093
Time to change the blind men and the elephant approach to Parkinson disease?|10.1212/wnl.0000000000001739
(Patho‐)physiological relevance of PINK 1‐dependent ubiquitin phosphorylation|10.15252/embr.201540514
Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats|10.1016/j.neuroscience.2015.07.016
Excessive Wnt/beta-catenin signaling promotes midbrain floor plate neurogenesis, but results in vacillating dopamine progenitors|10.1016/j.mcn.2015.07.002
Functional segregation of voltage-activated calcium channels in motoneurons of the dorsal motor nucleus of the vagus|10.1152/jn.00432.2014
Age-specific penetrance ofLRRK2G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium|10.1212/wnl.0000000000001708
KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity|10.1073/pnas.1505953112
Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial|10.1002/mds.26291
When DLB, PD, and PSP masquerade as MSA|10.1212/wnl.0000000000001807
Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score|10.1016/j.dadm.2015.05.004
Neuroimaging Analysis of the Dopamine Basis for Apathetic Behaviors in an MPTP-Lesioned Primate Model|10.1371/journal.pone.0132064
A lipid switch unlocks Parkinson’s disease-associated ATP13A2|10.1073/pnas.1508220112
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014|10.1016/j.jalz.2015.04.005
The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding|10.1016/j.jalz.2015.05.004
Proteostasis control by the unfolded protein response|10.1038/ncb3184
Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy|10.1186/s40478-015-0221-3
Nitrosative Stress in the Nervous System: Guidelines for Designing Experimental Strategies to Study Protein S-Nitrosylation|10.1007/s11064-015-1640-z
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease|10.1073/pnas.1509742112
Binding to serine 65‐phosphorylated ubiquitin primes Parkin for optimal PINK 1‐dependent phosphorylation and activation|10.15252/embr.201540352
Synthetic Proteins and Peptides for the Direct Interrogation of α-Synuclein Posttranslational Modifications|10.3390/biom5031210
CNS active O-linked glycopeptides|10.3389/fchem.2015.00040
Physician response to a medication alert system in inpatients with levodopa-treated diseases|10.1212/wnl.0000000000001745
Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson’s Disease Locus|10.1371/journal.pone.0128586
Fidelity of frequency and phase entrainment of circuit-level spike activity during DBS|10.1152/jn.00259.2015
Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation|10.1038/ncomms8314
Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study|10.1002/mds.26248
The Safety of Using Body-Transmit MRI in Patients with Implanted Deep Brain Stimulation Devices|10.1371/journal.pone.0129077
Genetic analysis of ten common degenerative hereditary ataxia loci in patients with essential tremor|10.1016/j.parkreldis.2015.06.004
Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson’s Disease Patients|10.1007/s00455-015-9612-7
The Quick Dementia Rating System (QDRS): A rapid dementia staging tool|10.1016/j.dadm.2015.03.003
Neuroimaging of Freezing of Gait|10.3233/jpd-150536
NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat|10.1016/j.expneurol.2015.05.021
Balancing the basal ganglia circuitry: A possible new role for dopamine D2 receptors in health and disease|10.1002/mds.26282
Regulation of the Neurodegenerative Process Associated to Parkinson’s Disease by CD4+ T-cells|10.1007/s11481-015-9618-9
Vascular Parkinsonism: Deconstructing a Syndrome|10.1002/mds.26263
Genetic Dissection of Horizontal Cell Inhibitory Signaling in Mice in Complete Darkness In Vivo|10.1167/iovs.15-16581
The Image and Data Archive at the Laboratory of Neuro Imaging|10.1016/j.neuroimage.2015.04.067
In Vivo 7T MRI of the Non-Human Primate Brainstem|10.1371/journal.pone.0127049
Parkinson's disease biomarkers program brain imaging repository|10.1016/j.neuroimage.2015.05.005
Cellular processes associated with LRRK2 function and dysfunction|10.1111/febs.13305
Hippocampal (subfield) volume and shape in relation to cognitive performance across the adult lifespan|10.1002/hbm.22825
Disclosure of research results in genetic studies of Parkinson's disease caused byLRRK2mutations|10.1002/mds.26250
Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease|10.1002/hbm.22822
Novel recruitment strategy to enrich forLRRK2mutation carriers|10.1002/mgg3.151
Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin|10.1002/humu.22808
Dopamine receptors D3 and D5 regulate CD4+T-cell activation and differentiation by modulating ERK activation and cAMP production|10.1016/j.jneuroim.2015.05.003
Emerging mechanisms of molecular pathology in ALS|10.1172/jci71601
Novel Methods and Technologies for 21st-Century Clinical Trials|10.1001/jamaneurol.2014.4524
Dopaminergic Lesions of the Dorsolateral Striatum in Rats Increase Delay Discounting in an Impulsive Choice Task|10.1371/journal.pone.0122063
Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease|10.1212/wnl.0000000000001609
Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease|10.1002/mds.26251
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease|10.1016/j.jalz.2014.12.009
Targeting β-arrestin2 in the treatment of l -DOPA–induced dyskinesia in Parkinson’s disease|10.1073/pnas.1502740112
Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients|10.1016/j.gene.2015.04.035
Impact of Parkinson's disease risk loci on age at onset|10.1002/mds.26237
Differential involvement of Ras‐GRF1 and Ras‐GRF2 in L‐DOPA‐induced dyskinesia|10.1002/acn3.202
Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case–control study|10.1038/npjparkd.2015.2
Structural Characterization of LRRK2 Inhibitors|10.1021/jm5018779
Classification of pallidal oscillations with increasing parkinsonian severity|10.1152/jn.00840.2014
LRRK2 mutations and neurotoxicant susceptibility|10.1177/1535370215579162
Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson's disease|10.1038/nn.3997
Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function|10.1016/j.nbd.2015.03.008
Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins|10.1016/j.nbd.2015.02.032
Minimal change multiple system atrophy: An aggressive variant?|10.1002/mds.26220
Onset of Mild Cognitive Impairment in Parkinson Disease|10.1097/wad.0000000000000088
Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor|10.1021/acsmedchemlett.5b00064
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials|10.1212/wnl.0000000000001451
Rationally Designed MicroRNA-Based Genetic Classifiers Target Specific Neurons in the Brain|10.1021/acssynbio.5b00040
Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism|10.1007/s00234-015-1515-7
Performance of the CogState computerized battery in the Mayo Clinic Study on Aging|10.1016/j.jalz.2015.01.008
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice|10.1016/j.nbd.2015.02.031
Activation of the E3 ubiquitin ligase Parkin|10.1042/bst20140321
Serum- and Glucocorticoid-Inducible Kinase 1 Confers Protection in Cell-Based and in In Vivo Neurotoxin Models via the c-Jun N-Terminal Kinase Signaling Pathway|10.1128/mcb.01510-14
The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study|10.1016/j.neurobiolaging.2014.12.037
Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease|10.3389/fnins.2015.00101
α-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation|10.1073/pnas.1417883112
Dual κ‐agonist/μ‐antagonist opioid receptor modulation reduces levodopa‐induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease|10.1002/ana.24375
ER proteostasis disturbances in Parkinson's disease: novel insights|10.3389/fnagi.2015.00039
Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies|10.1186/s13024-015-0010-2
Genetic analysis of FMR1 repeat expansion in essential tremor|10.1016/j.neulet.2015.03.027
Stiripentol for the treatment of super-refractory status epilepticus|10.1111/ane.12403
A visual review of the interactome of LRRK2: Using deep‐curated molecular interaction data to represent biology|10.1002/pmic.201400390
Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene|10.1002/mds.26213
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy|10.1186/s13024-015-0008-9
Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging|10.1212/wnl.0000000000001437
Low‐variance RNAs identify Parkinson's disease molecular signature in blood|10.1002/mds.26205
Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [11C]‐(+)‐PHNO and [11C]raclopride positron emission tomography imaging study|10.1002/hbm.22793
Constructing de Novo H2O2 Signaling via Induced Protein Proximity|10.1021/acschembio.5b00170
Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation|10.1007/s00401-015-1408-1
Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson’s Disease via Protein Semisynthesis and Mutagenesis|10.1021/ja5131726
Protection from cyanide‐induced brain injury by the Nrf2 transcriptional activator carnosic acid|10.1111/jnc.13074
Structural alterations of the intestinal epithelial barrier in Parkinson’s disease|10.1186/s40478-015-0196-0
Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study|10.1016/j.parkreldis.2015.02.026
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease|10.1002/mds.26170
Differential effects of severe vs mild GBA mutations on Parkinson disease|10.1212/wnl.0000000000001315
CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease|10.1016/j.parkreldis.2014.12.027
Sarcopenia and impairment in cognitive and&nbsp;physical performance|10.2147/cia.s76275
Chemogenomic Profiling of Endogenous PARK2 Expression Using a Genome-Edited Coincidence Reporter|10.1021/cb5010417
Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinsonâ€™s Disease Modifier Genes|10.3389/fneur.2015.00027
Computational analysis of the LRRK2 interactome|10.7717/peerj.778
Can Parkinson’s disease be cured by stimulating neurogenesis?|10.1172/jci80822
Molecular imaging of levodopa-induced dyskinesias|10.1007/s00018-015-1854-x
Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease|10.1007/s00401-015-1395-2
Novel Antioxidants Protect Mitochondria from the Effects of Oligomeric Amyloid Beta and Contribute to the Maintenance of Epigenome Function|10.1021/cn500323q
Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer’s disease patients|10.1016/j.neulet.2015.02.013
Cell penetrating peptide-mediated transport enables the regulated secretion of accumulated cargoes from mast cells|10.1016/j.jconrel.2015.02.005
Identification of Synaptosomal Proteins Binding to Monomeric and Oligomeric α-Synuclein|10.1371/journal.pone.0116473
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study|10.1093/brain/awu409
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung|10.1126/scitranslmed.aaa3634
Enhanced histamine H2 excitation of striatal cholinergic interneurons in l-DOPA-induced dyskinesia|10.1016/j.nbd.2015.01.003
Current Concepts in the Treatment of Multiple System Atrophy|10.1002/mdc3.12145
Chemical methods for the proteome-wide identification of posttranslationally modified proteins|10.1016/j.cbpa.2014.10.020
Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle|10.1016/j.pneurobio.2014.12.001
Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain|10.1016/j.neurobiolaging.2014.07.047
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity|10.1186/s40478-015-0185-3
Placebo effect of medication cost in Parkinson disease|10.1212/wnl.0000000000001282
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program|10.1111/neup.12189
Leucine‐rich repeat kinase 2‐sensitive Na+/Ca2+exchanger activity in dendritic cells|10.1096/fj.14-264028
Management of impulse control disorders in Parkinson's disease: Controversies and future approaches|10.1002/mds.26099
Extent of Inhibition of α-Synuclein Aggregation in Vitro by SUMOylation Is Conjugation Site- and SUMO Isoform-Selective|10.1021/bi501512m
Inducible nitric oxide synthase gene methylation and parkinsonism in manganese-exposed welders|10.1016/j.parkreldis.2015.01.007
Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol|10.1016/j.neuroimage.2015.01.004
Neuromelanin activates proinflammatory microglia through a caspase-8-dependent mechanism|10.1186/s12974-014-0228-x
Neurodegeneration with Brain Iron Accumulation: Diagnosis and Management|10.14802/jmd.14034
STEP 61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson’s disease|10.1073/pnas.1417423112
Regional cerebellar volumes are related to early musical training and finger tapping performance|10.1016/j.neuroimage.2014.12.076
Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau|10.1172/jci78421
The avascular zone and neuronal remodeling of the fovea in Parkinson disease|10.1002/acn3.146
Sensitivity to change and prediction of global change for the Alzheimer’s Questionnaire|10.1186/s13195-014-0092-z
Subthalamic stimulation modulates cortical motor network activity and synchronization in Parkinson’s disease|10.1093/brain/awu380
Automatic segmentation of the hippocampus for preterm neonates from early-in-life to term-equivalent age|10.1016/j.nicl.2015.07.019
Increases in frontostriatal connectivity are associated with response to dorsomedial repetitive transcranial magnetic stimulation in refractory binge/purge behaviors|10.1016/j.nicl.2015.06.008
Light sensitization of DNA nanostructures via incorporation of photo-cleavable spacers|10.1039/c5cc00082c
Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases|10.1615/critrevimmunol.2016015517
Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism|10.1159/000437228
Putamen–midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases|10.1016/j.nicl.2015.06.001
The microbiome of the human lower airways: a next generation sequencing perspective|10.1186/s40413-015-0074-z
Use of an Online Portal to Facilitate Clinical Trial Recruitment: A Preliminary Analysis of Fox Trial Finder|10.3233/jpd-140522
Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking|10.1002/mds.26126
Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD|10.1212/wnl.0000000000001184
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers|10.1212/wnl.0000000000001189
Parkin Mutations Reduce the Complexity of Neuronal Processes in iPSC-Derived Human Neurons|10.1002/stem.1854
Differential effects of goal cues on everyday action errors in Alzheimer’s disease versus Parkinson’s disease dementia.|10.1037/neu0000167
Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction Effects|10.1001/jamaneurol.2014.2757
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications|10.3389/fneur.2014.00242
n-3 PUFA supplementation benefits microglial responses to myelin pathology|10.1038/srep07458
Isolation and characterization of antibody fragments selective for toxic oligomeric tau|10.1016/j.neurobiolaging.2014.12.002
Regulation of caspase-3 processing by cIAP2 controls the switch between pro-inflammatory activation and cell death in microglia|10.1038/cddis.2014.514
Safety Study of Transcranial Static Magnetic Field Stimulation (tSMS) of the Human Cortex|10.1016/j.brs.2014.12.002
Striatal shape abnormalities as novel neurodevelopmental endophenotypes in schizophrenia: A longitudinal study|10.1002/hbm.22715
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease|10.1002/mds.26068
Systematic Optimization of Long Gradient Chromatography Mass Spectrometry for Deep Analysis of Brain Proteome|10.1021/pr500882h
The hTH-GFP Reporter Rat Model for the Study of Parkinson's Disease|10.1371/journal.pone.0113151
Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease|10.1016/j.parkreldis.2014.09.016
Manganism in the 21st century: The Hanninen lecture|10.1016/j.neuro.2013.09.007
Ten Years and Counting: Moving Leucine‐Rich RepeatKinase 2 Inhibitors to the Clinic|10.1002/mds.26075
Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial|10.1186/1745-6215-15-465
810nm near-infrared light offers neuroprotection and improves locomotor activity in MPTP-treated mice|10.1016/j.neures.2014.11.005
Lack of Replication of the GRIN2A-by-Coffee Interaction in Parkinson Disease|10.1371/journal.pgen.1004788
Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease|10.1016/j.parkreldis.2014.09.033
PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease|10.1111/febs.13127
Temporal profile of improvement of tardive dystonia after globus pallidus deep brain stimulation|10.1016/j.parkreldis.2014.11.013
Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease|10.1001/jamaneurol.2014.2704
Higher Frequency of Certain Cancers inLRRK2G2019S Mutation Carriers With Parkinson Disease|10.1001/jamaneurol.2014.1973
Novel Para-Phenyl Substituted Diindolylmethanes Protect Against MPTP Neurotoxicity and Suppress Glial Activation in a Mouse Model of Parkinson’s Disease|10.1093/toxsci/kfu236
Clinical markers for identifying cholinergic deficits in Parkinson's disease|10.1002/mds.26061
The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study|10.1002/mds.26065
Microglial and macrophage polarization—new prospects for brain repair|10.1038/nrneurol.2014.207
MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a|10.1016/j.jneuroim.2014.11.004
Neuroimaging biomarkers for Parkinson disease: Facts and fantasy|10.1002/ana.24291
Phosphorylation by PINK1 Releases the UBL Domain and Initializes the Conformational Opening of the E3 Ubiquitin Ligase Parkin|10.1371/journal.pcbi.1003935
Analysis of COQ2gene in multiple system atrophy|10.1186/1750-1326-9-44
Dopaminergic Neurotoxicants Cause Biphasic Inhibition of Purinergic Calcium Signaling in Astrocytes|10.1371/journal.pone.0110996
Latent growth-curve analysis reveals that worsening Parkinson’s disease quality of life is driven by depression.|10.1037/neu0000158
Antibodies and protein misfolding: From structural research tools to therapeutic strategies|10.1016/j.bbapap.2014.08.016
Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging|10.1016/j.jalz.2014.09.001
Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs|10.1016/j.neuron.2014.10.027
The Future of Research in Parkinson Disease|10.1001/jamaneurol.2014.1717
Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study|10.1016/j.neurobiolaging.2014.10.029
LRRK2 Transport Is Regulated by Its Novel Interacting Partner Rab32|10.1371/journal.pone.0111632
Design, synthesis, and evaluation of a selective chemosensor for leucine-rich repeat kinase 2|10.1016/j.bmcl.2014.10.079
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits|10.1016/j.nbd.2014.10.016
Spinal Cord Stimulation Alleviates Motor Deficits in a Primate Model of Parkinson Disease|10.1016/j.neuron.2014.08.061
Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology|10.1002/mdc3.12104
Role for NUP62 depletion and PYK2 redistribution in dendritic retraction resulting from chronic stress|10.1073/pnas.1418896111
Effects of Tyrosine on Parkinson's Disease: A Randomized, Double‐Blind, Placebo‐Controlled Trial|10.1002/mdc3.12082
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease|10.3390/diagnostics4040153
Cognition and Gait Show a Selective Pattern of Association Dominated by Phenotype in Incident Parkinsonâ€™s Disease|10.3389/fnagi.2014.00249
Striatal cholinergic interneuron regulation and circuit effects|10.3389/fnsyn.2014.00022
Mind matters: placebo enhances reward learning in Parkinson's disease|10.1038/nn.3842
New ghrelin agonist, HM01 alleviates constipation and L‐dopa‐delayed gastric emptying in 6‐hydroxydopamine rat model of Parkinson's disease|10.1111/nmo.12459
α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9)|10.1016/j.nbd.2014.10.007
Nonmotor Symptoms in LRRK2 G2019S Associated Parkinson’s Disease|10.1371/journal.pone.0108982
Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease|10.1016/j.parkreldis.2014.10.008
Sensitive measures of executive dysfunction in non-demented Parkinson's disease|10.1016/j.parkreldis.2014.10.007
Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis|10.1111/ene.12572
Refined phosphopeptide enrichment by phosphate additive and the analysis of human brain phosphoproteome|10.1002/pmic.201400171
What matters to people with Parkinson’s disease living in Australia?|10.1016/j.jocn.2014.06.097
Imaging prodromal Parkinson disease|10.1212/wnl.0000000000000960
Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer’s disease brains and human microglia|10.1016/j.neuroscience.2014.09.052
Treatment of myoclonus-dystonia syndrome with tetrabenazine|10.1016/j.parkreldis.2014.09.029
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo|10.1016/j.nbd.2014.09.013
Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex|10.1016/j.neurobiolaging.2014.09.023
Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis|10.1152/ajpgi.00258.2014
Network Analysis Identifies SOD2 mRNA as a Potential Biomarker for Parkinson's Disease|10.1371/journal.pone.0109042
Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson’s disease|10.1007/s11682-014-9317-9
Highlights of the Stockholm Congress: A Clinician's Perspective|10.1002/mdc3.12093
Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease|10.1016/j.neuropharm.2014.05.020
The Nuclear Envelope: An Intriguing Focal Point for Neurogenetic Disease|10.1007/s13311-014-0296-8
Hybrid Bayesian-rank integration approach improves the predictive power of genomic dataset aggregation|10.1093/bioinformatics/btu518
Resting-state networks link invasive and noninvasive brain stimulation across diverse psychiatric and neurological diseases|10.1073/pnas.1405003111
The Role of microRNAs in Mitochondria: Small Players Acting Wide|10.3390/genes5040865
Elevated levels of cerebrospinal fluid Î±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers|10.3389/fnagi.2014.00248
High Stability and Cooperative Unfolding of α-Synuclein Oligomers|10.1021/bi5007833
The Cognition and Emotional Well-being indices of the Parkinson's disease questionnaire-39: What do they really measure?|10.1016/j.parkreldis.2014.09.014
Comparison of voluntary and reflex cough effectiveness in Parkinson's disease|10.1016/j.parkreldis.2014.09.010
Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions|10.3233/jad-140162
Variation in the oxytocin receptor gene is associated with increased risk for anxiety, stress and depression in individuals with a history of exposure to early life stress|10.1016/j.jpsychires.2014.08.021
Archaerhodopsin variants with enhanced voltage-sensitive fluorescence in mammalian and Caenorhabditis elegans neurons|10.1038/ncomms5894
Ceruloplasmin potentiates nitric oxide synthase activity and cytokine secretion in activated microglia|10.1186/s12974-014-0164-9
DJ-1 Interacts with and Regulates Paraoxonase-2, an Enzyme Critical for Neuronal Survival in Response to Oxidative Stress|10.1371/journal.pone.0106601
Hemispheric asymmetry of electroencephalography-based functional brain networks|10.1097/wnr.0000000000000256
Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions|10.1016/j.neurobiolaging.2014.08.033
Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders|10.3389/fncel.2014.00271
Adipose and leptomeningeal arteriole endothelial dysfunction induced by β-amyloid peptide: A practical human model to study Alzheimer's disease vasculopathy|10.1016/j.jneumeth.2014.06.014
APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease|10.1001/jamaneurol.2014.1455
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease|10.1038/ng.3043
Olfactory identification in LRRK 2 G2019S mutation carriers: a relevant marker?|10.1002/acn3.95
Genetic variability in the regulation of gene expression in ten regions of the human brain|10.1038/nn.3801
Biochemical Assessment of Precuneus and Posterior Cingulate Gyrus in the Context of Brain Aging and Alzheimer’s Disease|10.1371/journal.pone.0105784
BDNF polymorphism associates with decline in set shifting in Parkinson's disease|10.1016/j.neurobiolaging.2014.08.023
Cadherin‐8 expression, synaptic localization, and molecular control of neuronal form in prefrontal corticostriatal circuits|10.1002/cne.23666
Correlation between orphan nuclear receptor Nurr1 expression and amyloid deposition in 5XFADmice, an animal model of Alzheimer's disease|10.1111/jnc.12935
Vagus Nerve Stimulation During Rehabilitative Training Improves Functional Recovery After Intracerebral Hemorrhage|10.1161/strokeaha.114.006654
Course of psychiatric symptoms and global cognition in early Parkinson disease|10.1212/wnl.0000000000000801
Interest in Genetic Testing in Ashkenazi Jewish Parkinson's Disease Patients and Their Unaffected Relatives|10.1007/s10897-014-9756-x
Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease|10.1016/j.parkreldis.2014.08.006
Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinsonâ€™s Disease|10.3389/fnagi.2014.00213
Modulation of corticospinal excitability by transcranial magnetic stimulation in children and adolescents with autism spectrum disorder|10.3389/fnhum.2014.00627
Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS|10.1016/j.parkreldis.2014.08.001
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α‐synuclein|10.1002/prp2.65
Independent Spanish Validation of the Unified Dyskinesia Rating Scale|10.1002/mdc3.12065
Imaging insights into basal ganglia function, Parkinson's disease, and dystonia|10.1016/s0140-6736(14)60041-6
Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants|10.1038/gim.2014.55
Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies|10.1016/j.parkreldis.2014.05.005
Neurobiology of microglial action in CNS injuries: Receptor-mediated signaling mechanisms and functional roles|10.1016/j.pneurobio.2014.06.002
Single-Cell Phenotyping within Transparent Intact Tissue through Whole-Body Clearing|10.1016/j.cell.2014.07.017
Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study|10.1093/brain/awu201
Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry|10.1038/srep05797
Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: Cognitive and neurochemical correlates|10.1016/j.parkreldis.2014.07.008
Naltrexone for impulse control disorders in Parkinson disease|10.1212/wnl.0000000000000729
A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy|10.1007/s13311-014-0294-x
A brain network response to sham surgery|10.1172/jci77193
A cell culture model for monitoring α-synuclein cell-to-cell transfer|10.1016/j.nbd.2014.07.003
Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats|10.1016/j.neurobiolaging.2014.07.011
ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo|10.1038/mt.2014.129
Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study|10.1152/jn.00383.2014
Subthalamic nucleus—sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease|10.1016/j.neurobiolaging.2014.07.004
A Neurodegenerative Vascular Burden Index and the Impact on Cognition|10.3389/fnagi.2014.00161
Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice|10.1073/pnas.1321785111
Noninvasive optical inhibition with a red-shifted microbial rhodopsin|10.1038/nn.3752
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers|10.1093/brain/awu179
Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid|10.1371/journal.pone.0101453
Genetic, Structural, and Molecular Insights into the Function of Ras of Complex Proteins Domains|10.1016/j.chembiol.2014.05.010
The role of extracellular vesicles in the progression of neurodegenerative disease and cancer|10.1016/j.molmed.2014.04.003
Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function|10.1016/j.expneurol.2014.04.032
Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations|10.1016/j.parkreldis.2014.06.018
Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies|10.1093/hmg/ddu334
Decreased Cough Sensitivity and Aspiration in Parkinson Disease|10.1378/chest.14-0066
Functional Brain Activity Relates to 0–3 and 3–8 Hz Force Oscillations in Essential Tremor|10.1093/cercor/bhu142
LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status|10.3389/fnmol.2014.00054
Overcoming obstacles to repurposing for neurodegenerative disease|10.1002/acn3.76
Parkinsonâ€™s disease-implicated kinases in the brain; insights into disease pathogenesis|10.3389/fnmol.2014.00057
Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease|10.1016/j.nbd.2014.06.009
Differential protein–protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways|10.1111/jnc.12798
Loss of glutamic acid decarboxylase (Gad67) in Gpr88-expressing neurons induces learning and social behavior deficits in mice|10.1016/j.neuroscience.2014.06.020
Hyperplasticity in Autism Spectrum Disorder confers protection from Alzheimer’s disease|10.1016/j.mehy.2014.06.008
Remote control of induced dopaminergic neurons in parkinsonian rats|10.1172/jci74664
Upstream deregulation of calcium signaling in Parkinsonâ€™s disease|10.3389/fnmol.2014.00053
A new approach to assess gambling-like behavior in laboratory rats: using intracranial self-stimulation as a positive reinforcer|10.3389/fnbeh.2014.00215
TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord|10.1007/s00401-014-1299-6
Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats|10.1073/pnas.1403215111
Extra‐nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study|10.1002/mds.25929
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents|10.1002/cne.23612
Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy|10.1016/j.neurobiolaging.2014.01.010
Leucine-Rich Repeat Kinase 2 Binds to Neuronal Vesicles through Protein Interactions Mediated by Its C-Terminal WD40 Domain|10.1128/mcb.00914-13
α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration|10.1016/j.celrep.2014.05.033
Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders|10.3389/fnmol.2014.00048
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex|10.3389/fnmol.2014.00049
Advanced Age, Cardiovascular Risk Burden, and Timed Up and Go Test Performance in Parkinson Disease|10.1093/gerona/glu070
Characterization of fibromyalgia symptoms in patients 55–95 years old: a longitudinal study showing symptom persistence with suboptimal treatment|10.1007/s40520-014-0238-7
Evidence for topographic guidance of dopaminergic axons by differential Netrin-1 expression in the striatum|10.1016/j.mcn.2014.05.003
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes|10.1093/hmg/ddu158
Post-Traumatic Shoulder Movement Disorders: A Challenging Differential Diagnosis Between Organic and Functional|10.1002/mdc3.12016
Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons|10.1016/j.nbd.2014.05.012
Peptidoglycan recognition protein genes and risk of Parkinson's disease|10.1002/mds.25895
The timing and amount of vagus nerve stimulation during rehabilitative training affect poststroke recovery of forelimb strength|10.1097/wnr.0000000000000154
Initial cognitive decline is associated with cortical thinning in early Parkinson disease|10.1212/wnl.0000000000000483
Progranulin Gene Delivery Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease|10.1371/journal.pone.0097032
Objective Assessment of Fall Risk in Parkinson's Disease Using a Body-Fixed Sensor Worn for 3 Days|10.1371/journal.pone.0096675
In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers|10.1002/mds.25893
Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology|10.1371/journal.pone.0094839
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation|10.3389/fnmol.2014.00032
Sequential Voluntary Cough and Aspiration or Aspiration Risk in Parkinson’s Disease|10.1007/s00408-014-9584-7
Pharmacological chaperoning of nAChRs: A therapeutic target for Parkinson's disease|10.1016/j.phrs.2014.02.005
Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects|10.1016/j.neulet.2014.04.027
High-throughput neuroimaging-genetics computational infrastructure|10.3389/fninf.2014.00041
Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease andGBAHeterozygotes|10.1001/jamaneurol.2014.313
Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1|10.1073/pnas.1321845111
Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span|10.1001/jamaneurol.2014.445
Enteric GFAP expression and phosphorylation in Parkinson's disease|10.1111/jnc.12742
MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration|10.1038/ncomms4633
Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration|10.1093/hmg/ddu178
The neurobiological basis of cognitive impairment in Parkinson's disease|10.1002/mds.25857
Positive Reinforcement Mediated by Midbrain Dopamine Neurons Requires D1 and D2 Receptor Activation in the Nucleus Accumbens|10.1371/journal.pone.0094771
Unaltered Striatal Dopamine Release Levels in Young Parkin Knockout, Pink1 Knockout, DJ-1 Knockout and LRRK2 R1441G Transgenic Mice|10.1371/journal.pone.0094826
The Thorny Problem of Dyskinesias: Dendritic Spines, Synaptic Plasticity, and Striatal Dysfunction|10.1016/j.biopsych.2014.02.019
Resistance of naturally secreted α‐synuclein to proteolysis|10.1096/fj.13-245852
Essential Tremor in the Elderly and Risk for Dementia|10.1155/2014/328765
Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)|
Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease (P1.016)|10.1212/wnl.82.10_supplement.p1.016
The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson’s Disease): Design And Methodology (P4.043)|
The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson’s Disease): Design And Methodology (P4.043)|10.1212/wnl.82.10_supplement.p4.043
Evaluation of mild cognitive impairment subtypes in Parkinson's disease|10.1002/mds.25875
Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?|10.1002/cne.23577
Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits|10.3389/fnsys.2014.00045
Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease|10.1016/j.neurobiolaging.2014.03.032
Accelerating Drug Development for the Field: Building Clinical Trial Recruitment Infrastructure in Parkinson’s|10.14524/cr-13-00066r1.1
Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?|10.1002/mdc3.12009
Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease|10.1016/j.nbd.2013.12.011
Tau acts as a mediator for Alzheimer's disease‐related synaptic deficits|10.1111/ejn.12504
Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer‐induced AMPA glutamate receptor signaling deficits|10.1111/ejn.12507
Tremor in Spinocerebellar Ataxia Type 12|10.1002/mdc3.12015
Differential role of CSF alpha-synuclein species, tau, and AÎ²42 in Parkinson's Disease|10.3389/fnagi.2014.00053
Barriers to investigator-initiated deep brain stimulation and device research|10.1212/wnl.0000000000000345
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy|10.1093/hmg/ddu138
Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson׳s disease|10.1016/j.brainres.2014.03.031
Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65|10.1042/bj20140334
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo|10.1093/brain/awu057
Tremor retrainment as therapeutic strategy in psychogenic (functional) tremor|10.1016/j.parkreldis.2014.02.029
EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population|10.1016/j.parkreldis.2014.03.004
Swallowing Outcomes Following Unilateral STN vs. GPi Surgery: A Retrospective Analysis|10.1007/s00455-014-9522-0
Fox Trial Finder, un nouvel outil pour la recherche clinique|10.1016/j.neurol.2014.01.360
Identifying blood-brain-barrier selective single-chain antibody fragments|10.1002/biot.201300550
Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein|10.3390/app4010066
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents|10.1002/cne.23583
Measuring the Lifespace of People With Parkinson’s Disease Using Smartphones: Proof of Principle|10.2196/mhealth.2799
Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort|10.1016/j.ajpath.2013.12.007
Association Studies of Sporadic Parkinson’s Disease in the Genomic Era|10.2174/1389202914666131210212745
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's disease|10.1002/mds.25859
Trait Impulsivity Is Associated with the Risk of Falls in Parkinson’s Disease|10.1371/journal.pone.0091190
Clinician versus machine: Reliability and responsiveness of motor endpoints in Parkinson's disease|10.1016/j.parkreldis.2014.02.022
Increased Precursor Cell Proliferation after Deep Brain Stimulation for Parkinson's Disease: A Human Study|10.1371/journal.pone.0088770
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the “active state” of its GTPase domain|10.1073/pnas.1323285111
Prodromal features for Parkinson's disease – baseline data from the TREND study|10.1111/ene.12382
Resting state functional MRI in Parkinson’s disease: the impact of deep brain stimulation on ‘effective’ connectivity|10.1093/brain/awu027
Concomitant pathologies among a spectrum of parkinsonian disorders|10.1016/j.parkreldis.2014.02.012
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients|10.1172/jci71640
The Role of Stable α-Synuclein Oligomers in the Molecular Events Underlying Amyloid Formation|10.1021/ja411577t
The effect of deep brain stimulation randomized by site on balance in Parkinson's disease|10.1002/mds.25831
Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials|10.1007/s00401-014-1256-4
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease|10.1073/pnas.1318306111
Heterogeneity in primary dystonia: Lessons from THAP1, GNAL, and TOR1A in Amish‐Mennonites|10.1002/mds.25818
Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons|10.1111/jnc.12672
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury|10.1016/j.jalz.2013.12.011
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease|10.1001/jamaneurol.2013.5528
Balance Testing With Inertial Sensors in Patients With Parkinson's Disease: Assessment of Motor Subtypes|10.1109/tnsre.2013.2292496
Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers|10.1097/nen.0000000000000046
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease|10.1016/j.neuroscience.2014.01.042
Transgenic mice expressing S129 phosphorylation mutations in α-synuclein|10.1016/j.neulet.2014.01.033
Clinical Comparison of 99mTc Exametazime and 123I Ioflupane SPECT in Patients with Chronic Mild Traumatic Brain Injury|10.1371/journal.pone.0087009
Treatment of Psychosis and Dementia in Parkinson’s Disease|10.1007/s11940-013-0281-2
Attentional resource allocation and swallowing safety in Parkinson's disease: A dual task study|10.1016/j.parkreldis.2013.12.011
Quantitative neuropathology associated with chronic manganese exposure in South African mine workers|10.1016/j.neuro.2013.12.008
ALS-FTD Complex Disorder due to <b><i>C9ORF72</i></b> Gene Mutation: Description of First Polish Family|10.1159/000362267
Blood-based biomarkers for Parkinson's disease|10.1016/s1353-8020(13)70025-7
Continuous in-home monitoring of essential tremor|10.1016/j.parkreldis.2013.09.009
Detraining outcomes with expiratory muscle strength training in Parkinson disease|10.1682/jrrd.2013.05.0101
Development of allosteric modulators of GPCRs for treatment of CNS disorders|10.1016/j.nbd.2013.09.013
Estrogen Receptor α Variants Affect Age at Onset of Alzheimer's Disease in a Multiethnic Female Cohort|10.1159/000355559
Osteopontin Expression in the Brain Triggers Localized Inflammation and Cell Death When Immune Cells Are Activated by Pertussis Toxin|10.1155/2014/358218
Oxidized DJ-1 as a possible biomarker of Parkinson’s disease|10.3164/jcbn.13-108
Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria|10.3233/jpd-130304
Peripheral Administration of the Selective Inhibitor of Soluble Tumor Necrosis Factor (TNF) XPro®1595 Attenuates Nigral Cell Loss and Glial Activation in 6-OHDA Hemiparkinsonian Rats|10.3233/jpd-140410
REM Sleep Behavior and Motor Findings in Parkinson's Disease: A Cross-sectional Analysis.|10.7916/d84b2zdf
Select E2 enzymes differentially regulate parkin activation and mitophagy|10.1242/jcs.147520
Temporal Characteristics of High-Frequency Lower-Limb Oscillation during Freezing of Gait in Parkinson’s Disease|10.1155/2014/606427
Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable|10.3233/jpd-140385
Therapy for Parkinson’s Disease: What is in the Pipeline?|10.1007/s13311-013-0242-1
Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease|10.1371/journal.pone.0085443
Human A53T α-Synuclein Causes Reversible Deficits in Mitochondrial Function and Dynamics in Primary Mouse Cortical Neurons|10.1371/journal.pone.0085815
Pedunculopontine Nucleus Area Oscillations during Stance, Stepping and Freezing in Parkinson’s Disease|10.1371/journal.pone.0083919
A noninvasive handheld assistive device to accommodate essential tremor: A pilot study|10.1002/mds.25796
Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates|10.1179/1743132813y.0000000305
Results of the citalopram to enhance cognition in Huntington disease trial|10.1002/mds.25750
The microtubule associated protein tau H1 haplotype and risk of essential tremor|10.1111/ene.12335
Oxidation-induced Structural Changes of Ceruloplasmin Foster NGR Motif Deamidation That Promotes Integrin Binding and Signaling|10.1074/jbc.m113.520981
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study|10.1016/s1474-4422(13)70293-x
Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3|10.1073/pnas.1312701111
Parkinson’s disease: what role do pedunculopontine cholinergic neurons play?|10.2217/fnl.13.61
Neuropathologic Heterogeneity Does Not Impair Florbetapir-Positron Emission Tomography Postmortem Correlates|10.1097/nen.0000000000000028
Atypical presentation of late‐onset Tay‐sachs disease|10.1002/mus.24146
Pure hereditary spastic paraplegia due to a de novo mutation in the NIPA1 gene|10.1111/ene.12284
Parkinson's Disease Biomarkers: Resources for Discovery and Validation|10.1038/npp.2013.246
Gait impairment precedes clinical symptoms in spinocerebellar ataxia type 6|10.1002/mds.25706
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia|10.1016/j.neures.2013.10.002
The mitochondrial rhomboid protease: Its rise from obscurity to the pinnacle of disease-relevant genes|10.1016/j.bbamem.2013.05.012
The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons|10.1007/s00401-013-1219-1
Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson’s disease|10.1016/j.neuroscience.2013.11.038
Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily|10.1093/hmg/ddt600
A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism|10.1016/j.neurobiolaging.2013.11.015
Widespread sex differences in gene expression and splicing in the adult human brain|10.1038/ncomms3771
Concordance and Discriminatory Power of Cough Measurement Devices for Individuals With Parkinson Disease|10.1378/chest.13-0596
A New Method for Quantitative Immunoblotting of Endogenous α-Synuclein|10.1371/journal.pone.0081314
Rare variants in LRRK1 and Parkinson's disease|10.1007/s10048-013-0383-8
Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?|10.1002/mds.25735
Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs|10.1371/journal.pone.0080705
Measurement of autophagy flux in the nervous system in vivo|10.1038/cddis.2013.421
DNAJC13 mutations in Parkinson disease|10.1093/hmg/ddt570
Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease|10.1016/j.neurobiolaging.2013.11.001
Tissue transglutaminase in Alzheimer's disease – facts and fiction: a reply to “Tissue transglutaminase is a biochemical marker for Alzheimer's disease”|10.1016/j.neurobiolaging.2013.09.042
GTP binding controls complex formation by the human ROCO protein MASL1|10.1111/febs.12593
Association of Parkinson Disease with Structural and Regulatory Variants in the HLA Region|10.1016/j.ajhg.2013.10.009
Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation|10.1016/j.bbrc.2013.10.159
SMG1 Identified as a Regulator of Parkinson’s Disease-Associated alpha-Synuclein through siRNA Screening|10.1371/journal.pone.0077711
Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones|10.1016/j.ejmech.2013.10.052
Integrative Pathway-Based Approach for Genome-Wide Association Studies: Identification of New Pathways for Rheumatoid Arthritis and Type 1 Diabetes|10.1371/journal.pone.0078577
Over‐expression of an inactive mutant cathepsin D increases endogenous alpha‐synuclein and cathepsin B activity in SH‐SY5Y cells|10.1111/jnc.12497
Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations|10.1002/mds.25647
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation|10.1016/j.nbd.2013.09.021
Phosphoproteomic evaluation of pharmacological inhibition of leucine‐rich repeat kinase 2 reveals significant off‐target effects of LRRK‐2‐IN‐1|10.1111/jnc.12483
Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration|10.1007/s00401-013-1193-7
Herp depletion protects from protein aggregation by up-regulating autophagy|10.1016/j.bbamcr.2013.09.006
Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder|10.1007/s13311-013-0222-5
Dopamine overdose hypothesis: Evidence and clinical implications|10.1002/mds.25687
The regulation and deregulation of Wnt signaling by PARK genes in health and disease|10.1093/jmcb/mjt037
Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin|10.1016/j.nbd.2013.09.019
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers|10.1007/s11682-013-9262-z
Coordinate Regulation of Mature Dopaminergic Axon Morphology by Macroautophagy and the PTEN Signaling Pathway|10.1371/journal.pgen.1003845
Epigenetic Landscape of Parkinson’s Disease: Emerging Role in Disease Mechanisms and Therapeutic Modalities|10.1007/s13311-013-0211-8
Crawling of effector T cells on extracellular matrix: role of integrins in interstitial migration in inflamed tissues|10.1038/cmi.2013.47
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats|10.1016/j.neuropharm.2013.09.017
Autonomic complaints in patients with restless legs syndrome|10.1016/j.sleep.2013.08.781
Thalamic cholinergic innervation and postural sensory integration function in Parkinson’s disease|10.1093/brain/awt247
Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate|10.3791/50523
Metabolomics and the search for biomarkers in Parkinson's disease|10.1002/mds.25644
The Evolving Role of Diffusion Magnetic Resonance Imaging in Movement Disorders|10.1007/s11910-013-0400-1
Imaging: What can it tell us about parkinsonian gait?|10.1002/mds.25534
Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control|10.1016/j.neurobiolaging.2013.08.008
Screening for early detection of parkinsonism using a self-administered questionnaire: A cross-sectional epidemiologic study|10.1016/j.neuro.2013.08.010
Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease|10.1016/j.parkreldis.2013.08.021
Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A|10.1093/brain/awt233
Patient‐control association study of the Leucine‐Rich repeat kinase 2 (LRRK2) gene in South African Parkinson's disease patients|10.1002/mds.25637
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study|10.1016/s1474-4422(13)70210-2
Parkinsonism syndrome in heterozygotes for Niemann–Pick C1|10.1016/j.jns.2013.08.033
5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model|10.1016/j.nbd.2013.08.014
Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson′s disease|10.1016/j.brainres.2013.07.025
Gene–environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models|10.1016/j.nbd.2012.06.025
Microglial Beclin 1 Regulates Retromer Trafficking and Phagocytosis and Is Impaired in Alzheimer’s Disease|10.1016/j.neuron.2013.06.046
P.19.3 Phenotypic characterization of the autosomal recessive (Pink-1 and DJ-1) gene knockout rat models of Parkinson’s disease|10.1016/j.nmd.2013.06.684
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo|10.1073/pnas.1309991110
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease|10.1001/jamaneurol.2013.3861
Insight into α-Synuclein Plasticity and Misfolding from Differential Micelle Binding|10.1021/jp402589x
Pesticides that inhibit the ubiquitin–proteasome system: Effect measure modification by genetic variation in SKP1 in Parkinson׳s disease|10.1016/j.envres.2013.08.001
MicroRNA profiling and the role of microRNA-132 in neurodegeneration using a rat model|10.1016/j.neulet.2013.08.001
The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants|10.1016/j.neurobiolaging.2013.07.013
Cholinergic Dysfunction in Parkinson’s Disease|10.1007/s11910-013-0377-9
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle|10.1042/bj20121772
Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus|10.1371/journal.pone.0070724
TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency|10.1002/ana.23999
Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium|10.1002/mds.25600
A Neo-Substrate that Amplifies Catalytic Activity of Parkinson’s-Disease-Related Kinase PINK1|10.1016/j.cell.2013.07.030
Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease|10.1002/jnr.23253
Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease|10.1371/journal.pone.0070274
PKCδ mediates paraquat-induced Nox1 expression in dopaminergic neurons|10.1016/j.bbrc.2013.06.085
Surgical Treatment of Parkinson Disease|10.1016/j.ncl.2013.03.007
LRRK2 secretion in exosomes is regulated by 14-3-3|10.1093/hmg/ddt346
Functional Neuroprotection and Efficient Regulation of GDNF Using Destabilizing Domains in a Rodent Model of Parkinson’s Disease|10.1038/mt.2013.169
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease|10.1093/brain/awt192
Reliability, Validity, and Sensitivity to Change of the Lower Extremity Functional Scale in Individuals Affected by Stroke|10.1016/j.pmrj.2013.07.001
Resource translocation drives 13C fractionation during recovery from disturbance in giant kelp, Macrocystis pyrifera|10.1111/jpy.12099
The MDS−UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease|10.1016/j.parkreldis.2013.06.010
Autophagy in axonal and dendritic degeneration|10.1016/j.tins.2013.04.001
Contribution of GTPase activity toLRRK2-associated Parkinson disease|10.4161/sgtp.25130
Increased Alzheimer’s Disease Neuropathology is Associated with Type 2 Diabetes and ApoE &#949;4 Carrier Status|10.2174/15672050113109990006
Intrabodies as Neuroprotective Therapeutics|10.1007/s13311-013-0193-6
α-Synuclein and Mitochondria: Partners in Crime?|10.1007/s13311-013-0182-9
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease|10.1007/s00401-013-1148-z
The Sac1 Domain of SYNJ 1 Identified Mutated in a Family with Early‐Onset Progressive P arkinsonism with Generalized Seizures|10.1002/humu.22372
Update on Dementia with Lewy Bodies|10.1007/s13670-013-0053-6
Variability of Stepping during a Virtual Reality Paradigm in Parkinson’s Disease Patients with and without Freezing of Gait|10.1371/journal.pone.0066718
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing|10.1038/gim.2013.73
Parkinson disease loci in the mid-western Amish|10.1007/s00439-013-1316-1
The Distribution of Phosphorylated Tau in Spinal Cords of Alzheimer's Disease and Non-Demented Individuals|10.3233/jad-121864
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia|10.1007/s00702-013-1048-3
Parkinson Disease Affects Peripheral Sensory Nerves in the Pharynx|10.1097/nen.0b013e3182965886
TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque|10.1016/j.neuropharm.2013.06.005
Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial|10.1093/brain/awt122
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases|10.1016/j.nbd.2013.05.017
Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study|10.1371/journal.pmed.1001462
Announcing a New Continuing Medical Education Course|10.1097/wnn.0b013e31829af2fb
The KV7.2/3 preferring channel opener ICA 27243 attenuates L-DOPA-induced dyskinesia in hemiparkinsonian rats|10.1016/j.neulet.2013.04.017
Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model|10.1371/journal.pone.0065129
Hedonic and behavioral deficits associated with apathy in Parkinson's disease: Potential treatment implications|10.1002/mds.25496
A causal link between prediction errors, dopamine neurons and learning|10.1038/nn.3413
Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques|10.1002/ana.23939
Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies|10.1096/fj.12-223842
In vitro-differentiated neural cell cultures progress towards donor-identical brain tissue|10.1093/hmg/ddt208
Rapid Generation of Functional Dopaminergic Neurons From Human Induced Pluripotent Stem Cells Through a Single-Step Procedure Using Cell Lineage Transcription Factors|10.5966/sctm.2012-0133
Structure–Activity Relationship of N,N′-Disubstituted Pyrimidinetriones as CaV1.3 Calcium Channel-Selective Antagonists for Parkinson’s Disease|10.1021/jm4005048
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease|10.1007/s00401-013-1121-x
Aberrant Protein S-Nitrosylation in Neurodegenerative Diseases|10.1016/j.neuron.2013.05.005
Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, &#945; -Synuclein Synthesis, Interleukin-1&#946; Release, and Cholinergic Action.|10.2174/1871523011312020003
Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains?|10.2217/fnl.13.14
Short- and Long-Term Effects of LRRK2 on Axon and Dendrite Growth|10.1371/journal.pone.0061986
Neuroimmunological Processes in Parkinson's Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity|10.1042/an20120066
Permeabilization of the Blood-Brain Barrier via Mucosal Engrafting: Implications for Drug Delivery to the Brain|10.1371/journal.pone.0061694
Correlation of Inner Retinal Thickness Evaluated by Spectral-Domain Optical Coherence Tomography and Contrast Sensitivity in Parkinson disease|10.1097/wno.0b013e31828c4e1a
Concurrent regulation of the transcription factors Nrf2 and ATF4 mediates the enhancement of glutathione levels by the flavonoid fisetin|10.1016/j.bcp.2013.04.010
TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies|10.1007/s00401-013-1110-0
Bee Venom and Its Component Apamin as Neuroprotective Agents in a Parkinson Disease Mouse Model|10.1371/journal.pone.0061700
α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats|10.1016/j.neuropharm.2013.03.038
α‐Synuclein: The Long Distance Runner|10.1111/bpa.12046
Lysosomal impairment in Parkinson's disease|10.1002/mds.25462
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients|10.1212/wnl.0b013e3182904faa
Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies|10.1042/bj20121742
Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease|10.1016/j.neurobiolaging.2013.02.016
Parkinson's disease cognitive network correlates with caudate dopamine|10.1016/j.neuroimage.2013.03.070
Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and parkinsonism|10.1016/j.parkreldis.2013.02.016
BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains|10.2174/1567205011310030010
Endogenous LRRK2 dimerizes and translocates to novel membrane compartments during monocyte activation|10.1096/fasebj.27.1_supplement.873.17
Gender differences in cholinergic and dopaminergic deficits in Parkinson disease|10.1007/s00702-013-1013-1
Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing|10.1261/rna.036863.112
Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy|10.1371/journal.pone.0059735
Measuring mild cognitive impairment in patients with Parkinson's disease|10.1002/mds.25426
Rasch analysis of anxiety scales in Parkinson's disease|10.1016/j.jpsychores.2013.02.009
Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization|10.1038/nature12043
CaMKII regulates diacylglycerol lipase-α and striatal endocannabinoid signaling|10.1038/nn.3353
Management of Deep Brain Stimulator Battery Failure: Battery Estimators, Charge Density, and Importance of Clinical Symptoms|10.1371/journal.pone.0058665
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder|10.1016/j.sleep.2012.10.015
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease|10.1038/srep01393
Interplay of LRRK2 with chaperone-mediated autophagy|10.1038/nn.3350
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation|10.1016/j.baga.2012.12.002
Dopamine and its metabolites in cathepsin D heterozygous mice before and after MPTP administration|10.1016/j.neulet.2013.01.035
Diabetes is associated with postural instability and gait difficulty in Parkinson disease|10.1016/j.parkreldis.2013.01.016
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm|10.1007/s00702-013-0998-9
Human α4β2 Nicotinic Acetylcholine Receptor as a Novel Target of Oligomeric α-Synuclein|10.1371/journal.pone.0055886
No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187)|10.1212/wnl.80.7_supplement.p04.187
The Coalition Against Major Diseases: Dopamine Transporter Neuroimaging as an Enrichment Biomarker To Enable Parkinson's Disease Clinical Trials (P06.049)|10.1212/wnl.80.7_supplement.p06.049
The temporal pattern of stimulation may be important to the mechanism of deep brain stimulation|10.1016/j.expneurol.2013.02.001
Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent|10.1371/journal.pone.0055031
Which dyskinesia scale best detects treatment response?|10.1002/mds.25321
The natural history of multiple system atrophy: a prospective European cohort study|10.1016/s1474-4422(12)70327-7
Money without collaboration won't bring cures|10.1038/nm0213-127
RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk|10.1016/j.neuron.2012.11.033
Simple system – substantial share: The use of Dictyostelium in cell biology and molecular medicine|10.1016/j.ejcb.2012.10.003
Should we disclose amyloid imaging results to cognitively normal individuals?|10.2217/nmt.12.75
White Matter Hyperintensities in Parkinson’s Disease: Do They Explain the Disparity between the Postural Instability Gait Difficulty and Tremor Dominant Subtypes?|10.1371/journal.pone.0055193
Differential Neural Activation Patterns in Patients with Parkinson's Disease and Freezing of Gait in Response to Concurrent Cognitive and Motor Load|10.1371/journal.pone.0052602
Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples|10.1002/btpr.1698
Caffeine consumption and risk of dyskinesia in CALM‐PD|10.1002/mds.25319
Alpha-Synuclein Pathology and Axonal Degeneration of the Peripheral Motor Nerves Innervating Pharyngeal Muscles in Parkinson Disease|10.1097/nen.0b013e3182801cde
Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease|10.1097/nen.0b013e3182805c72
MPP+‐dependent inhibition of Ih reduces spontaneous activity and enhances EPSP summation in nigral dopamine neurons|10.1111/bph.12104
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease|10.1016/j.nbd.2013.01.005
A Prognostic View on the Application of Individualized Genomics in Parkinson’s Disease|10.1007/s40142-012-0003-1
Reduced RAN Expression and Disrupted Transport between Cytoplasm and Nucleus; A Key Event in Alzheimer’s Disease Pathophysiology|10.1371/journal.pone.0053349
Screening for impulse control symptoms in patients with de novo Parkinson disease|10.1212/wnl.0b013e31827b915c
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers|10.1016/j.cortex.2012.12.017
Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review|10.1007/s00415-012-6798-6
Selective Knockout of the Casein Kinase 2 in D1 Medium Spiny Neurons Controls Dopaminergic Function|10.1016/j.biopsych.2012.11.013
A rare cervical dystonia mimic in adults: congenital muscular torticollis (fibromatosis colli)|10.3389/fneur.2013.00006
A Role for the Brain RAS in Alzheimer’s and Parkinson’s Diseases|10.3389/fendo.2013.00158
A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research|10.1242/dmm.011940
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease|10.1016/j.neurobiolaging.2012.07.018
Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?|10.1016/j.neuropharm.2012.06.020
ER Dysfunction and Protein Folding Stress in ALS|10.1155/2013/674751
Familial Aggregation of Cranial Tremor in Familial Essential Tremor|10.1159/000348553
Formation and Propagation of Tau Oligomeric Seeds|10.3389/fneur.2013.00093
Fovea and foveation in Parkinson's disease.|10.1037/a0031225
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)|10.2174/157015913804999469
Host and Microbial Factors in Regulation of T Cells in the Intestine|10.3389/fimmu.2013.00141
Isolation of Murine Postnatal Brain Microglia for Phenotypic Characterization Using Magnetic Cell Separation Technology|10.1007/978-1-62703-520-0_5
KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease Patients|10.1155/2013/242303
LRRK2: an éminence grise of Wnt-mediated neurogenesis?|10.3389/fncel.2013.00082
LRRK2: Cause, Risk, and Mechanism|10.3233/jpd-130192
Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γAgonist against MPTP|10.1155/2013/582809
Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort|10.12988/cems.2013.13026
The Current State and Needs of North American Movement Disorders Fellowship Programs|10.1155/2013/701426
The Molecular Chaperone GRP78/BiP as a Therapeutic Target for Neurodegenerative Disorders: A Mini Review|10.4172/2157-7412.1000128
The Role of Innate and Adaptive Immunity in Parkinson's Disease|10.3233/jpd-130250
The Role of Oxidative Stress in Parkinson's Disease|10.3233/jpd-130230
What’s to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?|10.4161/pri.23806
α-synuclein Imaging: A Critical Need for Parkinson's Disease Research|10.3233/jpd-130247
α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers|10.1371/journal.pone.0052312
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease|10.1073/pnas.1220399110
Activity‐dependent secretion of alpha‐synuclein by enteric neurons|10.1111/jnc.12131
In vivo neurochemical imaging of olfactory dysfunction in Parkinson’s disease|10.1007/s00702-012-0956-y
Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration|10.1073/pnas.1217296110
β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia|10.1002/mds.25213
Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations|10.1016/j.neuint.2012.12.001
Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals|10.1371/journal.pone.0050640
Capgras syndrome in Dementia with Lewy Bodies|10.1017/s1041610212002189
Competitive HIF Prolyl Hydroxylase Inhibitors Show Protection against Oxidative Stress by a Mechanism Partially Dependent on Glycolysis|10.1155/2013/598587
KIF6 719Arg Allele is Associated with Statin Effects on Cholesterol Levels in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients|10.3233/jad-2012-121015
Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop|10.1177/1740774512461859
Psychiatric Drugs Bind to Classical Targets Within Early Exocytotic Pathways: Therapeutic Effects|10.1016/j.biopsych.2012.05.020
Allopregnanolone Reinstates Tyrosine Hydroxylase Immunoreactive Neurons and Motor Performance in an MPTP-Lesioned Mouse Model of Parkinson's Disease|10.1371/journal.pone.0050040
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains|10.1016/j.expneurol.2012.11.020
LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models|10.1007/s00109-012-0984-y
Evaluation of TorsinA as a Target for Parkinson Disease Therapy in Mouse Models|10.1371/journal.pone.0050063
Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment|10.1016/j.expneurol.2012.11.007
Validation of nigrostriatal positron emission tomography measures: Critical limits|10.1002/ana.23798
Comparative Analysis of the Alzheimer Questionnaire (AQ) With the CDR Sum of Boxes, MoCA, and MMSE|10.1097/wad.0b013e3182769731
Pgc-1α Overexpression Downregulates Pitx3 and Increases Susceptibility to MPTP Toxicity Associated with Decreased Bdnf|10.1371/journal.pone.0048925
Randomized Clinical Trial of 3 Types of Physical Exercise for Patients With Parkinson Disease|10.1001/jamaneurol.2013.646
Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies|10.4161/mabs.21696
Genetic analysis of the FUS/TLS gene in essential tremor|10.1111/ene.12023
Missing Drivers with Dementia: Antecedents and Recovery|10.1111/j.1532-5415.2012.04159.x
Overcoming obstacles in Parkinson's disease|10.1002/mds.25260
Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease|10.1016/j.parkreldis.2012.09.007
Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease|10.1093/brain/aws254
Prospective cohort study of spinal muscular atrophy types 2 and 3|10.1212/wnl.0b013e318271f7e4
Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson's Disease in the United States|10.1016/j.parkreldis.2012.09.014
Phosphorylation of 4E-BP1 in the Mammalian Brain Is Not Altered by LRRK2 Expression or Pathogenic Mutations|10.1371/journal.pone.0047784
Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity|10.1093/hmg/dds431
Neurologist-associated reduction in PD-related hospitalizations and health care expenditures|10.1212/wnl.0b013e3182703f92
CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease|10.1007/s11481-012-9402-z
Genetic modification of the association of paraquat and Parkinson's disease|10.1002/mds.25216
Evaluation of Parkinson Disease Risk Variants as Expression-QTLs|10.1371/journal.pone.0046199
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology|10.1212/wnl.0b013e3182735e9a
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau|10.1038/srep00700
Cerebral blood flow in Alzheimer&rsquo;s disease|10.2147/vhrm.s34874
Fundamentals of transcranial electric and magnetic stimulation dose: Definition, selection, and reporting practices|10.1016/j.brs.2011.10.001
Reliability of a new scale for essential tremor|10.1002/mds.25162
The meaning of a “hippo” response on the Montreal Cognitive Assessment in Parkinson's disease|10.1016/j.parkreldis.2012.09.005
Toys and Gadgets: Construct Validity of Apathy in Parkinson’s Disease|10.1176/appi.neuropsych.11080195
Bid signal pathway components are identified in the temporal cortex with Parkinson disease|10.1212/wnl.0b013e3182703f76
GTP binding and intramolecular regulation by the ROC domain of Death Associated Protein Kinase 1|10.1038/srep00695
Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology|10.1038/ncomms2032
Brain activation pattern related to gait disturbances in Parkinson's disease|10.1002/mds.25139
Colonic inflammation in Parkinson's disease|10.1016/j.nbd.2012.09.007
Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2|10.1042/bst20120112
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease|10.1042/bst20120093
The Role of Alpha-Synuclein in Melanin Synthesis in Melanoma and Dopaminergic Neuronal Cells|10.1371/journal.pone.0045183
Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease|10.1002/mds.25157
Cerebral Amyloid Deposition and Serotoninergic Innervation in Parkinson Disease|10.1001/archneurol.2012.764
Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease|10.1073/pnas.1205102109
Increased risk of parkinsonism associated with welding exposure|10.1016/j.neuro.2012.08.011
Neuron‐to‐neuron transmission of α‐synuclein fibrils through axonal transport|10.1002/ana.23747
Parkinson’s disease is not associated with gastrointestinal myenteric ganglion neuron loss|10.1007/s00401-012-1040-2
Biochemical Characterization of Highly Purified Leucine-Rich Repeat Kinases 1 and 2 Demonstrates Formation of Homodimers|10.1371/journal.pone.0043472
Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation|10.1371/journal.pone.0043580
Caffeine and risk of Parkinson's disease in a large cohort of men and women|10.1002/mds.25076
Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration|10.1172/jci64575
Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research|10.1371/journal.pone.0043099
Discovery of Potent, Novel Nrf2 Inducers Via Quantum Modeling, Virtual Screening, and In Vitro Experimental Validation|10.1111/cbdd.12040
Reinforcing properties of Pramipexole in normal and parkinsonian rats|10.1016/j.nbd.2012.08.005
Sham surgery controls in Parkinson's disease clinical trials: Views of participants|10.1002/mds.25155
Roles of Education and IQ in Cognitive Reserve in Parkinson’s Disease-Mild Cognitive Impairment|10.1159/000341782
LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6|10.1093/hmg/dds342
Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson’s disease subjects|10.1179/1743132812y.0000000063
Förster Resonance Energy Transfer (FRET) Correlates of Altered Subunit Stoichiometry in Cys-Loop Receptors, Exemplified by Nicotinic α4β2|10.3390/ijms130810022
Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: Gene and smoking status interaction|10.1016/j.parkreldis.2012.07.007
The PRIPS study: screening battery for subjects at risk for Parkinson's disease|10.1111/j.1468-1331.2012.03798.x
Low nigrostriatal reserve for motor parkinsonism in nonhuman primates|10.1016/j.expneurol.2012.07.008
Protein disulfide isomerases in neurodegeneration: From disease mechanisms to biomedical applications|10.1016/j.febslet.2012.07.023
Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease [RETIRED]|10.1212/wnl.0b013e318263c443
Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)|10.1007/s00018-012-1071-9
The MAPT H1 haplotype is associated with tangle-predominant dementia|10.1007/s00401-012-1017-1
Large-scale replication and heterogeneity in Parkinson disease genetic loci|10.1212/wnl.0b013e318264e353
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment|10.1111/j.1365-2125.2012.04192.x
Health comorbidities and cognition in 1948 patients with idiopathic Parkinson's disease|10.1016/j.parkreldis.2012.06.004
GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor|10.1016/j.bmcl.2012.06.104
Anxiety and motor fluctuations in Parkinson's disease: A cross-sectional observational study|10.1016/j.parkreldis.2012.06.007
Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease|10.1016/j.parkreldis.2012.06.008
Neurotoxin‐induced selective ubiquitination and regulation of MEF2A isoform in neuronal stress response|10.1111/j.1471-4159.2012.07860.x
Serotonin transporter inhibition attenuates l‐DOPA‐induced dyskinesia without compromising l‐DOPA efficacy in hemi‐parkinsonian rats|10.1111/j.1460-9568.2012.08202.x
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability|10.1212/wnl.0b013e3182635645
Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease|10.1126/scitranslmed.3003985
Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor|10.1212/wnl.0b013e31825fdeed
Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies|10.1002/mds.25108
Daytime alertness in Parkinson's disease: Potentially dose‐dependent, divergent effects by drug class|10.1002/mds.25082
Gene expression in the Parkinson's disease brain|10.1016/j.brainresbull.2011.11.016
P1‐021: Diurnal and intersubject variability of cerebrospinal fluid biomarkers, Aβ‐40/42, alpha‐synuclein and DJ‐1 in healthy volunteers|10.1016/j.jalz.2012.05.296
P4‐308: CSF α‐synuclein, BETA‐AMYLOID 1–42 and tau proteins: Relationship to clinical parameters in early Parkinson's disease|10.1016/j.jalz.2013.08.089
Sonic Hedgehog Maintains Cellular and Neurochemical Homeostasis in the Adult Nigrostriatal Circuit|10.1016/j.neuron.2012.05.018
Normal and pathological gait: what we learn from Parkinson's disease: Figure 1|10.1136/jnnp-2012-302263
Stress-Induced Phosphorylation and Proteasomal Degradation of Mitofusin 2 Facilitates Mitochondrial Fragmentation and Apoptosis|10.1016/j.molcel.2012.05.041
Hormesis|10.4161/auto.20748
A Monoclonal Antibody-GDNF Fusion Protein Is Not Neuroprotective and Is Associated with Proliferative Pancreatic Lesions in Parkinsonian Monkeys|10.1371/journal.pone.0039036
Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system|10.1016/j.nbd.2012.06.005
The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling|10.1371/journal.pone.0039132
Brain amyloid and cognition in Lewy body diseases|10.1002/mds.25048
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations|10.1073/pnas.1203223109
Efficient determination of purine metabolites in brain tissue and serum by high‐performance liquid chromatography with electrochemical and UV detection|10.1002/bmc.2760
New Evidence of Mitochondria Dysfunction in the Female Alzheimer's Disease Brain: Deficiency of Estrogen Receptor-β|10.3233/jad-2012-120283
Testing NF-κB-based Therapy in Hemiparkinsonian Monkeys|10.1007/s11481-012-9377-9
Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons|10.1016/j.nbd.2012.05.012
Genomic determinants of motor and cognitive outcomes in Parkinson’s disease|10.1016/j.parkreldis.2012.04.025
Everyday Action Impairment in Parkinson's Disease Dementia|10.1017/s135561771200046x
Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: Ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex|10.1016/j.neuropharm.2012.05.017
Altered Pharyngeal Muscles in Parkinson Disease|10.1097/nen.0b013e318258381b
Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia|10.1038/jcbfm.2012.60
RGS10 exerts a neuroprotective role through the PKA/c‐AMP response‐element (CREB) pathway in dopaminergic neuron‐like cells|10.1111/j.1471-4159.2012.07780.x
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases|10.1093/hmg/dds161
Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys|10.1016/j.expneurol.2012.04.025
A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease|10.2174/187152712800792785
Can Parkinson's disease pathology be propagated from one neuron to another?|10.1016/j.pneurobio.2011.11.003
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature|10.1097/nen.0b013e31825018f7
Genetically engineered mouse models of Parkinson's disease|10.1016/j.brainresbull.2011.07.019
Role of Elongation and Secondary Pathways in S6 Amyloid Fibril Growth|10.1016/j.bpj.2012.03.047
Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women|10.1212/wnl.0b013e3182553c5b
Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase|10.1111/j.1349-7006.2012.02317.x
Recognition and diagnosis of sleep disorders in Parkinson’s disease|10.1007/s00415-012-6505-7
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease|10.1016/j.neuropharm.2012.03.029
The advent of AAV9 expands applications for brain and spinal cord gene delivery|10.1517/14712598.2012.681463
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1α|10.1038/emboj.2012.84
Biochemical premotor biomarkers for Parkinson's disease|10.1002/mds.24956
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease|10.1212/wnl.0b013e3182516244
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease|10.1016/j.nbd.2012.03.038
Prolonged Maturation Culture Favors a Reduction in the Tumorigenicity and the Dopaminergic Function of Human ESC‐Derived Neural Cells in a Primate Model of Parkinson's Disease|10.1002/stem.1060
Habitual intake of dietary flavonoids and risk of Parkinson disease|10.1212/wnl.0b013e31824f7fc4
Network correlates of disease severity in multiple system atrophy|10.1212/wnl.0b013e318250d7fd
Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining|10.1038/gim.2012.7
Activity enhances dopaminergic long-duration response in Parkinson disease|10.1212/wnl.0b013e31824f8056
Alzheimer's disease: Pathogenesis and prevention|10.1016/j.jalz.2012.01.011
Critical Role of Truncated α‐Synuclein and Aggregates in Parkinson's Disease and Incidental Lewy Body Disease|10.1111/j.1750-3639.2012.00597.x
Fixing the broken system of genetic locus symbols|10.1212/wnl.0b013e31824d58ab
The neuropathology of genetic Parkinson's disease|10.1002/mds.24962
Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders|10.1136/oemed-2011-100119
Cognitive performance of GBA mutation carriers with early-onset PD|10.1212/wnl.0b013e318253d54b
Ghrelin prevents levodopa‐induced inhibition of gastric emptying and increases circulating levodopa in fasted rats|10.1111/j.1365-2982.2012.01904.x
Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010|10.1097/nen.0b013e31824b211b
Measurement of Altered AβPP Isoform Expression in Frontal Cortex of Patients with Alzheimer's Disease by Absolute Quantification Real-Time PCR|10.3233/jad-2011-111337
Singing in groups for Parkinson's disease (SING-PD): A pilot study of group singing therapy for PD-related voice/speech disorders|10.1016/j.parkreldis.2012.02.009
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system|10.1007/s00702-012-0784-0
A comparison of nine scales to detect depression in Parkinson disease|10.1212/wnl.0b013e31824d587f
Pantothenate kinase‐associated neurodegeneration is not a synucleinopathy|10.1111/j.1365-2990.2012.01269.x
Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly|10.1212/wnl.0b013e318249f733
Functional selectivity induced by mGlu4 receptor positive allosteric modulation and concomitant activation of Gq coupled receptors|10.1016/j.neuropharm.2012.03.003
Pearls & Oy-sters: Functional MRI|10.1212/wnl.0b013e318248e57a
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease|10.1016/j.neuroimage.2012.02.066
Inhibition of Drp1 provides neuroprotection in vitro and in vivo|10.1038/cdd.2012.18
Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2|10.1002/ana.22687
Reduced Uptake of FDOPA PET in End-stage Liver Disease With Elevated Manganese Levels|10.1001/archneurol.2011.771
Biochemical Increase in Phosphorylated Alpha‐Synuclein Precedes Histopathology of Lewy‐Type Synucleinopathies|10.1111/j.1750-3639.2012.00585.x
Striatal Amyloid Plaque Density Predicts Braak Neurofibrillary Stage and Clinicopathological Alzheimer's Disease: Implications for Amyloid Imaging|10.3233/jad-2011-111340
Activation of the unfolded protein response enhances motor recovery after spinal cord injury|10.1038/cddis.2012.8
Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites|10.1212/wnl.0b013e3182494d51
Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy|10.1093/hmg/dds040
Anatomy of graft-induced dyskinesias: Circuit remodeling in the parkinsonian striatum|10.1016/j.baga.2012.01.002
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion|10.1212/wnl.0b013e318249f683
Comparison of enrollees and decliners of Parkinson disease sham surgery trials|10.1002/mds.24940
Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells|10.1038/ncomms1669
The association between Mediterranean diet adherence and Parkinson's disease|10.1002/mds.24918
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease|10.1111/j.1365-2125.2012.04208.x
Assessment of dual tasking has no clinical value for fall prediction in Parkinson’s disease|10.1007/s00415-012-6419-4
Characterization of TAE684 as a potent LRRK2 kinase inhibitor|10.1016/j.bmcl.2012.01.084
"""On"" state freezing of gait in Parkinson disease: A paradoxical levodopa-induced complication"|10.1212/wnl.0b013e3182477ec0
Pramipexole-Induced Increased Probabilistic Discounting: Comparison Between a Rodent Model of Parkinson's Disease and Controls|10.1038/npp.2011.325
TMBIM3/GRINA is a novel unfolded protein response (UPR) target gene that controls apoptosis through the modulation of ER calcium homeostasis|10.1038/cdd.2011.189
Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2|10.1016/j.bbapap.2011.12.009
Selective Small Molecule Inhibition of Poly(ADP-Ribose) Glycohydrolase (PARG)|10.1021/cb200506t
17α-Ethynyl-androst-5-ene-3β,7β,17|10.1155/2012/969418
A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease|10.1155/2012/324521
A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease|10.1155/2012/364684
Cognitive Profiles in Parkinson’s Disease and Their Relation to Dementia: A Data-Driven Approach|10.1155/2012/910757
Declining Quality of Life in Parkinson Disease Before and After Diagnosis|10.3233/jpd-2012-12083
Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging|10.1016/j.neurobiolaging.2010.02.006
Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application|10.1016/s1353-8020(11)70056-6
Imaging of microglia in patients with neurodegenerative disorders|10.3389/fphar.2012.00096
Importance of the Brain Angiotensin System in Parkinson’s Disease|10.1155/2012/860923
Interocular Asymmetry of Foveal Thickness in Parkinson Disease|10.1155/2012/728457
Is Freezing of Gait in Parkinson's Disease a Result of Multiple Gait Impairments? Implications for Treatment|10.1155/2012/459321
Modulation of Neuronal Survival Factor MEF2 by Kinases in Parkinson’s Disease|10.3389/fphys.2012.00171
Postmortem Interval Influencesα-Synuclein Expression in Parkinson Disease Brain|10.1155/2012/614212
Practical management of heterogeneous neuroimaging metadata by global neuroimaging data repositories|10.3389/fninf.2012.00008
Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging|10.3233/jpd-2012-11073
Recent advances in CSF biomarkers for Parkinson's disease|10.1016/s1353-8020(11)70017-7
SIRT2 as a Therapeutic Target for Age-Related Disorders|10.3389/fphar.2012.00082
Stem cell pathologies and neurological disease|10.1038/modpathol.2011.165
The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5′Untranslated-Region-Directed Translation Blockers of the Parkinson’s Alpha Synuclein Expression|10.1155/2012/142372
The Unified Parkinson�s Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function|10.1682/jrrd.2011.06.0103
Using stem cells and iPS cells to discover new treatments for Parkinson's disease|10.1016/s1353-8020(11)70007-4
Web-Based Assessment of Visual and Visuospatial Symptoms in Parkinson’s Disease|10.1155/2012/564812
Regulation of Physiologic Actions of LRRK2: Focus on Autophagy|10.1159/000332599
Pathophysiology of manganese-associated neurotoxicity|10.1016/j.neuro.2011.12.010
PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity|10.1093/hmg/ddr606
A novel neuroprotective therapy for Parkinson’s disease using a viral noncoding RNA that protects mitochondrial Complex I activity|10.1084/jem.20111126
Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers|10.1212/wnl.0b013e31823ed101
Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease|10.1016/j.bbr.2011.12.007
Feasibility, Safety, and Compliance in a Randomized Controlled Trial of Physical Therapy for Parkinson's Disease|10.1155/2012/795294
Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease|10.1002/ana.22691
Involvement of Perineuronal and Perisynaptic Extracellular Matrix in Alzheimer's Disease Neuropathology|10.1111/j.1750-3639.2011.00557.x
Membrane proteins in four acts: Function precedes structure determination|10.1016/j.ymeth.2011.11.001
Pathways towards an effective immunotherapy for Parkinson’s disease|10.1586/ern.11.163
Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences|10.1177/0891988711422527
Panels, Mini-Panels and Study Groups|10.1038/npp.2011.290
Biochemical and Morphological Characterization of the AβPP/PS/Tau Triple Transgenic Mouse Model and Its Relevance to Sporadic Alzheimer's Disease|10.3233/jad-2011-110608
CNTRICS Imaging Biomarkers Final Task Selection: Long-Term Memory and Reinforcement Learning|10.1093/schbul/sbr168
Quantitative telemedicine ratings in Batten disease|10.1212/wnl.0b013e3182377e29
Solvent exposures and parkinson disease risk in twins|10.1002/ana.22629
CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease|10.1039/c1ib00018g
Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats|10.1016/j.neuropharm.2011.10.016
Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s disease|10.1016/j.parkreldis.2011.10.009
Evidence-based guideline update: Treatment of essential tremor|10.1212/wnl.0b013e318236f0fd
Rebound symptoms following battery depletion in the NIH OCD DBS cohort: Clinical and reimbursement issues|10.1016/j.brs.2011.10.004
The role of the basal ganglia in learning and memory: Insight from Parkinson’s disease|10.1016/j.nlm.2011.08.006
Brain biochemistry in autopsied patients with essential tremor|10.1002/mds.24004
Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)|10.1212/wnl.0b013e318237f649
Striatal Pleiotrophin Overexpression Provides Functional and Morphological Neuroprotection in the 6-Hydroxydopamine Model|10.1038/mt.2011.216
A soluble α-synuclein construct forms a dynamic tetramer|10.1073/pnas.1113260108
Neuroprotective activities of regulatory T cells|10.1016/j.molmed.2011.08.005
Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: Unexpected ‘molecular switch’ from a closely related mGlu4 positive allosteric modulator|10.1016/j.bmcl.2011.09.131
Relationship Between CSF Biomarkers of Alzheimer's Disease and Rates of Regional Cortical Thinning in ADNI Data|10.3233/jad-2011-0006
Discovery, Synthesis, and Structure–Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4) with Oral Efficacy in an Antiparkinsonian Animal Model|10.1021/jm200956q
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease|10.1124/pr.110.003269
Cell Therapeutics in Parkinson's Disease|10.1007/s13311-011-0069-6
Plasticity in Early Alzheimer Disease|10.1097/tgr.0b013e31821e588e
Regulation of myocyte enhancer factor-2 transcription factors by neurotoxins|10.1016/j.neuro.2011.05.019
Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders|10.1016/j.bcp.2011.06.001
β-Hexachlorocyclohexane levels in serum and risk of Parkinson's disease|10.1016/j.neuro.2011.04.002
Apathy and Depression: Separate Factors in Parkinson's Disease|10.1017/s1355617711001068
GFAP mutations, age at onset, and clinical subtypes in Alexander disease|10.1212/wnl.0b013e3182309f72
Subthalamic nucleus stimulation reverses mediofrontal influence over decision threshold|10.1038/nn.2925
Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study|10.1002/mds.23934
BAX inhibitor-1 regulates autophagy by controlling the IRE1α branch of the unfolded protein response|10.1038/emboj.2011.318
Impaired Economy of Gait and Decreased Six-Minute Walk Distance in Parkinson's Disease|10.1155/2012/241754
Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress|10.1016/j.freeradbiomed.2011.08.030
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study|10.1016/s1474-4422(11)70175-2
Drug Targets from Genetics: Alpha-Synuclein|10.2174/187152711797247867
Familial Aggregation of Panic Disturbances in Parkinson's Disease|10.1176/appi.neuropsych.23.4.417
Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease|10.1016/j.ajhg.2011.08.009
A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease|10.1016/j.nbd.2011.08.014
Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus|10.1038/ncomms1453
Network correlates of the cognitive response to levodopa in Parkinson disease|10.1212/wnl.0b013e31822c6224
Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging|10.1002/mds.23917
Neurologist care in Parkinson disease|10.1212/wnl.0b013e31822c9123
Induction of pluripotent stem cells from autopsy donor-derived somatic cells|10.1016/j.neulet.2011.07.048
Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor|10.1016/j.neuroscience.2011.07.072
Cdk5: Mediator of neuronal development, death and the response to DNA damage|10.1016/j.mad.2011.04.011
The cholinergic system and Parkinson disease|10.1016/j.bbr.2009.12.048
Autophosphorylation in the Leucine-Rich Repeat Kinase 2 (LRRK2) GTPase Domain Modifies Kinase and GTP-Binding Activities|10.1016/j.jmb.2011.07.033
CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease|10.1016/j.brainres.2011.06.057
Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets|10.1016/j.bbadis.2011.07.004
Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesia|10.1093/brain/awr165
Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics|10.1007/s00702-011-0682-x
Olfactory dysfunction in LRRK2 G2019S mutation carriers|10.1212/wnl.0b013e318227041c
Obesity, diabetes, and risk of Parkinson's disease|10.1002/mds.23855
Effects of parkinsonism on health status in welding exposed workers|10.1016/j.parkreldis.2011.05.021
Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment|10.1007/s11910-011-0212-0
VPS35 Mutations in Parkinson Disease|10.1016/j.ajhg.2011.06.001
Disease‐related and genetic correlates of psychotic symptoms in Parkinson's disease|10.1002/mds.23806
Peripheral Lewy body pathology in Parkinson's disease and incidental Lewy body disease: Four cases|10.1016/j.jns.2011.06.003
Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium|10.1016/j.jns.2011.05.031
Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease|10.1371/journal.pgen.1002141
A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients|10.1016/j.jns.2011.05.021
Lrrk2 p.Q1111H substitution and Parkinson’s disease in Latin America|10.1016/j.parkreldis.2011.05.003
Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease|10.1093/brain/awr139
Incidental Lewy body disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders|10.1016/j.clinph.2011.03.033
Head injury, alpha‐synuclein Rep1, and Parkinson's disease|10.1002/ana.22499
Quantitative EEG as a predictive biomarker for Parkinson disease dementia|10.1212/wnl.0b013e318224af8d
Diagnosis and Referral Delay in Women With Parkinson's Disease|10.1016/j.genm.2011.05.002
Inclusion and exclusion criteria for DBS in dystonia|10.1002/mds.23482
Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease|10.1038/mt.2011.11
Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP?|10.1016/j.parkreldis.2011.02.017
Transcription Factor-Induced Lineage Selection of Stem-Cell-Derived Neural Progenitor Cells|10.1016/j.stem.2011.04.001
Stress and the risk of multiple sclerosis|10.1212/wnl.0b013e31821d74c5
Loss of Thr286 phosphorylation disrupts synaptic CaMKIIα targeting, NMDAR activity and behavior in pre-adolescent mice|10.1016/j.mcn.2011.05.006
Neurochemical phenotypes of myenteric neurons in the rhesus monkey|10.1002/cne.22679
Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease|10.1002/mds.23746
Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease|10.1002/mds.23792
Serotonergic mediated body mass index changes in Parkinson's disease|10.1016/j.nbd.2011.05.009
Repeatability of Aerobic Capacity Measurements in Parkinson Disease|10.1249/mss.0b013e31822432d4
PD biomarkers—use of α-synuclein reaches new levels|10.1038/nrneurol.2011.66
A family with parkinsonism, essential tremor, restless legs syndrome, and depression|10.1212/wnl.0b013e318219fb42
Parkinson's disease, cortical dysfunction, and alpha‐synuclein|10.1002/mds.23697
Abnormal calcium homeostasis and protein folding stress at the ER|10.4161/cib.4.3.15019
Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures|10.1007/s00702-011-0653-2
Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease|10.1007/s00401-011-0831-1
Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease|10.14802/jmd.11001
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications|10.1002/mds.23737
Priorities in Parkinson's disease research|10.1038/nrd3430
Group patient visits for Parkinson disease|10.1212/wnl.0b013e3182194bad
Biomarkers for Parkinson’s Disease|10.1126/scitranslmed.3002488
Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors|10.1016/j.phrs.2011.03.017
Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations|10.1002/mds.23655
Sequential requirements for the GTPase domain of the mitofusin Fzo1 and the ubiquitin ligase SCFMdm30 in mitochondrial outer membrane fusion|10.1242/jcs.079293
Probable RBD is increased in Parkinson’s disease but not in essential tremor or restless legs syndrome|10.1016/j.parkreldis.2011.03.007
A Genome-Wide Linkage Screen in the Amish with Parkinson Disease Points to Chromosome 6|10.1111/j.1469-1809.2011.00643.x
Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration|10.1001/archneurol.2011.53
Reduced uptake of [ 18 F]FDOPA PET in asymptomatic welders with occupational manganese exposure|10.1212/wnl.0b013e3182152830
Methylphenidate for gait impairment in Parkinson disease|10.1212/wnl.0b013e3182143537
Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy|10.1016/j.ajpath.2011.01.006
Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson’s disease|10.1111/j.1460-9568.2011.07660.x
Molecular insights into Parkinson's disease|10.3410/m3-7
Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With Aβ Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue|10.1097/wad.0b013e31821300bc
LRRK2 G2019S mutations may be increased in Puerto Ricans|10.1002/mds.23632
S-Nitrosylation of ApoE in Alzheimer’s Disease|10.1021/bi200266v
Tremor severity and age: A cross‐sectional, population‐based study of 2,524 young and midlife normal adults|10.1002/mds.23674
Do Stable Patients With a Premorbid Depression History Have a Worse Outcome After Deep Brain Stimulation for Parkinson Disease?|10.1227/neu.0b013e3182160456
Utilising functional MRI (fMRI) to explore the freezing phenomenon in Parkinson’s disease|10.1016/j.jocn.2011.02.003
Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia|10.1016/j.jalz.2010.08.228
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease|10.1002/ana.22321
Use of ibuprofen and risk of Parkinson disease|10.1212/wnl.0b013e31820f2d79
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2|10.1038/nchembio.538
Personality Characteristics and Motor Skills Attributed to Occupations in Parkinson Disease|10.1097/wnn.0b013e318218c5eb
White matter lesions in Parkinson disease|10.1038/nrneurol.2011.21
Solution-Phase Parallel Synthesis and SAR of Homopiperazinyl Analogs as Positive Allosteric Modulators of mGlu4|10.1021/co1000508
β2-Adrenergic Receptor Activation Prevents Rodent Dopaminergic Neurotoxicity by Inhibiting Microglia via a Novel Signaling Pathway|10.4049/jimmunol.1002449
Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients|10.1172/jci43871
In vivo demonstration that α-synuclein oligomers are toxic|10.1073/pnas.1100976108
MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy|10.1212/wnl.0b013e31820c30c1
Substantia nigra hyperechogenicity with LRRK2 G2019S mutations|10.1002/mds.23644
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease|10.1016/j.nbd.2011.01.024
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms|10.1007/s00401-011-0806-2
Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination|10.1212/wnl.0b013e31820ee1bb
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease|10.1111/j.1468-1331.2011.03353.x
Essential tremor and Parkinson's disease: Lack of a link|10.1002/mds.23509
From reinforcement learning models to psychiatric and neurological disorders|10.1038/nn.2723
Cyclin-G-associated kinase modifies -synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study|10.1093/hmg/ddr026
Prospects of Statins in Parkinson Disease|10.1177/1073858410385006
Discovery, Synthesis, and Structure−Activity Relationship Development of a Series of N-(4-Acetamido)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 (mGlu4) with CNS Exposure in Rats|10.1021/jm101271s
Use of Florbetapir-PET for Imaging β-Amyloid Pathology|10.1001/jama.2010.2008
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells|10.1172/jci43366
Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease|10.1096/fj.10-173625
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats|10.1016/j.neuropharm.2010.12.032
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas|10.1073/pnas.1012500108
The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen|10.1007/s00702-010-0513-5
Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons|10.1002/jnr.22549
Advances in Therapeutic Options for Gait and Balance in Parkinson’s Disease|10.17925/usn.2011.07.02.100
Basal Ganglia Disorders Associated with Imbalances in the Striatal Striosome and Matrix Compartments|10.3389/fnana.2011.00059
Do Somatic Mitochondrial DNA Mutations Contribute to Parkinson's Disease?|10.4061/2011/659694
Effect of Deep Brain Stimulation on Parkinson's Nonmotor Symptoms following Unilateral DBS: A Pilot Study|10.4061/2011/507416
Expert Testimony at the Food and Drug Administration: Who Wants the Truth?|10.1353/nib.2011.0046
MicelackingRas- GRF1 showcontextualfearcondition- ing butnotspatialmemoryimpair- ments:convergentevidencefromtwo independentlygeneratedmousemutant lines|10.3389/fnbeh.2011.00078
Models for LRRK2-Linked Parkinsonism|10.4061/2011/942412
Pre- and Post- GPi DBS Neuropsychological Profiles in a Case of X-Linked Dystonia-Parkinsonism|10.1080/13854046.2010.532812
Ras?ERK Signaling in Behavior: Old Questions and New Perspectives|10.3389/fnbeh.2011.00079
Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases|10.1155/2011/468952
Sleep Duration and “on” Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release|10.4061/2011/354760
Temporal Expression of Mutant LRRK2 in Adult Rats Impairs Dopamine Reuptake|10.7150/ijbs.7.753
Treatment With Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer's Disease Neuroimaging Initiative|10.1001/archneurol.2010.343
Olfaction in Parkin heterozygotes and compound heterozygotes|10.1212/wnl.0b013e31820882aa
Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration|10.1016/j.expneurol.2010.12.018
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions|10.1016/j.mcn.2010.12.011
Nicotine up-regulates α4β2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning|10.1085/jgp.201010532
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers|10.1212/wnl.0b013e31820a0e3b
Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice|10.1016/j.nbd.2010.12.008
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications|10.1016/j.tins.2010.09.001
Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics|10.2174/187152710793237386
N‐acetylcysteine prevents loss of dopaminergic neurons in the EAAC1−/− mouse|10.1002/ana.22162
Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains|10.1002/mds.23442
HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease|10.1038/nn.2692
Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration|10.1016/j.brainres.2010.11.006
SNCA Variant Associated With Parkinson Disease and Plasma α-Synuclein Level|10.1001/archneurol.2010.279
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression|10.1002/ana.22311
Chaperone-mediated autophagy: machinery, regulation and biological consequences|10.1007/s00018-010-0565-6
Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson’s disease|10.1016/j.parkreldis.2010.09.007
CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson’s disease|10.1007/s00702-010-0485-5
Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?|10.5041/rmmj.10011
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease|10.1126/scitranslmed.3001059
A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors|10.1038/ncomms1085
Biomarkers in Parkinson’s disease: a funder’s perspective|10.2217/bmm.10.89
LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease|10.1016/j.nbd.2010.04.002
Toxicological and pathophysiological roles of reactive oxygen and nitrogen species|10.1016/j.tox.2010.07.009
Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis|10.2217/bmm.10.94
Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis|10.1136/jnnp.2010.222042
Estimation of Particulate Mass and Manganese Exposure Levels among Welders|10.1093/annhyg/meq069
Qualitative Imaging of Adeno-Associated Virus Serotype 2–Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson Disease|10.1227/neu.0b013e3181f53a5c
A comparative study of Lrrk2 function in primary neuronal cultures|10.1016/j.parkreldis.2010.08.018
Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats|10.1016/j.neuropharm.2010.09.011
Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease|10.1016/j.expneurol.2010.09.001
Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment|10.1007/s00401-010-0744-4
Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease|10.1016/j.brainres.2010.08.099
CSF Aβ42 and tau in Parkinson's disease with cognitive impairment|10.1002/mds.23287
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease|10.1002/mds.23314
Systemic Weakness After Therapeutic Injections of Botulinum Toxin A|10.1097/wnf.0b013e3181f5329e
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization|10.1042/bj20100784
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease|10.1038/nm.2199
Clinical expression of LRRK2 G2019S mutations in the elderly|10.1002/mds.23330
Heart rate changes during freezing of gait in patients with Parkinson's disease|10.1002/mds.23280
Glutamate Receptor Ion Channels: Structure, Regulation, and Function|10.1124/pr.109.002451
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease|10.1038/ng.642
Using Voluntary Cough To Detect Penetration and Aspiration During Oropharyngeal Swallowing in Patients With Parkinson Disease|10.1378/chest.10-0342
Postmortem interval effect on RNA and gene expression in human brain tissue|10.1007/s10561-010-9210-8
Bid-mediated mitochondrial damage is a key mechanism in glutamate-induced oxidative stress and AIF-dependent cell death in immortalized HT-22 hippocampal neurons|10.1038/cdd.2010.92
Genetic variability at the PARK16 locus|10.1038/ejhg.2010.125
Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases|10.1111/j.1471-4159.2010.06834.x
Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 Vectors|10.1038/mt.2010.114
Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations|10.1002/mds.23221
LRRK2 variation and Parkinson's disease in African Americans|10.1002/mds.23163
Calcium channel blocker use and risk of Parkinson's disease|10.1002/mds.23191
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice|10.1016/j.nbd.2010.07.010
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization|10.1042/bj20100483
Characterization of axon guidance cue sensitivity of human embryonic stem cell-derived dopaminergic neurons|10.1016/j.mcn.2010.07.004
Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease|10.1172/jci42642
Quinazolin-4-one Derivatives: A Novel Class of Noncompetitive NR2C/D Subunit-Selective N-Methyl-d-aspartate Receptor Antagonists|10.1021/jm100027p
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations|10.1016/j.neurobiolaging.2010.05.009
Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS)|10.1016/j.bmcl.2010.07.007
Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia|10.1016/j.expneurol.2010.06.017
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease|10.1016/j.neulet.2010.06.009
Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS‐PD)|10.1002/mds.23151
Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease|10.1002/mds.22997
Low‐dose bafilomycin attenuates neuronal cell death associated with autophagy‐lysosome pathway dysfunction|10.1111/j.1471-4159.2010.06838.x
Dystrophin-associated protein scaffolding in brain requires α-dystrobrevin|10.1097/wnr.0b013e32833b0a3b
Risk of sleep-disordered breathing in Parkinson's disease|10.1007/s11325-010-0362-3
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice|10.1073/pnas.1004676107
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys|10.1016/j.nbd.2010.05.001
Prevention strategies for herpes zoster and post-herpetic neuralgia|10.1016/s1386-6532(10)70004-4
Lentiviral Overexpression of GRK6 Alleviates l -Dopa–Induced Dyskinesia in Experimental Parkinson’s Disease|10.1126/scitranslmed.3000664
Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm|10.1093/protein/gzq022
Patient-specific analysis of the relationship between the volume of tissue activated during DBS and verbal fluency|10.1016/j.neuroimage.2010.03.068
Parkinson’s Psychosis|10.1007/s11940-010-0072-y
Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders|10.1007/s00401-010-0664-3
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models|10.1242/dmm.004267
Microglia Activation and Anti-inflammatory Regulation in Alzheimer’s Disease|10.1007/s12035-010-8106-8
High regulatability favors genetic selection in SLC18A2 , a vesicular monoamine transporter essential for life|10.1096/fj.09-140368
Incidental Lewy body disease: Clinical comparison to a control cohort|10.1002/mds.22971
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions|10.1038/ng.536
Local institutional review board (IRB) review of a multicenter trial: Local costs without local context|10.1002/ana.21831
Parkinson's disease: Exit toxins, enter genetics|10.1016/j.pneurobio.2009.11.001
The relationship between uric acid levels and Huntington's disease progression|10.1002/mds.22907
Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats|10.1111/j.1460-9568.2010.07077.x
Mutational analysis of parkin and PINK1 in multiple system atrophy|10.1016/j.neurobiolaging.2009.11.020
MKK6 binds and regulates expression of Parkinson’s disease‐related protein LRRK2|10.1111/j.1471-4159.2010.06568.x
A Tangled Web – Tau and Sporadic Parkinson's Disease|10.3389/fpsyt.2010.00150
Biopsable Neural Tissues: Toward New Biomarkers for Parkinson's Disease?|10.3389/fpsyt.2010.00128
Evaluation of the Braak staging scheme for Parkinson's disease: Introduction to a panel presentation|10.1002/mds.22783
Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis|10.1016/j.neuron.2009.12.023
LRRK2 and the Stress Response: Interaction with MKKs and JNK-Interacting Proteins|10.1159/000285509
Maladaptive striatal plasticity in l-DOPA-induced dyskinesia|10.1016/s0079-6123(10)83011-0
Mitochondrial therapies for Parkinson's disease|10.1002/mds.22781
New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease|10.1002/mds.22636
Role of serotonin neurons in the induction of levodopa‐ and graft‐induced dyskinesias in Parkinson's disease|10.1002/mds.22792
The antipsychotic potential of muscarinic allosteric modulation|10.1358/dnp.2010.23.4.1416977
Therapeutic directions for Parkinson's disease|10.1002/mds.22790
α-Synuclein Gene May Interact with Environmental Factors in Increasing Risk of Parkinson’s Disease|10.1159/000315157
Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders|10.1016/j.parkreldis.2009.11.007
Comparative Transduction Efficiency of AAV Vector Serotypes 1–6 in the Substantia Nigra and Striatum of the Primate Brain|10.1038/mt.2009.286
Are there differences in cerebral white matter lesion burdens between Parkinson’s disease patients with or without dementia?|10.1007/s00401-009-0620-2
Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease|10.1007/s12640-009-9140-z
Glutamate Receptors as Therapeutic Targets for Parkinsons Disease|10.2174/187152709789824606
Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa|10.1016/j.neulet.2009.11.066
Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways|10.1002/syn.20725
Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease|10.3109/13547500903108423
LRRK2 in Parkinson’s disease: function in cells and neurodegeneration|10.1111/j.1742-4658.2009.07342.x
LRRK2 in Parkinson’s disease: in vivo models and approaches for understanding pathogenic roles|10.1111/j.1742-4658.2009.07343.x
VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease|10.1016/j.nbd.2009.10.011
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease|10.1212/wnl.0b013e3181c29356
Targeting of gp78 for ubiquitin-mediated proteasomal degradation by Hrd1: Cross-talk between E3s in the endoplasmic reticulum|10.1016/j.bbrc.2009.10.045
MitoPark mice mirror the slow progression of key symptoms and L‐DOPA response in Parkinson's disease|10.1111/j.1601-183x.2009.00542.x
Compacted DNA Nanoparticle Gene Transfer of GDNF to the Rat Striatum Enhances the Survival of Grafted Fetal Dopamine Neurons|10.3727/096368909x12483162196881
Genetic interaction between Lrp6 and Wnt5a during mouse development|10.1002/dvdy.22101
Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons|10.1111/j.1471-4159.2009.06404.x
Genomewide association study for onset age in Parkinson disease|10.1186/1471-2350-10-98
Is the N-Back Task a Valid Neuropsychological Measure for Assessing Working Memory?|10.1093/arclin/acp063
XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy|10.1101/gad.1830709
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease|10.1042/bj20091035
Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin|10.1007/s12263-009-0142-5
Hereditary parkinsonism: Parkinson disease look‐alikes—An algorithm for clinicians to “PARK” genes and beyond|10.1002/mds.22675
The cellular pathways of neuronal autophagy and their implication in neurodegenerative diseases|10.1016/j.bbamcr.2009.01.016
Dopamine Release at Individual Presynaptic Terminals Visualized with FFNs|10.3791/1562
Unexpected expression of α- and β-globin in mesencephalic dopaminergic neurons and glial cells|10.1073/pnas.0813216106
Detection of Protein Ubiquitination|10.3791/1293
Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration|10.1073/pnas.0900096106
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice|10.1073/pnas.0906334106
Chipping away at diagnostics for neurodegenerative diseases|10.1016/j.nbd.2009.02.016
Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects|10.2174/156720509788929318
Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons|10.1186/1750-1326-4-34
Targeting neural precursors in the adult brain rescues injured dopamine neurons|10.1073/pnas.0905125106
Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4)|10.1016/j.bmcl.2009.07.072
No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome|10.1002/mds.22701
Rapid selection of cyclic peptides that reduce α-synuclein toxicity in yeast and animal models|10.1038/nchembio.193
Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease|10.1002/gepi.20439
Correlation of Clinical Features With Argyrophilic Grains at Autopsy|10.1097/wad.0b013e318199d833
Elevated Serum Pesticide Levels and Risk of Parkinson Disease|10.1001/archneurol.2009.89
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis|10.1016/j.bbadis.2008.11.007
Parkinson Disease With Dementia|10.1097/wad.0b013e31819c5ef4
Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease|10.1208/s12248-009-9123-2
Using global statistical tests in long‐term Parkinson's disease clinical trials|10.1002/mds.22645
Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease|10.1038/nn.2349
Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease|10.1016/j.biopsych.2009.04.005
Synthesis and Evaluation of a Series of Heterobiarylamides That Are Centrally Penetrant Metabotropic Glutamate Receptor 4 (mGluR4) Positive Allosteric Modulators (PAMs)|10.1021/jm9005065
Subventricular zone neural progenitors from rapid brain autopsies of elderly subjects with and without neurodegenerative disease|10.1002/cne.22040
Teaching program for the Unified Dyskinesia Rating Scale|10.1002/mds.22563
A role for a novel protein, nucleolin, in Parkinson's disease|10.1016/j.neulet.2009.04.060
Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease|10.1016/j.expneurol.2009.04.023
Neurochemical biomarkers in the differential diagnosis of movement disorders|10.1002/mds.22510
Serotonin and Parkinson's disease: On movement, mood, and madness|10.1002/mds.22473
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction|10.1007/s00401-009-0538-8
Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells|10.1073/pnas.0902396106
Glycoproteomics in neurodegenerative diseases|10.1002/mas.20221
Motor patterns in Parkinson's disease: A data‐driven approach|10.1002/mds.22512
SNCA variants are associated with increased risk for multiple system atrophy|10.1002/ana.21685
Elevated P75NTR expression causes death of engrailed-deficient midbrain dopaminergic neurons by Erk1/2 suppression|10.1186/1749-8104-4-11
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease|10.1093/brain/awp044
Validity and Reliability of an Occupational Exposure Questionnaire for Parkinsonism in Welders|10.1080/15459620902836856
Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics|10.1016/j.tins.2008.11.006
Ceramide and neurodegeneration: Susceptibility of neurons and oligodendrocytes to cell damage and death|10.1016/j.jns.2008.12.010
Nicotine is a Selective Pharmacological Chaperone of Acetylcholine Receptor Number and Stoichiometry. Implications for Drug Discovery|10.1208/s12248-009-9090-7
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease|10.1016/j.nbd.2009.02.009
Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non‐human primate after overexpression of GDNF|10.1002/cne.22028
Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation|10.1172/jci37617
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies|10.1111/j.1471-4159.2009.05996.x
Long-term Transgene Expression in the Central Nervous System Using DNA Nanoparticles|10.1038/mt.2009.2
Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats|10.1016/j.neuropharm.2009.01.019
Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats|10.1016/j.neuropharm.2009.01.020
Expression and localization of lactotransferrin messenger RNA in the cortex of Alzheimer's disease|10.1016/j.neulet.2009.01.071
α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity|10.1038/ng.300
Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons|10.1073/pnas.0810996106
FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expression|10.1002/mds.22442
Funding of Parkinson research from industry and US federal and foundation sources|10.1002/mds.22446
Future of cell and gene therapies for Parkinson's disease|10.1002/ana.21473
Alzheimer Research Forum Live Discussion: Mice on Trial? Issues in the Design of Drug Studies|10.3233/jad-2009-0961
Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway|10.1016/j.nbd.2008.12.007
Differentiation of Neural Precursors and Dopaminergic Neurons from Human Embryonic Stem Cells|10.1007/978-1-60761-369-5_19
Linkage of cDNA expression profiles of mesencephalic dopaminergic neurons to a genome-wide in situ hybridization database|10.1186/1750-1326-4-6
Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead|10.1016/j.bmcl.2008.11.104
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease|10.1172/jci36470
Promise of mGluR2/3 activators in psychiatry|10.1038/npp.2008.156
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity|10.1186/1756-6606-1-17
The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile|10.1002/mds.22341
Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies|10.1186/1756-6606-1-16
Ephrin‐A5 regulates the formation of the ascending midbrain dopaminergic pathways|10.1002/dneu.20685
Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders|10.1007/s00401-008-0450-7
Stem cells in development of therapeutics for Parkinson's disease: A perspective|10.1002/jcb.21916
Gait is associated with an increase in tonic firing of the sub-cuneiform nucleus neurons|10.1016/j.neuroscience.2008.10.046
Genetic variation of Omi/HtrA2 and Parkinson's disease|10.1016/j.parkreldis.2008.08.003
Administration and Scoring Variance on the ADAS-Cog|10.3233/jad-2008-15312
Dietary Iron Intake and Risk of Parkinson's Disease|10.1093/aje/kwn273
JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration|10.1111/j.1471-4159.2008.05713.x
The Role of Lmx1a in the Differentiation of Human Embryonic Stem Cells into Midbrain Dopamine Neurons in Culture and After Transplantation into a Parkinson's Disease Model|10.1634/stemcells.2008-0734
Proteomics of Human Neurodegenerative Diseases|10.1097/nen.0b013e318187a832
Cost effectiveness of preventing falls and improving mobility in people with Parkinson disease: protocol for an economic evaluation alongside a clinical trial|10.1186/1471-2318-8-23
Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: A potential mechanism leading to chronic inflammation|10.1016/j.expneurol.2008.09.003
Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease|10.1002/prca.200800043
Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators|10.1016/j.bmcl.2008.08.087
Hsp104 antagonizes α-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease|10.1172/jci35781
Enantiomeric Propanolamines as selectiveN-Methyl-d-aspartate 2B Receptor Antagonists|10.1021/jm8002153
Generation of Stable Transgenic C. elegans Using Microinjection|10.3791/833
A Genome‐wide Scan in an Amish Pedigree with Parkinsonism|10.1111/j.1469-1809.2008.00452.x
GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein|10.1073/pnas.0802437105
UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals|10.1038/nature07181
Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4|10.1124/mol.108.049551
Neuronal gene expression correlates of Parkinson's disease with dementia|10.1002/mds.22184
Activation of recombinant NR1/NR2C NMDA receptors|10.1113/jphysiol.2008.158634
Application of a C. elegans Dopamine Neuron Degeneration Assay for the Validation of Potential Parkinson's Disease Genes|10.3791/835
Intranigral Lentiviral Delivery of Dominant-negative TNF Attenuates Neurodegeneration and Behavioral Deficits in Hemiparkinsonian rats|10.1038/mt.2008.146
Evaluation of α-synuclein immunohistochemical methods used by invited experts|10.1007/s00401-008-0409-8
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors|10.1016/j.nbd.2008.06.018
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study|10.1016/s1474-4422(08)70117-0
Strengths and limitations of genetic mouse models of Parkinson's disease|10.1016/j.parkreldis.2008.04.004
Value of genetic models in understanding the cause and mechanisms of Parkinson’s disease|10.1007/s11910-008-0045-7
Phosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis|10.1002/ana.21425
Pharmacological Characterization of Membrane-Expressed Human Trace Amine-Associated Receptor 1 (TAAR1) by a Bioluminescence Resonance Energy Transfer cAMP Biosensor|10.1124/mol.108.048884
Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease|10.1093/brain/awn101
Changes in attack behavior and activity in EphA5 knockout mice|10.1016/j.brainres.2008.02.047
Therapeutic cloning in individual parkinsonian mice|10.1038/nm1732
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases|10.2119/2007-00100.irvine
The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007|10.1007/s10561-008-9067-2
CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases|10.1309/w01y0b808emeh12l
Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism|10.1016/j.nbd.2008.02.011
Microglial responses to dopamine in a cell culture model of Parkinson's disease|10.1016/j.neurobiolaging.2008.01.001
Morphometric analysis of hypothalamic cells showing c-Fos proteins after movement restriction and EHF-irradiation|10.1016/j.pathophys.2007.11.001
Allosteric modulation of mGluR4 as a novel therapeutic direction for the treatment of Parkinson's disease|10.1096/fasebj.22.1_supplement.103.2
Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA|10.1007/s00702-008-0030-y
Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons|10.1186/1750-1326-3-3
Parkin mediates the degradation‐independent ubiquitination of Hsp70|10.1111/j.1471-4159.2008.05261.x
Programmed cell death and new discoveries in the genetics of parkinsonism|10.1111/j.1471-4159.2007.05106.x
Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP|10.1073/pnas.0705363105
In vitro high affinity α‐synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain1|10.1111/j.1471-4159.2008.05245.x
Lack of evidence for an association between UCHL1 S18Y and Parkinson’s disease|10.1111/j.1468-1331.2007.02012.x
Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model|10.1073/pnas.0711018105
Lesion of the centromedian thalamic nucleus in MPTP‐treated monkeys|10.1002/mds.21906
Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice|10.1172/jci32273
In vivo silencing of alpha-synuclein using naked siRNA|10.1186/1750-1326-3-19
Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson’s disease|10.1016/j.nbd.2007.08.008
Investigating Convergent Actions of Genes Linked to Familial Parkinson’s Disease|10.1159/000113697
The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis|10.1073/pnas.0710685105
Zinc inhibition of rat NR1/NR2A N‐methyl‐d‐aspartate receptors|10.1113/jphysiol.2007.143941
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions|10.2174/157015907782793667
Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease|10.1073/pnas.0704908104
VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease|10.1111/j.1471-4159.2007.05108.x
Reduced striatal tyrosine hydroxylase in incidental Lewy body disease|10.1007/s00401-007-0313-7
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes|10.1113/jphysiol.2007.143172
Murine models of acute neuronopathic Gaucher disease|10.1073/pnas.0708086104
Human Embryonic Stem Cell-Derived Dopaminergic Neurons Reverse Functional Deficit in Parkinsonian Rats|10.1634/stemcells.2007-0494
Special focus section: Gene therapy for Parkinson's disease|10.1016/j.expneurol.2007.09.006
Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of α‐synuclein over‐expression|10.1002/syn.20456
Myelin Basic Protein-primed T Cells Induce Neurotrophins in Glial Cells via α5β3 Integrin|10.1074/jbc.m702899200
Spatiotemporal Pattern of Striatal ERK1/2 Phosphorylation in a Rat Model of L-DOPA–Induced Dyskinesia and the Role of Dopamine D1 Receptors|10.1016/j.biopsych.2006.11.032
Proteomics of human cerebrospinal fluid – the good, the bad, and the ugly|10.1002/prca.200700081
Physiology versus pathology in Parkinson's disease|10.1073/pnas.0704254104
Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells|10.1073/pnas.0704091104
Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient mice|10.1073/pnas.0702717104
γ‐Synuclein and the progression of cancer|10.1096/fj.07-8379rev
Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease|10.1016/j.pharmthera.2007.02.002
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease|10.1002/ana.21157
Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease|10.1016/j.expneurol.2007.05.010
Differential regulation of Mn-superoxide dismutase in neurons and astroglia by HIV-1 gp120: Implications for HIV-associated dementia|10.1016/j.freeradbiomed.2007.03.022
Isolation of a Human Single Chain Antibody Fragment Against Oligomeric α-Synuclein that Inhibits Aggregation and Prevents α-Synuclein-induced Toxicity|10.1016/j.jmb.2007.02.089
Human embryonic stem cells for brain repair?|10.1098/rstb.2006.2014
Consumption of Dairy Products and Risk of Parkinson's Disease|10.1093/aje/kwk089
TNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice|10.1016/j.nbd.2006.11.012
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons|10.1073/pnas.0605208103
Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide|10.1016/j.neuint.2006.12.013
Molecular markers of early Parkinson's disease based on gene expression in blood|10.1073/pnas.0610204104
Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice|10.1186/1750-1326-2-10
Epidemiology of Parkinson's disease|10.1016/s0072-9752(07)83006-5
Essential function of HIPK2 in TGFβ-dependent survival of midbrain dopamine neurons|10.1038/nn1816
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease|10.1073/pnas.0606401103
Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson’s disease|10.1111/j.1471-4159.2006.04333.x
Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: A proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE|10.1186/1471-2105-7-475
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson's disease|10.1016/j.expneurol.2006.09.004
Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice|10.1073/pnas.0602116103
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study|10.1016/s1474-4422(06)70579-8
LRRK2 G2019S in Families with Parkinson Disease Who Originated from Europe and the Middle East: Evidence of Two Distinct Founding Events Beginning Two Millennia Ago|10.1086/508025
Malevolent lurkers no more: NMDA receptors come of age|10.1113/jphysiol.2006.114629
Diagnosis and treatment of Parkinson disease: molecules to medicine|10.1172/jci29178
Signals for the induction of nitric oxide synthase in astrocytes|10.1016/j.neuint.2006.04.007
Up-regulation of BDNF in Astrocytes by TNF-α: A Case for the Neuroprotective Role of Cytokine|10.1007/s11481-006-9020-8
Age-related changes in glutathione and glutathione-related enzymes in rat brain|10.1016/j.brainres.2006.03.063
Regulation of Inducible Nitric Oxide Synthase Gene in Glial Cells|10.1089/ars.2006.8.929
Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro|10.1016/j.yexcr.2006.03.012
Neural Subtype Specification from Embryonic Stem Cells|10.1111/j.1750-3639.2006.00008.x
Lipid-lowering drugs|10.1007/s00018-005-5406-7
Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease|10.1096/fj.03-1449com
Crossroads in GDNF therapy for Parkinson's disease|10.1002/mds.20861
Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.|10.1186/1742-2094-3-29
Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity|10.1186/1471-2202-6-71
HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis|10.1038/sj.cdd.4401769
Parkinson's disease andLRRK2: Frequency of a common mutation in U.S. movement disorder clinics|10.1002/mds.20751
High-Resolution Whole-Genome Association Study of Parkinson Disease|10.1086/496902
Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease|10.1096/fj.05-3735fje
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism|10.1111/j.1471-4159.2005.03428.x
Paraquat Neurotoxicity is Distinct from that of MPTP and Rotenone|10.1093/toxsci/kfi304
Directed Differentiation of Dopaminergic Neuronal Subtypes from Human Embryonic Stem Cells|10.1634/stemcells.2004-0365
Oxidative Damage in Parkinson's Disease|10.1089/ars.2005.7.627
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress|10.1073/pnas.0501282102
Parkin-deficient mice are not a robust model of parkinsonism|10.1073/pnas.0409598102
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease|10.1073/pnas.0405313101
Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia|10.1002/ana.20296
Cell therapy in Parkinson’s disease|10.1602/neurorx.1.4.382
Turning the heterogeneous into homogeneous: studies on selectively isolated GABAergic interneuron subsets|10.1016/j.ijdevneu.2004.07.012
Derivation of midbrain dopamine neurons from human embryonic stem cells|10.1073/pnas.0404700101
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging|10.1073/pnas.0403495101
It's a double knock‐out! The quaking mouse is a spontaneous deletion of parkin and parkin co‐regulated gene (PACRG)|10.1002/mds.20000
Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a|10.1073/pnas.1534900100
Neuroectodermal differentiation from mouse multipotent adult progenitor cells|10.1073/pnas.1834196100
Pitx3 is required for development of substantia nigra dopaminergic neurons|10.1073/pnas.0230529100
